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Placing Values at the Centre of Biotechnology Policy:
The Canadian Biotechnology Strategy and Women’s Health. Opening Remarks

Susan Sherwin

About the Author
Susan Sherwin is Munro Professor of Philosophy and a Professor of Women's Studies at
Dalhousie University. Her principal area of research is in feminist health care ethics. She
is the author of No Longer Patient: Feminist Ethics and Health Care (Temple University
Press 1992). She also served as Coordinator for the Feminist Health Care Ethics
Research Network which jointly produced The Politics of Women's Health: Exploring
Agency and Autonomy (Temple University Press, 1998). Much of her current work is in
the area of ethics and biotechnology.

About the Article
In these Opening Comments, Sue Sherwin explains the history of the Working Group on
Women, Health and the New Genetics, and the goals of the national Strategic Workshop
held on February 11 and 12, 2000 at York University in Toronto. At issue for concerned
observers of the federal government’s policy agenda for biotechnology, Sherwin
suggests, are “basic questions of values.” It is precisely the imperative of value definition
and judgment which necessitates democratic rather than bureaucratic policy
development in this burgeoning field. Yet the government’s approach to defining values,
Sherwin argues, has been inadequate at best, and incoherent at worst. Drawing on her
own work in the field of feminist health care ethics, Sherwin seeks to “clarify and order
the values underlying the Canadian Biotechnology Strategy” by investigating different
meanings of ‘freedom’ and ‘choice.’ She advocates what she calls “relational autonomy”
as a way to approach these ideals. Finally, Sherwin considers the structures and
processes through which values – other than those advanced by industry – can be
brought to bear in the development and deployment of policies. Despite the difficulty of
such a task, Sherwin commends the importance of engaging citizens in the development
of Canada-specific approaches to the assessment, promotion and restriction of
biotechnology. Only in this way, Sherwin argues, can our policies “reflect and help to
realize the deepest values of Canadians.”
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Introduction
Nearly two years ago, a small group
calling itself the Working Group on Women
and the New Genetics was formed under
the auspices of NNEWH (National
Network on Environments and Women’s
Health). As a group of Canadian
academics and community activists
sharing a concern with issues related to
women, health and genetic knowledge, we
structured our investigations around
feminist principles of social justice.
Specifically, we were concerned with the
absence of concentrated gender-specific
research investigating the impact of the
new genetics agenda on women. With
some seed money from NNEWH, we
began a series of teleconferences around
the need for greater research in the realm
of women’s health and the new genetics.
The membership of this working group
evolved a bit and soon settled into a core
team.1
The February 2000 workshop was actually
the second in a series of two national
strategic workshops. Last February
(1999), we organized a preliminary
workshop in Winnipeg to which we invited
a small group of community activists
concerned with women’s health issues.
They were asked to reflect on their
understanding of the implications of new
1

The Working Group for 1999-2000 consists
of: Patricia Lee, Fiona Miller, Roxanne
Mykitiuk, Yvonne Peters, Sari Tudiver, myself,
and our reluctant but fearless and much
overworked leader, Lorna Weir, Department of
Sociology, York University, Toronto. Though
Ann Rochon Ford has had to give up active
membership in the group, she was a very
important early member who helped to get us
going. The activities of the Working Group
have been facilitated by continuing support
from NNEWH. That support, supplemented
with grants from MRC, the Department of
Sociology at York, and the Dean of Arts at
York, allowed us to hold this workshop. We are
very grateful to all our sponsors.
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genetics for women’s health and their
sense of research priorities in this realm.
Building on the feedback from that
workshop, the Working Group decided to
try to focus the 2000 workshop’s
investigation of the implications of the new
technology for women’s health around the
three core themes of health, wealth, and
community. We re-framed our initial
agenda beyond genetics to the whole
range of biotechnology in the hope of
having an impact on the government’s
current efforts to restructure its approach
to the biotechnology industry. Our hope
was that the national strategic workshop
would provide an opportunity for
participants to define and begin to address
a series of fundamental, feminist questions
about the Canadian Biotechnology
Strategy (CBS) in relation to women and
health.
It is our view that that there are basic
questions of values related to the genetic
modifications of humans and other
organisms that must be identified and
addressed. These questions cannot be
resolved internally through state
bureaucratic processes, since they involve
questions of society’s value commitments.
Such decisions must be pursued through
democratic processes. Indeed, recognition
of the importance of public debate was a
major factor behind the federal
government’s 1998 efforts to solicit public
input on these matters through a round of
policy consultations. Many of us
participated in some of those sessions and
were confirmed in our sense that the level
of critical cultural knowledge and public
understanding of biotechnology is weak.
The development of socially accountable
strategic frameworks for state
biotechnology policy suffers from this
dilemma. We are particularly troubled by
the lack of attention directed at the
question of what these policies mean for
women. A distinctly feminist perspective
must be brought to bear on the

identification and investigation of the
values underlying biotech policy.
We use the term 'women and health' quite
expansively to refer to three processes:
the impact of policy and technology on
women's health; women's relationship to
medicine and health systems; and
women's 'interests' in health – health as
women's business – personally, culturally,
socially. We asked Workshop participants
to focus on the following: What are the key
questions to ask so that we might best
understand the impact the CBS will have
on women and health? What kinds of
research and action need to be
undertaken to answer these questions?
In deciding on participants for the
workshop, we sought out individuals
engaged in developing new knowledge or
in carrying out advocacy work. We tried to
structure the workshop to facilitate the
exchange of existing knowledge, and also
to produce new questions and to incite the
development of new knowledge and
advocacy. We intended the workshop to
be a forum for the design of future
research projects and activities, where
resources could be identified and networks
formed of individuals and groups
committed to taking the issues further. The
aim of the workshop was not to produce
consensus. We meant to stimulate and
facilitate rather than conclude. We hoped
to leave with a clearer sense of what
questions should be asked, what research
undertaken and what advocacy pursued to
deal with the Canadian Biotechnology
Strategy from the perspectives of women
and health. The collection of papers in this
Proceedings suggests that we
accomplished our goals.
I have the privilege of leading things off.
Let me do that by situating my own
research interests in the context of our
agenda. I work in the field of ethics, more
specifically feminist health care ethics. It is
very clear that there is need for sustained
feminist research directed at clarifying the

many vague suggestions found within the
government documents about the values
that should be guiding Canada’s
biotechnology strategy. We can begin by
documenting the incoherence in the
values expressed in the government’s own
statements of the values that form the
basis for policy directions. For example,
the expressed commitment to advancing
the health and well-being of Canadians is
often incompatible with the strongly
endorsed value of supporting industry.
Just making clear the competing and
incommensurate value frameworks that
are being proposed allows us to insist that
government be explicit about the priorities
it attaches to the various value systems at
work. Toward this end, it is particularly
important that we ask the familiar feminist
questions as to who is likely to benefit
from the various types of biotechnology
and who is likely to suffer from them. Let
me try to be a bit more specific.
It is essential that Canadians understand
the different forms of freedom and choice
that are proposed as a central value for
emerging policy. The terminology of
freedom and choice is often used to
represent quite different value systems.
Not surprisingly, industry is particularly
enthusiastic about market models in which
freedom is reduced to the ideal of
unrestricted consumer choice. In this
conception, government is assigned a role
of regulating trade to ensure accuracy of
information and adequate opportunities to
acquire the information necessary to make
a rational choice. This is especially tricky
terrain for feminists for we often hear our
own slogans about the importance of
“choice” and personal control over
decisions regarding our bodies invoked to
support industry’s right to market any
“health” or “reproduction” related product
or service directly to consumers.
We must, therefore, be very clear about
the type of personal freedom we
understand to be central to feminist
values. Specifically, feminists need to
3

insist that the personal control we demand
is not a matter of being granted
unrestricted access to problematic
technologies. Rather, we seek access to
opportunities that can support women’s
overall autonomy, and not increase their
oppression. We cannot decide whether
any particular consumer option meets this
criterion by examining it in isolation and
seeing if it meets some particular person’s
current desires or needs. To determine a
technology’s impact on personal autonomy
we need to investigate it in the context of
what opportunities are created or lost by
its introduction.
Elsewhere, I have proposed that we try to
understand the ideal in question through a
concept I call “relational autonomy”
(Sherwin, 1998) The idea of relational
autonomy is that we must critically
examine not only the decision-making
capacity of the agent to make rational
choices free of direct coercion, but also
the nature of the set of options from which
she must choose. Emphasis on the
relational dimension of autonomy (which
literally means self-government) is meant
to counter the familiar over-simplification
by which autonomy is equated with the
exercise of preferences without
interference. Relational autonomy
demands moral evaluation of the context
in which the person is being asked to
choose. In particular, agents should be
free of the “double binds” of oppression
that tend to reduce an individual’s options
to a set of harmful choices where the best
she can do is to select that option most
likely to minimize the resulting damage.
Relational autonomy is also distinguished
from consumer freedom in its appreciation
of the processes that are essential
elements of becoming autonomous. It
rejects the common assumption that being
autonomous is achieved merely by virtue
of reaching adulthood and being free of
explicit coercion. Under the consumer
choice model of freedom the self is
expected to approach important decisions
4

fully formed and self-transparent; but
selves are never fully formed, coherent,
consistent, and clear. When individuals
are faced with difficult personal decisions
they often surprise themselves with the
decisions they make. Real autonomy
comes not from entering such
circumstances with our values settled,
such that all we need is respect for our
well-articulated preferences, but from
having the opportunity to discover what
our values really are and how they apply
to the situation at hand. We need to
wrestle with the implications of serious
options to know what we stand for and
how we want to be treated. Thus, to
respect autonomy for individuals it is not
sufficient to leave them free to exercise
their preferences; rather we must provide
them with the resources necessary for
discovering what they truly value and what
sort of person they wish to be. It is our
reflective, considered values that demand
respect, not our current inclinations. Selfdiscovery and self-definition are relational
activities that are essential pre-conditions
of genuine self-direction.
Therefore, a consumer model of choice
with respect to various sorts of
biotechnologies cannot be equated with
the moral ideal of autonomy. The fact that
people are willing, perhaps even eager, to
purchase some form of biotechnology is
not evidence that this technology should
be brought to market. Individuals are often
in no position to resist technologies on
their own. If some form of technology is
normalized, the option of refusing it may
disappear. For instance, it is already
difficult for many women to resist prenatal
testing of their fetuses even if they are
committed to carrying the pregnancy to
term and the information available from
prenatal testing will be of no benefit to
them. Similarly, if the crops produced by
genetically modified seeds prove invasive
to other crops, or if they allow production
at vastly reduced rates for a few years,
independent farmers may be unable to
continue to plant traditional seeds in an

economically viable way. The fact that
women choose prenatal testing under the
mistaken belief that it will improve the
health of their fetus or that farmers choose
to buy seeds from the major distributors is
not evidence that the individuals
concerned are acting autonomously. Only
if their decisions reflect their deepest
values can we consider their actions fully
autonomous.
We need to do more than clarify and order
the values underlying the Canadian
Biotechnology Strategy, of course. We
also need to explore structures that can
ensure that the values selected will be
reflected in the policies our government
adopts. This project is especially
challenging, since it is difficult to see how
Canadians might actually go about limiting
the development of any potentially
profitable biotechnology industry. While
government is well positioned to foster the
development of favoured industries, it is
not as well equipped to restrict the
undesirable ones. Biotechnology
industries are particularly resistant to
government restrictions, for the companies
involved are typically engaged in a global,
not a national, marketplace. In fact, many
belong to that most postmodern of
phenomena: multi-national corporations
that are situated both everywhere and
nowhere. Producers effectively resist
national regulations on the grounds that
local restrictions would put them at an
unfair economic disadvantage in a
competitive global marketplace. Typically,
they are able to make credible threats that
they will move production to a different
jurisdiction if their interests are ignored.
Governments are understandably reluctant
to introduce policies that inhibit the growth
of industries when the jobs in question can
be easily moved off-shore. Indeed,
governments are far more inclined to
support than to restrict these new
industrial initiatives. For example, Health
Canada was very explicit in its recent
announcement that it would shorten the
waiting time needed before initiating phase

one drug trials from 60 days to two days
because it hoped such a move would
attract more pharmaceutical research to
Canada.
Moreover, it is not only the producers who
may resist national restrictions. In an era
where free trade has become a mantra of
politicians and economists, it is difficult for
nations to develop policies that effectively
protect their citizens from the potential
hazards of products originating elsewhere.
While consumers may welcome
government’s role in setting minimal safety
standards and promoting truth in
advertising, they tend to be rather
intolerant of government restrictions on the
availability of goods they personally
desire. In fact, many Canadians have
become quite adept at “cross border
shopping.” This means that if our
government ever does manage to finally
introduce its long-promised legislation to
regulate reproductive technologies, we
can anticipate that some Canadians will
side-step restrictions on reproductive
services (e.g., sex selection) through
travel to U.S. clinics. Similar action will be
taken for access to home-testing kits for
genetic traits, anti-aging potions, and even
organs for transplant if such products are
restricted in Canada but available for
purchase in other jurisdictions.
Nonetheless, I believe that Canada must
develop a national policy on
biotechnology. We need to do this in order
to protect and promote the personal
autonomy of our citizens, because
individuals cannot control the social and
material conditions that structure the
options they face; many of the
preconditions for relational autonomy can
only be achieved through political action.
In order to make certain that the options
facing Canadians in the realm of
biotechnology will promote and not limit
personal relational autonomy, it is
necessary for the government to develop
policies that reflect our national autonomy.
That is, they must be policies that reflect
5

and help to realize the deepest values of
Canadians.2
In order to develop such policies, we must
conduct exercises in collective selfdiscovery and self-definition about the
sorts of activities well informed citizens
wish to permit and the sorts of threats they
wish government to protect them from. It is
only through a complex exercise of
communication and debate that we can
decide what might constitute “Canadian
values” in the diverse, multi-cultural,
heterogeneous society we inhabit. In fact,
the federal government has recognized
that potential transformations of
fundamental values and understandings
are inherent in many forms of
biotechnology. It has undertaken efforts to
promote the conversations Canadians
must undertake in pursuing the activities of
self-discovery and self-definition that are
essential for genuine autonomy. For
example, more than ten years ago it
established the Royal Commission on
New Reproductive Technologies to advise
on policies in the realm of reproduction.
The Royal Commission conducted
extensive consultations with Canadians
and determined that we are united in not
wanting to be a society that treats children
or women’s reproductive capacities as
commodities to be bought and sold. By
exploring the meaning of this commitment,
the Commission learned that Canadians
did not think it appropriate to treat
reproductive activities, including the
contribution of embryos, eggs, and sperm
as commodities to be auctioned off to the
highest bidder.
In 1998, the federal government initiated
conversations central to self-discovery and
self-definition in the sphere of
biotechnology broadly defined. It held a
series of public consultations regarding
2

I do not believe that oppression of minorities
reflects national autonomy at all, but rather the
co-optation of ethical language in the service
of immoral abuses of local power.

6

development of a biotechnology strategy
which would “enhance the quality of life of
Canadians in terms of health, safety, the
environment and social and economic
development by positioning Canada as a
responsible world leader in biotechnology.”
(CBS, 1998). Ethical analysis was
understood to be a central element of
these deliberations. But as several papers
noted, the motivation for discussion was
couched in language aimed at facilitating
the development and promotion of
biotechnology industries and did not really
leave room for alternative strategies to
emerge. It is, therefore, essential that we
make clear the inherent contradiction
between a commitment to explore
Canadian values regarding biotechnology
and an assumption that the outcome of
such analysis will be a shared commitment
to support most biotechnology industries.
Last fall, the federal government took the
next step in its biotechnology strategy
process and appointed a 20 member
Biotechnology Advisory Committee
(CBAC). According to the Minister of
Industry “CBAC is an expert, arm's-length
committee created under the renewed
Canadian Biotechnology Strategy (CBS) to
advise Ministers, raise public awareness
and engage Canadians in an open and
transparent dialogue on biotechnology
matters. . . . CBAC will advise government
on broad policy issues associated with the
ethical, social, regulatory, economic,
scientific, environmental and health
aspects of biotechnology.” (CBAC, 1999).
Its express purpose is to facilitate
continued dialogue of self-direction and
self-definition in the pursuit of national
autonomy in the realm of biotechnology.
There is, however, plenty of reason to
worry about its effectiveness in achieving
this task. It is arguable that the advisory
panel of distinguished Canadians is not
representative of all concerned citizens;
certainly, there are many groups that fear
their views will not be represented nor
their voices heard. Health activists seem
to have been deliberately excluded and I

know of only one member who is explicitly
committed to a woman’s health agenda.
CBAC will need to find ways to promote
trust in its ability to fully engage Canadians
in self-discovery and self-definition and to
report accurately the outcomes of these
conversations if its advice is to carry the
necessary authority. One thing we can do,
here and in the future, is to begin to
formulate a substantive list of questions
regarding the impact on women’s health
that CBAC should attend to in its
deliberations. We might also propose
procedural ways that can facilitate
meaningful input from citizens who are
concerned with, and knowledgeable about,
women’s health.
Of course, self-discovery and selfdefinition are not the only elements of
autonomy. Self-direction is also required.
So far, the Canadian government has
been unwilling or unable to engage in the
final step of exercising national autonomy
in the realm of biotechnology. Despite the
thoroughness of its public consultations
and of its research and analysis, none of
the 293 recommendations of the Royal
Commission on New Reproductive
Technologies has yet been implemented.
It is still too early to determine whether
CBAC will be able to contribute effectively
to self-direction on biotechnology policy. It
is clear, however, that there are likely to
be structural impediments to its capacity to
influence policy, that is, to see its moral
analysis translated into national selfdirection. The panel reports to an intergovernmental agency in which the
Department of Industry plays a leading
role; the principal responsibility of this
ministry is to promote industrial
development. Such an arrangement does
not seem to be particularly conducive to
generating policy that may require
imposing restrictions or prohibitions on
certain industries.

processes that have been put in place
make it difficult for the government to hear,
let alone adopt, values other than those of
industry. We need to identify strategic
ways to demand more accountability from
government in:
1. identifying the appropriate values to
guide biotech policy; and
2. ensuring that the values agreed upon
do in fact structure both national and
international policies.
Protecting and promoting women’s health
must surely be fundamental to that
agenda. Our hope for the workshop was
that it would help to provide direction to
the research and political activities that are
essential elements of translating this
commitment into practice. Clearly, there is
much work for feminists to do in promoting
biotechnology policies that truly support
women’s health. The following papers
provide some guidance for how to
proceed.

So far, then, the biotechnology strategy
espouses interest in identifying and
reflecting the values of Canadians but the
7
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The New Genetic Therapies:
The Case of Herceptin for Breast Cancer

Sharon Batt

About the Author
Journalist and community activist Sharon Batt has written extensively about breast
cancer issues. She is the author of Patient No More: the Politics of Breast Cancer
(Gynergy Books, 1994) and co-founder of Breast Cancer Action Montreal. In July 1999
she began a two-year term as Nancy’s Chair in Women’s Studies at Mount Saint Vincent
University in Halifax.
About the Article
For many women’s health advocates, the challenge of genetics in relation to breast
cancer is the challenge posed by a new breed of genetic tests. In this piece, Sharon Batt
suggests that there are other challenges to consider. Batt introduces readers to a new
treatment protocol for breast cancer, involving a genetically engineered antibody which
targets a malfunction that is genetically associated − Herceptin (or Trastuzumab). As
Batt discusses it, the new drug Herceptin poses both new and familiar challenges. On
the familiar side of the ledger, and despite the hype to the contrary, this new genetic
therapy is no miracle cure; moreover, like the better known therapeutic protocol of
chemotherapy, Herceptin has dangerous adverse effects. On the less familiar side of the
ledger, this drug is exorbitantly expensive, and herein lies the new challenge. While this
drug and others like it that are coming down the pipe may provide new tools for fighting
cancer, they may also prove unaffordable. Batt argues that if the new era of biotech
medicine provides some medical assistance for the few, while contributing to the demise
of a public health care system for the many, women in general are unlikely to be the
winners.
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Introduction
Breast cancer is the number one killer of
mid-life women and has been for decades.
Treatments are harsh and have limited
benefits. An effective new treatment would
be welcome indeed, and one that worked
and had few or no adverse side effects
would transform the experience of breast
cancer beyond recognition. Enter the
Human Genome Project, promoted as
precisely the Aladdin’s lamp we’ve been
waiting for. Research mapping genes to
diseases will lead us into a world of just
such therapies, miraculously effective
because they are based on a true
understanding of how genes work. At least
that’s the hype. Women’s health
advocates need to weigh these claims,
balancing our scepticism of this project
against the desperate need of sick women
for more enlightened therapeutic
approaches to cancer.
Feminist discourse about breast cancer
and genetics has concentrated on the
issues related to genetic testing for breast
cancer susceptibility, especially the BRCA
1 and 2 genes, and on the reductionist
emphasis on genetics − to the exclusion of
environmental triggers – as the basis of
cancer. While these are critical issues, we
can’t neglect the questions arising from
genetic treatments that are now coming
onstream. Health Canada approved
Herceptin, the first novel gene therapy for
breast cancer, in August, 1999.
In the rest of this paper, I look at what we
know so far about what Herceptin does for
women with breast cancer, its side-effects,
its cost, how advocates are responding to
this new therapy, and the dilemmas the
drug presents for those of us concerned
about Canada’s biotechnology strategy.
What is Herceptin?

10

Herceptin is the first therapy of its kind
ever approved for the treatment of breast
cancer. Unlike cytotoxic chemos which
simply aim to kill the misfunctioning cell,
Herceptin aims to re-balance the process
that is misfunctioning. In this case, the
therapy is designed to correct an overproduction of the protein produced by a
certain oncogene (i.e., cancer gene),
which the defective gene uses to make the
cell cancerous.1 This gene has been
named “HER-2 neu,” a clever moniker for
a drug designed for women. HER-2 refers
to the protein, “Human Epidermal-growthfactor Receptor-2,” and neu is the name a
different scientist, who discovered the
gene first, decided to call it. Geneticists
refer to the production of excess protein as
"overexpression". Herceptin is intended to
correct the overexpression of the Her-2
protein.2
Because the Her-2/neu gene produces an
excess of the Her- 2/neu protein,
researchers developed what is called a
"monoclonal antibody" to attack the protein
and shut it down. (The body produces
millions of different antibodies − which
themselves are proteins −to attack
invading viruses and infections. A
"monoclonal" antibody is laboratory
manufactured, using genetic engineering.)
Researchers working on this problem in
the late 1980s were amazed and delighted
when they added the monoclonal antibody
to a petri dish containing breast cancer
cells that overexpressed Her-2/neu: the
cancerous cells stopped growing and
dividing. When they injected the antibody
into mice into which breast cancer cells
had been implanted, the tumours shrank.
1

NB. This genetic change is part of the cancer
process; it is not inherited.
2
Again, the language reverberates for
feminists: women have long been chastised as
overexpressing our emotions; now we have a
“women’s gene” that overexpresses and gives
us cancer.

Over the next decade, the antibody was
adapted for use in humans and then
tested in clinical trials using women who
had breast cancer tumours that tested
positive for Her-2/neu. (Bazell, 1998:42-3)
This modus operandi is very different from
traditional cancer chemotherapies, which
are systemic, and which are designed to
kill cancer cells. In theory, herceptin is a
huge therapeutic advance. As everyone
knows, conventional chemotherapy drugs
have horrible side-effects, because they
kill any rapidly dividing cell, healthy or
cancerous. What's more, they have not
been very successful in treating breast
cancer, especially in patients with
advanced disease − in fact, they often kill
the patient before the disease does. While
Herceptin was in development, the drug
was touted as a treatment that would work
better than cell-kill chemo and which
would have no side-effects at all. A
patient’s dream drug.
Does Herceptin Work?
Does Herceptin Work? The answer is
sometimes and sort of.

20.3 months from the beginning of
treatment; those who had chemo plus
Herceptin lived a median time of 25.4
months from the beginning of treatment.
(Slamon et al 1998). After two years of the
trial, researchers were announcing that the
addition of Herceptin to chemotherapy
increased patient survival by 22% (Zoler,
1999).
In the world of breast cancer treatments,
this was considered remarkable. Very few
chemotherapy trials have ever shown a
survival difference between two
treatments. On the other hand, this is far
from the miracle women with breast
cancer hope for.
The drug has been disappointing on a
number of other counts. First of all, it
benefits only a subset of women with
advanced disease. To see if she qualifies
for Herceptin, a woman is given a test to
see if she is one of the cancer patients
who are Her-2 positive; that is, one of the
25-30% of women with advanced breast
cancer who overexpresses the Her-2
protein.

Like most new cancer therapies, Herceptin
is being tested in patients with advanced
cancer, that is, in women whose condition
is very likely to be fatal. Twenty-five to
thirty percent of women whose cancer has
reached this stage have been found to
overexpress HER-2 − and they are women
whose disease is typically unusually
aggressive, or fast-spreading.

But even a positive Her2 test result is no
guarantee that Herceptin will benefit
women who take it. In the clinical trials
data, 32 percent who were treated with
chemotherapy alone showed tumour
shrinkage compared to 49 per cent of
Her2 positive women under the Herceptin
+ chemotherapy regimen. Even with the
combined treatment, 51 per cent of Her2
positive women did not respond to
Herceptin.

Clinical trial data for Herceptin have been
coming out since 1998. The original study,
which convinced regulators to approve the
drug, comprised 469 women with
metastatic breast cancer. Women treated
with a Herceptin-chemotherapy
combination lived longer than women
treated only with chemotherapy by a
median time of 5 months. Those who had
standard chemo lived a median time of

Other trials have suggested that
Herceptin-alone may be a useful treatment
for metastatic breast cancer. Because it
was considered unethical to deny
chemotherapy to women with cancer,
these trials have involved women who
have already had a course or more of
chemo, but whose cancer has returned. In
the largest trial of this kind, involving 222
women, the results were considered
11

significant. Herceptin produced a 15%
“response rate” (in other words, 15% of
these women had at least a 50% reduction
in the size of their tumours), for a median
time of 9.1 months. (Cobleigh et al,1999)
Adverse Effects
Though potentially a useful addition to the
treatment protocol for metastatic breast
cancer, Herceptin has not lived up to its
advance billing. As one American activist
summed it up, "While Herceptin may
represent an important new direction for
cancer therapy, the oncology community's
excitement about a 5.1 month median
survival benefit also shows how little has
been achieved since the war on cancer
began in 1971." (Schiff, 2000:23)
But more surprising for its proponents than
its limited efficacy, has been the extent to
which this drug is associated with adverse
effects. On the one hand, Herceptin is
generally given in combination with
chemotherapy drugs. The researchers'
thinking was that the antibody would hold
the cancer in check, while chemotherapy
attacked it (Bazell, 1998:137). If a selling
point for genetic treatments is that they are
more targeted and less toxic than cell-kill
chemotherapy, this advantage is
somewhat academic if the drug is given in
combination with a cell-kill regimen.
Another problem is that Herceptin can't
cross the blood/ brain barrier. Some
women whose metastases disappeared in
their liver, lung or bones eventually died of
brain metastases. (Bazell, 1998:170)
But most important is the apparent toxicity
of Herceptin for heart tissue. The cell-kill
chemotherapy regimen which is used is
already quite toxic − especially to heart
tissue. To everyone's surprise, Herceptin
actually increased the heart toxicity by
25%. This was the case even for those
women who had Herceptin-alone; in the
trial of 222 women noted above, 4.7%
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experienced what’s known as “cardiac
dysfunction.”
In May 2000, Genentech, the
biotechnology company that developed
the drug, sent out an alert to providers,
warning them to pay special attention to
heart function when prescribing this drug.
Genentech reported 62 serious adverse
events related to the use of Herceptin; 15
of these women died. The company noted
that while some of these events had been
observed in the clinical trials of the drug,
some were more severe, or new:
specifically, “adult respiratory distress
syndrome, anaphylaxis and death within
24 hours of a HERCEPTIN infusion.”
(Genentech, 2000)
Such extreme and fatal outcomes
prompted heart specialists to speak out
about the drug. They note that “heart
failure, like many cancers, is a progressive
disease, “and they argue that physicians
should take care that “patients do not
trade one lethal disease for another.”
(Feldman et al, 2000:272). Fear of cancer,
and particularly fear of breast cancer, is
clouding clinical judgement, in the view of
cardiovascular specialist Arthur Feldman
of the University of Pittsburgh Medical
Centre. “…if someone were to go to the
FDA with a new drug for heart failure or
cholesterol or high blood pressure – all of
which are leading killers of people – and
that drug was associated with even a 1%
incidence of cancer, it would never be
approved by the FDA,” said Dr. Feldman.
“No manufacturer would take the drug to
the FDA. Yet here is an anticancer drug
that is associated with a 28% incidence of
heart failure and it is approved.” (Gottleib,
2000) BMJ 2000; 321:259 (29 July)]
Given these results, the future of
Herceptin is not certain. What is certain,
however, is that other genetically
engineered drugs are on the way, and
some of the issues that Herceptin raised
are bound to recur.

The Price of Herceptin
No one involved in Herceptin’s
development ever expected the world’s
first designer breast cancer drug to be
cheap. A book about HER-2’s
development, by TV journalist Robert
Bazell, culminates at an oncology
conference in Los Angeles at which the
results of the clinical trials are presented to
an audience of 18 thousand delegates.
That evening, Genentech held a party for
its researchers, for the clinical trial
investigators, and for activists who had
helped promote the trial. "Everyone at the
party could celebrate an enormous
success,” Bazell (1998) writes. “Women's
lives would be saved and a huge fortune
would be made.”(186)
Drug pricing hasn't been an issue in breast
cancer until recently. The pricing of two
earlier drugs, tamoxifen and taxol made
some waves, but the cost of Herceptin is a
big issue. To give away the punch line, if
this drug were made available to all the
women with breast cancer who test HER-2
positive it, and the imitators sure to follow,
could bankrupt our health care system.
In the US, the FDA approved Herceptin in
October 1998; health Canada approved
the drug in August 1999. In the US,
Herceptin costs about US$2,000 a month;
the Canadian price is about $Can $16,000
for a 6-month course (Sibbald, 1999). This
is unprecedented for a breast cancer drug.
Insurance-wise, US patients fall into 3
categories:
• those covered by a private medical
plan, usually via their employers;
• those who qualify for MedicAid;
• and the "working poor, the 40 million
who have no medical coverage.
Genentech has agreed to provide
American women in this latter category
with HER-2 free of charge, although I
know of no figures showing how many

women actually take advantage of this
possibility.
Hoffman-La Roche, which took over
Genentech in 1990 (Bazell, 1998:54-55),
made it clear the company intended to cut
no deals to increase women’s access to
the drug in Canada. In a June 1999 letter
to a woman seeking access to the thenunapproved drug, Medical Director Dr Len
Walt wrote:
It is important to note that the
responsibility of providing new
therapies to patients is a shared one.
There are three critical sectors, each
with definitive accountabilities,
responsible for bringing new therapies
to Canadian patients.
•the pharmaceutical industry develops
and manufactures new products;
•Health Canada reviews the scientific
evidence in support of new products
and gives the manufacturer the
authority to distribute new products in
Canada;
•provincial and other funding
agencies ensure that adequate funds
are set aside to cover the costs of
new products introduced into the
health care system.
Each of these sectors should be held
accountable for delivering on their
responsibilities. The pharmaceutical
industry cannot make up for the
deficiencies in Health Canada or the
provincial funding agencies (Personal
Communication 1999).

In Canada, each of the provinces have
had to decide how to deal with the drug.
When it looked like Herceptin was a
benign cure, Ontario and BC decided to
cover the drug under medicare; it is not
clear what some other jurisdictions will do,
especially in light of information about
adverse effects.
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Our Patented Medicine Prices Review
Board sets the price of drugs like
Herceptin by comparing the prices in
seven other countries: the US, the UK,
Germany, France, Italy, Switzerland and
Sweden. The Canadian price can't be
higher than the median international price.
When Canada approved Herceptin, the
only other country the drug was available
in was the US, so the price was set
relative to the US price − and the US is the
only country in the world that has no
system of price controls on drugs.
Herceptin is being heralded as the
harbinger of a new era. In her introduction
to Bazell's book on Her2, geneticist Mary
Claire King, harkened back to Churchill's
declaration at the battle of El Alamein, in
1942: "Now this is not the end. It is not
even the beginning of the end. But it is,
perhaps, the end of the beginning."(Bazell,
1998:xi)
Herceptin is expected to be the first in a
long line of such treatment options. And to
a dying woman, the chance of being one
of the few patients for whom a drug like
this means a long-term remission, is
invaluable − especially when the
alternative is a median life expectancy of
20 months. But Genentech never intended
that this drug be reserved for dying
women. Cancer drugs are always tested
first on the terminally ill. Genentech hoped
to move Her-2 quickly to the status of a
front-line treatment, that is, a drug that is
prescribed immediately after breast
surgery (Bazell, 1998:175). Because of
cardiac toxicity, this is unlikely to happen
with Herceptin, but that will certainly be the
goal for other such drugs. And such a
strategy, while increasing the market for
manufacturers, poses additional
challenges for those who pay for health
care.
If the main goal of the Canadian
Biotechnology Strategy is to generate jobs
and goose the economy by encouraging
the manufacture and sale of profitable new
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treatments, Herceptin sets a positive
precedent for gene therapies to come.
From the standpoint of provincial
treasuries, however, the high cost of
Herceptin is clearly a problem.
Advocacy
From an advocacy standpoint, Herceptin is
an interesting test case of the two
competing philosophies described in
several of the papers included in this
volume.3
One can look at Herceptin as a possible
breakthrough that provides sick women
with a new choice, and stimulates the
economy at the same time. Or one can
look at Herceptin as the latest chapter in
an old story, the focus on downstream
solutions to cancer, while the upstream,
causal factors are ignored. One can
question the ethics of a system designed
to spin enormous private profits from the
genetic information provided by dying
women praying for a few extra months of
life.
Already, the cancer drug pricing issue has
fostered some strategic alliances. In
October, McGill medical ethicist Margaret
Somerville (1999) published a paper called
"The Ethics and law of Access to New
Treatments for Cancer." The paper was
financed by an educational grant from
Bristol-Myers Squibb, the maker of taxol,
another expensive cancer treatment with
modest benefits for patients. Somerville
argues that physicians have a primary
obligation of personal care to patients, and
that provinces must provide medically
necessary treatments as a condition of
receiving federal transfer payments. She
3

Herceptin brought other advocacy issues to
the fore, including the questions of
compassionate access, advocates’
involvement in clinical trial recruitment, and
fast-tracking of drug approval. These issues
are outside the scope of the present paper.

suggests that cancer patients would be on
firm ground in suing a provincial
government that denied potentially lifesaving care. Acknowledging the difficulty
this presents for a universal system, she
suggests that a parallel, private system in
Canada may emerge. “This would change
the locus of, but certainly not eliminate, the
difficult ethical and legal issues raised by
decisions on access to new or emerging
treatments for cancer,” she concludes.
Somerville also refers to a group of
"patients and advocates", "concerned
about timely access to new cancer
treatments in Canada" who conducted a
survey of provincial governments to find
out how decisions about access to drugs
are made in each province. This group has
issued press statements under a number
of names, including ACT (Access to
Cancer Treatments) and the Cancer
Advocacy Coalition of Canada, and its
activities are funded by major
pharmaceutical companies, including
Bristol Myers Squibb. In November, 1999,
the group convened a meeting of cancer
patients, oncologists, and representatives
from cancer agencies, to discuss
questions raised in Dr Somerville's report
and by their inquiry.
Interestingly, neither Dr. Somerville's
paper nor the advocacy group raise the
issue of drug pricing although the cost of
drugs is clearly the nub of the access
problem. Nor are the larger contexts of
overall medical care and the
environmental and social determinants of
health part of their discussions.
Yet surely an ethical analysis must take up
the cause of access for all needy patients,
not only the privileged. And in considering
the ethics of drug access, we also need to
address the broader implications of
skyrocketing drug costs for overall health
care.
Conclusion

Even though Herceptin is beginning to
seem like a false start for the new era of
genetic therapies, we cannot expect this to
always be the case. If the high cost of
treatments like Herceptin have the
potential to split our universal system into
two tiers, it's fair to assume women will be
over-represented in the bottom tier. It
would be ironic indeed if the very women
who come out in such numbers to “run for
the cure” and who volunteered for clinical
trials, were unable to access not only new
genetic therapies, but the hospital beds,
nursing care and other health services we
take for granted.
As an activist, I see Herceptin as a test
case for advocacy in biotech therapy. I am
concerned when I see women with breast
cancer, funded by industry and describing
themselves as advocates, promoting
access to new therapies as a right, in
isolation from its likely consequences. The
environmental movement calls industryfunded groups that present themselves as
green lobby groups as “Astro-turf groups”.
What should we call their counterparts in
the health field? I suggest we call them
“placebo health groups” − for sugar-coated
advocacy.
We need to be clear about the issue,
values and vested interests behind various
lobbies. Despite the novel language of
biotechnology, the central political
questions raised by the herceptin story are
familiar to feminists. Drugs have been
over-promoted to women before; the
issues of rising drug prices and corporate
influence on health policy are among the
galvanising issues of our age.

What can we do?
The anti-consumerist organisation
Adbusters has developed strategies to
disrupt the consumer culture, a process its
founders call "culture jamming". An
example is Buy Nothing Day, their day of
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“consumer fasting”. Canada’s
biotechnology strategy has been honed to
serve a consumerist economy, with no
public discussion of the consequences:
biotechnology activists need strategies for
“genome-jamming”.

We could boycott Runs for the Cure,
unless sponsoring agencies agree that the
money raised be used to finance
treatments that would be reasonably
priced, and unless the funds are
distributed equally to “upstream” disease
prevention work.

What might genome-jammers do?

“Choice” is an illusion if genetic treatments
are the only options on the menu; that is, if
prevention is excluded from serious
discourse; if lower-cost interventions are
not even tested; if treatment prices bear
no relationship to the true benefit of the
intervention for patients.

We could oppose private ownership of
genetic material for therapies; these
therapies are developed from specimens
donated by − or taken from − patients who
hope to see treatments developed for the
benefit of other cancer suffering
individuals, if not themselves.
We could boycott clinical trials by
companies that won't agree to price
controls, and which maintain secrecy
about their true R & D costs.
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Treatment choice is also a moot
advantage if we fail to provide adequately
for the needs of the dying, if our society
remains intolerant of people living with
disease and its consequences, and if our
worldview rejects the inevitability of death.
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About the Article
To talk about the new genetics, Patricia Kaufert argues, we need not only a new
language, but a new way of doing research. This new research approach must respect
the fact that our subject manifests itself in a multiplicity of forms, institutions and
meanings, and obliges consideration at different levels of analysis. Our research
methods must be more than multi-disciplinary, Kaufert writes; “If we are to capture some
element of this rapidly changing, chaotic world we … need an approach more akin to
collage, allowing for the constant addition of new pieces of information, new actors, new
technologies.” Kaufert’s paper teaches by example. Pursuing an initial review of breast
cancer genetics, Kaufert raises questions, and provides insight into women’s complex
decisions, uncertain medical options, health policy challenges and the connections
between research and trans-national profiteering.
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Introduction
While preparing what to say at this
workshop, I read the papers that the
conference organisers had loaded into my
e-mail. A diverse, marvelously exciting
collection – a series of bright lights shone
into the ‘black box’ of biotechnology. They
forced me into constantly scrapping what I
had written and starting over because a
paper, or a combination of papers, had
sparked a new idea, suggested a new
theme. What I finally wrote was not so
much a paper as a series of reflections.
The background papers for the workshop
covered the spectrum from micro to
macro, from the individual to the
community, from society writ large through
to microscopy of the individual cell, from
biotechnology in medicine to
biotechnology in agriculture. Reading them
as a package, one switches from the micro
level (the women reflecting on the risk of
breast cancer in Anne Robertson’s paper)
to the meso (Ken Basset’s discussion of
the policy issues faced by provincial
governments) and then forward to the
macro level (the role of the multi-nationals
in the agricultural and pharmaceutical
industries as discussed by Margaret
Eichler and Pat Armstrong).
Trained in different disciplines, the people
who wrote these papers brought insights
from ethics, history, anthropology, law, the
biological sciences, sociology and
medicine into their discussion of the new
genetics. The challenge for the workshop
was to find the connections between these
different voices and themes. Yet, the
critical importance of the workshop lay
also in its representation of so many
different perspectives on the new genetics
and so many different ways of collecting
and collating information and doing
research.
I agree very much with Abby Lippman that
we need a new language in which to talk

about genetics, but we also need a new
form of research. Although there are
important exceptions, the primary focus of
the social science literature on the new
genetics has been on the meaning of
genetic testing for the individual tested.
Some part of this choice may be dictated
by access to research funding, but it also
reflects a deep commitment to grounding
research on biotechnology in the
experience of the individual, particularly
the individual woman (Franklin and
Ragone 1998). While essential that this
type of focused, in depth work continue,
there are also many questions about the
new genetics, relevant to women, that this
type of research cannot answer.
Rayna Rapp recently wrote about the
need for research at the place “where the
cutting edges of genetic research
converge with social policy.” The problem
is that this “place” is one of relative chaos,
packed with a very disparate array of
actors, each with a particular perspective
on the new genetics. As a rough list, they
include the federal and provincial
governments, researchers, family
practitioners, geneticists and genetic
counselors, research funding agencies,
family practitioners, priests and ethicists,
families and multinational companies,
lawyers and providers of venture capital,
Myriad Genetics of Utah, Inc., and public
health departments. If we are to capture
some element of this rapidly changing,
chaotic world we also need an approach
more akin to collage, allowing for the
constant addition of new pieces of
information, new actors, new technologies.
In putting this paper together, I used the
background papers, but also drew on a
study with Margaret Lock in which we are
looking at the process by which a genetic
test moves out of the laboratory and into
the clinic. In addition, I made use of the
bric-a-brac of news and information picked
up from the media or the internet, as well
as small pieces of academic gossip, books
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read, conferences and meetings attended
and conversations held. I also drew on my
own background and experience in
different areas of research on women’s
health, although the result is best
described as idiosyncratic rather than selfreflexive. This is a collage rather than a
structured academic paper. It provides
very little by way of answers, but raises a
lot of questions.
Cassandra(s) and the Information Age
The first of these questions is the product
of a sleepless night, the result of talking
with Madeline Boscoe and then going
back to re-read what Abby Lippman had
written. At four o’clock in the morning, I
asked myself: “Can we stop it?” “It” being
roughly everything that sits under the label
‘biotechnology’; “we” being the doubters,
the luddites, those sceptical of the
promises of the new genetics, the critics
and questioners. Reluctantly, my answer
had to be “No”. Less optimistic of the
possibility of revolution than Abby
(particularly at four o’clock in the morning),
I see the momentum as too advanced, the
forces as too strong; the motivators –
particularly fear and money – as too
powerful. Where does this leave us?
Possibly in the role of Cassandra; a set of
truth tellers, crying doom, but condemned
never to be believed.
Yet, while pessimistic, I do not think that
things are altogether dark. There is
evidence, admittedly scattered, that some
people in some places are making some
choices. Companies have ‘chosen’ not to
use genetically modified foods. A number
of European countries chose to oppose
Canada and the US over the importation
of ‘Franken’ foods. Offered the
opportunity, some individuals have
‘chosen’ not to be screened for genetic
diseases. Women are very key to this
process as the implementation of many of
the new technologies depends on their
compliance, whether a willingness to
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buy/not-buy genetically modified foods, or
to be screened/not screened, or to have
their fetus screened/not screened. To
make decisions about the new genetics
within the terms of their own lives, women
need information and they need
information of many different sorts in many
different forms.
In the sense of being put together from
bits and pieces, patched together into a
whole fabric, we need research by
bricolage. As a brief illustration of what this
might mean, I have taken a single topic
and pursued it across different disciplines
and up and down different levels of
analysis from micro to meso to macro and
back again. There was time and space
only to raise questions rather than find
answers, but finding answers is not the
purpose of the exercise. It is rather to
show how the questions change with
every boundary crossed, but also how a
single question may have multiple
answers at many different levels.
Micro: the woman and the prophylactic
oophorectomy
My starting point is a prophylactic
oophorectomy. Attending a meeting of
oncologists, geneticists and genetic
counselors last year, I heard some one
discuss the advisability of a woman, tested
positive for BRCA1, having a prophylactic
oophorectomy. Looking back, I am not
sure why this shocked me as much as it
did, for I was already familiar with the
literature on the increased risk of ovarian
cancer among women testing positive for
BRCA1 and BRCA2. Possibly it was
because discussion was about a real
body, a real person, rather than part of an
academic debate.
Yet, my reaction was partly a product of
my work on menopause and my
knowledge of that clinical literature. The
bilateral oophorectomy, included in that
literature as a surgical form of menopause,

is recognized in this literature as having a
more severe impact on the body and as
producing more severe symptoms than
natural menopause. The orthodox clinical
response is to put a woman on immediate
and long term hormone therapy to control
her symptoms, protect her heart and the
density of her bones. As a quasiepidemiologist, the key question for me
was whether or not the routine prescription
of estrogen therapy would be advisable for
a young woman with a genetic predisposition to breast cancer. Yet even as
the question was framed in my mind, I
knew that not only is no information
immediately available, but that it is unlikely
to be in the future. For given the current
inability to closely monitor the ovaries for
the first signs of cancer, it would be
unethical to set up a controlled trial in
which healthy women with the same
genetic test results and the same surgery
are randomized to take or not take
estrogen. Unfortunately, this is only one of
the many questions within the new
genetics for which there is no absolute
answer.
Still thinking as a quasi-epidemiologist. I
wondered also what was the quality of the
evidence being used to advise a testpositive woman to have a bilateral
oophorectomy? A MEDLINE search
produced a small but very recent collection
of papers including one on the costs of
screening Ashkanazi Jewish women for
BRCA1 and BRCA2. Its authors claimed
an economic benefit, but only if women
who tested positive underwent
prophylactic surgery. Reviewing their
evidence, this conclusion represented an
enormous leap of faith even for a health
economist. More cautiously, the Cancer
Genetics Study Consortium advised that
there was “insufficient evidence to
recommend for or against prophylactic
oophorectomy as a measure for reducing
ovarian cancer risk”, but added that:
“Women with BRCA1 mutations should be
counseled that this is an option open to
them (Burke et al. 1997). The European

Familial Breast Cancer Collaborative
Groups came to a very similar conclusion.
While conceding that the data were
insufficient, they also advised that the
prophylactic oophorectomy was “a
reasonable option in high risk women”. A
third review of essentially the same
literature concluded that prophylactic
oophorectomy resulted in, at most, small
gains in life expectancy (Schrag et
al.1997).
Why would the members of these different
study groups and consortia – largely
geneticists and oncologists – recommend
something for which the epidemiological
evidence was weak by their own
admission. Broadening the initial
MEDLINE search by dropping ‘genetics’
as a key word produced several papers on
the use of prophylactic oophorectomy in
healthy women with healthy, but
postmenopausal, ovaries. Two of the
studies in the search reported on reviews
of the medical records of women with
ovarian cancer to determine if there had
been an earlier, but missed, surgical
‘opportunity’ to save them. (The
opportunity being the body opened, the
uterus removed, the ovaries left in place,
but subsequently becoming cancerous.)
Another paper, a survey of Irish surgeons,
reported that 88% of the participants
would remove the post-menopausal ovary.
A third paper based on a 1996 survey of
gynecological surgeons in Alaska, found
that 98% said that their usual practice was
to remove apparently normal ovaries in
postmenopausal women; 86% said they
would perform a prophylactic
hysterectomy in women with a strong
family history of ovarian cancer regardless
of age; 71% would be influenced by a
family history of breast cancer.
My naïve assumption that prophylactic
oophorectomy had gone out of style was
misplaced; it was clearly normative for the
majority of the surgeons in the two
surveys. Even more interestingly from my
perspective, the design of the two medical
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record reviews implied that failure to
remove was blameworthy. In all of these
studies, the underlying model is that the
ovaries, seen as likely to go bad, are best
removed before they can damage or
destroy the whole body. These few papers
were also a reminder that the “new”
genetics comes into being in the context of
“old” medical practice, which includes
existing beliefs about heredity and danger,
but also this very particular fear of the
cancer-prone ovary. The very new
contribution of the new genetics lies in
being able to test closely related women
and determine which ones are vulnerable
and which not. The problem is, however,
that this information is somewhat in
advance of the technological capacity to
determine when a predisposition turns into
an actual cancer, leaving the prophylactic
oophorectomy as still the primary
response.
Another part of my reaction, however, was
as an anthropologist rather than an
epidemiologist and owed something to
Terri Kapasalis’ (1997) account of the
history of the bilateral oophorectomy.
Once known as “Battey’s operation”,
practiced on slaves in the American South,
it became fashionable in the late
nineteenth century as treatment for
insanity in women. Although losing favor
among psychiatrists, the use of
oophorectomy was revived in the 1930s
and 1940s by gynecological surgeons,
who saw all ovaries as potentially
diseased and took pride in removing them
whenever possible. The temptation was to
write off the incorporation of this surgery
into the genetics discourse as another
example of the medicalisation of the
female body. My problem with this
interpretation was that it both cuts off
further discussion and turns women into
passive victims rather than active figures
in the increasingly complex dance that
decision making has become in heredity
cancer clinics across North America.
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In population terms, ovarian cancer is
relatively rare, but for the geneticist or
oncologist working in the heredity cancer
clinic, or for a woman from a family with a
history of heredity cancer, it is a common
and known risk. They have experiential
knowledge, based on actual women with
ovarian cancer, patients or family
members. Relative to this knowledge,
statistical knowledge questioning the
quality of the epidemiological evidence in
support of a prophylactic oophorectomy
will probably seem a relatively
meaningless component in the decision
making process. Yet, if one moves up a
level, from the micro to the meso, to the
level of provincial governments and
provincial cancer agencies, then this
information takes on a new relevance as
necessary evidence in health policy
decision making. Social scientists, but also
bioethicists although in a more abstract
sense, have tended to focus at the micro
level, the level of the woman and those
who meet with her in the clinical
encounter, namely the geneticist, the
oncologist, the genetic counselor. In the
next section, I want to shift to the meso
level, focusing initially on just one of these
figures, the genetic counselor.
The Clinic, the Government and the
Breast Cancer Gene
Seen through the eyes of a woman waiting
for her test results, a counselor should be
empathic, supportive and able to provide
her with the information she needs in
language she can understand. Most
Canadian women testing positive for
BRCA1 or BRCA2 within Canada will have
seen a genetic counselor, as their need for
counseling is still one of the most takenfor-granted assumptions of the Canadian
programs. Some Canadian women have
traveled to the United States for testing;
their number is unknown and so also is the
quality of their counseling care. Women go
to the United States usually because they
do not meet the strict criteria for testing set

by Canadian centres, or they do not want
to wait. When this paper was written
(February, 2000), the waiting period to see
a genetic counselor in my own province of
Manitoba was approximately one year.
The implications of waiting can be studied
at the micro-level by talking to the women
waiting and their families as was done by
Lodder et al. (1999). Alternatively, the
analysis can be moved to the meso level
and questions formulated at the level of
the clinic, the research agency, the
provincial ministry of health, and a local
cancer foundation or breast cancer
support groups. At this level, many of the
key questions are framed in terms of
traditional health policy issues, such as
training, funding, access, cost
effectiveness and evidence based
decision-making. Other questions,
however, have to do with the politics (but
also the ethics) of health care delivery.
There is, for example, an international
shortage of clinical geneticists and genetic
counselors, a reflection of the gap
between the rapid expansion in genetic
testing and the time needed to train those
capable of doing the diagnostic work-up
and the counseling. Around the time that
testing for BRCA1 was just getting started
in 1995, there were only two medical
geneticists per million population in the UK
and only about a 1000 board-certified
genetic counselors in the United States
(Reilly 1995). Many of these counselors
and geneticists will have trained when the
expectation was that they would work
within a prenatal screening clinic with very
different clients to those seen at a
hereditary cancer clinic, a different set of
diseases, and very different data on risk
and probabilities. How should training
change given a rapidly changing
knowledge base? How should the
numbers in training be increased? Who
should pay for this expansion? Counseling
has increasingly become the responsibility
of obstetricians and family practitioners;
most of whom had very little

undergraduate training in genetics and
systematic postgraduate training in
genetics is even more rare (Harris and
Harris 1999). Should the problem of
access to counseling be met by ‘retrofitting’ other health professionals, not only
the family practitioners, obstetricians and
oncologists, but also nurses and social
workers? Who should pay for further
training for these groups? Is one-on-one
counseling the best or only way? Would
an interactive video serve as a substitute,
or supplement to a live counselor as
Pershkin and Lerman suggest (1999)?
The issues and the questions are also
political. Access to genetic testing and
genetic counseling has rarely been evenly
distributed across geographical or social
space, favoring the white, the urban and
the middle class. As discussed in Ken
Bassett’s paper, so long as the scale has
been small and largely invisible outside
the amniocentesis or genetics clinics,
there has been little concern or protest. Is
this likely to change with the expansion of
genetic testing into high profile diseases
such as breast and ovarian cancer?
Already there are rumors of pressures on
ministers of health to increase the number
of counselors and to expand the number
of clinics testing for hereditary cancers.
The list of questions is long, although by
no means exhaustive. They are left
without answers, as their purpose is to
suggest that the questions about the
genetic counselor to be asked at the
health policy level have a quite different
resonance than if asked within the clinic of
the woman waiting. Yet, the length of her
wait is determined by how these questions
are answered. Possibly part of our
obligation as latter day Cassandra’s is to
keep women informed on how health
policy in this area is made and
implemented.
An equally long, if different set of
questions could be generated about the
test itself and looking towards the future.
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At present, most testing for BRCA1 and
BRCA2 in Canada is done in major
research laboratories. Who will own the
laboratory in which the test is done, pay
for its staff and its equipment, as testing
becomes a routine clinical service? Will it
be the government or the private sector? If
genetic testing becomes part of routine
clinical service, will it have to be shifted to
laboratories licensed by a foreign patent
holder? Will government still retain the
right to regulate all laboratories in the
province, or will the patent holder set
standards? Who will set the price of the
test and who will pay? Does genetic
testing, as some health bureaucrats in
some provincial ministries might argue, fall
outside the scope of the Canada Health
Act? Would making the woman pay fall
inside or outside her entitlements under
that act? Should we urge women that this
is an occasion for political protest and
lobbying the politicians for equitable
access to testing?

evidence of benefit from prophylactic
oophorectomy is too weak to justify the
use of public monies. While some health
activists might question what place genetic
testing for ovarian cancer should occupy
on a priority list of women’s health needs
given that current thinking suggests that
only 5% of ovarian cancers are genetic in
origin?

Genetic testing up until mid-1990s has
been a cottage industry, a small item on
the overall medicare budget line, often part
of block grants to departments of
pediatrics. Suddenly all this is changing
and very rapidly. The ‘old’ system is still in
place for the very rare genetic diseases
and for prenatal testing, but the money
used in genetic testing for BRCA1 or
BRCA2 is more likely to have come out of
a research budget, or a line item in the
budget of a cancer foundation. This
situation clearly cannot last, but how
important is it that women understand their
options?

The sums involved are quite large; for
example, a quick scan of the Breast
Cancer Bulletin (Summer, 2000) published
by the Canadian Breast Cancer Initiative
suggests that well over half the award
made out of a total of $14.4 million was
spent on some form of genetic research.

What are these options? Answers, selfobvious at the micro-level of the woman
being tested, are less clear at the level of
government or advocates for women’s
health? Will the demand for access to
genetic testing and counseling for breast
and ovarian cancer not only increase, but
become a woman’s health issue or at least
an issue for the breast cancer movement?
Yet, health bureaucrats might say that the
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Macro: Global Companies and Global
Politics
Moving from meso to macro, the questions
shift from cost to money and profits. This
level is occupied by a vast array of
speculators, venture capitalists,
multinational pharmaceutical companies,
universities, biotechnology companies,
and different levels of government, all
hoping to grow rich or at least financially
benefit. Even we benefit, doing research,
attending workshop such as this.

Research The connections between
the different institutions are also quite
tight. Myriad Genetics, the company
holding the patent for the BRCA1 and
BRCA2 breast and ovarian cancer
susceptibility genes, recently made a
deal with the National Cancer Institute
in the US to do full BRCA testing at a
cost of $1,200 per person, “less than
half the commercial costs”, but only for
researchers funded by NIH. Myriad’s
own Web site notes that the company
has formed strategic alliances with a
remarkable list of multinational
pharmaceutical companies, including
Bayer, Eli Lilly, Hitachi, Pharmacia,
Novartis, Roche, Schering AG and
Schering-Plough.

Research A small item of news late
last year noted that Myriad was trying
to move forward its patent claims in the
European market. British scientists
were furious over Myriad claims to
exclusive patent rights to what they saw
see as their own, British discovered,
genetic property, the BRCA2 gene.
Myriad countered by questioning the
quality of British testing.
An awareness of the history of our health
care has perhaps made women more
skeptical than men of the bright promises
of science. They also have somewhat
greater awareness than men that their
sicknesses may be profitable to others, but
mainly in the form of physician incomes
being increased by a little extra surgery, a
few more visits. The money to be made in
the new genetics is of a quite different
order and the mechanics of its making
very different to understand.

Conclusion
As the latter-day daughters of Cassandra,
our task may be less one of crying doom,
but rather one of collecting, sorting,
analyzing, critiquing and disseminating
information to women. To do this
effectively will require a degree of
openness to different types of knowledge,
a willingness to collaborate across
disciplinary boundaries, and the capacity
to seek out information from many
different sources. It will also require being
able to say when a question cannot be
answered, because there is no information
or the information is inaccessible. The
consequences of informing women as
health consumers may be as unexpected
and radical as learning to read the bible
proved to be for the making of the English
working class.
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Ethics and Genetics:
The Need for Transparency.
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Fern Brunger and Sue Cox remind researchers to be aware of the social location of their
own criticisms. “Political, economic and cultural contexts not only shape the production
of biotechnology knowledge,” they write; “they also shape how critiques of biotechnology
are produced and applied.” Observing their own advice to be transparent about the
motivations behind research agendas, Brunger and Cox outline two research priorities
which are intended as contributions to a strategy for building broader public debate.
First, they argue that “everyday meanings and experiences” in the encounter between
patients/consumers and biotechnologies must be attended to. Second, they recommend
a way to move beyond the limitations of individual consent or group consent in research
decision-making - through a process of collective negotiation.
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Introduction
The production of genomic/ genetic
knowledge occurs within political,
economic, and cultural contexts, and in
turn reshapes those contexts (Brunger and
Bassett,1998). As the lines between
science, industry, and government (as well
as patients, subjects, and consumers) are
becoming increasingly blurred, it becomes
more and more difficult to devise a
research strategy that will promote public
reflection on the range of effects that
seemingly beneficent technologies may
have on individuals, communities, and
society. How can we best ensure that
typically silenced voices are actively
engaged in debate in ways that promote
accountability and transparency of
science/ industry to the public?
Political, economic and cultural contexts
not only shape the production of
biotechnology knowledge and its
application; they also shape how critiques
of biotechnology are produced and
applied. The beliefs, values, and norms of
academic critics, no less than industry/
science, necessarily advance specific
perspectives, valorizing some voices and
not others. Given that research funding
within the social sciences is increasingly
linked to industry- and/ or communityalliances, we must be absolutely vigilant
about transparency, conflict of interest and
perceptions of conflict of interest. In other
words, deciding on strategies and setting
research agendas is a situated activity and
it is therefore not a value-neutral activity.
There is an ”agenda” just as the word
suggests. Thus it also follows that we
ought to make explicit the values,
economic incentives, and relations of
power which shape and guide our
priorization of particular research areas or
‘agendas’.
If we reject the notion that genetics has
one correct model of risk and reality that
the lay people are deficient in, then we
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must also reject the notion that academics
have a privileged way of understanding
the potential effects of biotechnology on
the lives of individuals and communities.
Lay knowledge and understanding is a
legitimate and specialized means of
making sense of the world; it is in this
sense never incorrect. It may be
inconsistent with other forms of knowledge
but it is never “wrong”. For example,
women asking for increased access to
genetic testing for breast cancer may
promote geneticization in a way that is
counter to prevailing feminist critiques of
biotechnology, but the perspectives and
experiences of such women should inform
our understanding of geneticization, and
not be dismissed as naïve or the effects of
false consciousness. Following from this,
we recognize that as academics whose
research focuses on the ethical and social
effects of new health technologies, we
have a moral obligation to be explicit about
the values and contexts that shape our
research; to engage the public in debate
around our research and its conclusions;
and to ensure that our research agendas
do not inadvertently silence important
voices.
What follows is a description of the
research ‘agendas’ that we have been and
wish to continue advancing. These
agendas involve collaborating with
communities to strategize for change in a
way that privileges the knowledge of
individuals in the everyday context.
1. Engaging with patients/
“consumers”1
1

The following is based on issues raised in a
research project on “Ethical and Moral
Dimensions of Genetic Risk: Huntington
Disease and Breast/Ovarian Cancer
Experiences" (Burgess, Cox, and D’agincourtCanning); and in a project on "The Social
Construction and Clinical Management of the
Hereditary Aspects of Autosomal Dominant
Polycystic Kidney Disease (Starzomski, Cox

It is crucial for feminists and activists
critiquing the biotech industry to continue
to focus on the political, economic and
social contexts shaping the production,
application and distribution of genomic/
genetic knowledge. However, it is equally
important to not lose sight of how the
understanding and use of genomic/
genetic knowledge both shapes and is
(re)shaped by individual fear and suffering
within families and communities (Cox and
McKellin 1999; Cox 1999). This entails
learning how genetic information is
understood, used, resisted, and reshaped
by patients/ consumers and moreover,
how this in turn shapes and transforms our
understandings of the process of
geneticization. Research must therefore
include examinations of the moral issues
and experiences most salient to
individuals and families who are the
potential or actual patients/ consumers of
genetic services. This includes learning
how the everyday meanings and
experiences of those at risk shape their
decisions to be or not be tested; and how
their experiences and decisions work to
promote or reshape geneticization.
An emphasis on everyday meanings and
experiences around the use or non-use of
genetic services by potential or actual
consumers continues to provide an
important counter to clinically-based
studies which typically employ a battery of
psychosocial questionnaires; it also offsets
bioethics' traditional concern with assisting
clinicians in determining their ethical
responsibilities vis a vis other patients.
Research to date has almost exclusively
studied the social and familial effects of
genetic testing as a clinical medical event,
emphasising ethical issues that raise
problems for the delivery of services to
individual participants in genetic testing.
We direct attention toward the non-clinical
understandings of, and effects of, genetic
testing in relation to everyday ideas about
and Cameron).

heredity and familial or ethnic identity in
the community setting.

2. Engaging with communities/
“subjects” 2
Genomic/ genetic research poses complex
issues of consent, banking, sharing of
data, recruitment, negotiating with specific
communities, and intellectual property
arrangements. Some of the ethical
concerns biotechnology raises for
communities, such as biopiracy in relation
to community DNA banking, insurance
discrimination related to ethnicity-based
genetic testing, and concerns about the
use of linked data bases to identify social
risk factors such as sexual preference or
workplace environment, fall outside of the
scope of the traditional ethics review
process. These broader concerns involve
risks to non-participants in the research.
The effects of genomic/ genetic research
on groups, that is, on those who do not
participate in research but are affected by
it, requires an assessment of whether
harms to non-participants are justified.
Traditionally in research ethics, individual
consent suffices. Informed consent is the
cornerstone of contemporary research
ethics with its historical roots in Western
scientific medicine and liberal theory
(Beauchamp and Faden 1986). In this
tradition, the collective good that is likely to
follow medical research cannot alone
justify the risks to individual participants.
Rather, individual participants must
knowingly accept the risks to them of
participation in specific research projects.
Informed consent does not work for
authorizing the effects of research on
groups. Some have suggested expanding
the notion of consent to include group
2

The following is based on issues raised in a
research project on “Culture, ethnicity, and
genetic testing” (Brunger, Burgess) and in
Burgess and Brunger, in press.
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“consent” (e.g. Weijer et al 1999). That
approach, however, raises complex issues
around representation and relations of
power: Who represents the group?
Paternalism – which is explicitly rejected
and avoided through the mechanism of
individual consent – is inevitable when
authorizing the effects of research on
groups, since someone has to speak for
the group.
Understanding the effects of research on a
group, and decisions about whether
research is acceptable to a group, must be
based on a carefully negotiated
understanding of diverse values and
beliefs within the group; and this
information must be understood in the
context of relations of power within and
between groups (Burgess and Brunger in
press). This negotiation, to be genuine,
must be conducted in ways that do not
overextend the authority of researchers,
group leaders, or ethics review boards.
Where possible, community-based
research should be conducted with, rather
than "on", community members, to enable
community members to help direct
research objectives and goals, to shape
research design and implementation, and
to participate in the dissemination of
research findings.
Summary
Our research strategy for identifying and
managing ethical issues raised by
biotechnology is to begin by learning how
individuals as “subjects” and “consumers”
are being shaped by, and also shaping,
geneticization. This entails emphasizing
the values and beliefs which shape the
production of genomic/ genetic knowledge
(e.g., the relationships between science,
industry, and government); and how this
“culture” of science affects, and is affected
by, the experiences of families and
communities. This background
understanding of the everyday meanings
around biotechnology within the context of
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family and community life is, for us, an
important step to knowing what kind of
research agenda to set.
Our goal is to not arrive at answers to
questions about the effects that the
biotech industry may have on families or
communities. It is, rather to come up with
a strategy for widening the space of public
debate in a way that:
(1) provides the public with information
about the production, distribution and
application of genetic knowledge;
(2) legitimizes lay knowledge;
(3) attends to a multiplicity of voices;
(4) welcomes dissent as a sign that all
voices are being attended to;
(5) allows the debate to be transparent
and public; and
(6) promotes the accountability of
government/ industry/ science to the
public.
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About the Article
"Genetics," "gender" and "choice" have all become mantra words, and in her work, Abby
Lippman raises concerns about how these terms are used, if not manipulated, with
respect to women's health. Thus, "genes," she writes, "may have something to do with
disease, but they certainly have little to do with women's HEALTH." And in her piece,
Lippman examines the consequences of applying the qualifier "genetic" to health and to
health care. She raises similar questions about the effects of identifying certain health
matters as being about gender, as distinct from sex, pointing out how the increasing
marketing of, and markets for, genetics and women's health, constantly twist the
meaning of these words as well as co-opt the concept of "choice."
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Introduction
The Canadian Biotechnology Strategy is
an expression of what I have called the
process/ideology of geneticization
(Lippman 1991).1 The CBS, in the name of
health and health care, and with the goal
of national economic growth, is geared to
support the “translation” of basic genetic
research into such "choices" as genetic
testing, genetically engineered drug
design (e.g., "pharming" and "designer"
drugs), genetically engineered animal
organs for human transplantation, and
gene "therapy." In fact, the CBS is
rationalized, in large part, on the promise
of increasing women's choices with
respect to health and health care. In what
follows, I will focus on the issues of
"choice" and geneticization, making some
general remarks about each and
proposing how some of the dangers to
women's health embedded in them might
be approached.2
Marketing (multiple) choice(s).
With health and economic policies
merging in the politics of neoliberalism,
and with health (care) seen as a source of
economic development, increasing the
choices women have is becoming a major
way to stimulate the economy. As a
consequence, feminist objectives for
1

. Geneticization refers to the increasing
tendencies to make distinctions between
people on the basis of what one believes are
genetic differences, to view most disorders,
behaviors and physiological variations as
determined (wholly or in part) by genes, and as
I have defined and use the term, comprises
ways both of thinking and of doing, applying
genetic technologies to diagnose, treat and
categorize conditions previously identified in
other ways.
2
More detailed examinations of choice and of
geneticization can be found in a recently
published paper, from which sections of this
text have borrowed heavily: Lippman A. 1999.

health, and the principle of choice that
women introduced into the health care
arena as essential for our well-being, are
being appropriated by politicians and
industry and turned into an array of
biomedical options for us to use or
undergo. Industry is encouraged (even
subsidized with public funds) to develop,
market and sell us choices in the form of
new drugs, new technologies and new
programs which, among other things, can
not only identify our health risks, but also
provide ways to manage them. And, with
risk increasingly the lens through which
choice is filtered – "you are at risk for...;
you can choose to do/undergo/... to
manage it" – a dangerous synergy
between a "tyranny of risk” (Lupton 1995)
and what has become a "tyranny of
choice" is catalyzed.
Clearly, this market-driven approach to
health (care) co-opts and manipulates
concepts of choice to rationalize industrydriven health goals. It also enables the
accelerating transfer of health financing
and services (in Canada and elsewhere)
from the public to the private sector in the
search for cost-containment
(governments) and profit (industry).
More and more, women's demands for
choice in how our health is promoted/
protected, and in how (and what) care is
available when we need it, are being
answered in the form of various (multiple
choice) biotech-based menus. These list
options from which individuals are
supposed to make selections for personal
curative medical care and preventive risk
management (with the selections often
unattractive – and almost certainly not
equally accessible to all women).
For instance, in response to demands for
healthy pregnancies and healthy babies,
women are offered a gamut of prenatal
tests. In response to demands for safer,
cleaner environments from which
carcinogenic materials are removed to
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protect our health, we are offered costly
procedures that will screen us for DNA
patterns thought to be associated with an
increased risk of developing breast
cancer, as well as with "prophylactic"
mastectomies, or expensive drugs (of
unproven safety) alleged to prevent breast
cancer (Batt 1994). The huge growth of
the commercial, for-profit health
information industry (Minkler 1989), which
produces books, magazines, websites and
packaged exercise programs to educate
us, as well as the boom in computer/
informatics technologies to identify
"manageable" risks and monitor our health
and health care (for example, algorithms
to assess a woman's risk of breast
cancer), result in still further options for us.
But the choices thereby manufactured do
not promote our health, ensure social
justice, and support a holistic view of
women's health. Rather, these “choices”
are evidence of the marketability of
women's health issues and concerns,
produced primarily for political/ economic
reasons and private profit.
This commercial – and downstream –
response to women's demands (for
choices), articulated both implicitly and
explicitly in the CBS, fails to address the
kind of choice in health care women have
fought for, and certainly does not meet our
demands for the powers we need to
choose and to protect our health. With
industry increasingly portraying itself as
responding to women’s needs when it
offers multiple choices for our selfimprovement, health promotion becomes
more of a product (i.e., objects, programs,
devices, etc. we can buy) than a goal
(Milio 1988). Even more, rather than
supporting structural changes that will lead
to improved health, the language of health
promotion is employed to justify the further
development of more technological and
pharmaceutical options, more sources of
information on health and so-called lifestyle, and more wellness programs for us
to purchase.
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This market approach reinforces
libertarian self-reliance without promoting
true self-determination and choice. Worse,
it serves to privatize want: what seems to
be a personal choice (e.g., to have
prenatal testing; to take tamoxifen) may
really be merely a substitute for societal
failures to provide what women truly need.
These include the resources (financial,
social, supportive) that would allow a
woman to mother a child with Down
syndrome; the guarantees that the water
we drink is not polluted with harmful
chemicals or bacteria. Downstream
choices (menus) of biologically-tailored
drugs are insufficient; the upstream
availability of safe jobs, clean
environments, safe contraceptives and
women-friendly work schedules are
needed for avoiding known risks to health
and preventing the disorders the drugs are
created to treat.
The manufacture and manipulation of
“choice” as a tool to commercialize and
further privatize health (care) presents
special risks for women insofar as options
are construed as gender related. Thus, the
commercial value in the (belated)
recognition by researchers and industry
that "women are not small men" is vast. It
is, perhaps, but a further stage in the
"corporatization of medicine" that Starr
(1982) described almost 20 years ago,
wherein health problems are seen as good
for business and economic growth. Today,
specific attention to women and their
medical risks and alleged needs for
medication creates a niche market with
lucrative potential; new commercial
projects to develop female-specific product
lines in health businesses turn chronic
conditions into investment opportunities
(Fuller 1998), with women's health
problems (e.g., osteoporosis, menopause,
depression, fertility/ infertility in particular)
among those likely to have the best return
on their investments (into research and
production of new drugs, new diagnostic
technologies, DNA markers of
susceptibility, new food products).

This commercial application of “gender
awareness” to justify female-specific
health product development for the
marketplace is a dangerously reductive
view of women's health needs. It helps to
hide, if not perpetuate, the many
differences between women and the
origins of health problems in inequitable
social/ political/ economic arrangements,
with this most recently exemplified, in
Canada, with the newly begun marketing
of women-specific cancer insurance
policies.
In co-opting women's demands for
empowerment, for choice, and for genderbased care, research and policy,
governments (as in the CBS) and the
private sector are playing on our
reasonable fears of paternalism,
overmedicalization and exclusion.
Furthermore, the current dominance of
economic conceptions of health and health
care displace/ manipulate feminists'
perceptions of these as having primarily
social, political, and economic
determinants. This makes it imperative to
be wary whenever "choice" is offered to us
as a solution to women's health concerns.
To re-establish choice in women’s terms,
to put choice in women's hands, means
not to focus on how to give women
responsibility for their health, through the
creation of multiple options, as the CBS
would have it, but on how to ensure all
women can be "response-able."3
To see how this might be operationalized,
how women could become able to make
the responses and choices they want for
themselves, consider, for an example,
prenatal screening and testing. Why not
require that for every government dollar
spent for these programs, $10, $100,

$1000 or more must be spent for the
children and their families living with the
condition for which testing is offered? This
might help make refusing prenatal testing
as much a choice as accepting it appears
to be. As well, it might give community
groups and disability activists the
resources they need to develop material
about the conditions for which genetic
testing is offered, to counter the stories
coming from the biomedical world, thereby
helping to ensure that women's choices
can be truly informed.
Further, why not insist that companies
developing screening tests (or expensive
medicines) for something that ails us apply
some of the profits from their sales of
these products towards addressing the
social determinants of women's ill health.
A formal "tithing" system, with money
deposited into a blind trust to be used to
care for those for whose disease one
seeks a DNA association, might be
another approach. And to give such
policies "clout," companies that contribute
could perhaps be offered some tax
advantage, with those refusing heavily
penalized.
As another policy, why not insist that
"charitable" status be granted to groups
and organizations that advocate for
change rather than allow this privilege only
for those that "pick up the pieces" of
harmful government policies. And in place
of "stakeholders" setting the policy agenda
for women's health and genetic and other
biotechnologies, why not insist on more
participatory democratic approaches (e.g.,
citizen juries, consensus conferences) and
engage in more discursive processes
(Davidson et al 1997) to debate and
decide on the choices we want for
ourselves and our communities.

3

. Insofar as “response-able” refers to what a
person is enabled to do, it embodies feminist
principles and avoids the potential for victimblaming contained within the sound-alike term,
“responsible.”

Geneticization.
Geneticization is as much implicit as it is
explicit in the CBS, and it is at odds with
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the concepts of health and health
promotion as understood by the women's
health movements and other social justice
seeking groups. Regrettably, however,
most of the critiques of the "new" genetics
have concentrated on the potentially
harmful consequences of using the
information that genetic (mapping, testing,
screening) projects will provide, and on
how the undesirable effects can be (must
be) controlled. In general, the "problems"
investigated are sequestered for analysis
in "ELSI"4 projects that deal with a variety
of ethical, legal and social issues related
to human genetics. The existence of these
projects suggests that by understanding
these problems, by maintaining specific
rules and regulations, and by adhering to
standard ethical principles, we can avoid
the undesired consequences. But this
downstream, managerial approach is
grossly insufficient, and perhaps even
irrelevant.
To begin, the majority of these critiques
tend, themselves, to be based on
reductionist thinking. They also legitimize
the very assumptions of essentialism and
determinism that they would otherwise
fault. Putting aside the need to distinguish,
when appropriate, between essentialism,
reductionism and determinism, it
nevertheless remains insufficient to restrict
analysis of geneticization to psychological,
legal and ethical consequences and their
management, and to base regulatory
proposals on misconceptions of what
genes do (see, for comparison, Caulfield
2000). Though necessary, these critiques
are not sufficient; they are certainly not
primary. They appear to take further
development and use of genetic
technology, and of geneticization, as faits
accomplis, and to perpetuate artificial
distinctions between means and ends,
between effects and side-effects, between
use and mis-use. They ignore how
geneticization is a new way of thinking
4

. ELSI is the acronym for Ethical, Legal and
Social Issues.
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even more than a new way of doing. Thus,
even when the hyperbolic claims made for
genetics are shown to be unsubstantiated,
the tendency to see "genes as the answer"
persists.
Prevalent "ELSI-type" assessments of
developments in applied genetics continue
to privilege liberal individualism, and the
latter, as Susan Wolf (1996) underlines,
mostly preserves those with power in
society. These assessments also gloss
over the importance of group membership,
isolating processes, techniques, and
services from societal trends (e.g.,
privatization, commercialization,
globalization, etc.) in which they are
embedded. Clearly, more fundamental
analyses of geneticization – social
evaluations in particular – are required to
clarify if "responsible genetics" is an
oxymoron, or if it can actually be practiced
(Vandelac, Lippman 1991). And new,
imaginative ways to assess geneticization,
fresh metaphors for speaking and writing
about things genetic, are urgently needed
if we are to begin these.
There are no detailed recipes for how we
might do these analyses or reframe our
thinking, but there are some practical
things we might consider. To start, if
health (and not the elimination of disease
and disability) is our societal goal,
collective approaches might be better than
individualized ones. If we want "genetic
responsibility," might it not be more
efficient to reverse the usual order of
subject and object and make society,
rather than the individual, accountable for
protecting our genetic "heritage." This kind
of approach would lead to such things as
supporting serious efforts to remove
known mutagens from the workplace,
renovating substandard housing to remove
lead-based paint, and demanding limits on
agribusiness, rather than to screening for
and then removing or vaccinating
"susceptible" workers or children.
Screening for situations "of risk" seems far
more sensible – and far more equitable as

corrective justice – than screening for
persons "at risk."
Risk situations, even more than genetic
risks, are not equally distributed.
Moreover, the likely synergy between
physical and chemical risks, and the
unequal distribution of the determinants of
health, may necessarily increase the
exposure of some groups of women (e.g.,
underemployment ! work in a bar !
exposure to second-hand smoke; poverty
! decreased resources for organic food
! increased pesticide exposure; racism !
ghetto-ized housing ! increased
exposure to toxic dump sites).
Geneticization, and the CBS of which it is
an expression, are pushed not only by
people claiming to do good, but also by
those with corporate interests and eugenic
idea(l)s. Geneticization is advanced by
people who seek financial gain by doing –
or underwriting – genetics: governments
and corporations, and also the media
which use "human interest" stories,
supposedly involving genetics, to sell their
papers and programs. Justifying mapping
the genome as the way to improve health,
and to provide medical cures, is doubtless
productive for molecular geneticists,
pharmaceutical companies, manufacturers
of laboratory equipment, insurance
companies, police forces, genetic
engineers and health ministers, among
others. But seeing things this way closes
the debate, suggesting we need only
regulate the "costs" (albeit broadly defined
in ethical, legal and social terms) of
genetics to obtain all the benefits. It is to
overlook how costs and benefits are not
distributed to the same groups, and how
risk management, as "exposure," is clearly
gendered. Moreover, more than costs and
benefits (economic and otherwise) are
involved in assessing the genetic
approach. It may be ethical – "costbeneficial" in some currency – but still
dangerous to women's health. The genetic
perspective itself, and not just its
consequences, is problematic.

Therefore, we need to change critical
strategies and go to the source, to
question the very ways geneticization
frames our thinking about such things as
similarities, differences, health, illness,
social justice and what it takes to have a
good life. We need not only to understand
– and underscore – the biological limits of
what a gene is and can do but, even more,
to devise ways to approach genetics/
geneticization that may help us reclaim our
rights as citizens for health and health
promotion.
One way to begin might be to delete the
word "health," a holistic term, when we
really mean the absence of disease, and
to reject the notion that there is something
usefully called "genetic health." Not only
are we unlikely ever to reach consensus
about its meaning, but trying to do so may
be a distraction. Genes may have
something to do with disease, but they
certainly have little if anything of relevance
to women's health. In a similar vein, we
could insist on a research agenda in which
it is assumed that biological conditions
have social explanations and actively
search for and invest in these. After all,
one can as reasonably link housing
conditions and osteoporosis, racism and
cardiovascular disease, ageism and hip
fracture, pet ownership and hypertension,
as one can link DNA patterns to these
conditions. Let's make these findings
media friendly so that they become the
banner headlines of newspapers.
Next, let's make it a practice to ask,
whenever we see the word "genetic" used
as an adjective, "why?" What is gained
and what is lost, and by whom, by this
qualification of some test, disease,
diagnosis. Similarly, let's ask, whenever
we see "autonomy" advanced as the basis
for ethical analysis, whether individual
choice or a richer concept is meant.
Adopting Sherwin’s (1998) relational
notion of autonomy would at the least
remind us that the notion of genetic
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"response-ability," what a person is
enabled to do, is at least as important as
the notion of genetic "responsibility," that
which those with power must assume.
For some final suggestions, let me invoke
the concept of justice. If we assume that
justice is simultaneously intragenerational
and intergenerational, and not think of it
merely as the principle for providing equal
access to some service, we might begin to
view health as a general (social) benefit,
not as a commodity to be bought and sold
in the marketplace. Thus viewed, our
health policies would, contrary to the CBS,
focus on such things as incomeredistribution, employment programs,
neighborhood revitalization, trade
agreements and global corporations.
Similarly, we might see social
determinants of health (poverty, racism,
illiteracy, etc.) NOT as barriers for an
individual to overcome but, instead, as
objectives for social/ societal change.
Going further, we might recognize a need
to redistribute health equitably, with the
consequence that some of us, the more
privileged today, may have to give up
some of our alleged benefits (use of hightech genetics, for example) to ensure that
others share equally in the resources
needed for health, even perhaps requiring
programs of affirmative action as
necessary to correct past injustices locally
and globally.
In this regard, "responsible genetics"
("responsible biotechnology") might at the
outset be defined as a policy which
acknowledges that we can't afford, either
economically or socially, the most recent
high-tech approach to disease(s). It would
favor a long-term sustainable approach
that gives priority to problems in proportion
to their importance in causing (or resulting
from) ill health and disability (see, for
comparison, the African American
manifesto about limiting genomic sampling
until there is improvement in the health
and education services to the community:
Jackson 1997). Following this policy (and
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again adopting from Sue Sherwin 1992),
only technologies which do not, in their
application, feed into oppressive
circumstances (for groups without power)
would be considered for research and
development, with only those that foster
the interests of un(der)privileged groups in
society admissible in practice. Thus, a
prerequisite for setting up any prenatal
diagnosis program would be the
guaranteed provision of adequate,
sensitive and baseline prenatal care for all.
No "new" technologies/ programs/
services would be introduced for some
women until a basic level of care was
assured for all women. Similarly, a new
technology or a new application of an old
technology (e.g., prenatal diagnosis) might
be considered for provisional use, but only
if it was demonstrably a resource to
respond to a situation for which no other
solution was thinkable, for which no other
way to resolve the particular problem
could be imagined (e.g., prenatal
diagnosis for Tay Sachs disease if painful
death is unavoidable for a child with this
condition). And, while I once proposed
doing health impact assessments before
the introduction of – even before
supporting the research for – a genetic or
reproductive technology, I would now
suggest what Labonte (1999) calls a
"health inequity impact assessment": will
use of this technology, will geneticization,
however defined, decrease health
inequities, especially those inequities
between and among women (rich and
poor, in the North and the South). Instead
of ELSI analyses, we need “ELSocJusI”
studies; beyond ethical, legal and social
issues, we must also consider social
justice issues.
Geneticization might possibly contribute to
the solution of some "problems" of
disease, it might even contribute to the
decrease of inequities downstream (a
possible example being the development
of medications for infectious diseases
based on knowledge of the DNA of the
organism), but we can't assess this yet –

and seem far from it. But, do we want to
intervene only downstream? Because I
don't believe doing so will either conform
to feminist principles of social justice or
address the many and varying women's
health needs and problems, I suggest that
we look upstream and first unpack the
problems whose solution is framed
through the lenses of biotechnology and

geneticization. Does either the definition of
a “problem” or the response to it in
technological terms lead to a better
solution for everyone than we might devise
if we asked why there was a problem in
the first place? Whenever genes (or
biotechnology) are said to be "the
answer," we must immediately ask: what is
the question? And who is talking.
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About the Article
Fiona Miller argues that genetic information has been, and will continue to be, the chief
product of the biotechnological “revolution” in medicine. While the quantity of this
information is certainly growing, there is, she argues, little that is fundamentally “new”
about such an approach. Given the non-revolutionary nature of much of the “new
genetics,” Miller suggests that insight can be gleaned from an examination of its history
and she offers a review of genetic counselling practices, practitioners and disease
scope. Miller’s review suggests that new technologies are unlikely to be the sole
determinants of the use of genetic information, and of changes in the health care system
which result from their use. Equally influential will be negotiations over the medical
control of genetic counselling practices, and the malleable and potentially expansive
ways of defining genetic disease. She adds that since women’s lives and feminist politics
have played such a complex role in the histories of genetic medicine and genetic
counselling, a gender-neutral analysis is unlikely to prove fruitful in the future.

41

Introduction
“Health” constitutes one of the principal
industrial opportunities under the
Canadian Biotechnology Strategy (CBS).
While a range of products are being sold
under this heading – vaccines, biologics,
biopharmaceuticals – a key product
continues to be genetic tests, tests which
provide information which is predictive, to
a greater or lesser extent, of specified
disease outcomes. Indeed, such tests are
expected to proliferate. Reading through
current medical and biomedical journals,
one is struck by the assumption that the
Human Genome Project heralds an era of
widespread molecular genetic tests,
predicting both Mendelian diseases, and
those diseases in which genetic factors
may play some ‘pre-disposing’ role (e.g.
SACGT 1999). Insofar as genetic
biotechnology promises a revolution in
medicine, it promises a revolution in the
availability of genetic information.
Therapeutic capacity, when discussed, is
generally acknowledged to lag far behind
diagnostic capacity (the ‘therapeutic gap’).
For the foreseeable future, and for most
people, genetic medicine is principally
about genetic information.
As an historian, what is especially striking
to me about expectations for the future of
genetic medicine is how non-futuristic they
seem. In this paper, I suggest that the
recent history of efforts to gather, interpret
and deal with genetic information
concerning health, disease and disability –
a process we can abbreviate by the
phrase “genetic counselling” – can tell us
quite a bit about current and future
practices. At the least, it can shed light on
what the real “drivers” of change are. For
while proponents of biotechnology in
health care would have us believe that a
revolution is upon us, and that this
revolution is a direct product of new
scientific and technical capacity, I would
argue that there is both more and less to
the story.
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In this paper, I tell four over-lapping
historical stories about genetic
counselling. The first history sets out the
basic chronology since the Second World
War, the second story adds questions
about health and medicine to this
narrative, the third interrogates the
‘genetic’ status of these practices, and the
fourth story asks questions about women.
Story One: Genetic Counselling
Today, genetic counselling is an
acknowledged practice – a key
complement to and justification for genetic
testing (Task Force 1997). The current
state of professional genetic counselling
has been developing since the 1940s,
when heredity counselling began to take
institutional shape in the Euro-American
world, and clinics were established in
Universities and research hospitals in
Canada, the US and the UK.
To a considerable extent, the timing of
early developments was a function of
shifts within the eugenics movement. As
Molly Ladd Taylor has argued, genetic
counselling promised a voluntary and
individualistic eugenics that dispensed
with the older strategy of enjoining
members of the middle classes to observe
their duty toward the race – a strategy
which had clearly failed by the late 1930s.
Instead, heredity counselling worked to
foster middle class desire. Its chief
advocates promoted a narrative of large,
happy families of “normal” children which
saw little place for divorce, disability or
childlessness (Ladd Taylor 1999). Into the
1960s, with the word ‘eugenics’ not yet a
universal term of opprobrium, genetic
counselling was frequently discussed as a
practical form of eugenics (Paul 1998).
Through the 1950s and 1960s the number
and scope of genetic counselling services
increased in tandem with the science and

profession of human genetics, which
assumed an institutional identity in North
America with the founding of the American
Society of Human Genetics (ASHG) in
1948. Indeed, genetic counselling should
be seen as a defining characteristic of the
emerging discipline of medical genetics
(then, a sub-field of human genetics), and
central to professional identity.
The 1970s brought increased visibility to
genetic counselling through the expanded
scope made possible by prenatal
diagnosis using amniocentesis, and the
expanded visibility of genetic science in a
decade of highly public efforts at in vitro
fertilisation, recombinant DNA (cloning
DNA), and genetic screening among
specified sub-populations (i.e. Ashkenazi
Jews for Tay-Sachs disease, AfricanAmericans for Sickle Cell Anemia). As a
consequence, this decade witnessed
professional innovation and consolidation
in genetic counselling practices and
practitioners. The post-W.W.II generation
of medical geneticists who had pioneered
genetic counselling, and repeatedly
debated its form and function, set out to
clarify the definition of the practice. This
new definition, published in 1975,
highlighted the centrality of
communication, non-directiveness,
voluntarism, and the provision of support
for decision-making (ASHG 1975).
In many ways, the new definition simply
codified existing protocols. But it differed in
one important respect from tradition.
Where genetic counselling had originally
been embedded within the research
routine of a professional medical
geneticist, the new definition conceived of
genetic counselling as a self-contained
practice. This shift reflected the fact that,
in its success, genetic counselling was
expanding beyond the purview of that
small band of researchers who had been
its pioneers. In fact, the 1970s witnessed
the emergence of a new practitioner
category which would devote itself
exclusively to the now self-contained

practice of genetic counselling. Originally
called the ‘genetic associate’ and soon to
be called the ‘genetic counsellor,’ this new
semi-profession involved a Master’s level
education which mixed scientific
knowledge with more formal training in
counselling practices (Kenen 1984;1997).
In the 1980s, molecular genetic tests
began to be added to the complement of
genetic tests already available for genetic
counselling. In addition to the predictive or
diagnostic information that could be
gleaned from family histories and
biochemical and cytogenetic
(chromosomal) tests, some few rare
diseases could be assessed using
recombinant DNA technology. It is these
molecular genetic tests that are expected
to expand so greatly in number, scope and
significance in the coming years as a
direct consequence of the Human
Genome Project and allied research.
According to the US Secretary’s Advisory
Committee on Genetic Testing, which
conducted “A Public Consultation on
Oversight of Genetic Tests,” in the
Summer of 2000, genetic testing is
clinically available for more than 300
diseases or conditions in the US, and tests
are under development for at least 300
more diseases or conditions (1999:5).
Story Two: What’s So Medical About
Genetic Counselling?
Contemporary discussions of genetic
counselling presume the obvious clinical
significance of this practice, and the
relevance of medical involvement in, and
management of, its conduct. Yet the
medical status of genetic counselling is a
relatively recent and contested
phenomenon. This peculiar fact about the
history of genetic counselling is very
important to the interpretation of its current
and future incarnations.
The pioneering band of post-W.W.II
medical geneticists who institutionalised
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genetic counselling in North America were
researchers first and foremost. Many were
trained as PhDs, but those who were MDs
were (as was not uncommon) working as
scientists. Genetic counselling should not
properly be called a ‘clinical’ practice,
then. It was an applied form of human
genetics, or eugenics. It piggybacked on
clinical institutions such as hospitals, and
benefited from collaboration with clinicians
with the competence to diagnose disease,
but was often funded as research, and
took much of its justification from its
articulation with research projects.
In addition, genetic counselling, as a
central component of medical genetics,
was distanced from the main traditions in
medicine in other ways in the inter-war
and early post-W.W.II decades. First,
genetic counselling proposed a rather
different modality of care than that
traditionally advanced by medicine. Rather
than treatment, genetic counselling offered
reproductive management in light of
information about the risk of disease in
offspring. Second, genetic counselling
proposed rather different protocols of
provider-client interaction than medicine:
emphasising knowledge transmission and
client decision-making, rather than
physician decision-making and paternalist
models of information management.
Finally, in addition to advancing work on
Mendelian diseases – diseases that
observed simple genetic laws – medical
genetics emphasised chronic and
congenital conditions with complex
systems of causation. In these early years,
medical genetics pressed notions of ‘predisposition’ even to infectious diseases –
as part of a marginal tradition within
academic medicine which resisted the
dominance of the ‘infectious disease
paradigm’ with its ‘magic bullet,’ antibioticdriven approach. At one of its early annual
meetings in 1952, for example, the
American Society of Human Genetics
sponsored a special symposium on the
genetic aspects of resistance to chronic
infectious diseases such as pulmonary
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tuberculosis, poliomyelitis and rheumatic
fever.
The growing acceptance of genetic testing
and counselling as aspects of ‘health’ care
since the 1970s can, in part, be attributed
to the developing congruence between
genetic counselling and new patterns in
medicine: the rise of a patients’ rights
agenda; the emphasis on prevention,
especially through lifestyle management;
and, growing interest in chronic and
congenital disease. But while the success
of genetic counselling reflects these
elements of conceptual convergence
between medical genetics and medicine, it
has also been hampered at an
organisational level by the outsider-status
of genetic counselling within the halls of
professional medicine.
In the first instance, professional medical
geneticists have faced significant
problems in securing funding for, and
retaining authority over, genetic
counselling. In particular, since many
medical geneticists were PhDs rather than
physicians, much manoeuvring was
required to avoid the strictures of medical
specialisation. In Canada, in the 1970s,
medical geneticists pursued block-funding
of genetic counselling through regionalised
centres, rather than a fee-for service
system, and they established a national
college in 1975 (Canadian College of
Medical Geneticists) to provide some
system of professional accreditation and
allow PhD-trained medical geneticists to
provide genetic services.
In the US, medical genetics began the
formal process of becoming an
acknowledged medical specialty in the
early 1990s, with the formation of a
College and Board. By the latter-half of the
1990s, this new specialty was able to
participate in the funding and practice
negotiations of the medical profession.
This is an extraordinary medical specialty
– one that permits PhD-trained workers to
practice clinically. Moreover, genetic

counselling continues to be definitional to
the identity of the medical geneticist.
Treatment protocols pertaining to genetic
disease, or which derive from genetic
information, are not managed by medical
geneticists but are dispersed among a
wide array of medical specialties. The
medical genetics specialty continues to be
defined by the ability to diagnose and
counsel: to procure and manage genetic
information in the clinical encounter.
Despite this formal success, the
integration of medical genetics within
medicine continues to be fraught. PhD
medical geneticists are a declining
proportion of medical genetics
practitioners, as the pioneering pattern of
blending research with applied practice
passes into memory. Moreover, those
medical geneticists who work principally
as genetic counsellors (rather than running
laboratories, for example) are devalued
within the medical profession. Charles
Bosk (1992), in his ethnographic study of
medically-trained genetic counsellors in a
major eastern US city, argued that the
devaluation of these practitioners is
attributable to their engagement in “social
dirty work” (63). In recent decades, then,
while the enthusiasm for genetic medicine
has increased, the status of genetic
counselling has come increasingly into
question. A reduced status is exemplified
by the rise of the Master’s level trained
practitioner, the genetic counsellor.
Moreover, there is much interest in
routinizing the genetic counselling
encounter, and shifting the obligation to
primary practitioners, with only complex or
highly risky cases referred to specialist
practitioners. Specialist genetic
counsellors, whether trained at the
doctoral or master’s level, are often
supportive of such an approach which
promises to raise their status. Yet this
tiering of genetic counselling, and the
successful integration of genetics into
medicine upon which it is premised,
implies a loss of control by professional

medical geneticists over the protocols
which govern genetic counselling.
The recent medicalization of medical
genetics – most obvious in calls for
standardized medical curricula for genetics
– promises to alter both the practices and
practitioners of genetic counselling. It is
likely that increased medicalization will be
an important force for enhanced and more
routinized use of genetic information in the
clinical encounter. Moreover,
medicalization encourages fee-for-service
systems of compensation, which are
themselves drivers of increased use.
Story Three: What’s so “Genetic”
About Genetic Counselling?
Much of the current interest in the
expansion and routinization of genetic
counselling rests on the belief that, as
some enthusiasts put it, “genetic testing
will soon become a commonly used tool in
primary care practice.” For this to happen,
advocates suggest, genetic testing will
have to expand beyond its current focus
on diagnosing a range of comparatively
rare disorders, to test for “genetic
predispositions” to various common
diseases (Cho et al 1997:314). Testing for
such “predispositions” could, at best,
provide individuals with complex statistical
risk estimates, and would seem to create
new dilemmas, as well as new
opportunities, for genetic counselling.
Many critics have identified problems with
the predisposition approach. Problems
stem from the uncertain predictive power
of such tests, and thus their potential
relevance to significant proportions of the
population (Hubbard and Lewontin 1996).
Moreover, the genetic predisposition
approach gives primacy to genetic forces
in systems of multiple causation. Such an
approach has been christened
“geneticization” by Abby Lippman (1991)
and sustains what Dorothy Nelkin and
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Susan Lindee (1995) call the “DNA
mystique.”
Though divided on the question of merits,
both proponents and critics of expanded
genetic testing are united in their
conviction that the predisposition
approach, and the uncertainties involved
in such diagnoses, are new. But are they?
I would argue that genetic counselling has
consistently dealt in uncertain predictions
and multi-causal conditions. Indeed, it has
grown by advancing an expansive reading
of genetic disease. Early genetic
counselling was premised on a slippage
between congenital and genetical disease
– between genetic disease and birth
‘defect’ – promising to help people “avoid
the tragedy of a defective child,” as one
popular periodical put it (Katz 1954:32).
Moreover, much of the advice provided in
the genetic counselling encounter involved
statistical risk estimates for conditions for
which no obvious Mendelian patterns of
transmission were known – for example,
cleft lip or palate. Finally, the development
and expansion of prenatal diagnosis in the
1970s entrenched the slippage between
congenital and genetical. Prenatal
diagnosis is, after all, principally
concerned with congenital conditions –
with problems manifest at birth – however
clear the genetic mechanisms of causation
may be.
Social historians of medicine have
consistently argued that disease identity is
never obvious. Instead, disease identity is
a contingent product of professional
identity, institutional relations,
technological capacity and patient
experience. Genetic diseases are no
different. What gets defined as a genetic
disease, and managed by medical
geneticists and genetic counsellors, is not
pre-determined by technology alone. Over
the course of their history, genetic
counsellors have expanded their
professional standing and medical
significance through a form of genetic
imperialism, or geneticization. They have
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claimed to possess interpretive capacity
with respect to a broad spectrum of
diseases, and have had to deal in
statistical risks concerning predisposition.
The genetic status of genetic medicine is
contingent and need not be accepted as
simply true. New molecular tests for
genetic predispositions, which suggest
that almost all diseases are genetic
diseases and can be managed through
genetic medicine, must be seen, in part,
as professional claims-making.

Story Four: Women and Genetic
Counselling
Women’s lives, their social roles and
feminist politics have intertwined in
complex ways with the histories of genetic
medicine and genetic counselling. If, as
I’ve suggested, genetic counselling has a
contingent relationship with medicine, and
genetic disease is a malleable concept,
then making sense of these historical
contingencies requires a gendered
analysis.
First, genetic counselling has drawn
heavily on women workers. In Canada, the
messy and marginal science of human
genetics was pioneered in the inter-war
and war-time years by workers who were
marginalised by their gender. Indeed, the
preponderance of women in early human
genetics research that was a result of
women’s marginality as scientific workers
has been influential in ensuring a
significant presence of women in the field
today. Moreover, as these women worked
to promote genetic counselling in Canada
in the 1940s and 1950s, they often
defended their place in university and
hospital communities by suggesting
women’s inherent capacity to engage in
such work. Women’s sensitivity and
communicativeness were advanced as
resources in the expansion of genetic
counselling.

The gendered social roles drawn upon by
pioneering Canadian practitioners, in the
1940s and 1950s, served as a more
general resource in the 1960s in the
creation of a feminised semi-profession to
aid in the genetic counselling encounter.
Sarah Lawrence College in the US,
originally a women’s college, initiated the
first Master’s level training program for
what were then called ‘genetic associates’
in 1969. In establishing this new semiprofession, its founders sought to service
a growing field with scientifically educated
women who otherwise had restricted
employment opportunities. Over the
course of the 1970s, counselling training
was added to the curriculum and by the
end of the decade the term ‘genetic
associate’ was coming to be replaced by
the term ‘genetic counsellor.’

being responsible for managing the
households affected by such ailments.
Moreover, enduring patterns of maternal
blame have been reproduced in genetic
counselling discussions, notably through
women’s responsibility for disabilities
associated with ‘late’ maternal age and for
X-linked diseases. Long before prenatal
diagnosis situated women at the centre of
much genetic counselling activity,
women’s lives and bodies were centrally
implicated by the reproductive decisionmaking, and the gendered constructions of
genetic risks, that have been constituted
through genetic counselling.

Master’s level trained genetic counsellors
have struggled with the low status and
constrained authority that is the corollary
of a female-dominated profession. At the
same time, this profession has been
consistently supportive of a feminist ethos
with respect to reproductive rights,
voluntarism and decision-making
autonomy (Wertz 1997). The challenged
status of genetic counselling within
medicine is symbolised and sustained by
the female dominance of this activity. That
genetic counsellors do what Bosk
characterises as ‘social dirty work’
demands investigation as a gendered
phenomenon.

Finally, women’s politics have been
implicated in the advance of genetic
counselling and genetic medicine
generally. While it would be false to
suggest that abortion rights were
advanced solely through demands for
genetic (or eugenic) abortions, the threat
of congenital disease has consistently
been one of the triumvirate of needs,
including rape and maternal ill-health, that
women have used to justify abortion to a
resistant medical profession, and the wider
public. On the eve of the 1970s in Canada,
amniocentesis was heralded as a
technology that might legalise abortion;
and in the US, one prominent women’s
magazine opined that prenatal diagnosis
could serve the career woman who wished
to postpone childbearing, without
increasing her risk of bearing a child with
Down’s syndrome.

In addition to the prevalence of women
practitioners in genetic counselling,
women have consistently, if only implicitly,
been conceived of as the principal objects
of such activities. In the early years of
genetic counselling, women were
positioned as the keepers of family
records. They were represented as most
likely to know about family patterns of
illness and thus were a crucial resource for
human geneticists as they reconstructed
pedigrees. Women were also deeply
implicated by patterns of familial disease,

Perhaps more importantly, and as has
been consistently observed, the women’s
health movement, in its demand for
choice, access to information, and
preventive self-care, has articulated a
politics that seems consonant with the
demands pressed by genetic counselling
and advanced through genetic testing.
Moreover, this liberal feminist ethos is of
sustained relevance to many women
today, and is a significant resource for
proponents of an expanded role for
genetic testing in medical and self-care.
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Conclusion
The Canadian Biotechnology Strategy
takes for granted the merits of new genetic
technologies for use in health care. It
advocates the development of these
technologies, and assumes that they
necessarily herald a new era of biotech
medicine. The histories that I’ve recounted
here suggest some ways to critically
evaluate these assumptions.
First, insofar as biotech medicine involves
genetic tests, there is much that will not be
entirely new about this new era. Genetic
tests pre-date the molecular testing
promised by the Human Genome Project
and allied research, and many of the
dilemmas of genetic tests – their uncertain
meaning, statistical complexity and decoupling from treatment options – are
decades old. I am not suggesting that
nothing is new here. Indeed, there are new
and significant challenges for medicine
and health care that are posed by biotech
medicine – such as the high cost of these
tests, their private ownership and thus the
difficulty of integrating them into
conventional lab routines. It is important to
recognise that what is new here are not
the technologies alone, but the new social
arrangements in which they are embedded
– social arrangements which are the
product of public policy decisions, such as
over-extended patent protection for
biotech “inventions”.
Second and by extension, genetic tests
have been and will be propelled into use
by very specific actors in the health care
system, even while the CBS fails utterly to
consider such actors. Genetic information
has been introduced into and managed
within clinical settings by an evolving mix
of practitioners who have jockeyed with
each other and with such institutional
powers as organised medicine. Who
provides genetic counselling, and in what
clinical context, matters. If more medical
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management of genetic information is
pursued, then we need to address the
tendency of medical practitioners to be
more directive than counsellors, and the
perverse incentives created by fee-forservice systems of compensation. I am not
suggesting that more investment in
Masters-level trained genetic counselling
is necessarily a better option, however.
While the feminised status of genetic
counselling may be responsible for its
under-resourcing, a feminist response
would not necessarily be to advocate for
more access to such services. We might,
on the contrary, wish to question the
construction of ‘communication’ as a
women’s issue, and to question the
relevance of a woman and health agenda
in supporting such services. What should
be understood is that the practice of
genetic counselling – whoever does it –
has been and will continue to be
fundamentally facilitative of genetic
medicine, and of an expanded use of
genetic tests.
Third, the extent to which genetic tests are
necessarily genetic is part and parcel of
negotiations over the practice of genetic
counselling and medical genetics. I would
argue that the commitment of human
genetics to genetical explanations is
historically contingent, rather than
necessary or inevitable. Moreover, I would
argue that the extent to which a disease is
understood and managed as genetic is a
negotiated outcome. The new era of
biotech medicine, if it is upon us, can be
managed differently – to emphasize social
and environmental systems of causation
and solution, for example.
The CBS would have us believe that we
are powerless before the advance of
science and technology. The best
response is to get on the bandwagon and
take what profits we can from this new
direction. Yet it is clear that there is a great
deal of contingency here – and social
analysts and activists can and should have
an impact on future directions.
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Unlike many contributions to this collection which provide critiques of biotechnology, and
biotechnology policy in general, Newman focuses on a specific technology – human
developmental gene modification, sometimes (though problematically) termed germ-line
gene “therapy”. Newman identifies specific dangers for women and for their children
where genetic modification of human embryos or fetuses is pursued. This paper also
presents an important gender analysis – pointing out that this kind of genetic
experimentation is reliant on the powerful desire and expectation that women will do
anything for their children. Further, Newman points to the fact that growing pressures to
pursue genetic experiments on developing fetuses and embryos are concurrent (and
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Introduction
Genetic modification of human embryos or
fetuses has been proposed for purposes
of both prevention of disease and
enhancement of capacity. The
development of sophisticated in vitro
fertilization methods, preimplantation DNA
analysis, improved techniques for gene
transfer, insertion, or conversion, and
embryo implantation procedures, have
made such interventions technically
feasible.
The hazards of genetic modifications to
humans have usually been discussed in
terms of somatic (body cell) modification,
in which only non-reproductive tissues are
affected, and germline (egg or sperm cell)
modification, in which changes to an
individual’s DNA can be passed down to
future generations. Indeed, this division
has led to the general belief that the only,
or main hazard of developmental
modification is the potential of
transmission of undesired alterations in
the germline.
But genetic modification of early embryos –
as well as chromosome and nucleus
transfer techniques, including cloning –
present hazards to the developing
individual, and in certain cases to the
mother, even if there is no germline
transmission to future generations. Genetic
manipulation of the human embryo, with or
without changes to the germline, is referred
to as developmental modification.
The hazards of germline transmission of
DNA modifications are obvious from a
reading of the literature on transgenic
animals. For example, germline
introduction of an improperly regulated
normal gene resulted in progeny with
unaffected development but enhanced
tumor incidence during adult life (1). Such
effects may not be recognized for a
generation or more.

It is important to recognize that many
hazards of developmental gene
modification are not eliminated if there is
no germline transmission. The biology of
the developing individual will still be
profoundly altered by the manipulation on
his/ her genes at an early stage.
Laboratory experience shows that
miscalculations in where genes are
incorporated into the chromosomes can
lead to extensive perturbation of
development. The disruption of a normal
gene by insertion of foreign DNA in a
mouse caused lack of eye development,
lack of development of the semicircular
canals of the inner ear, and anomalies of
the olfactory epithelium, the tissue that
mediates the sense of smell (2)
Interactions among genes and their
products are highly integrated, having
been refined over evolutionary time
scales, and often serve to stabilize
developmental pathways (the sequence of
structural and biochemical changes that
an embryo passes through on the way to
becoming a fully-formed organism) and
physiological homeostasis (the normal
state of dynamical balance among the
body’s many processes) (3-5). In addition,
the biochemical pathways used by the
organism and its cells to achieve this
stability and balance are overlapping,
rather than discrete or separable (6)
ensuring that any developmental genetic
alteration will have broad, uncontrolled
ramifications. Through experimental error,
unanticipated interactions among different
versions of the same gene, or poorly
understood regulatory mechanisms such
as imprinting (the parental source of the
gene – mother or father – affecting its
function), developmental genetic
manipulation risks altering sensitive
biological equilibria. Disrupting these
interactive systems is likely to have
complex and uncertain biological effects,
including some which only become
apparent during the development or
functioning of specific cells or tissues (7).
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Genetic alterations to the germline are
possible even where only body (somatic)
cells are targeted for DNA transfer. This
represents a hazard in many of the more
than 200 somatic gene therapy protocols
now in use. For example, the viruses that
are used to transfer DNA in some somatic
gene therapy protocols were able to infect
isolated mouse eggs in laboratory studies,
leading to germline transmission of a
transgene in the progeny (8). Although
removal of the external “shell” of the egg
was a prerequisite for infection of the eggs
in vitro, these “shells” are absent in the
early development of eggs in the ovaries.
These experiments thus raise the
possibility that modification of ova may
occur in women undergoing somatic gene
treatments, with unknown and
uncontrolled consequences to their
progeny.
In protocols that attempt somatic gene
therapy for life-threatening illnesses,
saving the life of the individual patient is a
value that must be balanced against
developmental risks, including those to the
germline of that individual, and indeed,
such considerations also pertain to
chemotherapy in cancer patients (9). With
respect to deliberate developmental
modifications, the story is quite different.
Not only is the “patient” (embryo or fetus)
and its progeny at risk from the procedure,
but so is the pregnant woman if the genes
are to be introduced in utero, since such
genes can also infect her tissues,
including her own germline, and entail
other risks to herself, such as cancer.
Clearly she is not in a position to give
informed consent on behalf of herself, or
the developing embryo, for a procedure
that has not yet been tested in humans,
and which promises no direct benefits to
her health (the usual justification for
experimentation on humans). However,
she will inevitably be under pressure to
assume such risks for the sake of her
baby.
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Even if the procedure is to be done in vitro
rather than in utero, the basis for informed
consent remains problematic. Here there
is no existing person whose life is in
jeopardy, but rather an embryo in a petri
dish that the egg or sperm donor (or
whoever else may gain the right to its
disposition) would like to have turn out
genetically differently. No truly informed
consent on the part of the potential
parents is possible, because no reliable
information would be available when it is
first attempted.
It is clear that pressures on women will be
growing over the coming years to submit
themselves to experimental genetic
procedures, first to prevent disease, and
eventually to enhance the appearance,
performance, and so forth, of her baby. It
is no accident that there are increasing
proposals to use newly obtained genetic
information to “improve” embryos by
manipulating the embryo (11, 12), rather
than for prenatal diagnosis. The new
genetic research has flourished during a
period in which there have been
aggressive attempts to reverse abortion
rights in the U.S.; consequently, the use of
prenatal diagnosis as a justification for
public funding of the science has been
taboo. This period has also been one in
which patenting and commercialization of
genes has been possible for the first time
(10), and eugenic ideologies, after their
post-World War II eclipse, have gained
new respectability among opinion makers
(13).
In evaluating proposals to use the new
genetics to remake human biology,
women should be aware of hazards to
themselves and their offspring from the
primitive state of the science and
technology, as well as the commercial and
reactionary political agendas behind these
efforts. Opposition to germline
engineering, and to other developmental
manipulations such as cloning, is
emerging among public interest advocates
(14-16). This new movement clearly has

natural affinities to ongoing efforts to

promote women’s rights.
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Introduction
As more genetic mutations are
‘discovered’ as being implicated in the
development of particular diseases, our
understanding of health risks is becoming
effectively geneticized (Lippman, 1991).
The case of breast cancer provides a
useful example of this geneticization of
risk. The identification of genes implicated
in the development of breast cancer (e.g.
BRCA1, BRCA2), has resulted in the
proliferation public information about
genetic risk for breast cancer through the
mass media. As well, this knowledge has
been translated into the development of
genetic testing ‘clinics’ that provide women
with genetic risk information – that is,
numerical estimates of their genetic
susceptibility for breast cancer.

and thus situate this growing public health
and medical practice in its broader context
(social, economic, political). In the second
section of this paper, I generally describe
the major themes that emerged from the
interview data in an effort to situate
individuals’ experiences of genetic testing
politically. In particular, I suggest that the
practice of genetic testing creates
possibilities for conducting oneself as a
moral and responsible citizen – citizens
who acquire knowledge of their genetic
risk, manage their genetic risk through
lifestyle modification and greater bodily
surveillance, and who inform their relatives
of their genetic susceptibility. In the final
section, I draw some conclusions and
identify some areas that deserve further
attention, debate and analysis.
I. Genetic Testing as a Neoliberal
Biotechnology

Public and professional discussions of
genetic testing and genetic risk more
generally tend to emphasize the benefits
of these biotechnologies for individual and
population health. For example, one
clinical genetics reference book describes
genetic testing as having “enormous
implications for prevention and treatment
(Offit, 1998: ix) by identifying those
individuals who are genetically ‘at risk’ for
particular diseases (e.g. breast cancer).
The potential benefits of genetic testing
technologies are also highlighted in the
Canadian Biotechnology Strategy Health
Sector Consultation document which
identifies early cancer screening and
detection (enabled by technologies such
as genetic testing) as a ‘key surveillance
area’ to facilitate health protection for the
population as a whole.

What is Neoliberalism? For the purposes
of this paper, I use the term neoliberalism
to characterize a particular way of
governing, or way of problematizing the
questions of government. In contrast to a
more straightforward description of
neoliberalism as a reactivation of market
principles or laissez-faire politics, this
conceptualization of neoliberalism directs
our attention towards thinking about
“government” as a way of thinking about
and acting upon problems. In other words,
neoliberalism is not just a set of political
ideals, but is a “political rationality”
(Foucault 1991; Gordon 1991) or “formula
of rule” (Rose 1996) that informs how
government is practiced.

Drawing on my experience conducting
interviews with individuals at risk for
familial melanoma, my primary aim in this
paper is to show how individuals’
experiences of genetic testing are related
to broader political, economic and social
arrangements. First, I situate genetic
testing as a neoliberal political technology,

From this point of view, questions
concerning government are not limited to
questions about the state or political
process. Rather, acts of governance occur
in many places and take many forms
(Dean 1999; Rose 1993). In the case of
genetic testing, for example, practices of
governance would include those carried
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out by the state (e.g. policymaking), the
practices related to the creation of
knowledge about genetic risk (e.g. the
Human Genome Project), the translation
of such knowledge into clinical practice
(e.g. the institutionalization of genetic
testing clinics), the education and training
of genetic specialists (e.g. medical
geneticists, genetic counselors) and the
practices of self-governance by which
individuals use genetic risk information to
alter their own behaviours.
Genetic Testing, ‘Right to Know’ and
‘Informed Choice’: Understood broadly as
a political rationality, neoliberalism
involves problematizing the questions of
government not in terms of top-down state
intervention, but rather towards the
development of conditions that facilitate
autonomous self-regulation (Petersen
1999). This characterization of
neoliberalism as a political rationality
allows for a consideration of how
individuals are governed through their own
self-regulation and exercise of choice
(Miller & Rose 1994).
The practice of genetic testing, and
discourses on genetic risk more generally,
are guided by the rhetoric of ‘right to know’
and ‘informed choice’ (Petersen 1998).
Being able to make informed decisions or
choices about one’s health is typically
used as a rationale for obtaining genetic
risk information. Consider the following
quote from a book on the psychological
consequences of genetic testing:
The provision of genetic information in
medical practice has the potential to
facilitate patients’ informed decision
making about reproduction and
personal risk modification. As such,
these advances have profound
implications for reducing the
incidence of genetic disorders and
for reducing morbidity and mortality
through early detection of disease in
individuals at risk. (Croyle & Lerman
1995:11, emphasis added)

The argument that genetic information
leads to informed choices which, in turn,
will lead to reductions in morbidity and
mortality relies on a conception of the
individual who not only exercises her ‘right
to know’ her genetic risk status, but who
also acts responsibly on the basis of that
information by modifying her lifestyle
accordingly (e.g. increasing frequency of
breast examinations). Indeed, this
expectation of ‘personal risk modification’
is stated explicitly in the above quote.
The importance of making ‘informed
decisions’ has also been taken up by
women with a family history of breast
cancer advocating for more accessible
genetic testing. For example, a recent
court ruling that women with a strong
family history of breast cancer would
receive provincial medical coverage for
genetic testing was described as an
‘important victory’ because it “could allow
hundreds of women to make informed
decisions about whether to take drugs or
have their breasts or ovaries surgically
removed as precautions against
developing cancer” (Abraham 1999).
Genetic Testing and Citizenship: Genetic
testing, as a practice and domain of
knowledge, constitutes one site for the
construction and exercise of citizenship
within neoliberal modes of governance.
Within neoliberal political arrangements,
experts (e.g. researchers, genetic
counselors) act as advisors and define
norms, yet individuals are called upon to
take an active role in decision-making
(Petersen 1999), to exercise their right to
know so that they can make informed
choices about their health. This imperative
is reflected and institutionalized in the
practice of genetic counseling which
emphasizes the importance of counseling
individuals in a ‘non-directive’ manner.
Thus, active involvement in decisionmaking can be considered as a key
mechanism by which individuals regulate
themselves—not through being coerced,
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but through the exercise of their freedom
of choice (Petersen 1999; Rose 1993;
Rose 1999).
As with other kinds of health risks (e.g.
lifestyle, environmental), the ways in which
ideas about genetic testing are framed and
clinically applied are founded on a
conception of the individual as an
‘enterprise’ who is required to adopt a
calculating attitude in terms of how they
conduct themselves (Lupton 1995;
Petersen 1997; Robertson 2000). This is
consistent with neoliberal political
rationalities in which individuals are
expected to govern themselves through
“processes of endless self-examination,
self-care and self-improvement” (Petersen
1997: 194). The practice of genetic testing
is an especially effective tool for activating
these processes. That is, through their
participation in genetic testing, individuals
are able to obtain information about their
genetic risk status, compare themselves to
genetic norms established by
epidemiological research, and receive
advice from health professionals as to how
they should regulate their own behaviours
(in light of their knowledge of a genetic
risk) to avoid disease onset in the future.
II. The Construction of Responsible
Citizens: Implications of Genetic
Testing for Subjectivity
In this section I discuss how the practice of
genetic testing constructs individuals as
responsible citizens who seek out and act
on genetic risk information to protect their
personal health as well as the health of
their family members. To do this, I have
included some insights from my
experiences interviewing individuals who
had were at various stages in the process
of undergoing genetic testing for familial
melanoma risk.
Constructing Women as Agents of SelfRegulation: The Duty to Manage Personal
Risk
58

The previous theoretical discussion
suggests that genetic testing recruits
individuals into processes of risk
management involving self-examination
and lifestyle modification. At a glance, this
may not seem different than non-genetic
forms of medical screening and
surveillance. However, genetic testing has
considerable potential to shape how
individuals understand and practice health
in the absence of disease or symptoms,
and thus to blur the distinction between
health and illness (Gifford 1986). In this
sense, genetic risk information constructs
particular body parts as potentially
dangerous (e.g. ovaries, breasts) prior to
the onset of symptoms. Thus, the practice
of genetic testing has serious implications
for how women experience their bodies
and construct their identities (Hallowell
1998; Koenig & Stockdale forthcoming),
and can encourage a person to
experience their own body as potentially
dangerous in everyday life (Kavanagh &
Broom 1998; Robertson 1998; Robertson
2000). As Koenig and Stockdale note with
regard to their work in the area of breast
cancer:
How will women understand ‘risks’ that
literally reside within them, in their
genes, over which they have little
control, and which they may already
have passed on to their children? Will
breasts and ovaries be experienced as
potential time bombs, harboring the
early stages of cancer, in need of
constant surveillance? (Koenig &
Stockdale forthcoming: 20)
Furthermore, unlike environmental or
lifestyle-related health risks, genetic risk is
‘embodied’ (i.e. located within the body)
and is typically not considered to be
amenable to therapeutic intervention
(Kavanagh & Broom 1998). While genetic
risk is distinct from lifestyle- or
environment-related risks, I believe it is an
error to consider different types of risk
discourses in health (e.g. genetic, lifestyle,

environmental) as completely
independent. This is because such a
separation neglects a major assumption
underlying genetic testing – that a
woman’s knowledge of her genetic risk
status will enable her to make ‘informed
choices’ with regard to her health. Rather,
by constructing new categories of genetic
normality, and situating particular body
parts as potentially dangerous, genetic
testing recruits asymptomatic individuals
as agents of self-regulation who manage
their health risks through self-imposed
lifestyle modifications (e.g. increased
frequency of breast self-examinations, low
fat diet). In turn, individual responsibility for
health through personal risk management
is emphasized.
The importance of informed decision
making, and its implications for how
individuals see and act upon themselves,
was obvious in my interviews with
individuals who were considering,
undergoing, or who had undergone,
genetic testing for familial melanoma risk.
In these respondents’ accounts, there was
a general consensus that “the more
information one had about one’s
health, the better” because this allowed
one to gain a greater “awareness” of
health risks and of bodily signs of
normality and abnormality (irregular
moles). In particular, the process of
genetic testing influenced how individuals
recognized ‘healthy’ and ‘unhealthy’ moles
such that they began to examine their
bodies through ‘clinician’s eyes’. In this
sense, genetic risk information was
seen as part of a plan of prevention
since it allowed individuals to take
appropriate and more informed action
through increased self- and medical
surveillance. As well, the need to become
more vigilant in terms of bodily
surveillance was seen by participants as
incredibly important since early detection
is key in avoiding more invasive forms of
treatment for malignant melanoma.

Constructing Women as Carriers of Health
Information: The Duty to Inform
Genetic risk information, being familial in
nature, not only has implications for
individuals undergoing genetic testing, but
also has implications for their family
members. While much research has
focused on the personal implications of
being identified as a ‘carrier’ of “defective”
genes, less attention has been paid to the
familial implications of identifying
individuals who are identified as
genetically at risk.
As a family-implicating medical
technology, genetic testing has specific
implications for the considerations
individuals make when deciding to accept
or defer genetic testing. For example, in
the interviews I conducted, it was clear
that decisions to accept testing were often
rooted in a sense of obligation to inform
current or future family members of any
undesirable traits that may have been
passed on. Information about genetic
risk was seen as especially useful to
“pass along to the family” to increase
familial awareness about potential health
risks and signs of possible hereditary
disease (e.g. irregular moles). In
particular, genetic risk information was
seen as having preventive benefits for
children by encouraging parents to
protect their children from the sun, and by
encouraging their children to be more
‘aware’ of their bodies and more vigilant in
protecting themselves from sun-related
risk
With respect to women in particular, other
research has shown that women will
overlook their own desire to not know their
genetic risk status for breast or ovarian
cancer so that they can provide genetic
risk information to their family members, in
particular their children (Hallowell 1999).
This calls into question whether decisionmaking is really autonomous, an aspect of
decision-making that is promoted by
genetic counseling.
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Thus, genetic testing create opportunities
for new forms of citizenship based on
familial obligation wherein individuals are
constructed as ‘carriers’, not only of
‘defective’ genes, but also of genetic risk
information. Within this logic, individuals
are recruited as agents of ‘health’ doing all
they can to ensure that their family
members are ‘armed’ with the information
necessary to manage and minimize their
own personal health risks. This ‘duty to
inform’ family members of potential
genetic susceptibility may have specific
implications for women, as they have been
traditionally considered responsible for
family health.
Concluding Comments
The previous discussion illustrates how
individuals are recruited as agents of selfand familial regulation, processes that are
consistent with active citizenship under
neoliberal forms of governance. It is not
my intention to propose that genetic
testing is necessarily oppressive, or to
suggest that these individuals are suffering
from false consciousness which is
masking an underlying ‘truth’ or ‘reality’.
Certainly, the majority of individuals who I
interviewed on the familial melanoma
project experienced genetic testing as
positive overall, and as providing them
with information that enabled them to
make personal health-related decisions,
and that they could pass on to other family
members. Still, the discussion presented
in this paper points to a number of areas
that are in need of further research,
analysis and debate.
The construction of individuals as agents
of self-regulation assumes that individuals
have the psychological and material
resources necessary to reduce health
risks, and, even if these resources are
available, that personal risk management
should take precedence over other
matters concerning everyday life.
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Furthermore, this assumes that personal
risk management through lifestyle
modification is a straightforward task, and
does not acknowledge that there may be
an overwhelming number of
recommendations for risk management
which may contradict one another (e.g.
conflicting mammography guidelines).
Finally, the focus on personal risk
modification reinforces a conception of
health, and responsibility for health, as an
individual undertaking, and thus other
conceptions of the determinants of health
(e.g. environmental influences on breast
cancer) and the actions which may be
taken to improve health (e.g. collective
action) are overshadowed.
The underlying assumption of one’s duty
to inform family members of potential
genetic susceptibility neglects to consider
personal and familial circumstances (e.g.
recent death of family member) which may
influence the amount of anxiety one
experiences from genetic testing, and how
individuals understand and communicate
risk information. Also, this assumption
does not consider that some individuals
may want to protect their family members
(in particular their children) from knowing
their genetic susceptibility to disease. In a
similar vein, the potential negative effects
on individuals and families of having
knowledge of genetic susceptibility are
often overlooked. In the interviews I
conducted, individuals felt that they were
well informed during genetic counseling
about the potential psychological effects of
knowing their genetic risk status yet, for
some, unexpected concerns emerged only
after they gave blood for genetic testing.
As well, more attention should be paid to
the personal consequences of receiving a
negative/ indeterminate genetic test result,
for such a test result may not necessarily
lead to feelings of relief as it can position
an individual in a state of greater
uncertainty regarding their genetic
susceptibility and the risk adjustments that
they should make in response to a
negative test result. In short, while genetic

risk information is often framed as
providing individuals with greater control
over their health, this claim should be
systematically evaluated through in-depth
empirical inquiry of individuals’
experiences of genetic testing.
Last, there is a need for research on how
women perceive and experience genetic
testing and genetic risk information in the
context of their everyday lives. While
research on ‘lay’ perceptions of health
risks is growing, a substantial amount of
this research focuses on the ‘accuracy’ of
lay perceptions of risk (Gabe 1995) – that
is, on whether lay perceptions are aligned
with biomedical perspectives. Implicit in
such research is the conviction that lay
perceptions are somehow lacking and are
in need of better and more timely
information so that individuals can become
better governors of their genetic fates.
This perspective on lay perceptions needs
to be countered with research that focuses
on how individuals understand risk
information and create meaning about
genetic risk in the context of their everyday
lives. Such an approach to research would
take into account a woman’s entire ‘stock
of knowledge’ (Petersen 1999) with regard
to genetic risk (including mass media, for
example) and would illuminate how
women actively construct meanings
around genetic risk. In particular, the
specifically gendered way in which women
experience a sense of familial obligation
as a result of their participation in genetic
testing would be a fruitful area of research,
and would have serious implications for
both practice and policy. A focus on
women’s experiences with genetic testing
would also help provide a more complete
picture of the ethical implications of such
practices, as it would shed light on the
influence of genetic testing on the
everyday lives of women and their
families. In this regard, the concept of
citizenship provides a promising way to
conceptualize personal experiences of
genetic testing within larger political
programmes. A focus on women’s

everyday knowledge about genetic risk
and genetic testing not only promises to
illuminate the links between subjectivity
and broader political currents, but may
also “provide the basis for exploring the
contradictions and tensions around
genetic knowledge and prevention and for
contesting the imperatives surrounding
genetic health.” (Petersen 1999: 137). A
major challenge will be to create
mechanisms that allow for input from such
research into decision making processes
and policy making.
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The … point is not that everything is
bad, but that everything is dangerous
… If everything is dangerous, then we
always have something to do. (Foucault
1984:343)
Introduction
The purpose of this discussion paper is to
explore the personal and political
implications of current discourses on
health and risk, and to suggest some of
the ways in which these discourses are
produced and shaped, in part, by existing
and emerging biotechnologies, specifically
diagnostic and screening technologies. I
use the term “discourse” in the sense that
Michel Foucault used it to refer to ways of
thinking, speaking and writing about a
particular area of knowledge, as well as
the actual practices associated with those
ways of thinking, speaking and writing.
Biomedicine, for example, continues to be
one of the major discourses on health,
tending to dominate over alternative
perspectives on health and healing such
as holistic or traditional medicine. This
paper is based on the premise that
discourses on health are never just about
health. Particular discourses on health
emerge at particular historical moments
and gain widespread acceptance primarily
because they are more or less congruent
with the prevailing social, political and
economic order within which they are
produced, maintained and reproduced.
That is, discourses on health are always
contingent. Moreover, because they are
always attached to other interests and
agendas – professional, economic,
political, cultural, ideological – discourses
on health, including discourses on health
risks, also function as repositories and
mirrors of our ideas and beliefs about,
among other things, what it means to be
human and the kind of society we can
imagine creating and how best to achieve
it. In this sense, discourses on health are
fundamentally prescriptive.

This paper is informed, in part, by
empirical research that I have conducted
on women’s accounts of breast cancer
risks. While the study discussed in this
paper has a phenomenological focus, in
focussing on women’s experiences in the
context of their everyday lives, it also is
based on the assumption that women’s
health experiences – specifically, the ways
in which they talk about their own personal
risks for breast cancer – are located within
the broader social, political and cultural
context which produces and shapes those
experiences. In other words, a
“phenomenology of risk” is a situated
phenomenology. This paper argues that
diagnostic/screening technologies are not
only part of the context that shapes
women’s health experiences, they are also
produced and implemented within that
same context. In addition, particular
diagnostic/screening technologies both
make possible and are made possible by
particular discourses on risk, which
themselves are produced within a
particular context. In other words, there is
a dialectical relationship between women’s
health experiences, prevailing discourses
on health risks and emerging
diagnostic/screening technologies. This
means that they must all be analysed
within the same social, political, moral,
cultural and ideological context.
It should be made clear at the outset that
this paper is not intended as a neo-Luddite
diatribe against biotechnology in general.
Some biotechnologies clearly have
enormous potential to improve health
overall – and women’s health, in particular.
However, it was clear from the CBS
documents that there exists a tension
between, on the one hand, the
consideration of social and ethical issues
related to the development and
deployment of biotechnology (Canada
1998a) and, on the other hand, the belief
that “industrial growth should be the
primary objective of the CBS renewal,
along with “provision for ‘unencumbered’
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basic research”, (Canada 1998b). As
noted in the CBS Health Sector
Consultation Document (Canada 1998c:8),
“the health sector bears a particular
responsibility to provide leadership to
society in imagining creative solutions that
articulate and balance emerging social
values with expanding technological
capabilities within regulatory policy
development” (emphasis added). This
paper seeks to contribute to achieving this
balance. Moreover, I will argue that in
addition to considering the social and
ethical implications of biotechnology as the
CBS documents call for, the dialectical
relationship between prevailing discourses
on risk and emerging diagnostic/screening
technologies also has significant personal
and political implications which must be
considered.
This paper consists of three parts: first, a
brief overview of my empirical study of
women’s accounts of breast cancer risks;
second, a discussion more broadly about
what this study indicates about the
personal and political implications of
prevailing discourses on health risks, and
some speculation about how these results
relate to current and emerging
diagnostic/screening technologies; and
finally, a consideration of questions –
empirical, policy, moral – which a critical
social science research agenda might
address with respect to the social
management of biotechnology.
I. Our Bodies, Our Enemies: Women’s
Accounts of Breast Cancer Risk
There have been a number of studies,
recently, specifically investigating women’s
perceptions of risk for breast cancer
(Black, et al. 1995; Breast Cancer Bulletin
1995; National Forum on Breast Cancer
1993; Hallowell 1999; Kavanagh and
Broom 1998; Koenig and Stockdale
forthcoming; Lipkus, et al. 1999; Lloyd, et
al. 1996; Mannheimer 1992; Potts 1999).
However, with a few exceptions, most of
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the studies of women’s perceptions of
breast cancer risk have employed a
number of psychosocial measurement
instruments and structured interviews with,
until recently (Hallowell 1999; Koenig and
Stockdale forthcoming), very few
phenomenological investigations of
women’s accounts of risks for breast
cancer.
According to Sandra Gifford (1986), one of
the few researchers who has conducted
phenomenological research on women’s
perceptions of risk for breast cancer, risk
for breast cancer becomes internalised
and is experienced as a state of being,
which leads to an ambiguous relationship
between health and ill-health: "This
ambiguity results in the creation of a new
state of being healthy and ill; a state that is
somewhere between health and disease
..." (215). As with illness narratives,
personal narratives of risk may help
women make sense of breast cancer risk
by providing an "arena for the negotiation
of reality" (Early 1982:1491). At the same
time, by leaving women feeling
"precariously perched between illness and
health" (Garro 1994:784), awareness of
risk "forces an awareness of the body as
separate from self" (782). As Baines says:
"For women with breast cancer, it is a
chronic disease; for women generally, it
can be a chronic problem" (Baines
1990:20).
In order to investigate the extent to which
this was the case, I undertook a study of
women’s accounts of breast cancer risks.
Focus groups and in-depth interviews
were conducted with 20 women recruited
from a pool of women who had attended a
Breast Health Clinic at a metropolitan
teaching hospital and had not been
diagnosed with breast cancer. Participants
were divided into 3 clinically-designated
risk groups – low, medium and high –
based on certain clinical criteria. Focus
groups and interviews were tape-recorded
and transcribed. The transcripts were then
subjected to a standard qualitative data

analysis to elicit common themes that
emerged from the women’s accounts of
risks for breast cancer.
The following analysis focuses, in
particular, on what study participants said
about two issues with respect to breast
cancer risk: firstly, their perceptions of
their own personal vulnerability to breast
cancer; and, secondly, how much control
they felt they, personally, and women in
general have over whether or not they
ultimately develop breast cancer. For the
sake of brevity, the three major themes
which emerged from analysis of the data
are briefly outlined below. Data, in the
form of direct quotes from the study
participants, supporting these themes is
provided in a longer paper based on this
study (Robertson 1999)
Breast worry: vulnerable and flawed – All
the participants expressed varying
degrees of “breast worry”. This worry had
three essential components: the
inevitability of breast cancer, the
constancy of this worry about breast
cancer, and the sense of the breasts as
flawed body parts (employing terms like
“time bombs” and “Achilles heel”).
Managing uncertainty: numbers and risk
status – Linked to the constant awareness
of vulnerability to breast cancer that these
women felt was the theme of uncertainty.
For some women this was expressed as
an awareness that uncertainty was
something they simply had to live with. For
others, it was expressed as a desire for
more certainty. One of the most common
strategies that women in this study used
for managing this uncertainty was to figure
out their own breast cancer risk status.
Many women appeared to be continually
adjusting their sense of their own risk
status over time as a result of
incorporating additional information or
making changes in their own health
behaviour.

Playing the odds: individual
responsibility/no control – Nearly every
woman in this study talked about the
individual responsibility that she and all
women have for reducing their personal
risks for breast cancer. This was always
framed in terms of individual responsibility
at the level of lifestyle behaviours such as
diet, smoking and alcohol consumption,
behaviours which they were well aware of
as “risk factors” for breast cancer.
While there was a general emphasis on
this kind of individual responsibility, at the
same time, many of these same women
recognised that there were many risks for
breast cancer that they had no real control
over. Significantly, even though most
women spoke about environmental issues
like polluted air, water and soil and food
additives, which they all considered to be
major contributors to increasing risks for
breast cancer, not one of the women in
this study talked in terms of collective
action at the social, political and economic
levels for reducing breast cancer risks,
such as lobbying for stricter environmental
controls or food regulation.
What appeared to happen was that
women tried to reconcile these two
conflicting issues – individual responsibility
in the face of limited or no control – with
the notion of "playing the odds". One
participant expressed how going back and
forth between these two poles of
responsibility and control kept her poised
on the edge of uncertainty. The result was
a fundamental bifurcation of body and self.
While this is a particularly eloquent and
poignant expression of this, every woman
in this study expressed some degree of
this bifurcation of body and self.
… I think that there's – say there's two
of me and one of me goes low-fat [diet],
doesn't drink or has the odd drink,
doesn't smoke, exercises, and the other
one smokes and drinks and eats so
that they're out like this, yeah, I think
I'm gonna – this one over here
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[indicating the “healthy lifestyle” self] is
going to have a lot better chance of not
developing cancer than this one over
here [indicating the “unhealthy lifestyle”
self]. I would say this one over here will
develop it if she has … the propensity.
But then the thing is both these two
people have the genes. They both have
an eighty-five per cent chance. Yeah,
and I would say this one over here, the
fat one, the smoking, alcoholic fat one,
will develop it. And this one over here,
the exercising obsessive, maybe she
won't get it; but there's a good chance
she will. But she seems to be smart
enough that she looks after her body
and she takes care of herself that she'll
get the proper help to deal with it better
emotionally, she'll nip it in the bud
because she's aware of it and she's
doing things about it, and she won't die;
whereas this one over here may not
realise she has it until it's too late.
(Donna, HR:29 - 31).
Donna, like all the women in this study,
have literally embodied prevailing
discourses on breast cancer risk, and
along with them, a particular political
rationality.
II. Embodying Risk, Embodying
Political Rationality
“Risk” has become one of the defining
cultural characteristics of Western society
at the end of the twentieth century (Beck
1992b; Douglas 1994; Douglas and
Calvez 1990; Douglas and Wildavsky
1982; Giddens 1991; Nelkin 1985; Renn
1992; Scott, et al. 1992). Perhaps, most
significant is that, in the current context,
the meaning of risk has shifted away from
being a neutral mathematical probability,
and has come to signify impending danger
(Douglas 1990; Lupton 1994b). A common
theme in much of this literature is that risk
consciousness reflects a new social,
political and moral order: “[the] risk
debates around which much of modern
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politics has been shaped are
quintessentially tied up with … the search
for new forms of legitimate order and
authority” (Wynne 1996:78).
As in other areas of life, “risk” has become
has become central to discourses related
to individual health; that is, risk has
become a common construct around
which health in Western society is
described, organised, and practiced, both
personally and professionally (Bunton
1992; Hayes 1991; Hayes 1992; Lupton
1995; Petersen 1996). The results of this
study demonstrate the extent to which the
participants embody discourses on risk, in
general and discourses on breast cancer
risk, in particular. This embodiment of risk
is expressed by the women in this study in
terms of a phenomenological experience
of “being at-risk” for breast cancer. There
has been much recent discussion about
the implications of this “at-risk”
consciousness (Castel 1991; Crawford
1994; Greco 1993; Lupton 1994a;
Petersen 1998; Petersen 1996).
Firstly, and as indicated by the results of
the present study, such consciousness
contributes to the emergence of a
particular form of subjectivity – that is, a
particular way of thinking about, relating to
the self in terms of the broader social and
political context within which the self is
embedded/located. The particular
subjectivity made possible by current
discourses on health and risk and the
resulting “at-risk” consciousness has been
described as the “entrepreneurial subject”
(Petersen 1996; Rose 1990; Rose 1993).
This captures the notion that “life should
be an enterprise of oneself” (Petersen
1996:48), a personal project, to be
continually and actively assessed,
managed, worked and improved upon
(Greco 1993; Lupton 1995; Petersen
1997; Petersen 1996; Rose 1993; Rose
1990); in turn, “this requires the individual
to adopt a calculative and prudent attitude
with respect to risk and danger” (Petersen
1996:51).

For the women in this study, this
enterprise is essentially an embodied one:
they manage their anxiety about being “atrisk” for breast cancer by managing their
bodies, that is, by adhering to particular
lifestyle behaviours such as low-fat diets,
not smoking, controlling their alcohol
consumption, practising stress
management strategies and managing of
their reproductive options in particular
ways. Where they are not actually
engaged in such “healthy” lifestyle
choices, they exhort themselves to
become so. Other investigators have
talked about "panic bodies" (Lupton, et al.
1995b; Lupton, McCarthy et al. 1995),
"risky bodies" or "risky selves" (Nettleton
1997), and even "dangerous bodies"
(Hallowell 1998) and "malignant bodies"
(Williams and Bendelow 1998). The
women in the present study appear to
manage their uncertainty and anxiety
about breast cancer by negotiating an
uneasy pact with their "treacherous
bodies".
The phenomenological experience of the
women in this study does not, of course,
occur in a vacuum; such experience is
always situated and located – socially,
politically, historically. In analysing the
portrayal of risks for breast cancer in
popular media, Deborah Lupton
(1994a:73) found that the Australian press
drew upon "dominant cultural metaphors
and discourses concerning femininity, the
individual's responsibility for illness, and
medical and technological dominance”.
These same themes were reflected in the
accounts the women in this study give of
their vulnerability to breast cancer.
Many scholars have written about how the
role of public health is central to the
reproduction of this risk consciousness.
(Bunton, et al. 1994; Bunton 1992; Lupton
1995; Nettleton 1997; Petersen and
Lupton 1996). For example, the
phenomenological consequences of the

public health practice of “risk assessment”
for the entrepreneurial subject are clear.
Preventive medicine and statistical
calculations in the context of
epidemiology are part of a moral
technology; by being made aware of
risks, the individual is told to provide for
and discipline the future, to calculate
future actions and dealings.
(Adelswards and Sachs 1998:207;
emphasis added)
The scope of public health would appear
to be almost limitless, for as Castel
observes, “for what situation is there for
which one can be certain that it harbours
no risk, no controllable or unpredictable
chance feature” (Castel 1991:289). And it
is diagnostic/screening technologies –
such as mammography and genetic
testing for breast cancer – which, in part,
have provided the means for public health
and preventive medicine to cast an everwidening “clinical gaze” – or more
specifically, a “technological gaze” – over
the health and lives of women, such that
“to be suspected, it is no longer necessary
to manifest symptoms … it is enough to
display whatever characteristics the
specialists responsible for the definition of
preventive policy have constituted as
risks” (Castel 1991:287).
Diagnostic/screening technologies are
instrumental in defining and assessing
these “characteristics”, resulting in a
“technologization” of risk. To date, these
have been largely imaging technologies –
such as mammography, ultra sound,
bone-density testing – but with the
enormous global effort being put into the
Human Genome Project, these
“characteristics” are becoming increasingly
genetic, surely confirming Lippman’s
(1992) early insights into the
“geneticization” of risk. With the current
push to make genes the ultimate “risk
factors”, the individualization of health, and
health risks, is complete. Health risks are
in the very “building blocks” that make up
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the person and not in the social, physical
or political environment.
Prevailing discourses on risk, and the
biotechnologies which both make them
possible and are made possible by them,
also have implications at a social and
political level. It could be argued that the
phenomenological experience of the
women in this study represents an
embodiment of a currently prevailing neoliberal rationality (Burchell 1993; Castel
1991; Greco 1993; Petersen 1997; Rose
1993; Rose 1990). The argument here is
that neo-liberal notions of individual
autonomy, the free market and limited
government are related, in a mutually
producing and sustaining way, to the
imperatives to “self-care” (Greco 1993) –
in the form of self-surveillance and selfregulation – which themselves are a
consequence of the phenomenological
experience of being “at-risk”. Petersen
makes this link between risk
consciousness and the prevailing political
order, characterised, in part, by the rapid
retreat of the welfare state.
Neo-liberalism calls upon the individual
to enter into the process of their own
self-governance through the processes
of endless self-examination, self-care,
and self-improvement. Given that the
care of the self is bound up with the
project of moderating individual burden
on society, it is not surprising … that
since the mid-1970s there has been a
clear ideological shift away from the
notion that the state should protect the
health of individuals to the idea that the
individuals should take responsibility to
protect themselves from risk. (Petersen
1996:48-49)
In other words, the entrepreneurial subject
is reconceived – and reproduced – as a
new kind of citizen: a neo-liberal citizen
who is autonomous, responsible and selfgoverning. Within this kind of rationality,
health and health risks are individualized
and, thus, depoliticized. It should,
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therefore, not be surprising that the
women in the study discussed here readily
took up prevailing discourses on breast
cancer risk, assigned themselves a “risk
status” and talked about the management
of breast cancer risk only at an individual
level and not at a collective or political
level.
It is to this extent that it could be argued
that, for the women in this study,
embodying risk represents the
embodiment of a neo-liberal rationality.
Diagnostic/screening technologies are
firstly imagined, and then developed and
deployed, within that same political
rationality which they, in turn, reinforce
and reproduce.
III. Implications for a Canadian
Biotechnology Strategy
The preceding discussion is offered as
some preliminary thoughts about the
dialectical relationships between prevailing
discourses on health risks, emerging
biotechnologies (specifically,
diagnostic/screening technologies) and the
prevailing social, political, moral, cultural
and ideological order (more specifically,
the current neo-liberal rationality). This
raises a number of questions at several
levels – social, political, ethical. What I will
attempt to do in this final section is to raise
two fundamental questions, to begin with,
which a critical social science research
agenda might address in relation to the
current Canadian Biotechnology Strategy.
Firstly, at a phenomenological level, I think
we need to understand more about how
women take up prevailing discourses on
health risks. It would appear that women,
generally, have willingly taken up certain
practices of self-surveillance and selfgovernance (eg. breast self exam, annual
mammograms, lifestyle management). It is
poignant to reflect on the extent to which
the notion of “Our Bodies, Our Selves”
(reflecting a political intention, on the part

of the women’s health movement, for
women to “re-own” their bodies – i.e. to
remove them from the clinical gaze) has,
within 30 years shifted to “Our Bodies, Our
Enemies” (reflecting a turning back of the
clinical gaze on oneself). But is this what is
actually happening? Do women take up
prevailing discourses on risk – and submit
themselves to the diagnostic/screening
technologies – wholly, uncritically? Or are
there pockets of resistance to these risk
discourses? What do these discourses of
resistance look like and, remembering
Foucault’s injunction to “look to the
margins”, where are they located?
In this respect, there are clear limitations
to the study reported here because of the
selective nature of the study sample. The
participants were all English-speaking
women of European – mostly northern
European – descent, middle-class, mostly
working and largely professional. More
significantly, they were all either selfreferred or referred by their family
physicians to the Breast Health Centre of
a major downtown teaching hospital in a
large urban centre. This in itself speaks to
a certain pre-selection in terms of class,
education, and other social locations of
these women. Because of this limitation,
the investigation of potential differences in
terms of a variety of social locations –
class, race/ethnicity, mother tongue,
sexual orientation – representing different
experiences of embodiment, was not
possible. For theoretical reasons, one
might expect very different results from
women who attend a Community Health
Centre in a low-income neighbourhood,
women who are recent immigrants,
women who live in rural settings or women
who have some other racial/ethnic/cultural
origin besides northern European. Further
research would illuminate how differently
embodied subjects take up, interact with
and transform prevailing discourses on
health risks in general and breast cancer
risks in particular.

In addition, remembering that
phenomenological experience is always
situated, comparative research would
indicate what and how different discourses
on health risks emerge within different
professional, political, legislative and
regulatory contexts (e.g., UK, USA and
Canada). For example, is there now a
global discourse of breast cancer risks or
are there jurisdictional variations? And
how does this impact on women’s health
experiences within these contexts?
Secondly, and related to the above
question (in ways which remain to be
explored) is the question of public
participation in the setting of the Canadian
public policy agenda for the development
and deployment of emerging
biotechnologies. The CBS documents
appear to address this issue, but the
nature of the suggestions and
recommendations makes it clear that this
represents a kind of “tokenism”, referring
to the “information needs” of the public
and strategies for “increasing public
awareness and understanding of
biotechnology products and processes”
(Canada 1998d:15). The assumption here
is that the public somehow doesn’t “get it”
with respect to biotechnology, and that
public knowledge is somehow a
“degenerate” form of knowledge. This is
often reflected in the reference to
“scientific evidence” and “lay beliefs”, as if
science, itself, were not a belief system.
The solution, according to the CBS, is to
make scientific knowledge more
“accessible” to the public.
Research points to gaps in consumer
awareness and understanding of
biotechnology … The attributes of
biotechnology applications often are not
directly evident to citizens. More work is
needed to determine the best way to
inform them about such technologies.
(Canada 1998d:14)
In other words, the suggestion here seems
to be that the biotechnology sector needs
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to engage in a public relations campaign.
Note, also, that not only understanding,
but also accepting, scientific knowledge
has become an attribute of citizenship. An
alternative view is to regard public (or
“lay”) knowledge as a legitimate,
competing knowledge system alongside
scientific knowledge (Brown; Balshem
1991), albeit less systematically
articulated. Further research into public
knowledges about health risks and what
happens to them as they enter the public
policy arena would be illuminating. Again,
comparative research would indicate how

different jurisdictions have addressed the
issue of ensuring (or, alternatively, limiting)
public participation in setting the public
policy agenda with respect to the
development and deployment of
biotechnology.
This Discussion Paper is offered in the
spirit of David Suzuki’s caution that
“science is too important to leave to the
scientists”. What this means for social
scientists is that, as Foucault said, “we
always have something to do”.
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About the Article
Agricultural biotechnology is the focus of Elisabeth Abergel’s paper. In illuminating the
recent history of GE foods in Canada, she identifies the way that the current prevalence
of GE crops and GE foods has been hidden from Canadians. The CBS is, for Abergel,
only the most recent version of a developing policy agenda at the federal level which has
worked to promote the industry, while obscuring the awareness of Canadians and
marginalizing ethical and social issues. Abergel’s analysis also highlights tensions for
feminists. The positioning of women as consumers, she suggests, limits the nature of the
critique that can be made in the name of women and women’s health. A feminist critique,
by contrast, needs to advance a broader social justice analysis. How, Abergel asks, will
these two positions interact
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The Context
The use of genetic engineering (GE) in
agriculture is highly controversial. The
ecological and human health impacts of
this technology for food production are
uncertain and contested. Throughout the
world, a growing number of scientists,
politicians and activists have been
criticizing the way in which GE has been
introduced in our fields and our food
system, pointing to the lack of rigorous
testing methods and the limited knowledge
about long-term health and ecological
consequences. European anti-GMO
(Genetically Modified Organisms) protest
has resulted in the adoption of a
precautionary approach to the regulation
of GE foods and the blockage of imports of
North American crops. Canada is a major
player in agricultural biotechnology; it is
the third largest producer of GE crops in
the world. Large public investments have
helped to foster the Canadian
biotechnology industry in the last two
decades. The Canadian government has
played a conflicting role in biotechnology,
simultaneously promoting and regulating
the products of genetic engineering.
North American resistance to GE is
growing, largely as a result of worldwide
concern. While the movement to block
GMOs in food is often associated with a
new health and environmental risk
awareness, it also represents a global
political movement, cutting across issues
of race and class, linking the struggles of
women, North and South, against the new
trade agenda. Feminist opposition to
agricultural genetic engineering has
focused on the corporate domination of
the food system, the ownership and
control of vital biological resources and the
marginalization of women’s role in global
food security.

profound ways, highlighting the complexity
of biopolitical issues facing women today.
The Canadian Biotechnology Strategy
(CBS) did not provide a viable forum for
women’s views to be heard, as no
opportunities to discuss the wider
implications of the technology existed.1
Early discussions about biotechnology
policy excluded public participation and
the development of regulations replaced
any kind of formal technology assessment.
The Canadian federal government has
played a contradictory role in the area of
biotechnology policy, promoting the
industry while protecting the health of
Canadians. As a result, the opportunity for
women’s groups to debate the use of
genetics for various applications was
missed. Canadian feminist discourse has
remained fairly compartmentalized in
terms of its critiques of biotechnology,
mostly relating to changes in healthcare
and the delivery of services for women.

Agricultural Biotechnology Policy
The first genetically modified organism to
be introduced in Canada was herbicide
tolerant canola in 1995, and there are
currently over 40 GE crops approved for
environmental release and commercial
application. Crops such as herbicide
tolerant and insect resistant corn,
soyabeans and potatoes have been
introduced into the Canadian food system.
Indeed, it is now estimated that over 60%
of all processed foods sold in Canada
contain GE ingredients.
Agricultural biotechnology has, until now,
targeted industrial applications (food
production and processing) leaving the
public wondering how GE might affect
them. These so-called “first generation”
1

As this short piece suggests, however,
health and medical applications of the
technology divide feminists in much more

This is separate from the Royal Commission
on New Reproductive Technologies that dealt
with a wide array of technologies which did not
exclusively involve genetic engineering.
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GE crops have opened the way for
“second generation” products also known
as “nutriceuticals,” incorporating
pharmaceutical and/or nutritional
components such as vitamins and
minerals considered essential to a
“healthy” diet.
When it comes to agricultural
biotechnology, Canada is characterised by
a lack of public debate and openness in
decision-making. Although the success of
GMOs was premised on consumer
acceptance, the Canadian public has been
systematically excluded from discussions
regarding the desirability and safety of
these products. As a result, these products
have largely remained hidden from public
view, in the regulatory system and in the
supermarket.
Canadian Regulation of GMOs
The Canadian federal government
designates all new plant varieties and new
foods derived from them as ‘Plants with
Novel Traits’ and ‘Novel Foods’, equating
biotechnology with traditional techniques
of genetic modification such as plant
breeding. In practice then, regulations
focus solely on the new characteristics of
GMOs (and foods derived from them) in
what has been called a reductionist
approach. New characteristics (genetic
traits) in themselves are rarely seen to
pose any new environmental or health
risks (i.e. herbicide tolerance can be
achieved through means other than GE
and herbicide tolerant plants are not new).
The adoption of a product-based
regulatory system focuses the approval of
'novel' organisms independently from their
method of production. A product or
commodity focus makes the techniques
and processes of genetic engineering
irrelevant as possible sources of hazards.
This ignores the inherent risks posed by
the technology, focusing the attention of
regulators and the public on the outward
characteristics of the novel plant and away
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from GE. The environmental and health
approval of GE foods is based on a
method of analogous reasoning comparing
the hazards/ safety of modified crops
against their natural counterparts. Hence,
the hazards of conventional agriculture
and current food practices establish the
normative baseline for the assessment of
GMOs. As a result, the acceptability of
risks is a negotiated process occurring
between regulators and crop developers.
The scientific data submitted for approval
of new crops is provided by the applicants
(mostly industrial interests); the results of
field and nutritional trials are not peerreviewed, nor are they independently
assessed by scientists; this information
remains strictly confidential and away from
public scrutiny.
On a more direct level, there are no public
information requirements for foods derived
through biotechnology and foods
containing GE ingredients. They are not
labelled. The system in place at the
moment in Canada is “voluntary labelling,”
meaning that food producers or
manufacturers have a choice to keep the
content of their products from consumers.
Unfortunately, despite repeated demands
by the Canadian public for the mandatory
labelling of all GM foods and ingredients,
the federal government persists in
defending the rights of industry to withhold
that information. Similarly, public
campaigns requesting the segregation of
GE from conventional crops have been
deemed too costly (it is argued that costs
would be passed on to consumers) and
too difficult to manage through the food
handling and processing system. What is
clear is that in this case, labelling would
give consumers the choice to knowingly
not purchase GE products. The results of
many public polls confirm this statement.
In any case, it is obvious that by keeping
GE out of the sight and mind of
Canadians, the industry hopes to gain
acceptance.

While labelling and segregation are
important issues in the anti-GMO
campaign, they also constitute a false
debate. For GE opponents, the question is
not simply about labelling or segregating
but it is about maintaining access to nonGE foods and products and calling for
sustainable alternatives.

the development of the industry in various
strategic sectors of the economy;

Now that GE products have been around
for a while and that people have been
consuming them, it becomes easier to
“banalize” the use of GE food. That is
precisely the strategy used in Canadian
biotechnology policy.

3. Public Concerns (1998-): this latest
effort is marked by the formation of a
Canadian Biotechnology Advisory
Committee whose primary function is to
channel public concerns to relevant
government agencies.

From NBS to CBS: Twenty Years of
Biotechnology Policy
Through the various phases of the
Biotechnology Strategy, first known as the
National Biotechnology Strategy (NBS)
and more recently the Canadian
Biotechnology Strategy2 (CBS), the federal
government charted the course of
biotechnology policy. It has provided the
impetus for the development of a
Canadian biotechnology industry through
funding programs and policy formulations.
The three phases of the CBS have
mirrored technological developments, from
R&D to marketing and more recently to
issues of commercialization and “public
participation.” The three phases
proceeded as follows:
1. Research and Development (19831988): funds were allocated to stimulate

2

The change in name reflects not only regional
interests in biotechnology but issues of
nationalism. Quebec has been a strong
supporter of biotechnology in the past and
represents an important player in the
pharmaceutical industry, however, objections
were raised about the “national” focus of the
last strategy. For this reason, the Strategy
Office at Industry Canada decided to rename
its latest policy forum the “Canadian
Biotechnology Strategy.”

2. Industrial Development and Regulatory
Policies (1988-1997): during this period
the regulatory framework was finalized in
order to facilitate the commercialization of
new biotechnology products, and finally;

The fact that public concerns formed the
focus of the most recent biotechnology
strategy is indicative of the federal
government's commitment to the success
of the industry. For many critics of the
Canadian approach, it appears as though
the Canadian biotechnology industry is
largely the product of the federal
government’s involvement, through
various policy initiatives and generous
public investments. This bias is expressed
in the framework developed for regulating
GE products which facilitates
commercialization (treating GE as
inherently safe) and serves to enforce the
acceptability of transgenic agriculture. As
a result, the formation of an arm's length
advisory body to deal with socio-ethical
issues reflects the government's lack of
commitment to ensuring a fair and
balanced policy process. In addition, the
choice of an advisory body as the
preferred mechanism for public
participation in biotechnology issues after
GE products have been approved for
consumption and marketed to Canadians
without their knowledge seems like
inverted logic.
The sequence of events of the NBS to the
CBS has essentially served to remove the
implicit 'ethics' contained in the current
regulatory system from public debate. This
was successfully achieved by the
exclusion and marginalizing of alternative
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voices during the development of the
technology. In other words, biotechnology
has often been described as an
autonomous technology, simply because it
did not originate from public demand but
instead from scientific advances. As a
result, it is recognised that this type of
technology generally neglects the “public
good,” leaving out important social
questions about technological change and
unintended health/ environmental
consequences. For this reason, the policy
process has tended to reflect the federal
government’s enthusiasm for the industry
at the expense of the public interest.
The social acceptance of biotechnology
has been tacitly built into government
promotional and management
programmes facilitated through the CBS.
However, It is now apparent that this
strategy has not been successful at
silencing critics of the biotechnology
industry. Clearly, one of the biggest
challenges to biotechnology is democratic.
Feminist Issues
The 'biopolitical' issues raised by this
technology divide women and feminists.
Debates over GE have largely been
portrayed as consumer issues. The fact
that women are the primary purchasers of
food and pharmaceutical products and are
often responsible for feeding and
maintaining the health of their families is
used to support this view. This implies that
resistance to these products and
technologies are defined as being
essentially 'consumer-based.' However,
the issues raised by GE go beyond this
simple analysis. For many women,
resistance to GE food is linked to wider
social and ethical questions about the
collective rights of people to be self-reliant,
have access to safe and healthy food and
live sustainably on the land. For many
activists such as myself, resistance to GE
in agriculture is one way of reflecting upon
the broader questions about the use of
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that technology to transform nature and
ultimately humans.
It has been my personal view, as a
feminist involved in agricultural and health
issues, that opposition to GE, although it
has the potential to express much deeper
concerns about the social use of
biotechnology for defining particular
models of society, raises some difficult
issues for women. I personally find the
separation of health from food and from
environmental issues as a whole artificial
and somewhat short-sighted. While there
is widespread agreement among women
that GE food may not be desirable for a
variety of reasons, the medical uses of GE
and the issues they raise are more
divisive. It appears as though public
reaction to the use of genetic technologies
for producing pharmaceuticals and for
medical interventions, such as gene
therapy or genetic screening, have been
mixed. They are generally viewed more
positively than the production of transgenic
foods. Unlike opposition to GE foods,
differences in the level of concern raised
by these technologies in healthcare often
emphasise deep disparities among
women, further polarizing feminists. Unlike
food issues that stress the collective
purpose of political action, many of the
possibilities offered by genetic
technologies as they relate to women’s
“health” tend to individualise problems,
leaving women with difficult if not
impossible choices. For other women, the
lack of access to these genetic
technologies is the issue. However, the
same “life science” companies are
appropriating, controlling and manipulating
genes for food and medical purposes.
They are, along with compliant
governmental authorities, precipitating the
rapid commercialization of new foods,
drugs and new technologies derived
through biotechnology without public
debate and consensus. For critics such as
Vandana Shiva, corporate and
technological control over reproduction (in
plants, animals and humans) represents

the ultimate patriarchal project. Opposition
to a technology such as GE is an
opportunity to reflect upon the values
embodied in that science and to consider
the role of women for the genetics
industry.

• How can feminists concerned about
biotechnology reconcile these
differences while respecting the
diversity of women’s individual
experiences?

Questions to Consider

• How can a conversation about
women and health incorporate these
apparent contradictions?

While I do not offer any solution to the
issues raised in this short paper, I propose
some questions that may provide the basis
of further discussions:

• Do such differences weaken feminist
discourse around genetic technologies?
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About the Article
Given the focus of most papers on the negative role of the state – as key promoter of
biotechnology – Pat Armstrong’s reasoned and critical defence of the state provides a
fresh perspective. The state is. she argues, the only agent capable of providing goods
such as universal health care, and comprehensive social services. Armstrong does not
adopt a romantic view of the state, however. She notes that the state has been
principally active in serving the needs of corporations. But this leads her, once again, to
seek to use the state: “It is precisely because the state is now so activist,” she writes,
“that we need to make demands on it.” Armstrong’s analysis is especially cogent in an
era of widespread state-led “reform” of health and social services – reform which can
seem deceptively attractive in light of past state failings. She cautions feminists to
ensure that our arguments are not turned against us. The feminist critique of the welfare
state, for example, is sometimes used to reduce social services; and the feminist critique
of medical priorities, and their often auxiliary role in generating health, has been used to
shrink health care services.
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Feminists have been very critical of both
the welfare state and of medical practices.
And feminists have warned against a
nostalgia for the past, for defending a
welfare state that did not support women's
welfare or women's health. In light of these
legitimate concerns, the state-sponsored
restructuring of health and social services
that has been underway in recent years –
often presented to the public as “reform” –
can seem very attractive.
With reforms done in the name of
challenging medical dominance and
welfare practices, many feminists have
found it difficult to oppose reforms and
many even offer support for reforms that
seem to respond to their issues. Indeed,
with reformers talking about empowerment
and community, patient rights and
continuity of care, evidence-based
decision-making, efficiency and
effectiveness, and a focus on primary care
combined with de-institutionalization and
the breaking down of the silos that
separated aspects of care, it is
understandable why reforms may have
some appeal.
However, I would argue that these reforms
are conducted within a context and
paradigm that result in these processes
meaning very different things to reformers
than they do to feminists, meanings that
are harmful for most women. The new
paradigm is a business paradigm, where
the business of government is business
and the only line is the bottom line.
Powerful forces – ones that are about
what Brendan Martin (1993) in his book In
the Public Interest calls the grubby hands
hidden behind the so-called free market –
at the international, national, provincial
and local levels are shaping reforms so
that efficiency and effectiveness are
defined in not only numerical but monetary
terms, and empowerment is based on
ability to pay. Continuity is for processes
not people; community means dumping
care work and costs on families, and

within them on women; evidence is
defined by the powerful in very positivist
scientific terms; entrance through a
primary care giver means both restricted
access and more formulas for care; and
patients' rights mean individual
responsibility, rather than collective
strength and shared risk.
This issue of patient rights can be
particularly thorny for feminists, even in
their own paradigms. As Sheryl Burt
Ruzek (1999:304) points out:
Individualism and choice are deeply
ingrained concepts in Western
feminism. They have been critical
precepts for extending reproductive
rights, widening options for maternity
care and giving patients a say in
decision making, in requiring consent
for medical care. But as useful as
individual choice is in these arenas, can
choice be taken as the first principle on
which to base a national medical
system? Are there other and competing
and conflicting principles that warrant
equal or greater consideration? Will a
market-driven consumer model of
health address pressing issues of
access and equity? To what extent do
individualism and choice conflict with
the need of society to ensure a single,
affordable standard of care for all?
Ruzek is talking to a US audience and of a
US system, where universal health care
has never existed. But her questions do
have resonance for Canadians, especially
as we increasingly look to the US for
models of reform. Her argument leads me
to another important issue in the feminist
approach, the problem of class and race
centred views dominating feminist
approaches to reform.
Many of these reform processes and
proposed institutions, as well as the stress
on individualism and choice, have positive
meaning for white, middle class feminists
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living in urban centres, but may be very
different for women with other locations.
For the homeless, the movement of care
"closer to home" may be punishment
rather than release from oppressive
institutions, empowerment may mean
denial of access to institutional care, and
choice based on finances or physical
location may mean no care at all.
I would also argue that we have no choice
but to look to the state for strategies that
can lead to better health care. Only the
state can provide universal access, only
the state can provide the overall planning
that can make care efficient in people
terms, only the state can create stability
and continuity, only the state is subject to
democratic control. Only the state is
powerful enough to counter the power of
the global corporations. This is not to
argue that the state has served women
well, or served to reduce inequalities
among women, or lately, to improve health
care. Rather, I would argue that the
current state is very active in serving the
interests of corporations, in regulating to
create markets and control populations,
increasingly directly through households
and through the privatization of health
care. It is precisely because the state is
now so activist that we need to make
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demands on it. It does make a difference,
and we need to make sure that the
difference it makes is different, both from
what the state is doing now and from the
past. To argue that the state did not create
equality is a challenge rather than an
indictment.
A second, and related issue, is the matter
of health determinants. Originally
championed by political economists
stressing the social forces that shape our
collective lives, health determinants have
been taken up as the new truth for health
reformers of every stripe. Indeed, the
health determinants literature has been
used as a justification for dramatic
downsizing within the public health care
system. However, as is the case with other
concepts, health determinants have been
transformed within this new context.
Unemployment, income, social support,
etc, have been redefined as individual
problems rather than as collective ones.
The risk, and responsibility, is understood
as individual, with that responsibility
increasingly enforced in Ontario and
Alberta by a neo-conservative state. I think
we have to re-appropriate health
determinants, initially by insisting that
states and markets be included in the list
as major determinants of health status.
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About the Article
Boscoe and Tudiver write from the vantage point of decades of experience advocating
for improving women’s health and health services in Canada. Having been centrally
involved in developing critiques of technologies and policies, the authors now turn their
attention to the practicalities of regulation and control. “How,” they ask, “can we
contribute to the regulation and management of bio-technologies?” This is not a simple
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Introduction
We are writing from our perspectives as
women who have worked for many years
in a community-based, women-centred
health centre, the Women’s Health Clinic.
In addition to providing health services to
women, the clinic is committed to health
education, advocacy and research
responsive to women’s needs. We have
participated in a wide range of federal and
provincial committees and task forces
related to new reproductive and genetic
technologies (RGTs); helped to develop
policy papers; conducted qualitative
research on women’s experiences with
RGTs; and have experience with coalitions
and networks in the women’s health
movement, locally nationally and
internationally. We are committed to
developing critical consumer health
information resources that locate issues in
a broader context, capture the nature of
current debate and discussion, and are
accessible to women from diverse
backgrounds.
Like many feminists, our interest in
biotechnologies has been principally
focused on the new reproductive and
genetic technologies, where genetic
science and women’s bodies meet most
intimately. Recognising these points of
intersect between our individual
experiences and the wider political and
social context allows “teachable moments”
– or crucial learnings to occur. For
example, we not only ask: “Should I have
this prenatal test?” and "Do I and my
family have the capacity to cope with a
child with particular disabilities and
challenges?" but also, "Does my
community provide the supports we will
need?" and "Should public or private
money be allocated to making such testing
available?”
Our contribution takes the form of a series
of basic questions. Some of these are
crudely formulated, because it is difficult at

times even to ask “the right” question. We
hope they will stimulate discussion and
contribute to a clearer understanding of
how to develop broad-based strategies for
generating knowledge and research and
for public education and action. Despite
promises of future benefits and cures, we
worry that the development of
commercially-driven biotechnologies
poses new, unforeseen risks to human
health and raises profound ethical
implications which have only begun to be
considered in public discourse.

How can we contribute to the
regulation and management of biotechnologies?
Social research and activism related to
biotechnologies have focused mostly on
the development of well articulated
“critiques”. While some general
frameworks for regulation have been
suggested, there are few models proposed
which would address the specific
challenges of regulation or other ways of
managing the technologies. We believe
this is an area of urgent need.
We can learn from discussions of
reproductive and genetic technologies by
women’s health groups. There have been
strong analyses and critiques,
documenting the discourse and meaning
of the technologies, as well as the
“choices” they provide. In contrast, there
has been little exploration of models for
regulation and management. Indeed, there
is ongoing debate regarding use of federal
criminal powers to regulate and even
prohibit certain technologies. Mechanisms
for management of prenatal genetic
testing are unresolved.
The development of regulatory
mechanisms for biotechnologies needs to
be situated in the context of existing and
shifting regulatory mechanisms and the
challenges these present. Health Canada
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is engaged in a “Transition Process” which
may offer opportunities for new linkages
and integration among departments on
these issues. A “Risk Management
Framework” is being developed. This is an
area for further research, public debate
and synthesis. This framework will need to
be reviewed with a cautious eye. The
language and vague terms do not
adequately describe what processes or
specific standards will be put in place.
There is a need for greater transparency
and public access to information about
regulatory decisions. For example, the
pressure from manufacturers and from
some consumers to bring drugs to market
more rapidly has implications for the
public’s health and safety since shorter
time frames for clinical trials means we
know less about long-term effects prior to
public use. As well, apparent gains in
public access to information are hard won
and often limited. For example, the recent
World Trade Organization decision
permitting labelling of genetically altered
foods for export does not in itself address
issues of safety, research, development
and corporate control. There is need for a
more sophisticated analysis of regulatory
mechanisms for both research and use of
these materials.

In the context of the regulation and
management of biotechnologies, how
will research be managed?
It appears difficult to clearly separate
laboratory research, research trials and
therapeutic or product applications of
biotechnology research. For example,
research in biotechnologies in plants,
animals and particularly humans removes
the concept of a “safe laboratory” or
“sealed environment.” As well, in vitro, in
vivo, clinical trials and clinical therapeutic
uses of biotechnology products are often
carried out simultaneously, ensuring
products are brought to market very
rapidly. While the use of inadequately
tested drugs, products and devices is not
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a new phenomenon (e.g. DES; other
hormones; and blood products),
biotechnologies seem to raise even
greater health and environmental
concerns. As consumers, professionals
and activists, we feel we are always
having to play “catch up” with new
technologies and techniques, asking to
regulate technologies, the introduction and
implications of which should have been
debated at a much earlier research stage.
We ask: how are proposals for
biotechnology research reviewed and how
is the resulting research monitored? Are
there constraints on the transparency of
such research? What is the impact of
corporate secrecy in research and
development? How is increasing
commercialization of research within
universities affecting the climate of critique
concerning research and monitoring? With
reduced public funding for universitybased research, there is increased
pressure for corporate-university
partnerships. How do university based
ethics review boards function in this
environment and to what standard? Do we
need new review processes?
What is the impact of the proliferation of
private research institutes on the potential
regulation and management of
biotechnologies? What will be the impact
of the restructuring of health research
within the Canadian Institutes of Health
Research and the proposed peer review
process? What mechanisms can be put in
place to track the impact of this
restructuring? Can the role and scope of
Research Ethics Review Boards be
strengthened, for example, to include the
use of “citizen panels” and juries in
reviewing complex ethical questions?
What effective models are there that could
be used? How can the public learn about
biotechnology research in an accessible
way, exploring the broader implications?
We look to those involved in the ethical
review of research proposals to address

the wider context within which such
research is being conducted and the goals
to which it is directed. Hopefully, there is
the will and capacity in the independent
academic / research community to do so.
The question remains: How will this be
done to benefit the public and not just the
individual or corporate sector?

Can we think “seven generations
ahead”?
Can we learn to think beyond the present,
even “seven generations ahead,” as
Aboriginal elders teach? How can the
“precautionary principle” be realistically
applied to specific situations in the
present, but envisioning the future? More
immediate pressures for livelihood often
overshadow a long-term perspective and
sound public health practices. For
example, we have seen communities
argue that environmental regulations
should be weakened or ignored because
of proposed short term benefits, such as
access to well paying jobs and the influx of
capital to sustain rural communities.
What does it take to develop broader
public consciousness in relation to health
and long term sustainability – to think
beyond the next paycheck (if there is one)
to future generations? What are some of
the personal, social, economic costs/ risks
of thinking this way? What are the costs/
risks in not doing so? How can we get our
governments, attuned to electoral time
lines, to apply the "precautionary principle"
with a vision of the future?

Must we always say “No”?
While wary of the possible long term
hazards of biotechnology, we ask: Are
there some aspects and applications of
biotechnology research that offer
therapeutic value and improved human
health outcomes to future generations – or
is that truly impossible to know? For

example, is there a qualitative difference
between some genetically modified
products (e.g. soy products; crops for
hardier climates) and “terminator
technology” seeds? Are there important
directions to research and applications
that mitigate suffering (e.g. genetic
screening for Tay-Sachs disease) but that
do not lead to the denials of human dignity
and human rights underlying eugenics?
Should we screen for diseases – or
susceptibilities to diseases – for which
there is no known cure, or which may be
triggered by complex social/
environmental/ emotional factors? What
about germ line research? Is there a
“continuum” with its inevitable “slippery
slope” – or are there qualitatively different
types of research? Is the question solely
about the capacities of the technologies or
is it also about who controls the
knowledge and its application within
private and public domains?
Further, if we in Canada say “no” to a
technology (e.g. cloning), what are the
implications of “leaky borders” – the
legalization of the same practice in
another country? How do patents and
international trade agreements shape
Canada’s ability to act within its borders?
In the realities of increasing corporate
consolidation, global markets and
commercialization of the products of
conception, what does it mean to say
“no”?

Can we nurture ‘critical
consciousness’?
Human genome mapping has the public’s
attention; the almost daily announcement
of a new gene discovery nurtures an
ideology of “geneticization” (as Abby
Lippman so insightfully characterizes it), in
which genetics is assumed to play a
determining role in social life.
Biotechnology research has transformed
the impossible into the possible. What
appeared unthinkable several years ago is
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now considered inevitable: buying and
selling genetic materials; patenting life
forms; trans-species genetic transfer;
cloning; selling Iceland’s “gene pool” for
research purposes. To our children, and
increasingly to us, these are ‘normal’ news
items.
What does ‘normalizing’ these processes
do to developing a critical evaluation and
assessment of the new biotechnologies?
As women hear about new technologies
and products, they naturally want options
to maximize their health and the health of
their families. But personal choices and
options are necessarily set in a context
that excludes other possibilities. The
challenge for policy makers is to direct
resources to social needs which will have
a broad impact on population health, while
also addressing the specific needs of
particular groups and individuals. How can
we distinguish in a meaningful way
between “real risk” and “presumed risk” for
individuals and ‘populations’ and create a
clearer lens for analysis? How do we apply
understandings of gender and social class
to this analysis? For example, we know
that in addition to appropriate health care
services, health is best addressed through
reduced stress, sound nutrition, exercise,
healthier work environments and better
housing – and by reducing poverty and
violence which affect the overall well-being
of so many women. Where does/ should
biotechnology research fit in the context of
addressing these social determinants of
health?
Are there creative and effective ways to
develop critical public consciousness
about the political, economic and scientific
"drivers" of biotechnology research and
applications? How do we debate the
alternatives?
GOING FORWARD
How can we make information about
biotechnology and its implications
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accessible to women and men from a
variety of backgrounds and
experiences?
How do we create spaces for
discussion and debate?
We have few opportunities to examine the
issues suggested by biotechnology
research. In fact, we are often confronted
with the implications and dilemmas of
these technologies in our role as
consumers: Should we purchase
genetically modified foods? Should we
consent to genetic screening? Would we
participate in a clinical trial for a procedure
using biotechnology? Should we donate
our embryos or cord blood? These
dilemmas take place in an environment
characterized by ‘individual consent’ and
limited information. Often, the issue is
raised at an emotionally charged time,
such as a crucial stage of pregnancy or
during family illness. The questions are
narrowly framed. The commercial and
other interests behind the development of
many of the technologies are rarely
considered.
Schools have little time or capacity to
teach about and discuss these issues to
prepare students for future dilemmas.
Ethicists, scientists and health
professionals may debate these issues but
the content of the discourse is usually not
accessible to the public. Sometimes the
press and other media raise issues and
initiate debate. Infrequently, public
discussion is generated through art or film
(for example, the NFB film, “On the Eighth
Day” on new reproductive technologies).
There is a lack of time, opportunities and
resources for most adults to engage in
constructive debate on these issues.
Governments, to date, have relied on
researchers and lobbyists to provide them
with policy direction. Public opinion is
measured by the numbers of letters to
ministers, attention in the public media and
polling results. Yet, as educators, we know
that it is in discussion and debate that

adults learn best and that we can come to
a much deeper understanding of the
broader social context to complex issues.
Appropriate information in accessible
formats is essential to help generate such
debate. Face to face or other types of
encounters (e.g. internet chat groups) can
offer settings for listening to others from
different backgrounds and perspectives.
Despite conflicting interests and opinions,
there may be the potential to develop a
‘working consensus’ or at least define the
terms of ‘constructive opposition’.
Recently, governments have become
more overtly committed to the involvement
of the public in policy development and
decision making. This change within the
regulation development processes offers
opportunities for engagement, but also
raises concerns. For example, the goal of
citizen engagement has been adopted
throughout Health Canada. (An Office of
Consumer and Public Involvement has
been created within the Health Products
and Food Branch). Women’s groups and
other non-governmental organizations are
receiving numerous requests for input on
crucial issues such as transgenic human
transplantation and regulation of natural
products – but few have the resources and
capacity to respond. As well, while some
processes for public involvement seem to
be committed to broad and diverse input,
other consultations appear carefully
controlled and managed as to content and
outcome.
We must continue to ask: How will
women’s groups and organizations,
particularly those that address the frontline health needs of women and their
families, find effective mechanisms for
education, critical synthesis and debate

AND for input into the decision making
processes on research and commercial
developments in biotechnology? Will there
be adequate resources for groups to be
able to respond and engage? At present,
some NGOs and individuals with interest
and expertise in these issues are part of
working groups that communicate online.
They require financial resources to
continue to develop well-researched
information, effective workshops and
symposia. Can policy and decision-makers
in government engage with women’s
groups on these issues in mutually
respectful, authentic ways? If so, how?
How does an agenda of social change, as
articulated, for example, in the Beijing
Action Plan, and in concepts such as
“Health For All by the Year 2000" move
forward? What, if any, is the role of social
protest movements in the year 2000 in
advancing these agendas? Strong
opposition has emerged in Europe to
genetically modified foods and to the
development and trade policies of the
major financial institutions. Protests
(Seattle, Montreal, Prague) show these
social movements capable of attracting
media attention and influencing global
institutions on these issues.
Activists, researchers, independent
academics and others from the
environmental, social justice, consumer
rights, farm and women’s movements, etc
are raising fundamental questions about
the course of development in the 21st
century. Biotechnology and its commercial
applications are at the centre of their
concerns. Perhaps the protesters are
reminding us that answers are being
proposed before many of the most basic
questions have been asked.
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About the Article
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Advancement Foundation International, and outlines gender-equality concerns and
issues for further research and action. Delahanty’s paper is motivated by the need to
inform people about the range of issues – from corporate concentration in agribusiness,
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Introduction
Separating the issues of health, wealth
and community in the context of women
and the new genetics proved a difficult
exercise, perhaps highlighting their
appropriateness. I have chosen four main
issues that are important to RAFI’s work.
These include:
1. the use of genetic research in the
pharmaceutical industry,
2. the corporate concentration in the life
industries.
3. the Terminator and Traitor
technologies,
4. the threat of genetic biowarfare.
A brief discussion of each issue is followed
by the key gender equality issues and
research and action needs.
1. Research and use of genetics in the
pharmaceutical industry.
Human Genetic Diversity Research is
being conducted and commercialized at
an alarming rate. Were the commercial
value of human genetic diversity research
ever in doubt, those misgivings were
unambiguously laid to rest when Iceland
sold its genetic heritage to the genomics
company deCODE, who, in turn, hawked
the human data to Hoffman LaRoche of
Switzerland for US $200 million. The
spectacular and controversial deal turned
genomics research overnight from an
obscure biotech niche industry into a
mainstream commercial venture.
Suddenly, almost unheard of genomics
companies like Millennium (US), Genset
(France), and Axys (US), are turning
diversity studies into a multi-billion-dollar
commercial product strategy aided and
abetted by researchers at universities and
even some governments. The extension of
patentability by the US Patent and
Trademark Office to single nucleotide
polymorphisms (SNPs- the smallest unit of

genetic variability) has further galvanized
commercial pharmaceutical enthusiasm
for the new industry. SNPs are the genetic
basis upon which diversity researchers
define their investigations and distinguish
individuals and human populations from
one another.
Given this full-scale commercial foray into
diversity research in combination with the
new methods of sampling and sequencing,
the pressing question for ethnically unique
populations and particularly for indigenous
peoples is no longer "Will we be
sampled?" but rather "Who will have
access to human genetic diversity, and will
it be subject to exclusive monopoly
control?" The commercial race for diversity
material is not faceless, but involves the
lives of particular groups of people in
increasingly alarming ways. The potential
violation of basic human rights, particularly
with respect to research subjects' health
and social well-being, appears to be
increasing. Further, in many of the studies
it seems likely that researchers are not
obtaining fully informed consent from their
research subjects. Finally, more general
ethical questions about the patenting and
commercial use of this genetic material
have simply not been adequately
addressed.
An example of these problems in genetic
research can be found in studies by
genetic diversity researchers at Harvard
University who, in collaboration with a
number of pharmaceutical companies,
including Millennium Pharmaceuticals, a
biotechnology firm based in Cambridge
Mass., have been conducting large scale
genetics studies in China. At least 14
projects are underway in China,
encompassing as many as 200 million
Chinese citizens. The projects include
research on obesity, schizophrenia,
pulmonary disease, atherosclerosis,
hypertension, and colon cancer.
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There is a mounting body of evidence
suggesting that the rights and protection of
the research subjects, mostly located in
Anhui Province in China, are being
violated. In many cases, the research is
being conducted under conditions where
proper informed consent is likely not being
obtained. The real health risks associated
with many of the research studies are
accentuated by a situation where health
systems, particularly in the rural areas,
have completely broken down due to the
changes in the Chinese economy.
According to many health workers and
other observers, the blood supply is
heavily contaminated and syringes and
needles are re-used and unsterilized. In
many cases, the research is being
conducted in China specifically because
the population does not have access to
modern medicine. The Harvard
researchers are not ensuring that their
research subjects are provided access to
known therapeutic drugs – a situation that
would not be tolerated in the US.
In a country where researchers cannot
guarantee the privacy of their research
subjects, confidential information may lead
to prejudiced government authorities
having full access to the research data.
Serious ethical questions arise in projects
that attempt to uncritically capitalize on the
poor human rights situation in China, for
example, by using the detailed
reproductive records of Chinese women.
Not least, many of the studies will be of
absolutely no benefit to the people being
studied – who need a bowl of rice, not
gene therapy.

Key Gender Equality Issues:
• What are the specific threats to
women of genetic diversity research?
• How does gender inequality in health
care affect the risk posed to women
from such research?
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• How can feminist concepts of
informed consent be used in discussing
this issue?
• How has the notion of "choice"
advocated by western feminists been
co-opted by corporate and commercial
interests (and by the Canadian
government) in discussions about the
new genetics and health.

Research and Action:
Research.
• Monitoring the increasing
commercialization of genetic diversity:
who is doing the research, where is it
conducted, which groups are the
targets of the research, what are they
looking for.
• Follow-up research focusing on
individual cases of abuse.
Action.
• Life patenting, particularly patenting
gene sequences, needs to be
challenged in the courts, the legislature
and by the public. In particular, there is
an urgent need for a public debate on
this issue which is currently being
decided in the courts rather than
through a democratic and accountable
process. The meaning of the CBS in
the discussion about patenting is clear:
they mean to ensure that patenting is
approved in Canada.
• Cases of abuse of research subjects
need to be publicized. Peoples and
governments should declare a
moratorium on all human diversity
collection and commercialization until
certain agreements are in place. At the
international level, action must be
expected from the UN Human Rights
Commission, from the World Health
Organization, and from UNESCO’s
International Bioethics Committee
(which has woefully neglected the
intellectual property and commercial

issues arising from human DNA
collection).
• Nationally, governments could review
their medical ethics and research
protocols to guarantee the rights and
dignity of their citizens. In particular,
governments might consider legislation
that would criminalize the collection or
removal of human germplasm without
the prior informed consent of the
individual, their community, and the
national government.
• The issue of the patentability and
Human Rights associated with human
tissues must be discussed by the UN
General Assembly. An outstanding
concern is the place of human
biodiversity within the framework of the
Biodiversity Convention. Although most
countries concur that human diversity
should not be managed by the 1992
Convention, legal interpretation of the
Convention suggests that human
biodiversity is part of the agreement. In
order to correct this problem and assign
responsibility more appropriately, the
General Assembly may seek an
Advisory Opinion from the International
Court of Justice (ICJ). The ICJ could be
asked to determine the position of
humans within the Biodiversity
Convention and whether or not
patenting of human tissue, as required
by the World Trade Organisation
(WTO) contravenes Human Rights.
2. The corporate concentration in the
new genetic industry
The intense corporate concentration, and
the financial incentives which characterize
the new genetic industry are the clear
backdrop to much of the Canadian
Biotechnology Strategy. Any concerted
feminist response to the CBS requires an
understanding of just how significant these
interests are. Important elements of this
concentration involve the issues of
intellectual property and ownership of life,

both of which are important subtexts in the
Canadian Biotechnology Strategy.
The 'life industry' comprises the giant,
transnational enterprises that dominate
commercial products for agribusiness,
food and pharmacy. Loosely defined, the
Gene Giants include the transnational
enterprises that dominate commercial sale
of pesticides, seeds, pharmaceuticals, and
food and animal veterinary products. The
1990s saw a swift and bold concentration
of power in the life industry – a trend that
has shown no signs of abating. A steadily
shrinking number of corporate Gene
Giants control expanding market share
over agribusiness, food and pharmacy.
These are the transnational enterprises
that aim to manipulate, control, patent and
profit from life. Market dominance
combined with monopoly patents gives the
Gene Giants unprecedented control over
the products and processes of life – the
biological basis for commercial food,
farming and health.
To conclude that transnational
corporations rival the power of the nation
state is a gross understatement. Indeed,
the Economist reported that when
corporate executives were negotiating the
merger of Travelers and Citicorp, one of
the negotiators mused: 'Can anybody stop
us?' The only response was 'NATO.'
Since 1996, virtually every major seed/
agrochemical company has invested in
plant genomics research. Driven by the
increased efficiency of genomics
technology and fierce competition among
major agbiotechnology firms, investment in
crop genomics has accelerated
dramatically. Particularly noteworthy is the
very minor participation of public sector
researchers in agricultural genomics. After
the Gene Giants and their genomics
partners stake patent claims to molecular
bits and pieces of commercially important
plant genomes – what will be left for the
public sector? With patents in hand, the
Gene Giants have the legal right to
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determine who will get access to plant
genomic material and at what price.
Unchecked corporate power coupled with
the vanishing role of public sector
research will affect all areas of global
health, agriculture and nutrition. Neglect of
the public good is inevitable when the
research agenda is determined by the
private sector in pursuit of corporate
profits. There is a widening knowledge gap
between rich and poor, men and women,
both within and between the industrialized
North and the impoverished South. Access
to food, health and nutrition – once
considered a fundamental human right – is
now subject to the whims of the free
market system.

Key Gender Equality Issues:
• With the development of so-called
'functional foods' and 'nutraceuticals'
the lines between food and medicine
are blurring, further enticing food
processors, agbiotech firms and drug
companies to merge complementary
interests in food, biotechnology and
pharmaceuticals – what are the
implications of these changes for
women who are the primary consumers
of such products?
• How does corporate concentration in
the life industry affect the ability of
women to resist?
• How does this concentration further
polarize gender inequality in wealth and
control and access to resources?
• How quickly is the gap widening as a
result of the unchecked corporate
power?
• How has public sector research been
affected by the increase in corporate
concentration and what impact has/will
that have on women's health concerns?

Research.
• Continue monitoring the Gene Giants
to determine what direction the mergers
are headed in.
• Examine the implications of the
consolidation of the power of the Gene
Giants on world food security and
gender equality.
• Pay close attention to consolidations
and mergers, for example,
pharmaceutical companies are
"vertically integrating" by taking over
cancer research centres. In other
words, who is paying the doctors who
are prescribing the drugs.
Action.
• The concentration of economic power
in the hands of the Gene Giants, and
the privatization of science and
technology is not being systematically
addressed by intergovernmental
bodies. These issues should be at the
top of the list for UNESCO.
• The Consultative Group on
International Agricultural Research
(CGIAR) – the world's largest
international agricultural research
network – runs the risk of irrevocably
distorting its mandate to serve the
world's poor farmers if it pursues the
path of high-tech proprietary science in
partnership with transnational Gene
Giants. It must instead strengthen its
research synergy with national
programs and small farmers, including
women farmers.
• The Food and Agriculture
Organization (FAO), which 20 years
ago held a major conference on
agrarian reform and rural development,
urgently needs to revisit and strengthen
its commitment to farmers and food
security.
3. Terminator and Traitor Technology

Research and Action:
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The infamous Terminator technology
identified by RAFI in March 1998 is a

technique for genetically altering a plant so
that the seeds it produces are sterile. It is
a threat to agricultural biodiversity and the
wellbeing of 1.4 billion rural people, most
of them women, who depend on farmsaved seed and local plant breeding. In
January 1999 RAFI revealed that virtually
all the Gene Giants (Monsanto, Novartis,
Astra/Zeneca, DuPont, BASF, Rhone
Poulenc) are working on their own genetic
seed sterility patent claims. Over two
dozen new patents reveal that engineered
seed sterility is not an isolated research
agenda, it's the Holy Grail of the
agricultural biotechnology industry. As a
result of public pressure, Monsanto has
backed down from its position on the
Terminator, however, the US government
still holds the patent and refuses to agree
not to use it. In fact, both the corporation,
Delta and Pineland, and the USDA which
jointly hold the patent are planning on
going full speed ahead with this
technology. The corporations which
rejected Terminator, including Monsanto,
have since morphed and spun off parts of
their company, indicating how flimsy
corporate promises can be in a climate of
increased mergers and consolidations.
The new generation of Terminator patents
goes beyond the genetic neutering of
crops. The patents reveal that companies
are developing suicide seeds whose
genetic traits can be turned on and off by
an external chemical 'inducer' – mixed with
the company's patented agrochemicals. In
the not-so-distant future, we may see
farmers planting seeds that will develop
into productive (but sterile) crops only if
sprayed with a carefully prescribed
regimen that includes the company's
proprietary pesticide, fertilizer or herbicide.
The latest version of Monsanto's suicide
seeds won't even germinate unless
exposed to a special chemical, while
Astra/ Zeneca's technologies outline how
to engineer crops to become stunted or
otherwise impaired if not regularly
exposed to the company's chemicals. A
Novartis patent (US 5,789,214) describes

a process for chemically regulating a
number of developmental processes in
plants – such as germination, sprouting,
flowering, fruit ripening, etc. The patent
specifically mentions that the chemical
regulator can be applied to plants in
combination with a fertilizer or herbicide.
RAFI calls it 'Traitor Technology.' (For
more information and in-depth analysis,
see RAFI Communiqué’s and press
releases on Terminator and 'Traitor Tech,’
at http://www.rafi.org/ ).
If companies can genetically program
suicide seeds to perform only with the
application of proprietary pesticide or
fertilizer, it means they will dramatically
increase sales of their patented
agrochemicals and other proprietary
inputs. Chemically-dependent suicide
seeds are a dazzling technological
achievement and a brilliant marketing
strategy, but it's grim news for farmers, the
environment and global food security.

Key Gender Equality Issues
• Given that the majority of the world's
farmers are women, and that the majority
of the world's seed savers are also
women, the issue is dramatically important
to the well-being of women. The seeds are
cultivated and exchanged in accordance
with local needs and traditions. The loss of
the potential characteristics of traditional
varieties is a matter of survival for women
who anyway cannot afford agricultural
inputs. Most of the genetically modified
varieties are for herbicide resistance,
however, women in most of the world,
particularly in the south perform the
weeding activities, therefore the impacts
on women of these varieties may be
different in terms of labour.

Research and Action:
Research.
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• Further research to monitor
Terminator and Traitor patents.
• Research on the potential socioeconomic and health effects of
Terminator and Traitor on women.
Action.
• The USDA must be pressured to
reject the Terminator.
• Other national governments should
take action at the WTO and elsewhere
to reject Terminator and Traitor
technologies on the basis of public
morality.
• The Ad Hoc Working Group revising
the Biological and Toxic Weapons
convention should challenge the US
research as a violation of Article One of
the Protocol.
• The Convention on Biological
Diversity must reverse its earlier
decision allowing commercialization of
the Terminator and related
technologies.
4. A Related Risk: The Specter of
Biological Warfare:
Those of us who monitor biotechnology
have paid too little attention to its military
applications or its impact on democratic
institutions. It is almost impossible to
distinguish between peaceful,
humanitarian uses of genetic research and
the development of genetic weaponry.
According to Dr. Pauline Lane of the
University of East London, 'The line
between medical research and warfare is
often difficult to distinguish and [it] is a
difficult area to monitor.' (Lane, 1999). A
report released in January 1999 by the
British Medical Association warns that
biomedical research could be perverted to
develop 'weapons which may become a
major threat to the existence of Homo
sapiens, and a development of
biotechnology which perverts the
humanitarian nature of biomedical
science.' (Boseley, 1999. The report is
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entitled “Biotechnology, Weapons and
Humanity,” by Prof. Malcolm Dando).
Although RAFI first expressed concern
over the likelihood of crop-targeted
biological warfare at Bogève in 1987, our
warnings elicited little interest until the
Terminator patent was granted on March
3rd, 1998. Suddenly, the potential to
switch a suicide sequence in the seed on
or off with a chemical promoter posed real
concerns about economic sabotage – the
real "eco"-terrorism. Would it be possible
to insert the Terminator into seed exports
and "bury" the trait for several generations
of planting – or activate the trait through
some remote command, chemical, or
atmospheric condition? Such speculation
seemed paranoid to many. However, the
basis for concern was provided exactly
one year to the day before the Terminator
patent was allowed. On March 3rd, 1997,
the South African Government, having
admitted that the former apartheid regime
had undertaken biowarfare research on
both crops and ethnic populations, tabled
a list of twenty crop pathogens it had
investigated for possible weaponization.
South Africa’s study was presented in
Geneva to the ad hoc group of countries
considering ways to strengthen biological
warfare treaties. Then, in June, 1999,
Scientific American published a stunning
report by researchers at the University of
Bradford in the UK that chronicled crop
and livestock biowarfare research not only
in South Africa but also in the USA, the
UK, Russia, and Iraq. While some of the
history dates back to World War II or the
Vietnam War, the Iraqi work took place in
the 1990s and included bioengineering of
wheat pathogens that could have
devastated food security in the Middle
East.
In November 1998, the London Sunday
Times reported that scientists are
attempting to engineer deadly biological
organisms to produce 'ethno-bombs' that
are capable of targeting human victims by

ethnic origin (Mahnaimi and. Colvin,
1998).
In early January 1999, Craig Venter of
Celera Genomics told the American
Association for the Advancement of
Science that his company was on the
threshold of constructing the world's first
simple artificial life form, based on 300+
genes borrowed from a simple microbe.
But Venter's team announced that it would
halt further work because artificial
organisms could be misused and become
a template for deadly biological weapons
in the hands of bioterrorists (Cohen,
1999).
In a world in which a handful of
transnational enterprises dominate
agricultural biotechnology; in a world
where the Terminator is the platform
technology upon which all new biotech
breeding is undertaken; it is not difficult to
believe that corporations or governments
would use the technology to impose their
will. A textiles trade dispute with South
Asia, for example, could lead to the denial
of a modified Roundup herbicide needed
to ensure the rejuvenation of Monsanto’s
cotton seeds containing the Terminator
sequence. An agricultural dispute with
France could lead to the same threat to
France’s BT maize crop. Brazil’s soybean
harvest – a major export competitor with
U.S. farmers – would be rendered
defenseless if the U.S. soybean breeder –
or the US government – withheld the
critical chemical protector. Eco-terrorism
could prove to be far cheaper and much
faster as a means of resolving trade
disputes than WTO arbitration processes
that are both lengthy and uncertain. In the
1970s, a U.S. Secretary of Agriculture
appointed by the same U.S. president who
unilaterally dismantled biowarfare
stockpiles nevertheless felt entitled to
acknowledge that food is a political
weapon. The policy continues.
During the World Food Summit of 1996,
the United States argued that the Right to

Food should not become part of the final
declaration. They eventually lost.
However, the USA won its argument that
sovereign states need not strive to be food
self-sufficient as long as they were food
self-reliant – that they could afford to buy
the difference between national need and
national production. Now, with Terminator
Technology, food deficit countries are
faced with the possibility that their national
production will be wholly dependent upon
foreign exports of critical chemical
inducers.

Key Gender Equality Issues:
• How can women, particularly in
developing countries, resist the danger
of economic bio-terrorism?
• What are the differential impacts on
women from such biological disasters?
• Women are less likely to grow cash
crops than men in the developing
world, how would this affect the impact
on women of bioterrorism? Could there
be a "feminist bomb?" (maybe there are
characteristics that all feminists
share??!?!)
• How might the right to be food selfreliant rather than food self-sufficient
have a differential impact on women?

Research and Action:
Research.
• Research on the questions identified
above.
• Monitoring new traitor technologies.
• The connection between the military
and the human diversity collections
must also be monitored.
Action.
• Action could be taken at the level of
the 1972 Biological and Toxic Weapon
Convention (BTWC), signed by 141
countries, which bans the development
and production of biological weapons.
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The Convention is currently impossible
to enforce because it lacks
mechanisms for oversight and
enforcement. In 1998 negotiators met
in Geneva to strengthen the BTWC, but
efforts to develop a legally-binding
compliance protocol were stalled
because pharmaceutical and biotech

representatives voiced concern about
industrial espionage and the theft of
intellectual property (Anonymous,
1998). A conference to review the 1972
Convention is due in 2001, which might
be an opportunity to raise the issues of
the use of terminator and traitor
technologies as biological weapons.
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About the Article
Margrit Eichler takes the Canadian Biotechnology Strategy to task for its claim to support
Sustainable Development. Eichler proposes a set of criteria for truly sustainable
development, and evaluates the CBS in light of these criteria by focusing on the CBS’s
claims relating to agricultural biotechnology and bioengineered foods. Eichler
demonstrates that the risks of bioengineered foods are ignored by the CBS in its inflated
listing of potential benefits. Hazards to health, and to sustainability, are posed by these
products, and by the environmental and social relations of their production. “The
problems that genetically modified foods are supposed to solve,” Eichler argues “are all
due to a combination of economic, social, cultural and government factors, and need to
be solved at that level.”
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Introduction
In its CBS documents, the government
repeatedly commits itself to sustainable
development within the framework of its
biotechnology strategy. For instance, it
identifies advancing the principle of
sustainable development as one of its
roles (Canada 1998a:6, 8-11) and
presents it as one of the prominent guiding
ethical principles and values identified in
other countries for biotechnologies (12).
Sustainable development is defined as "a
commitment to consider the needs of both
present and future generations" (12). In
the following, I will provide a short critique
of this definition and propose an
alternative one, and then apply it to the
issue of biotechnology and food.
Critique of the CBS definition of
sustainable development
A commitment "to consider" the needs of
future generations is no guarantee that
these needs will be respected. To be
meaningful, there needs to a firm
prohibition against engaging in practices
that are likely to harm future generations
or that would lead to passing on fewer
natural resources than are available to this
generation.
An undifferentiated statement concerning
"generations" makes no acknowledgement
of different access to various resources
within a generation (present or future). At
present, the world has ample resources to
satisfy the needs (although not the wants)
of all humans on earth. Canada, in
particular, has ample resources to satisfy
the needs of all Canadians. Nevertheless,
a larger number than ever before lack the
necessities of life at present. This is
relevant at two levels: for one, unless
there is perceived social justice at present,
people will be unwilling to give up anything
for future generations. For the other, a
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society that fails to distribute resources
equitably for people who are currently
alive will have no yardsticks with which to
determine what is equitable between
generations. Indeed, our reckless
utilization of non-renewable resources
demonstrates that we are incapable of
preserving these resources, and our
utilization of theoretically renewable
resources (fish, forests, water, high quality
farm land, etc.) demonstrates that we
deplete them not only for future
generations but even for those alive now.

Alternative definition of sustainable
development
Sustainable development can be
defined as a condition in which all
human imperatives, and particularly the
economic, social, cultural and
governance imperatives, are met –
subject to the constraints imposed by
the ecological imperative to remain
within the planetary bio-physical
carrying capacity.
We can understand:
• the economic imperative as securing an
adequate material standard of living for all;
• the social imperative as the creation or
maintenance of social structures that are
beneficial to all those involved;
• the cultural imperative as a cultural and
spiritual base that acknowledges our
dependence on the ecosystem, our
interdependence with other humans,
transcendence of material accumulation
as the road to human fulfillment and
commitment to non-violence; and
• the governing or decision-making
imperative as an effective and legitimate
decision-making structure capable of

implementing policies to fulfill the other
imperatives (see Eichler 1999).
We now have a set of criteria that we can
apply to biotechnology. If a particular
policy moves us closer to meeting these
imperatives, while remaining within the
bio-physical carrying capacity of the earth,
these technologies are either sustainable,
or at least more sustainable than present
alternatives. Either condition must be seen
as positive. If a policy fails to move us
forward, it cannot be identified as
sustainable.

Applying the sustainability criterion to
bioengineered food
Bioengineered food is put forward in the
CBS as a means to protect health and
prevent disease. The following benefits
are detailed (Canada 1998b:6-7):
•

it will enable us to produce more
healthful food with higher
nutritional quality;

•

it can produce novel, desirable
nutrient and medicinal contents in
food that will virtually eliminate
human and animal nutritional
deficiencies;

•

it will improve the availability of
therapeutic products;

•

it will provide an inexpensive and
abundant supply of compounds
with potential health benefits, such
as fructans, which are good for
digestion and can be used as lowcalorie fat substitutes;

•

it will prevent diseases by
enhancing the levels of those
compounds in food that are known
to have beneficial physiological
effects, such as carotenoids in
tomatoes and peppers that have

anti-cancer properties or onions
with elevated levels of quercetin-a
(a compound that can prevent
stomach cancer);
•

it facilitates the development of
new foods for Canadians who
suffer from food intolerance
disorders, e.g. new plants or
cereals that are similar to wheat
but non-toxic to persons with
coeliac disease.

There are apparently no negative effects
that merit mention.
Let us compare this list of benefits with the
statements made in a recent World Health
Organization report (Daar and Mattei
1999:89-96). Here we find some
discussion of potential problems with
bioengineered food. Such problems
include:

•

•

bioengineered food may result in
unpredictable allergies to proteins
not usually found in food products,
but now present as a result of
inserted genes;

•

many food products are being
introduced stealthily. "For example
60% of consumer food products
(margarine, chocolate bars, baby
food) contains soybean material,
much of which is now sold,
sometimes without labeling, as a
mixture of unmodified and
genetically modified soybeans”
(94);

•

there are reports of lapses in
observing guidelines/ laws
regarding agricultural release into
the environment;

there are potential dangers of
conflict between nations in the future
with respect to issues of patents, "biopiracy" and the sharing of the fruits of
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research. "Thus, it seems, there are
enormous potential, perceived, and
unquantifiable risks." (94)
In other words, the World Health
Organization identifies both potential
health risks, as well as other problems,
with genetically modified foods.
Taking a step backward, we need to ask
ourselves whether the problems that bioengineered foods are supposed to
address are identified appropriately. In
general, the most healthful food is locally
produced, and fresh. There is enough food
available in the world (although it is not
clear whether in Canada) to feed all.
Canada imports a lot of food, but that is
tied up with the demise of local food
production, and the desire for exotic foods,
rather than an incapacity, in principle, to
feed ourselves. Canada’s – as well as the
world’s – food needs are thus an
economic, social and political (and partially
cultural) problem, rather than a
technological one.
While the rhetoric employed often sounds
noble – e.g. to alleviate or even eradicate
hunger in the world – the driving force
behind all of these efforts is profit. Hence
the major effort is not directed towards
developing healthier foods for consumers,
but in genetically engineering crops to
make them pesticide tolerant, improve
appearance, allow for longer shelf life and
allow for long distance transportation. All
of these are practices which directly
increase our already very high level of
unsustainability, by increasing pesticides –
a poison in nature – over organic methods
of farming, by favouring agribusiness over
local production.
Such practices are at least partially
responsible for creating some of the
problems bioengineered foods are
proposed to solve. This is particularly the
case for food intolerance. We have
witnessed a huge increase in immune
system deficiencies in the last two
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decades, of which food allergies are only
one. One might argue that the pollution in
our environment, which includes large use
of pesticides, is a cause of such
breakdowns. It seems ironic, then, to
propose as a cure more of the same.
I would argue that the problems that
genetically modified foods are supposed to
solve are all due to a combination of
economic, social, cultural and government
factors, and need to be solved at that
level.
Looking briefly at the four imperatives in
my definition of sustainable development,
there is a great likelihood that genetically
modified crops will worsen the situation
both for family farms in Canada and for
third world farmers. GM crops will make
Canada even more dependent on largescale agribusiness and further reduce
local autonomy over our food supply.
Agricultural biotechnology therefore runs
counter to the economic imperative as well
as the social imperative. With respect to
the cultural imperative, open-air planting
(of GM crops) is disrespectful, in a
multitude of ways, toward the ecosystem –
denying our ultimate dependence upon it.
There are already documented cases of
unintended cross-pollination between
genetically modified and non-GM crops
under open-air planting conditions.
Several species of insects are threatened
by the genetically modified crops (the
Monarch butterfly has received some
public attention recently). There is no longterm, cautious testing of the potential longterm impact of GM crops on the
ecosystem, as would certainly be
appropriate, given the potentially very
serious consequences (cf. Weizacker
1995). Just as antibiotics resulted in socalled "superbugs" which do not respond
to these same antibiotics, so the profligate
use of pesticides may result in super-pests
as well as weeds which are hardier than
other crops – to name just one of the
many dangers. With respect to the
government imperative, our governments

are giving up more and more of their
decision-making to corporate entities as
they push biotechnology as a prime
industrial growth strategy.

Looking at this selection of factors, then,
we must conclude that contrary to the
claims made in the CBS documents
genetically altered food may have potential
health hazards, and that it moves us in a
direction of even greater unsustainability.
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nature of the state. The state is currently undergoing restructuring, Mykitiuk argues.
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these processes. On the one hand, the new genetics contribute to a re-defined ‘neoliberal’ self, which is responsible for the private management of real and potential risks to
health. On the other hand, the new genetics appeal to the state as a means to develop
the industrial potential of the knowledge-based economy, particularly in the health care
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Canadian Biotechnology Strategy and the reorganization of the federal Health Protection
Branch, together with legislative foot-dragging on the new reproductive and genetic
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protection to the encouragement of capital accumulation. This form of privatization is
paralleled by a move to the individual as the site of governance through the self
regulation of genetic risk.”
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Introduction
The link between genetics and
privatization is not intuitively obvious.
Genetics is a branch of biology that deals
with the heredity and variation of
organisms, and understands such
variation to be located in one’s genes.1
Privatization refers to the process of state
restructuring attendant on the economic
and political forces set off by
globalization.2 Contrasted in this way,
genetics is aligned with the realm of the
natural, the empirically verifiable and the
material essence of the individual
organism. Privatization stands on the
opposite side of the nature/culture divide.
It is a politically inspired project; the
creation of human design. However, as I
suggest in this paper, there is a significant
affinity between the new genetics and the
recent projects of privatization and neoliberalism.
Privatization is largely a political and
economic phenomenon – entailing a shift
in state form from Keynesianism to neo1

.Victor McKusick (1993:2351), whose
catalogue of human genetic conditions is a
classic in the field, defines “genetics” in the
following way:
[T]he science of biological variation; human
genetics: the science of biological variation
in humans; medical genetics: the science of
biological variation as it relates to health
and disease; and clinical genetics: the part
of medical genetics concerned with health
and disease in individuals and their families
or the science and practice (art) of
diagnosis, prevention, and management of
genetic disorders.
2
For the past three years I have been part of a
SSHRC funded collaborative research project
– based at Osgoode Hall Law School – on
Women, Law and the Challenge of
Privatization. This paper emanates from my
part in that project – a study of genetics in a
post-Keynesian era – and is adapted from a
presentation made before the Feminist Legal
Analysis Section of the Canadian Bar
Association, March 25, 2000.

liberalism, as well as a shift in governing
practices. It derives its economic
momentum from the notion that the
Canadian state must reduce the fiscal
burden of social welfare programmes
which have become too costly in the
globalized market economy, while
simultaneously creating the conditions for
capital accumulation. In one sense,
privatization refers to the effort to reduce
public debt and alleviate the pressures on
public finance by eliminating, scaling back
or transferring to the private realm of the
market or the family, services that were
formerly provided by the welfare state.
Privatization also refers to a more farreaching restructuring of social and
economic institutions, and aims at the
actual promotion of private sector interests
in the economy as a means of meeting
global competition. In this sense,
privatization refers to an active and
conscious restructuring of state institutions
to favour the market and private
investment. Increasingly, the public sphere
embraces as its governing logic market
rationales and practices. As Janine Brodie
(1995:6) suggests: “governments are
effectively acting as the midwives of
globalization, transforming the state
apparatus, development strategies and
regulations to respond to the ‘perceived
exigencies’ of a global economy.”
At a discursive level, privatization is also
about privacy, individual choice and selfreliance. One of its core ideas is that the
preferred mode of social arrangement is
one that allows individuals to control their
lives as they see fit, without interference
by others and government. It is a view
about economic arrangements and
normative social relations that distrusts
collective solutions to problems, indeed
imagines problems as individualized and,
therefore, outside the purview of collective
response. Thus, within neo-liberalism, the
best form of regulation is one which is selfgoverning, where the governance of
individual subjects promotes processes of
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self-regulation and provides the
circumstances under which people may
effectively govern themselves.
My original entry into thinking about
privatization and state re-structuring in the
context of globalization was through the
doorway of genetic and reproductive
technologies – but, primarily genetic
technologies. When I first began thinking
about this issue, I was principally
interested in examining how genetic
technologies and therapies – the
anticipated fruits of the much celebrated
and publicly-funded international effort to
map and sequence the human genome –
were going to be configured in the postKeynesian, restructured, neo-liberal state.
If genetic services were truly the public
goods they were promised to be, how
would they be allocated/ accessible in a
health care context where evidence-based
medicine, cost containment,
individual/consumer choice and
restructuring were the mantras of the day?
At the same time, I was also concerned
about, and interested in, how the
information that is the product of genetic
testing and screening was going to be
used in the context of the leaner, meaner
state. If genetic diagnostics are capable of
producing information about the health
risks and genetic characteristics or
capacities of the individual tested – or their
biological family members, fetus or
possible progeny – will this information be
used in invidious ways to mark certain
citizens or prospective citizens, or their
characteristics, as deviant, abnormal,
socially undesirable or risky? Is there a
sense in which the new genetic
technologies are being used, or are
capable of being used, as a means of
literally creating the responsible,
autonomous, citizen of neo-liberalism –
that citizen who makes no legitimate
claims on the state but rather, who freely
exercises their capacity for choice and
manages their own self care?
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The ways in which specific genetic
technologies serve to restructure, and
privatize the relationship between the
citizen and her/his health have been the
subject of considerable feminist
scholarship in recent years. These are
certainly areas of concern. Yet, more is at
work at the level of state practices and
legislation in relation to the new genetics.
In Canada, genetic technology as a whole
is being actively promoted by some
branches of the state, in particular,
Industry Canada. At the same time, Health
Canada, the branch of government which
indeed has the mandate to regulate the
social, legal and health consequences of
the new genetic technologies, lags further
and further behind. The Canadian
Biotechnology Strategy and the
reorganization of the federal Health
Protection Branch point to a shift in state
policy from social protection to the
encouragement of capital accumulation.
This form of privatization is paralleled by a
move to the individual as the site of
governance through the self regulation of
genetic risk.
The advent of the new genetic
technologies and the policies of
privatization corresponding to globalization
are not independent of one another. The
pattern emerges of an interdependent
process whereby biotechnology is at once
promoted by the state as the high
technology answer to the hollowing-out
effects of globalization, and justified on the
basis of its contribution to health. The
changing understanding of health and
health care brought about by genetic
technologies in the post-Keynesian state
connects the fostering of biotechnology as
a form of industrial production, and the
privileging of individual responsibility and
risk management in the realm of health. In
this sense, the role of biological
technologies may be seen as both
symptomatic and as an important
constitutive factor in the transformation of
the state in the post-Keynesian era.

The Canadian Biotechnology Strategy
The development of the Canadian
Biotechnology Strategy (CBS) is a key
component of an industrial strategy aimed
at reaping the benefits of a “knowledge
based economy” to meet the challenges of
globalization. It is a way of capitalizing on
genetic information. It is worth noting that
the Organization of Economic Cooperation
and Development (OECD) defines
“knowledge” in the “knowledge based
economy” as, “the acquisition of
intellectual property through learning or
research” (OECD 1989). It is important to
recognize that the appropriation of genetic
information as intellectual property is an
integral aspect of the knowledge based
economy in general and the Canadian
Biotechnology Strategy in particular.
The “vision statement” of the CBS was
formulated as,
To enhance the quality of life of
Canadians in terms of health, safety,
the environment, and social and
economic development by positioning
Canada as a responsible world leader
in biotechnology (CBS 1998a:8).
The CBS and Health
According to the federal government,
“[B]iotechnology’s greatest impact both in
Canada and world wide has been in the
health field. More than 90 percent of the
advanced biotechnology products on the
world market are related to health” (CBS
1998b:1) Projections are that health
products will continue to dominate the
biotechnology arena. It is significant that
the lead Department for the co-ordination
and development of the Canadian
Biotechnology Strategy is Industry Canada
with the involvement of six other
departments, including Health. Moreover,
the strategy seems to be one designed to
accommodate the ethos of the

marketplace and not that of the health
care system. While the CBS is promoted
as a strategy to develop the tools to
improve the health and well being of
Canadians through “more reliable health
surveillance, disease diagnoses and
therapies,”(CBS 1998b:3) its principal goal
is to promote industrial activity and
economic returns “to position Canada as a
responsible world leader in the
development and sale of biotechnology
products and services” (CBS 1998c:2).

Genetics and Changing Definitions of
Health
There cannot be an industrial strategy
without a market. In the new biotech age,
that market is intended to be primarily in
health products and processes. However,
in the creation of that market, our very
definition and understanding of health is
transformed. In adopting a new genetic
understanding of health, we are changing
our definitions of health and disease and
creating entirely new categories of
embodied individual health risk. Genetic
technologies constitute a significant
departure from conventional medical
technologies in that these new
technologies do not, for the most part,
treat an existing condition or diagnose a
disease in progress. Genetic testing often
has the effect of identifying individuals with
genetic susceptibilities to particular
diseases, but who are otherwise well, as
unhealthy, or at least, to mark their health
as suspect. Thus, the alleged predictive
ability of genetic testing is problematic as it
takes for granted that awareness of one’s
personal risk status, as defined by genetic
testing, is important to the individual, and
that awareness will encourage behavioural
changes such as to prevent the future
development of the predicted condition. By
creating the category and increasing
awareness of genetic risk, the
biotechnology industry creates a market
for its products – genetic tests – which the
responsible health care consumer feels
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compelled to use in order to determine
their own risk status or that of their future
offspring. A prime example of this dynamic
was at work in the case of BRCA1&2
testing with the attendant controversy and
litigation about public funding for private
testing in Ontario.

The Health Protection Branch of Health
Canada and its “Transition” Program
Nowhere has the shift in governmental
roles been so apparent as in the recently
proposed transformations of the Health
Protection Branch within Health Canada. It
is this branch which is responsible for,
among other things, regulating the safety
of drugs and devices including those
related to the new genetic technologies.
Arguing that the new reproductive, and
especially the new genetic, technologies
do not correspond physically or
conceptually to the medical devices and
pharmaceuticals traditionally licensed and
regulated by the Health Protection Branch,
Health Canada has suggested that its
regulatory and legislative framework is
inadequate, and launched a so-called
“transition” program. This initiative to
renew Health Canada’s mandate of health
protection corresponds to the restructuring
of the Canadian state in a climate of
privatization. Not surprisingly, the
transition program includes strategies to
externalize the costs of regulation by
enhancing cost-recovery and the
development of stronger relations with
industry. The effort to externalize the costs
of regulation corresponds with a reduction
of in-house research and scientific activity.
One of the central safeguards proposed
under the HPB Transition Program is to
pass legislation making it illegal for a
manufacturer to place a dangerous
product on the marketplace. Such
legislation is expected to force
manufacturers to be more explicitly
responsible for ensuring product safety
due to enhanced and more rigorous
liability. As the law now stands however, it
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is the Federal government, and ultimately
the Minister of Health, who is responsible
for ensuring product safety before
approving a product for release onto the
market. Currently, the government is
primarily accountable to the public for
safety and the protection of public health.
The proposed legislation alters this
situation by shifting responsibility from the
government to private industry. Moreover,
it creates a situation where instead of
Health Canada being primarily responsible
for ensuring product safety prior to public
exposure, industry carries this
responsibility. Health Canada’s
interventions are activated after a danger
has been detected through market use
(i.e. protection through the threat of a
harsh punishment, instead of protection by
preventing product entry onto the market
in the first place).
Health Canada acknowledges that its
regulatory system is shifting away from a
model where assessments are made inhouse towards one, which it calls a
“networked” model, including universities
and industry. This new model is defended
as more consistent with access to the best
scientific knowledge and expertise,
although the Health Protection Branch
transition team is apparently still grappling
with the problems of accountability raised
by this model. I suggest that this new
model is consistent with the relativized
position of the post-Keynesian state,
testifying to the contradictions of the
state’s role in health protection versus
industrial promotion. To illustrate, one of
the goals of the transition process is to
promote “efficiency” in speeding up
regulatory approvals. Speedier
introduction of new pharmaceuticals is
obviously in the interests of industry, but
glosses over the potential tradeoffs
between accelerated introduction of new
products and the assessment of possible
risks. The changing emphasis in health
protection is consistent with the goals
articulated in the Canadian Biotechnology
Strategy. Increasingly, the Health

Protection branch will depend on its clients
to achieve the regulatory purpose of its
mandate. Diffusion of accountability and
responsibility forms its own kind of
“privatization”.
There is no evidence that Health Canada
or the federal government seeks to
abandon its mandate in health protection,
or that it is blind to the ethical concerns
which have been raised. Instead, the
renewal of the mandate for health
protection occurs in a context where the
role and meaning of the state is shifting,
and where the autonomy of the Canadian
state in relation to international trade
agreements, and the demands of
multinational corporations, is shrinking.
The implementation of the privatization
agenda is not therefore bringing about the
deregulation of health, rather the manner
in which health is being regulated is
changing. Health is increasingly being
regulated as a commodity rather than as a
public good, and health care as a business
rather than as a public service. In this
context, it is interesting to note that one of
the proposed name changes of the Health
Protection Branch was to call it the
“Management of Risks to Health” branch.
No longer is the federal government to be
involved in protecting the health of society
from unsafe pharmaceuticals and medical
devices, but it is positioning itself to
manage the risk inherent in such
commodities and mediate between the
interests of industry and the citizen public.
From a central concern with health care
provision and public safety, the state has
now shifted to a principle concern with the
requirements of production and capital
accumulation.
The Regulation of Genetic and
Reproductive Technologies
Despite the fact that the Royal
Commission on New Reproductive
Technologies reported more than seven
years ago (1993), no new legislation has

been passed regulating the health and
social implications of these technologies
despite a significant amount of public
support for such regulation. The federal
government did introduce one piece of
legislation, Bill C47, which died on the
order paper of the last Parliament, and
one discussion paper with legislation
promised before the Fall of 2000. The
important fact, for my purposes here, is
not what is in the proposed legislation but
the discrepancy between the urgency with
which the Canadian Biotechnology
Strategy and the restructuring of the
Health Protection Branch have been
pursued, and the hesitancy and caution
with respect to the introduction of
legislation to regulate the health effects of
the new reproductive and genetic
technologies. In the climate of state
restructuring and privatization, study of the
new genetics reveals how the priorities of
the state in relation to health have shifted
from protecting the public good to
promoting the interests of industry, and
creating the conditions for health to be a
site of corporate profit making and capital
accumulation.
Conclusion: About New Biotechnology,
Accumulation, The Discursive Shift
around Health, The Role of the State
and Law.
I have arrived at two major conclusions
with respect to the introduction of genetic
technologies and the ways in which these
are regulated in Canada. The first
conclusion – little discussed in this paper,
but discussed more widely in feminist
monographs3 – concerns the ways in
which the market for genetic technology
shapes our understanding of health and
3

Both areas of privatization are discussed and
analysed, in depth, within my book chapter,
“Private Bodies, Public Parts: Genetics in a
Post-Keynesian Era,” in the forthcoming book
edited by Brenda Cossman and Judy Fudge.
(Toronto: University of Toronto Press, 2001).
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risks to health. With genetic tests
marketed as a kind of health-risk kit,
individuals are being called upon to
undertake self-surveillance in the name of
reducing the burden of disease on
themselves and on society as a whole.
Thus, genetic testing and genetic
understandings of health, are seen as a
means to create the ideal citizen of the
post-Keynesian order – one vigilant about
her/his economic burden or contribution to
society and willing to discipline themselves
or their procreative activity in the name of
maintaining healthy and productive
citizens. It is particularly through the
genetic surveillance of potential offspring
that women become the gatekeepers of
the new social order, with genetic
technology introducing a new gendered
division of labour with respect to
maintaining a disciplined order of
productive citizens.
The second conclusion has to do with the
nature of regulation and law in the postKeynesian era of the new genetics. Here,
the problem or phenomenon we witness is
not simply “deregulation” in the service of
the market, but rather a different kind of
regulation and a shift in the legal paradigm

of regulation. Instead of deregulation, we
find a re-regulation intended to make
possible the greater appropriation of
intellectual property and its capitalization.
What the Canadian Biotechnology
Strategy, the restructuring of the Health
Protection Branch and the paralysis with
respect to legislation on reproductive and
genetic technologies illustrate is not just
the promotion of the biotechnology
industry, but a redefinition of the public
interest. The state no longer sees itself as
defending the public interest against the
private interest of private actors, but sees
itself as promoting the interests of private
actors as the potential benefactors of the
public through the production of health
commodities. In so doing, however, the
state is also changing the nature of
regulation. In moving away from defining
and representing the public interest, and
towards a model of product liability and
intellectual property, the state is shifting
the arena of adjudication into the area of
commercial law and away from public and
constitutional law. This entails not only a
different set of concerns, expertise and
evidentiary rules but also a shift into a
social arena with its own gendered
hierarchy.
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Nandita Sharma discusses Vandana Shiva’s (1997) argument that the development of
agricultural biotechnology is akin to the closing of the commons. Like the latter social
revolution, biotechnology grants private rights to previously shared properties – in this
case germ plasm and plants, rather than fields and forests – but with many of the same
social consequences. Sharma’s analysis suggests why genetically modified (GM) foods
have provoked such opposition, not only among consumers in the global North, but
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that the “ethical values” proposed by the CBS are untenable – being premised on faith in
the value of genetically engineered (GE) crops and foods. She warns against any
accommodation by feminists, arguing that total opposition is the only credible stance.
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In the document, The 1998 Canadian
Biotechnology Strategy: An Ongoing
Renewal Process, the Canadian
government outlines how best to market
biotechnologies. Indeed, this is the major
aim of this report. This becomes clear
through a number of statements, such as
“The Government of Canada has
consistently expressed its support for
biotechnology as a priority” or the
government’s position that biotechnologies
“offer significant economic benefits,
particularly in exports and job creation”
and to “safeguard the environment.”
Nowhere in this document are the
concerns expressed by independent
women, farmers, scientists and other
concerned groups. Instead, the
government presents its public relations
strategy designed to pacify people in
Canada into accepting the legitimacy of
the biotechnology industries’ plan to
expand and make greater profits. Although
the biotechnology industry is engaged in a
wide array of initiatives in further
technology development, including
reproductive and genetic technologies,
pharmaceutical products and a number of
key areas in agriculture, it is the latter that
I will concentrate on. Indeed, the
biotechnology industries’ incursion into
agriculture has been one of the main
rallying points upon which groups in the
global South and North have galvanized
people’s opposition. This is not a
coincidence.
It may be difficult for those of us in the
North who, when we think of farming,
picture the gigantic mono-cropped fields of
the North American prairies, but 80% of
the world’s farmers continue to be
engaged in small-scale farming. Nowhere
in the world have industrial agricultural
methods become more entrenched than in
North America. There are still small-scale
farmers left in Europe. And, of course,
most of the farmers of the global South
continue to be small-scale farmers. Thus,
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it is no coincidence that the greatest
struggles against the biotechnology
industries have occurred in the South and,
to a lesser extent, in Europe, and most of
them have been organized by or through
small-scale farmers and organizations run
by them or working with them in solidarity.
Nor is it a coincidence that here, in North
America, we are just beginning to organize
ourselves effectively on the issue of
biotechnologies and agriculture.
The furor over the “life sciences” foray into
agriculture rests on the basic fact that the
biotechnology corporations have arrived at
new technologies of colonialism. That is,
they have devised new means by which to
continue to dispossess people of their
ability to live outside of a capitalist political
economy – new processes by which to
enslave them. Let us not forget that the
social process by which people are
transformed into workers continues to
mark the expansion of capitalism. The
wide-scale destruction of the rural
economy in the South can be said to be
the major effect of this latest period of
“globalization.” It is the movement of
women and men from a devastated and
privatized countryside into the “free export
zones” throughout the South (and
increasingly the North) that has allowed for
the creation of a “global assembly line.”
One of the key technologies of colonialism
today is the patenting of life forms.
Through this process, biotechnology
corporations are engaged in a wide-scale
appropriation of common property. As
Vandana Shiva rightly points out,
patenting is the late 20th century form of
“enclosing the commons” (1997). As in the
past, this theft is ideologically concealed
through claims of the sanctity of private
property. This argument is apparently
legitimate for those whose consciousness
has been wholly shaped through
acceptance of white, capitalist
patriarchies. In the global South, at least, it
is women who produce the majority of

their own, their family’s and their
community’s everyday needs. It is women
who, year after year, save the seeds
necessary for survival. Indeed, women
everywhere have created elaborate,
community-strengthening, ways to honour
their productivity and the productivity of
nature. By patenting their very means of
survival and saying that it is the private
property of the owners of some
transnational corporation that is usually
located half-way around the world, the
biotechnology corporations – and the
governments and international governing
institutions supporting them – are ensuring
the destruction of the rural economy and
its replacement with industrial agriculture
on farms owned by fewer and fewer
people. This is the goal. It achieves two
things: the replacement of small-scale,
ecologically-sound agriculture with
industrial agriculture and, two, the creation
of a working class dependent solely on
capitalists for their livelihood. This goal is
currently being achieved in many ways.
The main goal of the promoters of
industrial agriculture has always been to
prevent farmers from saving their seeds.
This is now possible through
biotechnologies, such as the “Terminator”
technology, the “Traitor” technology and,
ultimately (and even without these), the
patenting of life forms. Of course, it is not
the technologies alone that are
responsible. They are only the mechanism
of ruling, not the rulers themselves. What
makes these technologies possible and
perhaps more importantly, actionable
today, are social relations based on
unequal exchange between the North and
the South, racism, sexism and capitalist
political economies.
Thus, it comes as no surprise that one of
the major selling points of the new “life
sciences” in regard to the “advantages” of
biotechnologies is its promise to “feed the
growing world’s population.” In this one
statement is condensed the entire gambit

of white, capitalist patriarchy. In this one
statement it is assumed that
a) population growth results from ‘Third
World’ women having “too many”
babies;
b) people starve because of this and;
c) ‘Third World’ peoples need the help
of ‘First World’ people and their and
“advanced” technologies.
Of course, embedded within this discourse
is the notion that it is ‘backwards’ to be a
small-scale farmer, that the destruction of
the rural economy is a “good” thing and
that finding an industrial job is the goal of
the world’s people. Indeed, this is the
textbook definition of a “modern” person in
the “development” literature. These
ideological notions contribute to the
expansion of white, capitalist patriarchies
that make women the dependents of men,
make people the dependents of capitalists
and make the South dependent on the
North. Also hidden from view is that in
reality it is men who exploit the wealth of
women’s labour, it is the capitalists who
steal the fruits of workers’ labour and it is
the North whose ravenous consumption
practices are dependent on the theft of
Southern wealth.
The Canadian state is a wholesale
supporter of continuing to base social
relations throughout the world on this
exploitative model. Indeed, this
government is acting according to a script
that reads as if it was written by people in
biotechnology industries. For example, the
government says that “biotechnology has
the potential to increase…sustainable
development” (Canada, 1998:5). Contrary
to growing evidence, but in a repetition of
the company line, the government says
that genetically engineered (GE) crops
allow farmers to apply fewer chemical
pesticides and herbicides.
This government also wants Canada to
“have a prominent role in the emerging
science of genomics, including genome
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mapping and gene sequence
technologies” (Canada, 1998:19). They
further add that they want to make
“Canada’s international development
assistance policies and programs” fit into
the CBS vision and goals, “particularly with
regard to the developing countries to
which Canada exports or is likely to
export” (Canada, 1998:16). And, the
government states that “modernizing
Canada’s intellectual property laws and
ensuring their effective administration
would significantly improve the domestic
investment climate in biotechnology”
(Canada, 1998:16). In other words, they
want to make sure that current patent laws
in Canada are in line with WTO (World
Trade Organization) guidelines that
sanction life patents.
Importantly, throughout this document is
the government’s concern that people (redefined as consumers) accept and be
confident in and comfortable with new
genetic technologies. In particular, the
government is concerned with people’s
fears of eating genetically engineered
foods. For instance the government’s own
polls show that a majority want to see
labeling of such foods so they can
distinguish between them and untampered
foods. Thus, they stress that “the public
wants assurance that biotechnology
products and services are safe for
humans, animals and the environment”
(p.14). Not coincidentally, the Canadian
government has gone into a
communications venture with the
biotechnology industry in a new media
institution designed to convince people
that there are indeed benefits to the
consumption of genetically engineered
foods and that this is safe. I, like many of
you, have been subjected to corporate
propaganda being voiced as if it was a
public health message (e.g. GE is nothing
new. Organically making cheese is a form
of GE. So is the process of making yeast,
beer, etcetera. Genetically adding alien
nutrients is sound science and good public
health policy, ad nauseum).
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While the government recognizes that a
much more effective sell job is needed
before people will happily eat genetically
engineered foods, it argues that the best
way to sell biotechnologies is to link them
with community health concerns. In the
Canadian Biotechnology Strategy
document, then, the government states
that “people are more likely to accept
applications such as new drug therapies
that clearly address health needs, and are
less likely to accept applications that offer
less obvious benefits.” Is it a coincidence,
then, that we have been seeing huge
spreads within the Globe and Mail (just to
use one example) on the health benefits of
patenting and biotechnologies?
Another one of the ways the government
wants to secure public approval for
biotechnologies is to have so-called public
consultations on what are called the “core
values” of an ethics framework. This is
especially troublesome since the
government makes it very clear that they
wish to “enhance the quality of life of
Canadians in terms of health, safety, the
environment and social and economic
development by positioning Canada as a
responsible world leader in biotechnology”
(Canada, 1998:8). Obviously, this set up
already precludes a real debate since it
takes the application of biotechnologies for
granted.
I believe that we need to take a very
strong position against attempts to co-opt
the women’s movement into participating
in the establishment of the so-called
ethical “core values” on the use
biotechnologies. It is simply impossible to
simultaneously act ethically while working
to enclose people’s common spaces,
destroy people’s ability to be selfdeterminant, concentrate the world food
supply in a small number of hands, crosspollinate GE crops with organic ones, etc.
It is the practices of the biotechnology
corporations that are unethical. We cannot
allow ourselves to separate their actions

from an abstract, philosophical statement
on the “ethical” standards of
biotechnologies.
First, this method of securing “approval” is
manipulative as it only gets to the lowest
common denominator. We have seen this
occur through other government
consultations, namely “public
consultations” on immigration policy,
citizenship policy, social welfare policy,
poverty, etc. whereby the concerns of
feminists have been pitted against the
concerns of neo-Nazis, corporate lobbyists
and anti-feminists and the government has
been able to slide up the middle (which
itself has shifted much to the Right) and
act as the reasonable arbitrator of “public”
interests.
Secondly, the government has provided a
built in role for biotech corps by saying that
one of their key goals is commercialization
of biotech and then stating that it is the
private sector that has the “lead
responsibility” for this (Canada, 1998:10).
Moreover, would any of us seriously
consider that the Canadian government is
going to uphold whatever “ethical”
standards we might like to see given that
commercialization of new biotechnologies
is the government’s biggest priority?
I believe that we need to radicalize our
message in total opposition to the
biotechnology industries. In this regard, let
me repeat the position of the Basmati
Action Group (of which I’m a founding
member). We support the outright banning
of GE crops being grown and sold in
Canada. This is the only ethical response
by those living in a country that is a major
producer and exporter of GE foods.
We believe that by simply labeling GE
foods, we fail to act in solidarity with those
people who have little choice in what they
eat, those people whose main source of
food is not from the grocery store and
those farmers around the world who are
trying to maintain GE-free crops. By

saying that we will settle for labeling of GE
foods, we are buying into the liberal-choice
model that tells us that those who eat
chemically-infested foods are “choosing”
to do so, that those who eat food that is
GE (after it has been labeled as such) are
also “choosing” to do so. This takes the
heat off the people who are supplying us
with toxic food.
By settling for labeling of GE foods, we are
saying that we don’t value the
Precautionary Principle. We say that by
allowing consumers the “choice” to buy
GE foods or not, that we are ready to
leave it to the market to determine whether
this food is safe or not. Finally, the issue
for most of the world’s people is not what
is being sold on the shelf but what is being
grown in the field. Only by banning GE
crops can we ensure that natural
biodiversity will not be destroyed.
Following the mass, direct action in
opposition to the WTO in Seattle in
November, 1999, I can attest to the fact
that radicalizing our message and
mobilizing people in total opposition to
processes that unleash oppressive and
exploitative practices is more effective
than trying to make reforms.
For me, my involvement in the protests in
Seattle was a turning point. It was in
Seattle where I saw our power as a
grassroots movement against capitalist
globalization being strengthened,
consolidated and radicalized. This is partly
because our direct actions showed the
moral and strategic bankruptcy of the
small minority who would have us cooperate with the WTO instead of shutting it
down. These are the people who allow
themselves to be co-opted by national
governments in desperate need of a
legitimacy fix. These are the people who
have allowed themselves to be portrayed
as the “reasonable protestors” in contrast
to “the violent rabble” on the street.
Indeed, after the grassroots’ power that
people demonstrated in Seattle, it is more
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distressing than ever to see a small
number of NGO “leaders” selling the WTO
as “fixable,” as “reformable,” as “open to
democratization” when it is clear to most
that the only good WTO is no WTO.1
What we need to do is figure out how to
re-shape people’s consciousness to
recognize the benefits of overthrowing the
current ways of organizing our world. The
best way to do this is to provide
alternatives. One thing that is really
inspiring is the knowledge that in
agriculture (as in safe, effective
reproductive health), women already know
how to realize an alternative to white,
capitalist, patriarchal forms of organizing
our relationship to our food and with each
other. In agriculture, there are women who
know how to grow food organically, in
small-scale, with community help. This is
the only kind of agriculture that we can
support ethically. Eating the fruits of this
kind of labour should not be a luxurycommodity available only to a small
number of relatively well off people in the
world. We need to keep in mind that just
40 years ago, most of world was able to
grow and eat organic foods. It was the
values of the so-called ‘Green Revolution’
that was sponsored by industrial
agricultural and petrochemical industries,
promoted by national governments and
enforced by the World Bank and the
International Monetary Fund, and the
1

It should come as no surprise that those who
led the most effective protest seen in North
America for the last thirty years were those of
us who did not see much, if any, benefit from
the supposed “golden days” of the 1950s and
60s. We were the ones who never saw any
good come from “negotiating” with the beast.
We, Indigenous activists, street-identified
young people, women of colour, working-class
women and men who were never included in
the labour aristocracy, Gen X’ers (who
perhaps knew better than many in North
America that the beast had no loyalties to
them) and more – all of us, together, refused to
compromise. Here, in the belly of the beast, we
became indigestible.
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incredible proliferation of chemicals into
the world’s food supply, that resulted in the
loss of organic food for life forms on the
planet. This is what we must reclaim.
A radical position on biotechnologies is the
message we ought to be sending to the
recently established Canadian
Biotechnology Advisory Committee that
reports to the new Biotechnology
Ministerial Coordinating Committee,
responsible for overseeing the
implementation of the government’s
strategy. We in the Basmati Action Group
have been circulating a flyer pointing out
the government’s position on
biotechnologies and giving people the
address and e-mail of the CBS taskforce
so they can directly send this message to
these guys. Much more grassroots work
needs to be done by all of us. The only
hope we collectively have for the
continued life of this planet and for the
struggle for social and ecological justice is
to mobilize a mass movement in
opposition to the biotechnology industries
and the people whose sexism, racism and
able-ism fuel the global capitalist system.
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About the Article
Moved by a recent trip to Laos, Penny Van Esterik links her analysis of the Canadian
Biotechnology Strategy to the lives of women in Canada and abroad by contemplating
the role of genetically modified food-stuffs. Her narrative highlights the jarring
inconsistencies between the promises made in the name of biotechnology, and the lived
experience of most of the world’s women. Van Esterik’s analysis also highlights some of
the inconsistencies between feminist and consumer models of protest. “As consumer
protests against GE foods increase,” Van Esterik asks, “will poor women make ends
meet with discount produce, cardboard tomatoes, and processed foods that last longer
on the shelves, but that have been rejected by others with more resources – both
knowledge and money?”
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Introduction
After a recent trip to Laos (Lao PDR) in
January 2000, as a member of a team
which introduced food security and gender
into a project on natural resource
management, I find that I view genetically
engineered (GE) foods and biotechnology
strategies in a different light. Here I want
to raise points from a personal and
advocacy perspective which derive from
this experience.1
Lao Stories - January 2000
On the plane, on the way to Vientiane, the
capital of Lao PDR, I overhear AsianCanadian businessmen discussing new
crops introduced into Vietnam through the
Canadian International Development
Agency's (CIDA’s) joint ventures. They
discuss the opportunity for field trials in
Lao PDR. Settled in my hotel room in
Vientiane, I am hooked up to CNN and
between news of the Montreal meetings
on the Protocol on Biosafety are
interspersed commercials for "Life
Industries" and the wealth they will bring to
Asian entrepreneurs and their western
business partners. The next day I travel 40
kilometres in 3 hours over non-existent
roads to the village of Ban Hai Tai where I
speak with women about food security.
Food security to them is the ability to feed
their children, access to land to grow local
varieties of glutinous (sticky) rice, and
access to forests for wild products
(providing food diversity and medicines).
There has been little incentive to introduce
HYV (high yielding varieties) of glutinous
rice to Lao PDR, because there is no
commercial market and farmers prefer the
taste of their local varieties.
1

I have written in a more academic manner on
issues of infant feeding, food security and
development in: Van Esterik, Penny, and
Carole Counihan. Eds. 1997; Van Esterik,
1999a, 1999b, 1997, 1996a, 1996b, 1996c.

In spite of extreme poverty, exceptionally
high maternal mortality rates
(656/100,000) and high infant and child
mortality rates (142/100,000), the
community is sustained by two interaction
cycles:
1. the production of breastmilk and its
delivery to a newborn, and the transfer
of knowledge about breastfeeding from
grandmother to mother to daughter;
2. the production of food from seed to
plant to seed to plant and the transfer
of knowledge about how to grow and
prepare food in different localities,
seasons and circumstances.
Just as these women know how to
preserve their own seeds for future
harvests, so breastfeeding women
preserve and transmit knowledge of
breastfeeding. In contrast, North American
women came close to losing knowledge
about breastfeeding, so that there was
nearly a lost generation who did not value
breastfeeding or know how to manage
lactation. Seeds and children both have to
be nurtured to grow and reproduce.
Nothing should break these self-reliant
cycles of nurture. Yet both cycles are
under threat by some of the same
processes – even the same corporations.
Consider the research on genetically
engineered human proteins which were
bred into Herman, the first transgenic dairy
bull, bioengineered to carry a human gene
for producing milk with human proteins,
lysozyme and lactoferrin. Lactoferrin has
natural anti-oxidant, anti-bacterial, antiviral, and immune stimulating properties
and is present in human milk. When added
to infant formulas, this "wellness
ingredient" was said to simulate the
composition of breastmilk. Herman's
female offspring were to produce these
proteins at a lower cost for commercial
uses such as in infant formula. The
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products were to be launched in 1996. For
some reason, the bioengineering of
human milk proteins was considered
"ethically safe." That is, manufacturers did
not expect resistance. However, after
protests from several groups (including the
Rural Advancement Foundation
International, RAFI and International Baby
Food Action, IBFAN), the transgenic
product was redefined as containing
modified lactoferrin and was sold as a
product to cure AIDS.
Infant formula made from human protein
bioengineered in the milk of transgenic
dairy cattle is certainly not human milk,
and is far removed from breastfeeding. But
the GE ingredients would provide an
opportunity for the development of new
marketing strategies: "just like mother's
milk" would have a new appeal. New infant
feeding products with ingredients such as
nutritional oils providing two essential
acids DHA and ARA, present in breastmilk
but until recently absent from all breastmilk
substitutes, are targeted for fullterm and
preterm infants – a marketing strategy
which may be used with GE foods. The
proliferation of soy-based infant formulas
is particularly disturbing, since GE soy is a
key ingredient, and the health effects on
premature and fullterm infants is as yet
unknown.
In March, 1998, the Delta and Pine
Company patented the terminator
technology, a biotechnology invention that
will permit its owners to create and market
sterile seeds by programming plant DNA
to kill its own embryos, irretrievably
breaking the plant to seed to plant cycle
on which human life depends. The
purpose of this technology is to increase
the value of seed owned by American
companies and open up new markets in
third world countries. In 1999, these
companies vowed not to commercialize
terminator seeds. But according to RAFI,
Delta and Pine Land Seed Company is
moving aggressively to commercialize
these “suicide seeds.” Monsanto bought
122

the company that developed and patented
this terminator technology in May, 1998
and in June, 1998 American Home
Products (AHP), home of Wyeth along
with many agro chemical products,
attempted to buy Monsanto. AHP would
have become the largest agro/ chemical/
pharmaceutical/ "Life Industries" company
in the world, if the merger had not fallen
through over disagreements over who
would be "boss". And as agrotoxins
bioaccumulate in the food chain and begin
to appear in mother's milk, we would have
come full circle, as Wyeth also produces
infant formula.
And so I think back to these Lao women,
managing to feed their families with so few
resources, and wonder what the future will
bring, with a new bridge to Thailand, and
new roads to Vietnam bringing in tins of
"old" infant formula without the "new"
ingredients already present in their own
milk, and the possibility of our oversees
development assistance programs funding
field trials for "new" seeds to improve on
their "old" seeds.
Women and Food
At the World Food Summit in 1996, Maria
Meiss and Vandana Shiva organized a
Women's Food Day to highlight how the
policies being decided largely by men in
the formal FAO summit were likely to
affect women. They asked why women
were not consulted and why the concerns
of women farmers, entrepreneurs and
consumers were not being heard. Perhaps
it is because what many women know
about food is used to nurture others; this
knowledge is hard to protect, easily shared
through communal cooking, food and
recipe exchanges and "potluck" meals.
Women's influence on the food system is
greatest in households and communities.
What many men know about food
becomes property, commodity, with
access protected through intellectual
property rights, copyrights and patents.

The faces of men are particularly visible at
national and international food forums
where they represent industry and trade
concerns. In a world where everyone was
dependent on multinational corporations –
or worse, one giant corporation – for their
seeds, medicines and food, whose views
would prevail? Consider the inducements
that companies would offer to end such
self-sufficient practices as planting a
garden with your own seeds or
breastfeeding your baby. To share food
and seed is normal practice for women;
will it become a crime to share ideas or
seeds according to the new regimes run
by companies like Cargill and Monsanto?
Currently, I am introducing this topic to my
nutritional anthropology class, using
Nottingham's (1998) Eat Your Genes as a
text. The book has no entry for women,
feminism, gender, reproduction or any
suggestion that GE foods are of special
concern to women. However, what women
are putting in their bodies has implications
for their own health and that of the next
generation.
As family food managers on a daily basis,
women are targets for industry messages
designed to promote acceptance of GE
foods. Messages will appeal to women's
sense of fairness, to give the new products
and companies a fair hearing, and to think
of those who do not have access to
sufficient food. Industry knows the appeal
of the argument that GE foods are the
answer to hunger and food insecurity. And
they will no doubt stress the ‘right to
choose’, a phrase that has a special
meaning for many women activists, yet
should flash warning lights when used by
government and industry.
Women have been in the forefront of
protests against the speed and extent of
the introduction of GE foods. In matters of
family food, women are cautious,
suspicious of changes, for whoever cooks
is tuned into how new foods taste and
cook.

Food Security??
Food security means having enough food
to maintain a healthy and productive life
today – and in the future. Communities
enjoy food security when all individuals in
all households have access to food –
adequate in quantity and quality,
affordable, acceptable, appropriate and
readily available from local sources on a
continuing basis.
In the fall of 1999, an article in the Toronto
Star featured a number of male chefs
banding together to protest the use of GE
foods; they planned to use only organic
foods in their expensive restaurants. In
this city of food boutiques and food banks,
where will the foods containing GE foods
be located? As consumer protests against
GE foods increase, will poor women make
ends meet with discount produce,
cardboard tomatoes, and processed foods
that last longer on the shelves, but that
have been rejected by others with more
resources – both knowledge and money?
What will GE foods do to ease the burden
of hunger and food insecurity in Canada
and elsewhere? What assurances do we
have that future generations will not be
affected by what they were fed before and
after birth? Monsanto, Cargill and Nestle,
among the largest corporations in the
world, are exercising increasing control
over what we eat and feed our children,
and even the governments we elect, but
they are not contributing to food security.
In our advocacy work, it is important to
examine how corporate power is exerted
in places in the world where Canadian
technology has spread, often through
CIDA's development assistance programs.
GE foods are presented by industry as
"nothing new" but a result of our
increasing control over the domestication
of plants and animals over the past 10,000
years. My position is that GE foods are a
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radical break in the evolution of food
production, not a continuity. Why?
Because of the speed with which changes
are occurring, and corporate control over

the process. Thus, we are in need of
totally new policy, research and advocacy
approaches to address problems raised by
GE foods.
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Becky Holmes reduces the Canadian Biotechnology Strategy to its most fundamental
element. The Strategy, she writes, “is about wealth – simply put.” Yet this wealth is not
equally distributed, nor are the negative consequences of advancing biotechnology
necessarily encountered by its beneficiaries. Reviewing several papers in the collection
which take biotechnology and wealth as their theme, Holmes outlines some of the
contradictory ways that wealth and health interact in the CBS. She warns against several
of the most commonly invoked “band aid” solutions, and advocates those that might
work to assert the management of biotechnology in the public interest. Finally, Holmes
encourages Canadians to take advantage of international perception – however flawed.
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Introduction
The Canadian Biotechnology Strategy is
about wealth – simply put. The
government documents are filled with
phrases such as 'economic potential,'
'worldwide market,' 'generate revenue,'
'future jobs,' 'increase … international
competitiveness.'
The Working Group on Women, Health
and the New Genetics and the rest of the
Workshop participants constitute a sample
from the wealthiest 10% of North
Americans – the wealthiest 2% of the
world's citizens. From wealth, can we step
aside and analyze wealth?
For some 10 years now I've done feminist
technology assessment using a system of
queries I've devised. From that system, I
shall select one query: For whom are the
benefits? To whom fall the costs/ risks? In
this situation we can look at wealth as one
benefit and poverty as one risk.
Let's look at a semi-hypothetical example:
Suppose we bioengineer a wheat plant
minus the gene that gives people wheat
allergies. Who benefits, besides the
biotech companies? People with wheat
allergy who also have enough money to
buy it. To whom fall the costs? Many
people: workers in and near the fields and
other consumers, who develop allergic
reactions to the much more potent
allergens in the pesticides and herbicides
necessary to allow that new plant to grow.
Wealth and health go hand-in-hand in this
example: wealth with health versus
indigence with illness. It would be cheaper
to devise and manufacture delicious
breads from ordinary corn and rice, which
almost everyone could afford to eat.
Now for the Canadian Biotechnology
Strategy, who is to get wealthy?
Multinational corporations? In most of the
submitted papers the answer is a strong
'yes.' These corporations are driven to
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accumulate wealth not only for their CEOs
and Board members, but also for their
stockholders. Stockholders! I'll come back
to these later.
Who else is to get wealthy? Will the
Canadian government coffers expand
through taxes on corporations? And then,
will the government use those monies to
improve the health determinants (see Pat
Armstrong's essay, this volume) for
Canadians? Theoretically this could
couple health for citizens with wealth for
tax coffers. But, note in the CBS’s Health
Sector Consultation Document that
Canada claims to have the most generous
research tax credits in the world. The
policy priority then, appears to be ensuring
private profit rather than wealth
distribution.
Who else is to get wealthy? Will it be many
citizens of Canada, as individuals, who
gain employment in those biotech firms?
Although a very small percentage of the
population may acquire job opportunities,
many of the technician-level jobs may be
hazardous, healthwise. In any countdown,
however, one must offset such gains by
jobs lost in agriculture.
Let's turn from the benefits list to the costs.
Some costs will accrue to farmers,
especially women-as-farmers, as Margrit
Eichler makes abundantly clear. Some
costs will accrue to women-as-foodshoppers, women-as-cooks, and womenas-unpaid-home-nurses. Some costs will
accrue to women-as-health-careconsumers, since their health may be
jeopardized both by the food they eat and
by their encounters with the medical
system. A very few may have improved
health due to some high-tech treatment,
with ancillary cutback in health care for the
majority of Canadians. A biotech emphasis
may indirectly (and possibly directly)
maintain the diversion of monies from
improving health determinants and

increase the gap between the haves and
the have-nots.
Let's look at Penny Van Esterik's excellent
example: the chefs of Toronto protest GE
foods and do not use them in their haute
cuisine, while the poor and homeless eat
them in food pantries and soup kitchens.
Let me put out, however, two examples
that seem to uncouple the health-withwealth partnership. One is the drug
herceptin, as discussed by Sharon Batt.
Women who can purchase or can
persuade their health insurers to purchase
for them (in both cases, 'wealthy') might
find themselves taking a drug that may be
a hoax or has serious side effects.
My second example is the use of the drug
DES in Chicago in the 1950s. In hospitals
there, white women who threatened
miscarriage got the drug, but it was never
offered to black women, obviously
because of racial prejudice. The result is
that clear cell cancer of the cervix is
extremely rare in black women.
Papers in the “Wealth” Session
Now I turn to a few comments on specific
papers in the collection for this session. I
commend and praise these authors for
their perception and their ability to hit nails
on their heads. I shall emphasize and
expand a few of their points and be a bit
skeptical about some proposed solutions.
First let me underscore Julie Delahanty's
and RAFI’s concern about Human
Genome diversity research – research to
sample populations all over the globe to
see how little bits of their DNA differ.
Humans have 98% of the same DNA as
chimpanzees, and each one of us in this
room has 99.999% of the same DNA as
each other. A tremendous amount of
wealth is passing among corporations over
finding those teeny 0.001% differences.
Shares of their stocks rise on the stock

market. RAFI’s term 'Gene Giants’ puts it
very well. Yet there's no 'product.' The rich
are getting richer, and they can afford it
when the bubble bursts.
Iceland is a clear example. Samples of
DNA of 261,000 of the 270,000 citizens of
Iceland are now in the freezers of Hoffman
LaRoche in Switzerland. I believe they
plan to follow each citizen until he or she
dies. And then try to find the differences in
DNA between the stroke victim and the
diabetic, between the fisherman who fell
through the ice and the drunkard. Wealth,
real wealth, enters the picture here. But
scientists are divided as to whether
citizens of Iceland will benefit in any way
(Lewis, 1999).
Jumping from Iceland to Canada, I
endorse Nandita Sharma's point that the
main aim of the Canadian Biotechnology
Strategy is to market biotechnologies. As
she says, “throughout this document is the
government's concern that people accept
and be confident in and comfortable with
new genetic technologies.” “The media,”
she continues, “are being used to promote
the benefits and safety of genetically
engineered food.” Finally, she notes,
"corporate propaganda [is] being voiced as
if it was a public health message."
It happens that allaying the public's fears,
and promotion of its project, also were and
still are the unwritten goals of the U.S.
Center for Human Genome Research’s
ELSI program (Ethical, Legal, and Social
Implications) (Andrews 1999:206). For
instance, many grants are awarded for socalled 'education' projects, although that
word is not in their title. (The word
'education' here simply means
propaganda or indoctrination.) ELSI has
never awarded a grant to any project
suspected of being critical of the basic
premise: the very existence of the Human
Genome Project.
Now let me turn about and ponder one of
Elisabeth Abergel's concerns. She admits
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the fact of "governmental promotional
programmes," but feels that although most
women would agree about opposing GE
food, the medical uses are, as she puts it
'more divisive' among women. This is an
important point. For we cannot, must not,
forget women who are not in our midst, for
example, the mothers of children with
genetic disabilities. Many of them believe
that biotechnology is on the verge of
finding a genetically engineered cure for
the disease in their families. My own view
is that such beliefs result from
propaganda, but should feminists quench
their faith and dreams? If so, how?
Similarly, Madeline Boscoe and Sari
Tudiver ask, "Must we always say NO?"
And then flush out this question
wondering, “Are there some aspects … of
biotechnology … that reflect careful
evaluation, promising therapeutic …
outcomes in the long term … not
necessarily dependent on corporate
monopoly control for their development
and marketing?"
By 1992 in the United States there were
over 130 'genetic support groups,' each
one focused on a particular genetic trait in
their members' kindreds. Eighty percent of
these had women CEOs or presidents.
These leaders are very knowledgeable
about how close the search is for finding
'their' gene, who is searching, and what, if
any, attempts at treatment are going on.
To be sure, they are middle class and
educated, so the 'wealth' issue surfaces
here again. And here again are faith and
dreams, but among some very wellinformed women.
This leads into Pat Armstrong's concern
about a "market-driven consumer model of
health." We need reforms in medicine and
welfare, she says, but the new focus is
harmful to most women, simply because
the paradigm is business, and efficiency is
measured in monetary terms. The women
who are empowered are those with the
ability to pay. Look again at the women
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CEOs I just mentioned. Most of the
genetic conditions in their kindreds are
rare diseases, ones that occur so
infrequently in the population that it would
never lead to corporate profits to develop
a test to detect that gene – the so-called
orphan diseases. Therefore, these women
pressure foundations for grants; some of
them lobby Congress to develop such
tests or to subsidize corporations to do it.
In recommending policy we need to know
that such women exist.
Now, to return to Hoffman LaRoche in
Switzerland and its ilk. Rare diseases are
not profitable. So they turn to the big killers
of the wealthy. Most wealthy people in this
world do not die of rare genetic diseases,
but of heart attacks, strokes, diabetes,
AIDS, Alzheimers, and various cancers.
And let's add in murder and suicide so we
can invent a violence gene and a suicide
gene. The ultimate in genetic reductionism
is to find in human DNA the
predispositions to such conditions as
these. Just exactly how is my personal
Grim Reaper going to stalk me? The Gene
Giants can make big bucks saying that
they've found the codes for a given
Reaper. What happens then? Their clients
can do little but worry. Yes, they can abort
a fetus or impose a 'life-style change' on
their kids or themselves. But when the
doorbell rings, it then might be another
Grim Reaper.
Solutions: Band-Aid Approaches
Band-aid approaches are what Industry
Canada hopes, I think, will satisfy any
public clamor, measures that can allay the
public's worries so that biotech can go full
steam ahead. Two of these that worry me
are:
A) Labeling of all GE food. The basic
drawback to labeling is that it accepts
the existence of GE food – labelling
implies approval and acceptance of
GE foods, as Sharma explains.

Another drawback is that it forces
woman-as-shopper to make choices. A
woman simply trying to feed her family
should not have to do an ethical
evaluation of each specific engineered
food: has the introduced gene escaped
into weeds, does it require specific
pesticides and fertilizers sold at high
cost, does it produce sterile seeds,
etc.?
B) Putting regulations in place and
announcing this to the public. In her
opening comments Sue Sherwin
describes the 20-member advisory
committee (the Canadian
Biotechnology Advisory Committee,
CBAC) as not representative and
including no health activists. Thus, the
first problem with band-aid approach B
is how to get the government to form
an appropriate regulatory body.
Because of current love affairs
between governments and global
corporations, any regulatory body most
likely will be designed to keep that love
relationship intact.

Two weeks ago I was witness to a good
example of governmental fear of genuine
regulation. I attended a 'public
consultation' in Baltimore on 'supervision
of genetic testing.' An excellent committee,
more than half of them women (and some
of those, feminists-in-spite-of-themselves),
had prepared the document we were to
critique (SACGT, 1999). But it was clear
that this blue-ribbon committee was under
the strong constraint of not impeding any
biotech firms from devising more and more
genetic tests. Their document avoided the
word 'regulation' and used instead
'guidelines.' I found myself in a miserable
little discussion group with several
representatives from biotech companies.
"Too much regulation already," they said.

Most of you have heard that in January
2000 the U.S. National Institutes of Health
(NIH) halted gene therapy trials at the

University of Pennsylvania (Barbour, 2000:
384; Horton, 2000: 329). After one death
came to light, it was eventually discovered
that there had been 691 deaths or serious
incidents in other clinical trials of gene
therapy (Nelson and Weiss, 2000: A01).
For some two years the U.S. Food and
Drug Administration (FDA) has been in
charge of genetic engineering
experiments; it keeps confidential any
reports it gets (Smaglik, 2000: 5). Adverse
events are also supposed to be reported
to the NIH, but many researchers said
they did not know about that requirement
(ibid.). Some scientists claim that the
deceased patients would have died
anyway from their condition, since most of
them were terminally ill with cancer (Ibid.).
Here I tease out several points:
(1) it's obvious that we have to be vigilant
that regulations do not backfire – so
that they end up not benefiting the
public because they have stirred up a
backlash; we have to be ready to deal
with the complaint that regulations hold
back the progress of science;
(2) corporations may protest regulations
by going where there are no
regulations in place, for example, in
the U.S. where government-funded
experiments on embryos are
forbidden, preimplantation diagnosis
and other fiddling with human embryos
simply goes on in the private sector or
in countries without regulations;
(3) any regulations should define 'adverse
events' and include a specific place
and method to report these. Let us all
dream that any such events in genetic
experimentation (plants, animals,
humans) must be reported to the
Women's Health Movement.
Solutions: Possible Effective
Approaches
Use the media. Several commentators
noted that the media are part of the
problem. Yes, they are mesmerized by
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biotechnology. If a scandal breaks out,
they'll zero in on that temporarily, but then
go back to being mesmerized. For
example, although the 'gay gene' is only a
hypothesis based on equivocal evidence,
the media often now blithely mention 'the
gay gene.'
One problem in the U.S. is that the major
commercial networks and newspapers are
parts of huge conglomerates that include
pharmaceutical houses and
agribusinesses. Television documentaries
are definitely censored. It's hard to believe
– when you seem to be getting both sides
of a question in investigative reporting –
but any TV documentary that appears has
already passed corporate censorship. Yet
as individuals, most journalists are
ethically committed to the truth, even if
their stories get suppressed.
Because of this basic personal integrity,
one way to use the media is to go first
through the alternative press, which will
welcome reports we write. The February
2000 issue of Mother Jones published
"Pandora's Pantry," an article on GE
foods. Such pieces may then be seen by
reporters from the mainstream media, and
from time to time critical articles have
appeared in the New York Times.
Go through stockholders. Can we get
biotech stockholders to take a stand? We
all know the example of South Africa. Big
stockholders, usually institutional
investors, such as universities and labor
unions egged on by their constituencies
(students, workers, alumni), divested
stocks from firms that were doing business
in South Africa. Or, they chose not to
divest when companies were following the
'Sullivan Principles' of human rights with
their employees. This led to the fall of
apartheid. Now, can we invent principles
under another name and try the same
thing with genetic engineering? How about
the 'Sherwin Principles'?
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Global Activism. We can join global
actions or create and recruit globally to our
own actions. Fritolay, a subsidiary of
Pepsico, has told its suppliers that it won't
buy genetically engineered corn.
Apparently this did not come from
stockholder pressure, but Fritolay realized
that consumers were getting wary. (As far
as I know, they still use bt potatoes for
their potato chips.) And after the country of
Brazil forbad the planting of GE soybeans,
more and more countries switched to
buying their soybeans from Brazil
(Passoff, 2000).
Help from the state. Despite its poor track
record with women, the Canadian
government can protect its citizens. Pat
Armstrong says, "Only the state is
powerful enough to counter the power of
the global corporations . . . precisely
because the state is now so activist [in
serving the interests of corporations] we
need to make demands on it." Nandita
Sharma has far less faith as she describes
a government in league with corporations
broadcasting propaganda as if it were a
public health message. Yet – and it really
has nothing to do with GE – it's ethically
right for the state to take responsibility for
health determinants.
Hold fast on not patenting life forms. I want
to urge Canadians to hold fast to your
current patent laws, and not succumb to
the argument to "modernize Canada's
intellectual property laws," i.e., not to put
them in line with the World Trade
Organization guidelines.

In Sum
I have a strong affection for Canada
having spent at least 35 summers
camping or traveling in many of your
provinces, dating back to the fifties when a
picture of the Queen was in every parlor.
And Canada produces some remarkable
feminists, many of whom have
intellectually and spiritually enriched my

life. So – my pro-Canada sentiment wants
Canada to be wealthy or, better
expressed, wants no one in Canada to be
poor.
I am not alone in these positive feelings
about Canada. Canada has an
international reputation of high moral
standards, of being a moral leader. Many
Canadians scoff at such an interpretation,
because you know only too well about so

many specific instances of immoral
actions, especially against your aboriginal
peoples. But I am speaking of the global
perception of your country, whether or not
this can withstand close scrutiny. Thus I
urge you to make use of that moral
argument, the argument that Canada
should do what is morally right and be
proud of an international stance that holds
morality above expediency.
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Introduction
In international policy circles it is
increasingly recognized that the
conservation of biological diversity (or
biodiversity) is integrally related to the
preservation of cultural diversity and that
indigenous peoples and local communities
hold traditional ecological knowledge of
great potential value and importance in
global efforts to achieve sustainable
development objectives. Such peoples
and their knowledges are endangered.
This paper will consider global efforts to
value and preserve traditional ecological
knowledges, the use and significance of
digital technologies in facilitating the
preservation of this cultural diversity, and
point to issues that require further
research.
After introducing the policy issues, the
paper will consider the obligations of
Austria, Belgium, Bulgaria, Canada,
Luxembourg, Switzerland, and the United
Kingdom (hereinafter the Council Parties)
under the Convention on Biological
Diversity (hereinafter the CBD), and
initiatives taken by the Council Parties to
protect traditional ecological knowledge
both domestically and internationally; it
also addresses some important regional
initiatives and provides examples of
academic and non-governmental
organization (NGO) activities. Given the
importance that the CBD attaches to
intellectual property rights (IPRs) and the
enormous body of literature that
addresses the propriety of IPRs as a
means of protecting traditional
environmental knowledge, the paper then
considers the role of IPRs with respect to
the preservation of cultural diversity1 and

1

. A recent survey of important works may be
found in King and Eyzaguirre. An enormous
bibliography is maintained by Graham Dutfield
and is operated from Oxford University at the
website for the Working Group on Traditional

proposals to amend IPRs to make them
less conducive to the misappropriation of
cultural knowledge. The paper next
addresses indigenous uses of the Internet,
with particular attention to cultural
revitalization efforts. More general usages
of digital technology to assist in the
protection of biodiversity and indigenous
knowledge are then surveyed with
emphasis upon the potential cultural
impacts of these activities on indigenous
peoples and local communities. Areas of
recommended research are identified at
the end of each section.
The Relationship Between Cultural
Diversity and Biodiversity
Human cultural diversity, it is believed, is
threatened on an unprecedented scale
(Posey 3). Languages are generally seen
as major indicators of cultural diversity—
the codifications, heritages, and
frameworks which constitute a society’s
unique understanding of the natural and
social world. An estimated half of these
will disappear within the next century
(UNESCO). Since 4,000 to 5,000 of the
6,000 languages in the world are spoken
by indigenous peoples, and these are the
most endangered of languages, the loss of
cultural diversity will affect these peoples
disproportionately. The countries which
contain peoples speaking the largest
numbers of languages are also those that
house the greatest biological diversity in
terms of species and variations in
interspecies, and include the greatest
numbers of indigenous and communities
with traditional, near-subsistence
livelihoods. Although no universally
accepted definition of indigenous peoples
or of traditional communities exists, the
majority of the world’s rural populations
live in direct dependence upon their
knowledge of and use of local ecosystem
Resource Rights:
<http://users.ox.ac.uk/~wgtrr/bib1.htm>.
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resources. These resources are also
disappearing at an alarming rate with dire
consequences for those peoples whose
livelihoods depend upon them.2
The world’s poor rely upon biological
products from local sources for 85% of
their needs (e.g., for food, fuel, shelter,
medicine, etc.), over 1.4 billion rural
people rely upon farm-saved seeds and
local plant breeding for their subsistence,
more than three quarters of the world’s
population relies on the knowledge of local
health practitioners and traditional
medicines for their primary medical needs,
and over half of the world’s drugs are
derived from plants (Crucible II Group 1:1).
New plant genetic resources are needed
in the pharmaceutical, agricultural, and
biotechnological industries on a regular
basis, yet the social and cultural conditions
that nurture their ongoing development
and ensure their continuing variation are
threatened.
Plant genetic diversity is considered a
human legacy but it is one that is
sustained largely by the uncompensated
2

. According to an Australian report on
biodiversity, “[t]he loss of rich, biologically
diverse environments (such as the Amazonian
forests) through activities such as logging, land
clearance and mining and development has
profound consequences in its impact on the
culturally diverse groups of indigenous peoples
whose livelihoods depend on these
environments. There is in this sense a direct
relationship between biological diversity and
cultural diversity; maintenance of the former
can help preserve the latter. The reverse is
also true, since indigenous peoples are often
the custodians and stewards of biological
diversity, the maintenance of cultural diversity
is an important factor in the conservation of
biological diversity.” Commonwealth of
Australia, Biological Diversity and Indigenous
Knowledge, Research Paper 17 (1997-8).
Available at
<http://www.aph.gov.au/library/pubs/rp/1997-9
8/98rp17.htm.>. See Muhlhausler for further
discussion of the relationship between
language, culture, and biodiversity.
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work of culturally diverse, politically
vulnerable, and impoverished peoples.3
Only to the extent that such practices are
supported, encouraged, and maintained by
in situ conservation measures will
biodiversity be maintained.4 Hence, the
CBD Preamble recognizes the “close and
traditional dependence of many indigenous
and local communities embodying
traditional lifestyles on biological resources,
and the desirability of sharing equitably
benefits arising from the use of traditional
3

. As Swaminathan and Castillo write: “Tribal
and rural farming communities have a long
tradition of serving as custodians of genetic
wealth, particularly landraces often carrying
rare and valuable genes for traits like
resistance to biotic and abiotic stresses,
adaptability, and nutritional quality. Several
land types that carry valuable genes are
preserved by farmers for religious functions
and they constitute valuable material for
conservation and sustainable use. Women in
particular have been the principal seed
selectors and savers” (Swaminathan and
Castillo xii).
4
. According to the Crucible II Group:
Local and indigenous peoples who speak
ancestral languages are severely
threatened by loss of sovereignty over land,
resources, and cultural traditions and the
promotion of linguistic assimilation. As they
become increasingly marginalised local
people lose local scientific knowledge,
innovative capacity, and wisdom about
species and ecosystem management. As
one scholar concludes: “Any reduction of
language diversity diminishes the
adaptational strength of our species
because it lowers the pool of knowledge
from which we can draw.” The loss of
traditional farm communities, languages,
and indigenous cultures all represent the
erosion of human intellectual capital on a
massive scale. It is tantamount to losing a
road map for survival, the key to food
security, environmental stability and
improving the human condition. Thus, it is
increasingly difficult to talk about the
conservation and sustainable use of genes,
species and ecosystems separate from
human cultures (Crucible II Group 1: 9-10
citing R. Bernard).

knowledge, innovations and practices
relevant to the conservation of biological
diversity and the sustainable use of its
components.” This is indicative of a global
recognition that biodiversity preservation is
an inherently multicultural process.

and traditional knowledge is believed to be
on the rise.6 For example, a survey
conducted by the Indian Drug
Manufacturers’ Association found that of
the 668 pharmaceutical patents filed in
1997, the vast majority included the use of
ayurvedic knowledge (traditional Indian
Indigenous knowledges may be understood medicinal systems) with minor
as the cultural knowledges of local peoples modifications in methods of extraction and
concerning the everyday realities of living
processing.7 Research to ascertain the
use of indigenous and traditional
that are the product of a direct experience
knowledge innovations and practices
with nature and a particular, local
(hereinafter ITKIP) in the intellectual
ecosystem.5 Indigenous knowledge, “the
unique, traditional, local knowledge existing properties granted to others is both difficult
within and developed around the specific
and expensive to accomplish given the
conditions of women and men indigenous
limited information that most states
to a particular geographic area” (Grenier
provide to the public and the limited forms
1998), is collectively held and, until
of disclosure required of most patent
recently, was also predominantly
applicants. States concerned with the
communicated orally and from generation
preservation of cultural diversity should
to generation. Such knowledge is dynamic consider amending their intellectual
and adaptive, socially shared and
property regimes to enable such research.
communicated, and usually recognizes an
equilibrium among natural forms
Although claims concerning the biopiracy
understood to form elements of a cosmos. of traditional knowledge abound, it is not
It embraces knowledge of location,
always clear precisely how traditional
movements, spatial relationships and
knowledge practitioners are or will be
temporal cycles, and is not restricted to
precluded from continuing to engage in
knowledge of entities and their parts.
applying and developing such knowledge
“Nature” is less likely to be understood as
as a consequence of these appropriations.
something to be conserved and more likely Moreover, it is not at all evident that
to be understood as an extension of society patents based upon ITKIP are, in fact,
and an integral part of human
valid given that they generally involve an
interdependence.
“obvious” technology applied to ITKIP that
lacks the quality of novelty. Nonetheless, it
Just as indigenous peoples and local
is manifestly inappropriate for state
communities are increasingly under siege
regimes to put the onerous and expensive
by forces of urbanisation,
burden of challenging the validity of such
proletarianisation, linguistic assimilation,
6
logging, mining, and large-scale
. As Graham Dutfield explains, “[a]lthough
development projects, they find that the
outsiders have collected knowledge and
genetic resources they manage and
biological resources from traditional peoples
develop using their knowledges and
for centuries, ‘bioprospecting’ (the search for
and collection of biological material and
technologies are of increasing value to
traditional knowledge for commercial ends,
others. “Biopiracy” of genetic resources
5

. For a discussion of the various definitions of
indigenous knowledge and how these are
situated in relation to conventional, formal, or
scientific knowledges, see Dei, Hall and
Goldin-Rosenberg.

with particular reference to the pharmaceutical,
biotechnological and agricultural industries)
has intensified in recent years.” Dutfield,
Rights (505).
7
. Cecilia Oh citing Vandana Shiva, “India:
Granting MNCs Absolute Monopolies.” Third
World Network Features. 1999.
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IPRs upon the impoverished and
vulnerable holders of such knowledge (or
even upon the nonprofit NGOs that
support them).

IT IS RECOMMENDED THAT COUNCIL
PARTIES UNDERTAKE FURTHER
RESEARCH TO CONSIDER:

•Means to amend intellectual property
regimes to enable interested parties to
ascertain when and if intellectual
property rights are being granted for
works and innovations that appropriate
indigenous and traditional knowledge,
innovations, and practices and are
thereby invalid to the extent that such
knowledge, innovations and practices
are not novel and the uses made of
them are obvious amongst those
peoples or in those communities.

The Convention of Biological Diversity
and the Recognition of Traditional
Knowledge
States who are party to the CBD are
obliged : 1) to respect, preserve and
maintain knowledge, innovations and
practices (KIP) of indigenous and local
communities embodying traditional
lifestyles relevant for the conservation and
sustainable use of biological diversity
(Article 8(j)); 2) to develop and use
traditional and indigenous technologies
(Article 18(4)); 3) to promote the wider
application of such knowledge with the
approval and involvement of the holders of
such KIP; 4) to encourage the equitable
sharing of benefits arising from the use
thereof; and, 5) to ensure that their
intellectual property regimes support
rather than undermine these objectives
(Article 16(5)). Technology transfer to lessdeveloped countries is encouraged in
exchange for the provision of such
knowledge. For some advocates, “the
cumulative effect of these provisions is to
make it mandatory for governments to
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enact a law recognizing indigenous and
local community knowledge systems. In
any event they are entitled to enact such a
law to fulfil their obligations under the
CBD” (Nijar, Perspectives). With very few
exceptions,8 states that are party to the
CBD have yet to introduce legislation
explicitly protecting ITKIP, or to consider
what the interaction between a system of
collective rights and a traditional IPR
regime would involve.
Existing international trade and intellectual
property agreements do not pose any
obstacles to undertaking such an initiative.
Indeed, to the extent that Article 8 of the
Trade Related Aspects of Intellectual
Properties Agreement (hereinafter TRIPs)
under the World Trade Organization
(WTO) allows states to take measures to
protect public health and nutrition and to
promote the public interest in sectors of
8

. Exceptions include laws in the Philippines
and Peru. In the Philippines, the Indigenous
Peoples’ Rights Act of 1997 recognizes that
indigenous cultural communities and
indigenous peoples have, as part of their rights
to cultural integrity, rights to control bio-genetic
resources, indigenous knowledge systems, in
addition to rights to control, develop, and
protect vital resources, health practices,
resource management systems, and
agricultural technologies. For a critical
discussion of the legislation see Rovillos,
Indigenous Peoples. The Ley de Biodiversidad
or Biodiversity Law passed in Costa Rica in
1998 initiated the process of developing a sui
generis regime for protecting the KIP of
indigenous and local communities but also
explicitly established the juridical recognition of
these rights without any requirement of
registration or prior declaration. The
parameters of these community intellectual
rights will be determined in consultation with
indigenous peoples and peasants. See
discussion in Dutfield, Intellectual Property
110-3. In Thailand, a draft bill recognizing the
collective rights of traditional healers and
benefit sharing for the commercial use of
traditional knowledge provoked an almost
immediate challenge by the United States in
1997. See Correa.

vital importance to their socio-economic
and technological development, it can be
argued that measures taken for the
protection of ITKIP fulfills these objectives.
After all, more than 80% of the world’s
peoples depend upon such knowledge for
their health care, ongoing pharmaceutical
development depends upon it, and the
continued viability of local agricultures
ensures global food security.9
The Council Parties have all signed and
ratified the CBD. Most of the Council
Parties are funding research into ITKIP
relevant to the maintenance of biological
diversity. Other Council Parties (for
example, Belgium, Luxembourg, and
Bulgaria) have not linked their
commitments to preserve biodiversity with
considerations of cultural diversity and
have approached biodiversity largely as if
it pertained entirely to natural
environments untouched by human
interaction.10 This, however, is rarely the
case.
9

. Indeed, according to Gurdial Singh Nijar, “[a]
law to protect and further the knowledge
systems of indigenous peoples and local
communities would clearly contribute to the
promotion of technological innovation in
furtherance of the social and economic welfare
of large segments of the Third World’s
populace” (Nijar, Perspectives).
10
. Bulgaria, for example, ranks amongst the
most biologically diverse countries in Europe
with huge numbers of endemic species and is
home to many traditional and rare cultivars.
Not surprisingly, given its accessiblity to
Western researchers, it has also been subject
to exploitation including the illegal gathering
(and export) of edible fungi, medicinal plants,
snails, and reptiles (Bulgaria 6). Bulgaria is a
rich source for botanical drug species within
Europe and is eighth in the leading export
countries in the botanical drugs trade. Wild
botanical drugs continue to be collected by
villagers who have traditional knowledge of
their usages (Lange and Mladenova 135-46).
Although, restrictions on collecting, trading,
and exporting species have been established,
legislative initiatives have been oriented
towards the preservation of biological

Traditional knowledge held within the
European Council Parties includes KIP in
relation to hedgerow maintenance, animal
husbandry, forestry, fish-pond and bog
management, orchard fruit growing, herbal
medicines and traditional knowledge of
phytonutrients. To a limited degree, the
cultural dimensions of these practices are
recognized in domestic legislation and
regional regulation. Austria has passed
legislation to document, protect, conserve
natural and cultural landscapes.
Switzerland defines the preservation of
biological diversity so as to imply the
“protection and maintenance of rare
habitats of great value, including traditional
and cultural landscapes” (Swiss Agency
25). The European Council Parties are
also subject to European Union (EU)
regulations with respect to the
conservation, description, collection and
use of genetic resources in the agricultural
sector (Council of the European Union,
Reg. No 1467/94) and European
Community (EC) objectives to maintain
agricultural and forestry sectors that
manage resources so as to preserve
cultural landscapes. Cultural landscapes
can only be preserved to the extent that
the traditional KIP which developed them
is simultaneously safeguarded.
Surveys of domestic biodiversity in Council
Parties are ongoing and, in some cases,
the cataloguing activity has been
accompanied by a corresponding digital
database network with international
linkups (e.g., Austria 21). Inventories of
the biogenetic reserves of the Council of
Europe are currently in preparation and
most of the Council Parties are still in the
process of documenting autochthonous
animal and plant species. Council Parties
understand that the homogenization of
modes of cultivation threatens the
existence of certain species and that
resources rather than the continued cultivation
of the cultural knowledge that sustains this
biodiversity.
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species will likely decline to the extent that
heterogenous cultivation activities are
abandoned.11 Therefore, although few
specific measures to protect domestic
traditional KIP have been taken, the
importance of the relationship between the
presence of particular species and
particular forms of cultivation—many of
which are likely to vanish unless
recognized, recorded, and supported—is
widely acknowledged. Council Parties
have implemented a number of measures
as incentives to preserve the in situ
preservation of biodiversity.12
11

. For this reason, Austria has committed itself
to the objective of sustainable agriculture
which “couples an ecological, site-specific
adaptation of production methods to a highly
structured and diverse cultural landscape”
(Austria 14). Agricultural policy in Switzerland
aims “to sustain forms of traditional
exploitation, particularly those which have
contributed to the formation of landscapes and
to increase the diversity of ecosystems” (Swiss
Agency 33), whereas the United Kingdom
recognizes “the importance of those traditional
skills and practices upon which many valued
habitats depend” (United Kingdom 28).
Switzerland has long had legislation designed
“to preserve indigenous animal and plant
species, biotopes and landscapes”(The
Federal Law on the Protection of Nature and
Landscape (1966) in Swiss Agency 15), a land
planning law that allows for the protection of
areas “of great ecological or cultural
importance” (The Federal Law on Land-Use
Planning (1979) in Swiss Agency 16) and,
most recently, a fund of Sfr. 50 million was
established “to contribute to the conservation
of traditional rural landscapes, and to
safeguard ancient methods of exploitation,
cultural heritage, and natural landscapes”
(Swiss Agency 17).
12
. Commitments to traditional cultivation
methods may be matched by “compensation
payments for disadvantaged areas” (Austria
26) that serve to encourage farmers in
marginal areas, such as montane farming
zones, from abandoning agriculture and
thereby help to ensure the continuing
cultivation of local biodiversity. More generally,
agro-environmental grants and “ecological
compensation” programmes have been
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Ex situ collections of genetic resources—
including genebanks, seedbanks,
herbariums and microbial culture
collections—exist in most of the Council
Parties.13 As the United Kingdom’s
National Report on Biological Diversity
established by Council Parties to remunerate
farmers for conservation activities, cultivation
of traditional varieties, sowing indigenous wild
plants in fallow lands and gardens, engaging in
organic and integrated agriculture,
safeguarding biotopes, and as compensation
for lost income caused by the abandoning the
practice of more intensive resource use. More
still could be done. It is estimated that Europe
has lost 75% of its plant genetic diversity within
the last century and that the revitalization of
genetic and cultural diversity will depend upon
support for organic plant breeding, the
development of organically produced seeds
and in situ management of a “diversity of
cultural plants [which have] evolved from
generation to generation, in the hands of many
farmers and in many different landscapes”
(Wyss and Wiethaler, 37). On these points,
see Eric Wyss and Cornelia Wiethaler eds.,
Final Report on the International Conference
on Biodiversity and Organic Plant Breeding,
nd
rd
2 and 3 December 1999 in Frick
Switzerland. The Report provides information
on the organic breeding sector in all of the
European Council Parties except Bulgaria. A
database of available organic seeds and a
bulletin board for exchange of information on
organic breeding and propagation will be
created at <http://www.biogene.org>. For a
series of studies on the importance of
preserving agricultural genetic diversity in situ,
see Brush, ed.
13
. The Swiss Federal Office of Agriculture,
following upon the Food and Agricultural
Organization’s World Plan of Action,
emphasised preserving the adaptive potential
of cultivated plants. To this end, the Swiss
Commission for the Conservation of Cultivated
Plants (CPC) has attempted to inventory all
concerned institutions and the genetic material
that they safeguard. The Millennium Seedbank
Project at the Royal Botanic Gardens in the
United Kingdom both banks and supports the
reintroduction of plant species and the
Commonwealth Potato Collection is also an
important repository.

acknowledged, however, much
“biodiversity information remains scattered
across the country in many different and
incompatible forms” (United Kingdom 26).
Only to the extent that information
networks are created that are accessible,
regardless of where the information is
held, will the potential of information
technology to promote biodiversity begin
to be realized.
Most Council Parties house or are party to
the network of international genebanks
established under the Food and
Agriculture Organization (FAO) and the
FAO promotes widespread access to
these resources. Currently the network
includes 12 genebanks but 31 additional
countries have declared an intention to
join their genebanks to this network. If
accomplished, this amalgamation would
incorporate into one network 46% of all of
the planet’s plant genetic resources
(Austria 46). The vast majority of crop
germplasm held in these banks was
collected from farming communities in the
developing world (Crucible II Group 1: 2022). However, the rights of providers of
this material to have a stake in any profits
made in the successful commercial
application of it is still under dispute. A
related area of controversy requiring
further research is the propriety of IPRs in
genetic resources held in trust by the
Consultative Group on International
Agricultural Research (CGIAR) in the
sixteen international agricultural research
centres it supports. In 1996, the CGIAR
endorsed the principle that its centres
would not claim legal ownership or apply
IPRs to the germplasm held in trust and
would require recipients to abide by the
same principles. What remains disputed is
the propriety of claiming IPRs in varieties
and technologies developed from CGIAR
germplasm to the extent that this
germplasm was developed by indigenous
peoples and local communities.
Mechanisms to provide compensation to
the farmers’ communities from which such

germplasm was taken may need to be
developed.
Many of the European Council Parties
have participated in and contribute to the
ministerial process, “Environment for
Europe,” which is intended to implement
the “Pan-European Biological and
Landscape Diversity Strategy” that, in turn,
provides the European framework of the
CBD. Within Europe, the location of
biological diversity in economically
underdeveloped regions has been
recognized and more developed Council
Parties have devoted resources to the
preservation of biodiversity in these less
developed regions.14 The degree to which
development initiatives in Eastern Europe
could be linked to efforts to document and
preserve traditional KIP needs to be
further investigated.
Amongst the Council Parties, the United
Kingdom is unique in having Dependent
Territories with both biological and cultural
diversity that are considered endangered.
The British Virgin Islands (BVI), the
Cayman Islands, Gibralter, Jersey and St.
Helena are included in the UK’s ratification
of the CBD. However, at least seven other
territories are not included. In all of these
territories, older members of the local
populations are likely to have significant
traditional knowledge about local
biospheres that is undocumented and,
without recognition or support, is not likely
to be passed onto successive generations.
A biodiversity database is being developed
in the BVI, but no recognition of ITKIP
appears to accompany this initiative.

14

. Switzerland, for instance, has supported
projects to conserve biological and cultural
diversity in the region of Lake Onrid, between
Albania and Macedonia, in addition to other
ecosystem management projects in Estonia,
Hungary, Bulgaria and Russia. The UK Darwin
Initiative has supported the development of
local expertise in peatland management in
Eastern Europe.
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Development priorities in many Council
Parties have focussed upon environmental
issues in less-developed countries, but
such commitments to sustainable
development are not always coupled with
any evident concern for the relationship
between natural resource management
and cultural diversity.15 This is an area that
requires considerable research if
‘sustainable development’ initiatives are to
support the preservation of cultural
diversity.16
In Canada, indigenous and traditional
knowledge has been the subject of several
commissioned research reports and
traditional knowledge is now considered a
source for consultation in environmental
impact assessments. However, the
15

. The Belgian government, for example, has
invested in regional environmental
management and database projects in West
and Central Africa (as well as in China and
Eastern Europe) but the cultural dimensions of
these initiatives are underdeveloped. The
Swiss Agency for Development and
Cooperation, on the other hand, has a portfolio
of 36 projects devoted to biodiversity in Latin
America, Asia, and Africa, several of which
have the conservation of indigenous
knowledge of cultivation as a priority (Swiss
Agency 50). The Darwin Initiative funds UK
biodiversity experts in projects that will help
developing countries meet their obligations
under the CBD. The EU funds the Central
Cordillera Agricultural Program in the
Philippines, a project which has attempted to
integrate indigenous peoples’ resource
management knowledge and practices as well
as traditional health methods into its
community development programmes.
Tragically, a lack of understanding on the part
of development authorities and government
environmental officials about the effect of
introducing new species alongside indigenous
varieties led to the extinction of traditional
varieties of great significance to local cultural
practices (Rovillos, Interphasing).
16
. In recognition of this, the Canadian
International Development Agency supports
the work of Cultural Survival in compiling an
international directory of indigenous
conservation projects in the Americas.
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Northwest Territories is the only provincial
government to have developed a policy
pertaining to traditional knowledge.
Acknowledging that aboriginal knowledge
is a valid and essential source of
information about the natural environment
and its resources, this policy recognizes
that traditional knowledge is best
preserved through continued use and
practical application, expresses a
commitment to incorporate traditional
knowledge into government decisions and
actions where appropriate, and also
commits to provide in kind support to
aboriginal cultural organizations studying
traditional knowledge.17 Indigenous
peoples have been on the Canadian
delegations to the CBD and Canada has
funded off-delegation indigenous NGOs to
participate in CBD discussions of
traditional and indigenous knowledge
protection. A World Intellectual Property
Organization (WIPO) fact-finding mission
in November 1998 involved consultations
with indigenous groups across Canada to
consider the viability of IPRs for protecting
ITKIP.18
NGOs based in the Council Parties have
been active participants in international
fora focussing upon these issues and in
specific projects in developing countries
that are documenting and preserving

17

. See
<http://www.gov.nt.ca/Publications/Policies/5206_6.htm>.The Dene Cultural Institute, for
example, is providing guidelines for use and
access to traditional knowledge for
government and industry planning projects and
environmental impact assessments. See
<http://www.deneculture.org/tradknow.htm>.
18
The Union of British Columbia Indian Chiefs
hosted an international conference on the
protection of indigenous knowledge in
February 2000 entitled “Protecting Knowledge:
Traditional Resource Rights in the New
Millennium” (February 24-26, 2000 at
Vancouver, British Columbia, Canada). For
more information on this conference, see
<http://www.ubcic.bc.ca/protect.htm>.

ITKIP.19 European NGOs, however, have
been critical of the EC’s draft Biodiversity
Action Plan, noting that the discussion
paper circulated in January 2000 made no
reference to issues of food security,
TRIPs, bioprospecting, or biopiracy.20 One
reason for this was the failure of the EC to
involve NGOs in the early stages of the
discussion process.21 NGOs with global
19

. In Austria, the Austrian Rainforest Program
is involved in projects in cooperation with
indigenous peoples in Brazil and Costa Rica,
while the Vienna Institute for Development and
Cooperation has been working with the
Embera peoples in Panama to reactivate their
traditional knowledge about tree species so as
to conserve and revitalize these varieties. The
International Development Research Council
(with offices in Canada and Switzerland) has
funded the Crucible II Group project, and funds
projects for preserving indigenous knowledge
and digital networking in India, Peru, the
Philippines, Vietnam, Nepal and Papua New
Guinea (PNG). Rural Advancement
Foundation International (RAFI) in Canada,
has been instrumental in bringing the issue of
biopiracy to international attention and in
researching and challenging intellectual
properties that are based upon indigenous
knowledge of plant genetic resources.See the
following materials from Rural Advancement
Foundation International (RAFI): Captain
Hook, the Cattle Rustlers, and the Plant
Privateers: Biopiracy of Marine, Plant, and
Livestock Continues. 11 May 2000; and, Plant
Breeder’s Wrongs: An Inquiry into Potential for
Plant Piracy through International Intellectual
Property Conventions. 26 August 1998.
<http://www.rafi.org/web/publications.shtml>.
20
. These European NGOs include: Fern,
Greenpeace European Policy Unit, Birdlife
International, Royal Society for the Protection
of Birds, Swedish Society for Nature
Preservation Arbeitsgemeinschaft für
Regenwald und Artenschutz, Friends of the
Earth England Wales and Northern Ireland,
World Wide Fund for Nature. See Joint NGO
Comments on the draft EC’s Biodiversity Plan
(Version 12/1/2000) at
<http://www.gn.apc.org/fern/NGO%20stateme
nts/biodiversity%20action%20planhtm.htm.>
Posted February 13, 2000, 3.
21
. These European NGOs point EC member
states to Articles 5 and 6 of the Council

links to indigenous peoples are often the
most significant source for information
about ITKIP and the threats posed to
indigenous peoples’ cultural survival.
Finally university research institutes and
independent researchers in most Council
Parties are engaged in biodiversity
research related to ITKIP in both domestic
and foreign arenas.22 Overseas projects
are often undertaken in conjunction with
developing countries’ governments and
researchers with the aim of improving
international cooperation on biodiversity
and cultural landscapes. In many of the
regions that these researchers visit, local
peoples are engaged in the task of
recording traditional knowledge.23 Such
researchers do not always share their
Resolution on Indigenous Peoples which notes
“the key role played by indigenous peoples in
the conservation and sustainable use of
natural resources, the positive contribution of
indigenous peoples in the development
process, the vulnerability of indigenous
peoples” and the need for development
projects that contribute to enhancing
indigenous self-development. Articles 5 and 6
of the Council Resolution on Indigenous
Peoples are annexed to the Joint NGO
Comments. See note 20, 6-7.
22
. The Swiss Academy of Sciences project,
The Swiss Biodiversity Forum, for instance, is
supporting a research project on “Local
Ecological Knowledge of Swiss Farmers and
its Influence on Actual Landuse Behaviour”.
For information on this research project, see
the homepage at
<http://www.unibas.ch/mco/research_mueller.h
tm>.
23
. For example, local researchers are
attempting to archive the over 814 distinct
cultures in PNG in order to ensure the survival
of forms of indigenous knowledge. This
knowledge will be put on the Internet to make it
more widely available. With one of the largest
concentrations of biodiversity in the world,
coupled with its cultural diversity, PNG attracts
researchers from around the world. For more
information on this archival project, see
“Webbing New and Traditional Knowledge.”
<http://www.PanAsia.org.sg/hnews/pg/pg01i00
1.htm>.
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information with people within the country,
however, and local peoples are often
unaware of even published information
pertaining to their own cultural ancestry
and ITKIP. Research into the feasibility
and consequences of making government
research funding and publication
subventions contingent upon the
repatriation of research information to local
informants and host governments is
needed. This might be one means by
which Council Parties could contribute to
developing countries’ efforts to preserve
cultural diversity.

IT IS RECOMMENDED THAT COUNCIL
PARTIES UNDERTAKE FURTHER
RESEARCH TO CONSIDER:

•How states can link their commitments
to preserve biodiversity with
considerations of cultural diversity and
the cultural dimensions of ITKIP in both
domestic legislation and regional
regulation.
•How the relationship between natural
resource management and cultural
diversity can be recognised in all
environmental protection measures
such that the preservation of cultural
landscapes serves to preserve the
ongoing development of cultural
diversity.
•How a system of collective rights that
recognizes ITKIP, encourages its use,
and facilitate the equitable sharing of
benefits derived therefrom would be
integrated with or recognized by
domestic intellectual property regimes.
•How surveys of domestic biodiversity
which aim to protect domestic
traditional knowledge could involve the
participation of older members of the
local populations in order to obtain and
incorporate undocumented traditional
knowledge about local biospheres and
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involve younger generations so as to
increase their appreciation for such
knowledge.
•What type of support is needed for
organic plant breeding, the
development of organically produced
seed, and in situ management of a
plant diversity amongst different
farmers and in different landscapes.
•The propriety of claiming IPRs in
varieties and technologies developed
from CGIAR germplasm developed by
indigenous peoples and local
communities as well as compensatory
mechanisms for farmers’ communities
of origination.
•The degree to which development
initiatives in Eastern Europe could be
linked to efforts to document and
preserve ITKIP.
•How the relationship between natural
resource management and ITKIP can
be recognized to develop sustainable
development initiatives that support the
preservation of cultural diversity.
•The desirability of making government
research funding and publication
subventions contingent upon the
repatriation of research information to
local informants and host governments
and how this could be funded by
Council Parties as one way of assisting
developing countries in joint efforts to
preserve cultural diversity.
The Contested Role of Intellectual
Property Protections
Obligations under the CBD that serve to
protect cultural diversity by preserving
ITKIP relevant to biological diversity are
congruent with the Council Parties’
obligations pursuant to international
environmental commitments and human

rights covenants as well as domestic
foreign aid policies oriented towards
sustainable development. They are also in
accord with the current agenda of the
WIPO which has made the protection of
traditional knowledge a priority. WIPO’s
1998 fact-finding missions on traditional
knowledge, innovations, and culture
involved holders of ITKIP in consultations
regarding the dimensions of regional
ITKIP, the development of research
protocols to govern scholarly and research
access to ITKIP, the need to distinguish
between sacred and secular dimensions of
ITKIP when considering dissemination and
reproduction, and the need for recognition
of traditional knowledge in policy-making
processes for sustainable resource
management.24 The lack of any such factfinding mission to European countries was
unfortunate as these missions have raised
consciousness about the significance of
ITKIP around the world and have helped
to mobilize traditional communities and
indigenous peoples to document and
protect such knowledge and to consider
the appropriate means for its valuation and
exchange.
The active role of WIPO in raising public
awareness of the significance of ITKIP
does not, however, indicate any broad
consensus that the intellectual property
framework is appropriate for recognizing,
valuing, and compensating ITKIP. Indeed,
many indigenous peoples and NGOs
representing traditional farmers and those
practising subsistence agriculture have
denounced attempts to impose intellectual
property protections on third world
countries.25 These are not isolated
24

. For example, see World Intellectual
Property Organization, Fact Finding Mission on
Traditional Knowledge, Innovations, and
Culture to North America. November 16-30,
1998. Doc. No. WIPO/ FFM N-AM/IMR/98/4.
11 November 1999.
<http://www.wipo.org/eng/main.htm>.
25
. In its Programme for the Protection and
Promotion of Biodiversity and Community
Rights, for example, the Third World Network

opinions. The resistance to patents in the
area of food and agriculture has provoked
street riots involving over a half million
farmers in India, various indigenous
refusals to permit researchers to enter
ancestral areas, and dozens of
declarations by indigenous peoples,
including The Seattle Declaration of
Indigenous Peoples at the WTO meetings
in 1999 (which continues to make the
rounds on the Internet and to attract the
signatures of more and more indigenous
peoples and NGOs).26 The Seattle
Declaration opposes the patenting of
lifeforms, micro-organisms, plants animals
and all of their parts and natural processes
and insists upon the principle of prior
informed consent and the right of veto by
indigenous peoples with respect to the
appropriation of indigenous seeds,
medicinal plants, and related knowledge
(TWN) has commissioned a series of papers
on the ways developing country governments
should implement their Trade-Related Aspects
of Intellectual Properties Agreement (TRIPs)
obligations while taking into account the need
to protect and preserve biodiversity and
community knowledge, innovation and
practices (CKIP) and the means to ensure that
traditional and indigenous knowledge is given
a vital role in scientific and technological
policies relating to the sustainable use of
biodiversity. In nearly all of the papers
commissioned for the second year of the
programme, the patenting of lifeforms is
rejected and the intellectual property system
itself is denounced for undermining indigenous
peoples’ rights, knowledge, and livelihoods.
See, for example, Egziabher; Ho and Traavik;
and, Tauli-Corpuz.
26
. One of the many websites where this
document can be found is:
<http://www.wtowatch.org/library/admin/upload
edFiles/Indigenous_Peoples_Seattle_Declarati
on.htm>. Ultimately, it suggests that the
cultures of indigenous peoples, their
knowledges, cosmologies and values provide
the most viable alternatives to dominant
models of economic growth and exportoriented development and that the imposition
of IPRs forecloses the capacity of indigenous
or traditional knowledges to serve this vital
role.
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about these lifeforms. It is increasingly
unlikely that existing IPR regimes will be
used as the primary means for protecting
ITKIP.27 However, there is still further
27

. For various legal and administrative reform
proposals see Dutfield, Rights; Australian
Institute; and Simpson. Although Volume One
of The Crucible II Group provides an excellent
coverage of the policy framework and the
opportunities and constraints that it provides,
Volume Two (forthcoming) promises to provide
more precise options for legal reform.
As Victoria Tauli-Corpuz (Director of Tebtebba
Foundation, Inc., the Indigenous Peoples’
International Center for Policy Research and
Education) writes in “TRIPs and Indigenous
Peoples”:
Intellectual property rights are monopoly
rights given to individuals or legal persons
(such as transnational corporations) who
can prove that the inventions of innovations
they made are novel, involved an
innovative step, and are capable of
industrial application. Indigenous
knowledge and cultural heritage are usually
collectively evolved and owned. If
indigenous peoples have to use Western
IPRs to protect their own knowledge and
innovations, they will have to identify
individual inventors. This will push
unscrupulous indigenous individuals to
claim ownership over potentially profitable
indigenous knowledge which will cause the
further disintegration of communal values
and practices. It can also cause infighting
between indigenous communities over who
has ownership over particular knowledge or
innovation.
The concept of exclusive ownership and
alienability which is inherent in TRIPs will
have to be internalized and imbibed by
indigenous peoples even if it goes against
their usual practice of making available
such knowledge for the common good. The
identity and survival of indigenous peoples
as distinct peoples depends to a large
extent on the age-old practice of common
sharing of some resources, knowledge and
skills which are not alienable. With TRIPs,
indigenous peoples will now have to think
of how their knowledge will be protected
against so-called ‘biopirates.’ Sharing of
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research to be done to determine how IPR
regimes can be improved so as not to
undermine forms of cultural diversity.
Despite a fairly overwhelming consensus
that IPRs will not serve the range of
relevant indigenous needs, it is widely
recognized that membership in the WTO
creates state obligations which will require
the introduction of some new legal rights
and the need to legally justify the refusal to
introduce other forms of intellectual
property protection. Current legal regimes,
it is argued, sanction the usurpation of
farmers’ traditional knowledge.28 Only if
knowledge becomes a dangerous
proposition because it might be
appropriated by those who have the
capacity to use the system to claim
exclusive ownership over such knowledge
and commercialize it.
Although typical, the assertion that
corporations may claim exclusive ownership
over knowledge appropriated from indigenous
peoples is inaccurate. Only the particular
application of such knowledge, providing that it
is itself novel and involves an innovative step
(or in patent parlance, is not obvious to a
person of ordinary skill in the art) will be
protected. The patent holder does not gain
thereby an exclusive rights to the common
knowledge that underlies the particular
technology, nor does the commercial
application preclude the continuance of prior
noncommercial usages of such knowledge.
Nonetheless, patents are being granted that
should not be granted based upon a proper
application of these legal principles, and
threats to enjoin alternative usages are often
made by intellectual property holders even
when they do not legally have rights of the
scope that they assert. The assumption by
indigenous peoples that the legal claims made
by intellectual property holders are valid ones
that the Western legal system supports is,
however, part of the problem that needs to be
addressed.
28
. This form of creativity, it is argued, is likely
to continue to be usurped, marginalised and
eventually extinguished by plant breeders’
rights which do not respect indigenous
creativity:

states are prepared to independently
protect ITKIP and to limit plant breeders’
rights will ITKIP, and the cultural diversity
it manifests, survive.
Given the TRIPs obligation to protect plant
varieties, it is asserted that any new
breeders’ right introduced should be
subject to a public interest proviso that
precludes the granting of such a right
when the public interest so requires. This,
it is suggested, will be the case “where
biodiversity is adversely effected, where
the variety poses a possible hazard to the
agricultural system and to human, animal
and plant life, based on the precautionary
principle, where the introduction of the
variety might affect the innovative capacity
and indigenous technologies of farmers,
healers, indigenous peoples, and local
communities”(Nijar, Perspectives).
Moreover, it is suggested that states pass
laws to protect and respect the knowledge
of indigenous peoples and farming
communities with respect to plant varieties
that would provide for a proprietary right of
such peoples to any variety developed by,
or essentially derived from, the knowledge
of indigenous peoples or traditional
farming communities, recognizing co-

The Union for the Protection of Plant
Varieties (UPOV) allows for breeders’ rights
in respect of plant varieties that are
‘improved’ modifications of farmers’
germplasms. UPOV 1991 extends the gap
between source materials and improved
varieties in terms of value and ownership
rights attached to them. This revised
instrument allows for both breeders’ rights
and patents for plant varieties. Finally, the
TRIPs Agreement under the WTO allows
for patents over life forms and requires that
plant varieties be protected by patents or a
sui generis system. In all of these
instruments, the definitional constructs
preclude recognition of innovations that are
inter-generational, collective and for the
social good—hallmarks of the way
indigenous people create and innovate
(Nijar, Perspectives).

ownership among communities if
necessary (Nijar, Sui Generis).
All of the Council Parties (with the
exception of Luxembourg) currently
adhere to the Union for the Protection of
Plant Varieties (UPOV). Research is
needed to determine if the introduction of
a public interest provision would be
congruent with UPOV obligations and
whether recognition of communallydeveloped varieties could coexist with a
plant breeders’ rights regime based upon
UPOV principles. If Council Parties were
to refuse to grant patents upon plant
varieties and to incorporate this definition
of the public interest in their national plant
breeders’ rights legislation (putting the
onus of proof upon the applicant for the
exclusive right, perhaps supplemented
with a right of standing for indigenous
peoples or NGOs with a history of activism
in this area), then the perceived tendency
of the intellectual property system to
sanction biopiracy and to promote
biotechnology of dubious safety and
harmful cultural consequences would be
greatly alleviated. Considerable research
needs to be done, however, to ascertain
how and when the introduction of
genetically modified varieties affects local
plant life and in what ways the introduction
of new varieties affects innovation
activities in indigenous and local
communities. Such assertions are often
made, but are seldom adequately
documented.
A strong case can be made that more
information about intellectual properties
being applied for and granted should be
made available digitally and in a form
accessible to more of the world’s peoples.
Indigenous peoples and holders of
traditional knowledge should be able to
use digital technologies to ascertain if
patents, for example, are being granted on
technologies which are based on
traditional knowledge, involve an “obvious”
step in technological development, and/or
for subject matter that lacks the necessary
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quality of novelty given publication
activities known to them. Unfortunately,
very few patent regimes enable patents to
be challenged on these legitimate legal
grounds before a patent is issued. More
and more information about patents has
been recently made available on the
Internet and some of these services are
free.29 However, the availability of this
information may be of only limited value to
indigenous peoples and the NGOs that
support them. Patent information is
opaque (even to lawyers) and patent
claims are often written to obscure rather
than reveal the scope of the subject matter
claimed to deter competitors or to
encourage them to license the technology
rather than risk infringing it. Even
assuming that patent and plant breeders’
rights documentation was so clear,
adequate, and accessible that indigenous
peoples, third world farming communities,
and interested NGOs could assess their
validity, the cost of challenging these
rights is enormous. Further research
needs to be done into the benefits and
savings of a patent prosecution process
that would enable indigenous peoples
(and market competitors who might be
inclined to support indigenous challenges
to monopolies in their fields) to challenge
pending patent applications on
conventional legal grounds and for public
interest purposes.

IT IS RECOMMENDED THAT COUNCIL
PARTIES UNDERTAKE FURTHER
RESEARCH TO CONSIDER:

•How IPR systems can be improved so
as not to undermine forms of cultural
diversity.
•The possibility of introducing a public

interest proviso that precludes the
granting of plant breeders’ rights when
the public interest so requires.
•Whether the introduction of a public
interest provision would be congruent
with UPOV obligations and whether
recognition of communally authored
varieties could coexist with a plant
breeders’ rights regime based upon
UPOV principles.
•Means to provide for a proprietary
right of indigenous peoples and farming
communities to any variety developed
by or essentially derived from the
knowledge of indigenous peoples or
traditional farming communities,
recognizing co-ownership among
communities if necessary.
•How and when the introduction of
genetically modified varieties affects
local species and ecosystems.
•How the introduction of new varieties
is likely to affect innovation activities in
indigenous and local communities.
•How information about intellectual
properties being applied for (or granted)
may be made digitally available in a
form accessible to more of the world’s
peoples.
•The benefits and savings of a patent
prosecution process that would enable
indigenous peoples (and market
competitors who might be inclined to
support indigenous challenges to
monopolies in their fields) to challenge
pending patent applications on
conventional legal grounds and for
public interest purposes, and/or before
a patent is issued.

29

. For a list of patent sites, see Newton, How
to Find Information. The British Library also
offers access to this information at
<http://www.bl.uk/services/bsds/pxp/overview.
html>.
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Indigenous Peoples, Cultural Diversity,
and the Internet

Indigenous peoples have been active
users of the Internet, using it to
communicate amongst themselves and to
others, to gain access to resources, to
publish and access databases, and to
provide alternative perspectives on issues
that are not covered in mainstream media
(Cisler 1998). Apple Computer’s Library of
Tomorrow project, for example, funded
several library, networking, and language
preservation projects with American Indian
tribes and similar initiatives are now
underway around the globe.30
In some indigenous communities, elders
have rejected new information
technologies, but others see the Internet
as a tool for cultural survival.
Unfortunately, in many areas of the world,
electronic communications systems tend
to reinforce traditional hierarchical social
structures which isolate and marginalise
many indigenous peoples (Donaghy
1998). Whereas in the U.S. and Canada,
indigenous networks have received
extensive technical support from
universities, in areas like Latin America
such collaboration is rare (Donaghy 1998).
European states and regional
governments can assist in these efforts.31
30

. As Delgado and Becker write: “Computer
technology has been taught in a manner which
makes indigenous peoples recall the way their
languages work. Most of these languages work
on an ‘agglutinative’ principle; a root word
provides the base and an infinite number of
suffixes are added according to the situation.
Computer technology, listservs, newsgroups,
and web sites work in this way as well” (1998).
31
. The “Inkarri” information centre on
indigenous issues, sponsored by the Basque
county of Vitoria-Gasteiz, illustrates this
possibility (Inkarri Site). Similarly, a web site
functioning from Geneva has enabled a team
of indigenous peoples to concentrate on
Andean issues (Pueblo Indio Site). Within
Europe, EU funds created for cultural and
economic development in sparsely populated
areas have been used by the Sami to adopt
digital technology to further the marketing of
traditional crafts. However, the failure of the
Swedish government to recognize Sami other

Although many sites on the World Wide
Web are effective in advocating on behalf
of international reforms and mobilizing
support amongst Northern activists unless
these sites broadcast simultaneously in
indigenous languages they not serve as
organizing tools for indigenous peoples in
the South. For many indigenous
languages, however, new fonts must be
developed for use in digital
environments.32 This is a first and
fundamental step in the drive to realize the
potential of new information technologies
for preserving cultural diversity. The
maintenance, use, sharing, and
recognition of ITKIP is also dependent
upon the revitalization and revaluation of
indigenous languages.
Media experts in Canada’s Northwest
Territories are optimistic that the Internet
will help to preserve Dene, Inuit, and Métis
identities and prevent the further erosion
of aboriginal languages. Contemporary
research indicates that language
maintenance and revival tend to be
accompanied by a reaffirmation of cultural
traditions, a revitalization of ITKIP, and a
renewal of traditional relationships with the
environment (Maffi 2000). The isolation of
many indigenous communities may be
overcome by the Internet because it
than those engaged in reindeer husbandry as
having indigenous identity, has limited the
extent of computer and Internet education.
Only one Sami language has digital type fonts,
moreover, and without support for font
development, the potential of the Internet to
assist in the survival of these endangered
languages will not be realized (Forsgren 1998).
32
. For instance, even though most people in
Burma are not permitted to use the Internet,
Burmese in exile have taken advantage of it to
spread information about repression in Burma
and to organize resistance activities. Members
of an indigenous human rights and
environmental organization have traveled
through border areas to teach computer skills
to Mon and Karen peoples who have now
developed digital fonts for use in
communications that document military abuses
(Fink 1998).
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arguably provides an ideal medium for
aboriginal communications.33
33

. Northern News Services copy editor, James
Hrynyshyn, believes that “the Internet is an
ideal match for Aboriginal tribes, providing the
necessary economy of scale to support
electronic publishing for such small
constituencies...because the Internet can
support an admixture of audio, video, and text,
transcending the print medium, it is ideally
suited to the oral story-telling traditions of the
Aboriginal Community” (Zellen 1998). Indeed,
the small town of Inuvik has one of the fastest
public Internet connections and the Gwich’in
and Inuvialit globally market traditional art from
their home pages. The Oneida Nation had a
web page before the White House did and
through it has educated an entire Chinese high
school on Oneida culture, attracted visitors
from Europe to its cultural centre, and created
interest in the Middle East in the dissemination
of Oneida design (Polly 1998). In the South,
interactive electronic conferencing has enabled
indigenous peoples living in remote areas to
share common concerns and exchange
information about their shared problems in
relation to nation states. The Zapatista uprising
against the Mexican government upon the
ratification of NAFTA marked the beginning of
the political use of Internet technology by
indigenous groups. The Maya in Guatemala
are attempting to electronically retrieve any
and all information pertaining to their cultures
to revive their traditional languages and to
legitimate their claims to their ancient
territories. The Kuna in Panama have become
international advocates of indigenous peoples’
stewardship over biodiversity and its
relationship to indigenous rights of selfdetermination.
Digital video camcorders will enable
indigenous peoples to share cultural
performances and practices, making ITKIP
globally available, or at least available to other
indigenous peoples if that is the more
desirable end. Stories told by elders and
traditional practices can both be filmed and
recorded so that they can ‘speak’ to their
descendants for eternity. This is only valuable,
however, insofar as their descendants can
speak their languages and have viable
opportunities to use these practices in a
context where they are respected and
supported.
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Indigenous peoples who no longer reside
on ancestral lands have used the Internet
to revitalize their indigenous identities
while those who did not formally belong to
indigenous groups have rediscovered their
ethnic heritage through Usenet group. The
Internet has afforded them opportunities to
trace their own histories.34 The Hawaiian
indigenous language, long outlawed and
facing extinction, has been reintroduced in
the school system through the use of
computer technology, the development of
fonts, the Internet linkage of peoples
learning the language, and the
authorization of Microsoft to create a
Hawaiian language version of the Internet
Explorer programme (Donaghy 1998).
This example suggests some inherent
limitations on the potential of new
information technologies to aid in the
preservation of cultural diversity. To the
extent that most Internet browsers, email
programmes, web page designs, existing
fonts, html authoring programmes, and
Internet multimedia applications are
proprietary technologies, indigenous
peoples are put at a profound
disadvantage when attempting to adapt
them for indigenous language use.
Intellectual property holders are under no
obligation to license these technologies, or
even to license them at less than market
rates, regardless of whether these new
language versions are being put
exclusively to nonprofit usages that further
international legal norms and human rights
commitments. The possibility and
feasibility of introducing new exemptions
34

. Indigenous Assyrians, forbidden to teach
their own language, develop their cultural
identity, or refer to themselves as a people in
many Middle Eastern countries, have used the
Internet to reconnect with Assyrians in exile all
over the world and to educate the global
community about their culture, persecution,
and aspirations (Gabrial 1998). Continued and
renewed usage of the Syriac or Aramaic
language through the World Wide Web,
however, will only be possible if compatible
fonts are developed.

into domestic copyright, trademark, and
patent regimes to further indigenous use
of such technologies is a topic that
requires further research.
The lack of women’s involvement in
indigenous digital culture is a serious
shortcoming and, given that indigenous
women are often custodians of language
and tradition as well as major holders of
ITKIP (particularly with respect to
traditional medicine and agricultural
techniques), this remains a significant
obstacle to realizing the full potential of
Internet technology for preserving cultural
diversity. Further research needs to be
done exploring effective means for
involving more indigenous and rural
community women in indigenous use of
digital technology for biodiversity and
cultural preservation purposes.
When asked whether he had any advice
for “those who would follow in your
footsteps and try to preserve their culture
using a web page,” the Oneida Indian
Nation’s Internet coordinator, Dan
Umstead, advocated caution in sharing
cultural knowledge: “Remember, if you put
it up, people will use it. So carefully plan it
all out beforehand” (Polly 1998). To the
extent that there are cultural precautions
and prohibitions concerning the use and
reproduction of particular knowledge,
imagery, stories, or texts, these are
unlikely to be known or respected in
cyberspace. The Internet could become a
means of educating others about such
indigenous systems of intellectual property
and online license agreements based
upon indigenous cultural principles could
also be devised. Further research on the
prospects for recognizing and enforcing
indigenous customary law in cyberspace is
needed.
IT IS RECOMMENDED THAT COUNCIL
PARTIES UNDERTAKE FURTHER
RESEARCH TO CONSIDER:

•Developing fonts for indigenous

languages to maximize use of new
information technologies for preserving
cultural diversity and the maintenance,
use, and compensation for ITKIP upon
which global biological diversity
depends.
•The feasibility of devising online
licensing agreements based on
indigenous cultural principles.
•The possibility and feasibility of
introducing new exemptions into
domestic copyright, trademark, and
patent regimes to further indigenous
use of digital technologies for cultural
preservation and revitalization
purposes.
•New and effective means for involving
more indigenous and rural community
women in the use of digital technology
for biodiversity and cultural
preservation purposes.
•Prospects and opportunities for
recognizing and enforcing indigenous
customary law in cyberspace.
Digital Technology, Biodiversity
Preservation, and the Protection of
Indigenous Knowledge
Digital technology is widely used for
biodiversity preservation purposes and
many state and NGO initiatives are
underway to develop electronic storage
and communications media to meet CBD
objectives. National contacts exist in each
of the Council Parties for the ‘clearing
house’ mechanism being established
under the CBD to promote and facilitate
technical and scientific cooperation (Article
18.3) with respect to the sustainable use
of biodiversity (Article 10), the sharing of
benefits derived from the use of
biodiversity (Article 19.2), and the
involvement and equitable sharing of
benefits with indigenous and local
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communities (Article 8(j)). Many of these
clearing houses are in their infancy and
currently operate more as catalogues or
inventories. Most have been launched on
the Internet.35
Work is underway to create a single
international facility for information on
biodiversity—the Global Biodiversity
Information Facility or GBIF—that will link
the clearing house mechanisms with other
“databases on the distribution of plants,
animals, and microbes around the globe,
detailed genome maps, compilations of
the physiological functions of organisms,
and information about the behaviour and
function of species within ecosystems”
(Environment News Service). Such
international maps, however, are not
necessarily conducive to the goal of
preserving cultural diversity to the extent
they presuppose a singular knowledge of
35

. The Belgian Institute of Natural Sciences,
for example, launched the web site of the
Belgian Clearing House on October 7, 1996. It
was the second to be added to the official list
of National Focal Point Clearing-Houses on the
Internet and provides several options for
searching for information on biological diversity
in Belgium and elsewhere. Like other such
sites, it provides hyperlinks to other national,
regional, and thematic clearing houses as well
as linking to the CBD, and the United Nations
Environmental Programme. The site also
houses the CBD clearing houses for Niger, the
Congo, Chad, Mauritania, and Burkina Faso.
Within the framework of the Belgian Research
Network (BELNET), the Workgroup on
Biodiversity has launched a two-part initiative.
The first part is an inventory of biodiversity
resources in Belgium—not limited to
biodiversity in Belgian territory—that refers to
universities, research institutes, botanical
gardens, zoos and aquaria, museums, nature
education centres, associations, libraries and
nature reserves. The second part of the
initiative will create an inventory of the content
of the databases on biodiversity kept in
Belgium. The linkage between biodiversity and
cultural diversity could be made more explicit
in such projects.
<http://www.naturalsciences.net/bchcbd/homepage.htm>.
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the properties of biodiversity that might be
universally shared. For instance, a key
feature of the GBIF will be a database
containing the names of all known
organisms which, it is envisioned, will
“ensure a single global nomenclature for
all named living organisms” (Environment
News Service). It is, however, precisely
the continued existence of multiple
systems of knowledge about natural
organisms and their culturally specific
classification systems, nomenclatures, and
linguistic relations to ecosystems that is
key to maintaining the cultural diversity
upon which biodiversity depends.36
Other government departments may also
use the World Wide Web for public
education purposes with respect to ITKIP.
The federal environmental ministry in
Canada, for instance, posts commissioned
reports on indigenous and traditional
knowledge to its web site (Lambrou 1997;
Mann 1997; Brockman 1997) as well as
more general examples of the Canadian
government’s acknowledgment of the
value of ITKIP in environmental policies
(Blanchet-Cohen 1996). The government
of India is producing CD-ROMs of its
traditional medicinal plant knowledge
36

. Most of the world’s linguistic diversity is
carried by small communities of indigenous
and minority peoples. Indigenous and minority
languages encode distinct forms of knowledge
and cognitive maps of local ecosystems that
cannot simply be translated into dominant
languages. Nor can such diversity be reduced
to nomenclature. Ethnobiologists now
recognize that traditional ecological knowledge
is not about entities per se, such as natural
kinds, but about natural processes and
relations among entities, such as the
relationships among plant and animal species
or between humans and the ecosystem.
Moreover, this knowledge is not carried simply
in linguistic terms but in grammar and speech
formulas and culturally conventionalized ways
of expressing spatial, temporal and causal
relations. The relationship between landscapes
and languages is in many cases mutually
constitutive. See the extensive discussion in
Maffi (2000).

which will be distributed to patent offices
worldwide to provide a database of prior
art. This database may serve to prevent
the issuing of patents such as U.S. Patent
5,401,504 which claimed the use of
turmeric for promoting wound healing
when the practice had been known for
centuries and published in India for over
thirty years. Few developing countries
have the resources to document and
digitally disseminate ITKIP in this fashion.
For many indigenous peoples facing
pressures of assimilation and territorial
encroachment, the governments of the
states in which they are resident are not
bodies that can or will be entrusted with
such knowledge. There is a need then, to
support indigenous peoples’ own efforts
and those of supportive NGOs to develop
and provide such databases as well as
protocols for access to data and benefit
sharing. Research is necessary, however,
to ascertain the extent to which some
forms of knowledge should be kept
confidential and for what purposes.
Indeed, a concern with confidentiality has
resulted in the deployment of a trade
secret model in one Ecuadoran project
(Bodeker 12). In this project, local and
indigenous communities are invited to
participate in depositing and cataloguing
traditional knowledge in a restricted
access database, a determination of the
public domain status of the knowledge will
be made by the database administrators
and, to the extent that more than one
community shares potentially proprietary
knowledge, a cartel of communities will be
established to negotiate Material Transfer
Agreements with the CBD state
government and those interested in
exploiting the knowledge for commercial
use. Further research needs to be done to
ascertain the viability of similar trade
secret models in other regions, the degree
to which violations of database
confidentiality give rise to legal recourse,
the extent to which such agreements
should be respected and recognized in
national and regional patent regimes, and

the desirability of amending patent law to
do so.
The Sociedad Peruana de Derecho
Ambiental has proposed that all patent
applications in the future should include a
sworn statement as to the genetic
resources, as well as the associated
knowledge, innovations and practices of
indigenous peoples and local communities
utilized directly or indirectly in the research
and development of the subject matter of
the patent application. This proposal could
also be extended to plant breeders’ rights
applications (Bodeker 12) and would entail
the submission of evidence of prior
informed consent from the country of
origin and the local community.37 Further
research needs to be done to determine if
such a requirement is compatible with the
TRIPs Agreement (and preliminary
research indicates that it is, if
characterized as an aspect of the novelty
requirement) but such an amendment is
widely urged. In 1997 the Indian
government submitted a paper to the
WTO’s Committee on Trade and
Environment that criticized TRIPs on the
basis that patent applicants were not
asked to make such disclosure.
Facilitators of both the People’s
Biodiversity Registers38 and the Local
Innovations Database39 initiatives in India
argue that the documentation of
community knowledge will only be

37

. For a longer discussion of making prior
informed consent a condition precedent for
receiving a patent see Coombe.
38
. This project is sponsored by the World
Wildlife Federation India and is co-ordinated
with the Centre for Ecological Sciences of the
Indian Institute of Science and the Foundation
for Revitalization of Local Health Traditions in
Bangalore. For more information on People’s
Biodiversity Registers, see Gadgil et al.
39
. This project has been developed by the
Society for Research and Initiatives for
Sustainable Technologies and Institutions in
Ahmedabad and is managed by Professor Anil
Gupta of the Indian Institute of Management.
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successful if intellectual property regimes
are so modified.
Other electronic databases and digital
networks are being established in
developing countries with support by
Council Parties and Council Party NGOs.40
40

. For example, the Swiss Agency for
Development and Cooperation supports The
Farmer’s Rights Information Service (FRIS)
developed by the M.S. Swaminathan Research
Foundation to educate the public about India’s
heritage of biodiversity and current issues of
significance in the preservation of agrobiodiversity, including the need for incentives
to support ongoing activities of genetic
stewardship. As the founder’s introduction
explains, “exchange of information, technical
and scientific cooperation, research and
training, public education and identification of
suitable financial resources are all important
for arresting the loss of agro-biodiversity”(FRIS
Website).The web site operates as part of an
emerging network that links local and
indigenous communities in conservation
efforts:
With the emergence of democratic systems
of governance worldwide and with the
onset of the information superhighway, the
widespread involvement of grassroots level
peoples' organizations in the conservation
movement is becoming feasible. In addition
to information dissemination through
printed and electronic media, ‘awareness
through action’ programmes will have to be
fostered in schools and colleges
(Introduction, FRIS Website).
The website’s founder believes that “the
information age has provided tools such as the
Internet and GIS mapping to promote a
learning revolution in agriculture” and uses the
site to participate in this revolution. The site
operates as a tutorial and teaches that:
entitlements, asset reform and technological
empowerment of the poor will be essential in
ensuring economic access; and, that gender
perspectives must be integrated into the
development of appropriate technology
transfers and the information dissemination
process if agriculture is to serve as an
instrument of income and livelihood
opportunity. The site is linked to videos of
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“experts” espousing the importance of
traditional and tribal peoples and their
knowledge in preserving biodiversity and to a
set of “field videos” that take web visitors to
sacred groves whose genetic diversity is
maintained by tribal peoples as places of
worship, to an interview with a local farmer,
and to local peoples engaged in traditional
methods of seed storage.
From the site, web surfers may “visit” tribal
communities in the Indian states of Tamil
Nadu, Kerala, and Andhra Pradesh, where
they will gain information on the social
customs, agricultural practices, and knowledge
of medicinal and other useful plants held by
tribal peoples. Such information, however, is
described in general rather than disclosed in
specificity.
More specific information is provided for
Orissa, a centre of origin for traditionally
cultivated varieties (landraces) of rice assumed
to contain many valuable genes particularly for
resistance/ tolerance to various biotic and
abiotic stresses and thus to hold promise for
utilization in future plant-breeding
programmes. The multimedia database
contains details on the morphological and
agronomical characters of the rice variety, the
donor farmers’ name and the community, and
location and date of collection for landraces
from five areas inhabited by tribal peoples who
continue to grow these varieties. Visitors will
find pictures of the individual who cultivated
the variety, his or her tribal affiliation, and the
location of the gene bank in which the landrace
has been deposited.
More problematic, from the perspective of
preserving cultural diversity, are the Orissa
site’s detailed descriptions of the sacred
groves located in tribal areas. Not only does
the site name and locate these, it describes
the species found there, and the particular
taboos that local peoples observe. To what
extent does such a practice operate as an
invitation to those who would appropriate local
knowledge about species which, by virtue, of
local cultural prohibitions, are likely to have
unique genetic properties? What protection
has been afforded to these peoples against
biopiracy? Is cultural diversity maintained by
practices that expose local belief systems to
such international and indiscriminate scrutiny?

Such databases may have consequences
for the future potential of peoples to
benefit from this cultivation activity. To the
extent that such publication does create a
record in the public domain, it may operate
so as to prevent the appropriation of such
knowledge and resources in patent claims
and plant breeders’ rights asserted by
others. Again, this will depend upon the
willingness of patent offices to recognize
this as “prior art”. However, the option of
local peoples’ profiting from such
knowledge as a trade secret may also be
foreclosed by such publications. Further
research needs to be done on the likely
legal and cultural consequences of such
publications before knowledge of a
sensitive, sacred, or potentially proprietary
character is posted on the Internet.
Protocols for local peoples’ prior informed
consent to govern such postings need to
be established.
Traditional systems of medicine and local
knowledge of plant genetic resources are
especially diverse in India. In order to
counter the general public devaluation of
the traditional knowledge of those in
marginalised communities and to ensure
compensation to communities and
individuals for the commercialization of
such knowledge, community knowledge
databases are being created. Such
decentralized databases may serve a
number of local cultural and ecological
purposes and are networked to a national
database that promotes the use of such
knowledge for the benefit of local
communities. Access to the contents of
such registers is therefore restricted to
communities of origin who, it is
anticipated, will be able to charge fees to
others, create tariffs, and negotiate
contractual arrangements. Further
research on the implications of various
forms of confidentiality for local peoples
needs to be carried out. On the one hand,
access restrictions no doubt lessen
misappropriations. On the other hand, to
the extent that such knowledge is acquired
and used, the fact that such information

was not in the public domain could make
any patent based upon it difficult to
challenge because prior art in many
jurisdictions does not encompass private
databases (Dutfield, Protecting, 122).
Ultimately, a global linkage of such
databases might enable individual and
collective innovators to receive both
acknowledgment and compensation for
commercial applications of their KIP while
enabling small investors, entrepreneurs,
and local innovators and communities to
locate each other for the purposes of
business development. Such a system
could maintain linkages with regional and
national patent offices which would
universalize prior art so that traditional
knowledge is respected and
acknowledged.
In terms of their capacity to preserve
cultural diversity, however, it is important
to remember that ITKIP thrives to the
extent that it is used in ongoing human
practices to meet new challenges, not to
the extent that it is archived. As Agrawal
argues, “divorced in archives from their
cultural context, no knowledge can
maintain its vitality or vigour”(Agrawal
429). The danger of the archival approach
is that it “may deflect attention from the far
more important priority of protecting
traditional knowledge in situ which of
course requires that attention be given to
the cultural, spiritual, and physical wellbeing of the knowledge holders and their
communities” (Dutfield, Protecting, 109).
Some indigenous peoples are concerned
that the effort to document traditional
knowledge indicates that outsiders value
traditional knowledge much more than
they respect those who generate it. Many
indigenous peoples have made it clear
that concern for the protection of IKP
should be subsidiary to the recognition of
indigenous peoples’ rights to selfdetermination and territorial rights.
Linked database initiatives—like the
Honeybee Network which documents and
puts onto the Internet actual video
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demonstrations of sustainable agricultural
technologies in several languages—
provide a means for local and indigenous
communities around the world to share
traditional knowledge; they may be
considered a form of technology transfer.
Again, such postings pose particular
problems to the extent that they may be
legally deemed to be anticipations that will
preclude the issuance of patents for such
technologies in the future.41 To the extent
that the sharing of ITKIP helps to meet the
health and food needs of other local
communities, it seems inequitable that
such disclosures should preclude
innovating communities from later
41

. As I have argued previously: “because the
law [of patents] encourages secrecy and the
privatization of knowledge until its potential
commercial application becomes clear, third
world innovators cannot share knowledge with
others who may desperately need it, nor can
they seek to attract investors who may be able
to transform it into a better source of revenue
for local communities. A group like the
Honeybee Network is therefore in a difficult
position. Prior to the publication of knowledge
in the newsletter, the network must attempt to
aid either the community or the individual in
establishing a legal right. In most cases,
however, the innovation will not have reached
the point of patentability because the capacity
for industrial application remains to be
ascertained, and there is little investment
capital available to explore the possibility. In
the meantime, the knowledge may be valuable
in alleviating poverty amongst other indigenous
and local peoples and enriching their
livelihoods. Third World networks and
networks of indigenous peoples face an
untenable choice between not publishing in
order to maintain the potential for future patent
benefits, in which case they withhold useful
information from those in dire need of it, or
publishing it with the knowledge that in
assisting others, one risks forfeiting the fruit of
one’s labors. Such a choice violates human
rights norms that encourage the sharing of
benefits, the flow of information, the right to
share in progress in the arts and sciences,
cross cultural exchange, and the right to
sustainable development and a healthy
environment” (Coombe 113).
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benefitting from its commercial
exploitation. Further research needs to be
done on the potential for distinguishing
between kinds and forums of publication
as modes of “anticipation” and the viability
of introducing exemptions for indigenous
knowledge registers and database
linkages in current patent regimes.
It is imperative that local cultural norms
with respect to distinctions between
sacred, secular and sensitive knowledge
are respected in any and all digital use of
traditional knowledges. The Indigenous
Peoples’ Biodiversity Information Network
(IPBIN), which was developed as a
mechanism to help indigenous peoples to
communicate and build capacity in
implementing the indigenous and
traditional knowledge provisions of the
CBD, advises against the posting of any
ITKIP on the Internet, keeps several of its
online discussion forums closed to the
general public, monitors links to ensure
ethical relationships to posted material,
and is developing protocols to govern
clearinghouse mechanisms to ensure that
these do not operate to the detriment of
indigenous peoples’ cultures. Further
research into the protocols developed by
indigenous peoples and respect for such
protocols in all Internet activities supported
by Council Parties would assist efforts to
preserve cultural diversity.
IT IS RECOMMENDED THAT COUNCIL
PARTIES UNDERTAKE FURTHER
RESEARCH TO CONSIDER:

•The viability of trade secret models for
protecting ITKIP in digital
environments, the degree to which
violations of database confidentiality
give rise to legal recourse, the extent to
which such agreements will be
respected and recognized in national
and regional patent regimes, and the
desirability of amending patent law to
respect the norms and agreements of
confidentiality developed by indigenous
peoples and traditional communities.

Conclusion
•The compatibility of the TRIPs
Agreement with the suggested
requirements that: 1) all patent
applications include a sworn statement
as to the origins of genetic resources,
as well as any associated knowledge,
innovations and practices of indigenous
peoples and local communities utilized
directly or indirectly in the research and
development of the subject matter of
the patent application; 2) evidence of
prior informed consent from the country
of origin and the local community be
submitted with patent and plant
breeders’ rights applications that
involve genetic resources and ITKIP.

In conclusion, Council Parties’
international legal obligations under
environmental and human rights regimes
provide opportunities to ensure that digital
technologies are utilised in a way that
serves to preserve biological diversity in a
fashion that simultaneously preserves and
revitalizes the world’s cultural diversity.
The recommendations for future research
contained herein are designed to ensure
that these efforts are undertaken with full
awareness of the complexities posed by
the need to balance intellectual property,
trade, and environmental considerations
with cultural diversity objectives.

•The legal and cultural consequences
of Internet postings before ITKIP of a
sensitive, sacred, or potentially
proprietary character is posted.
•The emergence and development of
protocols for indigenous peoples’ and
local communities’ prior informed
consent for Internet postings of ITKIP
and means of respecting such
protocols in all Internet activities directly
or indirectly supported by Council
Parties.
•Implications of various forms of
confidentiality for local communities
and indigenous peoples’ biodiversity
and cultural diversity preservation
needs.
•The potential for distinguishing
between kinds and fora of publication in
ascertaining whether patentable subject
matter has been “anticipated” and the
viability of introducing exemptions for
restricted access indigenous
knowledge registers and database
linkages between local communities as
permissible forms of technology
transfer in current patent regimes.
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Appendix – Acronyms
CBD
CGIAR
Council Parties
EC
EU
FAO
GBIF
IPBIN
IPRs
ITKIP
KIP
NGOs
TRIPs
UPOV
WIPO
WTO
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Convention on Biological Diversity
Consultative Group on International Agricultural Research
Austria, Belgium, Bulgaria, Canada, Luxembourg, Switzerland,
United Kingdom
European Community
European Union
Food and Agriculture Organization
Global Biodiversity Information Facility
Indigenous Peoples’ Biodiversity Information Network
Intellectual property rights
Indigenous and traditional knowledge, innovations and practices
Knowledge, innovations and practices
Non-governmental organizations
Trade Related Aspects of Intellectual Properties Agreement
Union for the Protection of Plant Varieties
World Intellectual Property Organization
World Trade Organization

Stepping into the Breach:
Provincial Funders Replace Federal Regulators in Defense of Public Priorities and
Safety

Ken Bassett

About the Author
Ken Bassett is a cultural anthropologist, practising physician, and university-based
provincial health policy consultant. He is the Senior Medical Consultant at the BC Office
of Health Technology Assessment, and the Chair of the Drug Assessment Working
Group of the Therapeutics Initiative for the province of BC. Bassett’s central academic
interest is the relationship between scientific evidence and public policy as these relate
to gender, class, ethnicity and geography. Currently, Bassett’s primary concern is the
erosion of science into a marketing tool.

About the Article
From his perspective as an academic active on the ‘front line’ of health-care policy in
BC, Ken Bassett describes the opportunities which are available in the province to
challenge corporate influence on health-care. According to Bassett, if the Canadian
Biotechnology Strategy (CBS) is left uncontested, provincial health services are likely to
be overwhelmed by the activities of the pharmaceutical and device industries, whose
agendas place profits ahead of need, promoting remedies that are usually expensive,
often useless, and sometimes dangerous. Bassett’s paper offers direction for provincial
payment agencies and university research review committees on how to fill what he
sees as the void left by federal de-regulation of the industries involved in the health
sector.
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Introduction
Science has made magnificent
achievements across several centuries in
the understanding of nature, in controlling
it and sometimes even overcoming it. The
very power of science has enabled its use
as a tool for society to challenge dogma,
particularly religious doctrines designed to
maintain political and economic
dominance of church over state.
In the modern age, however, the
seemingly dominant power of science has
itself become a resource for the corporate
agenda. In as much as commercial
interests appropriate science to advance
their political and economic programs,
science risks losing its independence and
becoming co-opted as part of the new
dogma in the theology of corporate
profiteering.
Using the language and the very
institutions of science, manufacturers have
adopted a liturgy of product promotion in
which effectiveness claims are
exaggerated and safety concerns
minimised. For scientists, academics and
researchers who cherish the neutrality of
science, it is of the greatest importance
that this developing pattern of ‘belief’
should be challenged.
My primary activist work is in two formal
roles. I am Senior Medical Consultant at
the BC Office of Health Technology
Assessment (BCOHTA). Health
technology assessment is a discipline
which conducts systematic reviews of
clinical efficacy and effectiveness
evidence. I am also Chair of the Drug
Assessment Working Group of the
Therapeutics Initiative. The Working
Group is responsible for systematic
reviews of all new drugs submitted to
Pharmacare, the Ministry of Health
Department responsible for the Provincial
Drug Benefit Plans in BC.
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From these evaluative perspectives, I
have been able to recognise that the
problem areas faced by women and
society as a whole in relation to the CBS
do not differ in substance from a long list
of health-related initiatives directed at
women throughout the second half of the
20th century.
I begin by looking at reciprocal federal and
provincial responsibilities in health: as the
federal role diminishes, the provincial role
grows. Then I describe two provincial
strategies which have proved more or less
successful in countering commercial
interests, by promoting social interests in
health. I cite almost exclusively our
(BCOHTA’s) reports, not because they are
either unique or definitive in these areas,
but because they provide additional details
of our provincial social advocacy. I end
with a description of the osteoporosis
‘disease management model’, a disturbing
example of how commerce has moved to
dominate health-care.
1. Federal De-regulation
Federal regulation of food and drugs
developed in the wake of the thalidomide
disaster in order to restrict market access
until safety was proven and, in the case of
drugs, efficacy established. Manufacturers
explicitly bore the burden of proof. More
recently, however, Canadian federal policy
has favoured Industry Canada over
Health/ Agriculture/ Environment Canada,
primarily through de-regulation of most
sectors of the economy. In the case of the
Health Protection Branch (HPB), deregulation has meant non-enforcement of
current regulations and the introduction of
new, less-stringent legislation. In keeping
with this less stringent legislation, the
burden of proof in product licensing is
gradually reversing. Manufacturers need
to meet lower and lower standards of proof
of safety and efficacy. Researchers,

publicly or privately-funded, more and
more, must prove harm.
The CBS reflects these federal deregulatory, pro-industry trends. The CBS is
strong on supporting an internationally
competitive industrial strategy, but weak
on making the case for safety
requirements. In this sense, I see the
position of the CBS as not just indicating
the future direction, but as showing the
current realities of federal policy.
Others know much more than I do about
the potential costs and benefits of
providing input to federal policy-making
processes such as the CBS. My
suggestions, therefore, are limited to the
provincial level: how best to support social
interests within the federally de-regulated,
pro-industry context.
2. Provincial Mandate
Diminishing HPB regulation could not have
occurred at a worse time. The past decade
has seen phenomenal growth in the
economic power, and with it the political
influence, of the drug and device industry.
In addition, during the same time period,
the drug and device industry has sought a
more insidious mechanism to control the
health-care sector: by influencing how
people and professionals think and
behave in relation to health, and to what
are termed healthy and un-healthy
lifestyles.
This industry now has the power and
capability to create its own need. It can
promote certain tests (predictive and
diagnostic); therapeutic strategies (which
may include genetically-engineered drugs)
and massive ‘educational’ strategies for
administrators, medical professionals, and
patients. As I shall later describe in
relation to the management of
osteoporosis, the marketing strategy forms
a package, including a ‘disease
management model’ that supports an

immensely profitable market structure.
This package is readily – in fact
specifically – suited both to a population
primed to accept pharmaceutical
‘solutions’ to social problems, and to
physicians trapped in busy, fee-for-service
clinical care settings.
Without federal policy to effectively limit
the market’s access to the health sector,
provincial purchasers and regulators of
health services, devices, and drugs take
on an increasingly important role. They
must mediate between individuals seeking
health care, and manufacturers seeking to
provide goods for the marketplace. They
must select which services to fund, for
whom, and to what extent, all within
capped, global budgets. This task is not
just difficult, it is all but impossible,
requiring meaningful prioritisation among
items as diverse as housing for people
with disabilities, life-saving techniques,
sophisticated diagnostic imagingtechnology, and numerous other
interventions demanded by an increasingly
‘informed’ population. All this within a
‘capped’ or finite budget.
To add to their burdens, diminishing HPB
standards for proof of effectiveness and
safety have greatly increased the
responsibilities of provincial purchasers.
They, rather than Health Canada, must
now determine the scientific validity of
effectiveness and safety data, and
interpret competing claims of benefit
versus harm.
3. Provincial Strategy
The strategy we have used to balance
commercial with social interests at the
provincial level is based on one principle:
focus upstream on key decision-makers.
‘Upstream’ means early attention to the
purchasing-funding process where
decisions are made about what is to be
made available to communities, hospitals
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and clinics. The corollary is ‘Downstream’,
the points where these programs, tests or
technologies are used.
‘Upstream’ or province-wide decisions
regarding funding and regulation are
preferred because they involve fewer
individuals, usually in senior management
or executive positions, and acting
according to relatively strict rules of
conduct within standing committees
having explicit mandates. They can
therefore be identified and reached by
independent researchers, publicly-funded
assessment institutes, and by social
activists working with limited budgets and
small staff.
Downstream utilisation in local medical
clinics, by contrast, involves diverse
settings and numerous individuals with
different values and expectations. Clinical
settings are the areas most strongly
influenced by the drug and device industry
through clinical practice guidelines and
direct-to-consumer advertising. Similarly,
downstream utilisation in local hospitals
varies widely and is equally vulnerable to
direct commercial control.

Two upstream provincial opportunities that
we have used to counter the commercial
dominance of health (defined broadly) are:
1) University and Hospital Ethical
Review Committees, under a duty to
ask not only if research meets ethical
standards, but also if it is valid science
and serves public interests;
2) provincial and regional committees
charged with purchasing tests or drugs.

1) University and Hospital Research/
Ethics Committees
Most drug and device research in Canada
requires approval by a research ethics
committee, usually associated with a
university or health-care institution or
program. Strengthening these committees
and expanding their mandates to review
scientific validity as well as ethics could
provide a significant opportunity to counter
the CBS, at the provincial and community
levels.

For example, in BC, only one hospital has
a Technology Assessment process able to
consider the medical necessity of new
technology. Instead, most hospitals
encourage new technology because it is
an important source of prestige and, in the
case of diagnostic technology,
desperately-needed funds. Hospitals in BC
can use diagnostic technology as a
funding source because they are able to
bill the provincial payment plans for
services provided to ‘out-patients’ visiting
their facility. Meanwhile, all ‘in-patient
costs, including diagnostic tests, must be
paid from the global hospital budget.

Although these committees have not
customarily considered issues of scientific
validity or social relevance of research,
this role is gaining increasing importance
in the absence of alternative forums to
raise these issues. Moreover, assessing
scientific validity fits with the Helsinki
Agreement which states that research
must have "a reasonable likelihood that
the populations in which the research is
carried out stand to benefit from the
results of the research." Our Technology
Assessment Office has helped some
committees in the effort to examine
whether proposed research is scientifically
valid or a marketing tool.

Given this situation, concerns over a given
technology, however legitimate, are
unlikely to be most effectively presented
downstream. In consequence, “Focus
Upstream” is the best strategy.

A scientifically-valid study would enrol a
sufficient number of reasonably
representative patients to answer a
question regarding benefit or harm.
Marketing studies, by contrast, enrol
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relatively few patients from as many
settings as possible, and measure shortterm changes in body parameters such as
blood pressure or cholesterol, known to
favour the proposed test or clinical
intervention.
The strategy of focussing on study validity
has had some success in slowing the
introduction of new, virtually unstudied
treatment technology in the province
(Bassett et al 1998).
We have also worked with the larger
Health Regions in BC to strengthen their
research and ethical review processes.
Device manufacturers often target regional
hospital systems to familiarise a medical
community with their equipment and
service personnel.
For example, manufacturers interested in
introducing a new laser treatment in
urology approached several regional
hospitals for participation in a clinical study
(Bassett and Kazanjian 1996). The laser
technology was rejected when the
research review committee noted that the
study, although ethical, was too small and
too poorly designed to result in
scientifically-valid findings. A different
region in the province accepted the
research study because the manufacturer
offered the technology at reduced cost at
the end of the study period.

2) Provincial Purchasers and Regulators
A second opportunity to support social as
opposed to commercial interests occurs
with provincial regulation and purchase.
Since 1995, the Drug Assessment
Working Group of the Therapeutics
Initiative has produced approximately 200
reports assessing the effectiveness and
safety of new drugs submitted to the
Provincial Drug Benefit Plans for payment.
The reports have influence public drug
plan funding policy in BC.

Our Health Technology Assessment Office
has also had some success at influencing
diffusion of diagnostic imaging technology
into the province. Diagnostic technology
can only be provided in an accredited
facility which must obtain a specific licence
to bill the provincial fee-for-service plan.
Licensing is the jurisdiction of a joint BC
Medical Association-BC Ministry of Health
committee, where government
representatives have shown themselves
prepared to challenge assumptions
regarding patient benefit from a new
technology. Working with these
government individuals, one-on-one, we
have been able to successfully support
their challenges on the state of scientific
knowledge. In the case of bone mineraldensity testing, for example, a moratorium
on licensing in BC effectively blocked
diffusion of this unproven technology for 3
years (Green et al 1997).
Laboratory tests, similar to diagnostic
devices, need a ‘fee code’ within the
provincial health insurance payment plan.
Establishing a fee code and payment
conditions can take several years alone,
because fee codes are fought over in a
very competitive environment within the
BC Medical Association itself. The BCMA
is dealing with a capped global budget.
The fee code must also be approved by
the provincial government which again
provides an opportunity for raising issues
of social concern. Our work on prostate
specific antigen screening is an example
of the successful use of this approach. We
argued effectively that the scientific
evidence did not support mass screening
as providing greater benefit than harm
(Green et al 1993).
4. Disease Management Models: The
Ultimate Public Advocacy Challenge
Disease management models promoted
by drug and device manufacturers are
crafted with great sophistication, and
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aimed at the long-term medical
management of health issues across the
life-span. They develop measurements,
and propose specific drug therapies
designed to alter those measurements.
The goal of the disease management
model is to have drug prescription based
on and assessed in terms of the
measurements.
Disease management models have seen
phenomenal marketing success: blood
pressure testing and treatment (Kawachi
and Conrad 1996), cholesterol testing and
treatment (Savoie et al 2000), glucose
testing and treatment for adult onset
diabetes (Management 1998). In all
instances, the issue is not whether the
drug alters the test result; it may do so
unequivocally. Nor is the issue whether
the test can identify a risk factor for an
actual clinical event such as a heart attack
or stroke. All these indicators are accepted
as population-based risk factors for clinical
events. The issue with disease
management models is that they
exaggerate the treatment benefit both to
individuals who achieve some benefit and
to others, by extrapolating findings beyond
those people in whom a benefit has been
found. In other words, for individuals,
disease management models focus
attention away from problems of diet,
exercise, lifestyle, poverty, unsafe
environments, and onto specific
measurable, alterable physiological
components. For populations, disease
management models divert limited funds
from alternative, often more cost-effective
programs.
Genetic disease management models are
not yet as sophisticated as other disease
management models. While geneticallymanufactured drugs and hormone and
enzyme replacement products are in
current use, there is not as yet an example
of a treatment that alters a test result for a
genetic disease parameter. Genetic
disease management models are
proceeding, however, with treatments
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such as ‘herceptin’ (see Batt, this volume).
Herceptin does not itself alter the original
genetic characteristics. It is, however,
dependent on genetic tests to determine a
woman’s suitability.
Nevertheless, whether considered a
genetic or non-genetic disease, the
problem remains the same for provincial
policy-makers and regulators. The drug
and device industry presents disease
management models within a carefullyorchestrated marketing strategy. The
ability of provincial governments to
respond effectively has been diminished
by fragmentation over different
departments, with isolated individuals with
different mandates.
5. The Osteoporosis Disease
Management Model: Upstream
Success, Downstream Failure
We believe the upstream focus is both
necessary and appropriate for our limited
resources. However, we recognise that it
is the downstream activity which
determines who is the ultimate winner,
public or corporate.
The most recent and dramatic example of
an upstream success, but downstream
failure is provided by the osteoporosis
disease management model. Destined to
become the most successful disease
management model to date, it is designed
to medically manage bones and bone
health across the life-span. The model
brings together bone mineral density
(BMD) measurements with specific drugtherapy designed to alter those
measurements.
BMD testing is an x-ray technique used to
assess bone structure and to predict future
fracture risk. The problem is that BMD is a
very poor test for predicting which women
will and will not suffer future fractures
(Green et al 1997). Nevertheless, low
BMD is very actively promoted to well

women. This despite the fact that drug
treatment of low BMD (necessarily offered
for long-term use) has not been shown to
reduce the fracture rate of well women, the
group targeted for BMD testing (Kazanjian
et al 1999).
From the early 1990s, numerous
researchers, women’s activist groups and
the provincial Women’s Health Bureau
argued that the osteoporosis disease
management model diverts attention away
from problems of diet, exercise, lifestyle,
unsafe walking, shopping environments,
and focuses instead on the specific,
measurable, alterable component of bone
structure - which is not necessarily
connected to disease outcome.
Our technology assessment office showed
provincial policy makers that this disease
management model diverts funds from
effective programs shown to reduce
fracture rates (NHS 1996). The
Therapeutics Initiative argued that
available hormone and bisphosophonate
(Fosomax) therapy was of very limited,
and likely transient, benefit. The latter
drugs remained as restricted drug benefits
in the province. As mentioned above,
support for individuals in the Ministry of
Health resulted in a 3 year moratorium on
BMD diffusion in the province (Bassett
1999).
In the end, however, no one person and
no committee could adequately argue for
social needs or consequences, nor solicit
sufficient public or expert opinion to
counter the disease management models
being rolled out by the drug and device
industry. In short, once BMD technology
became available to clinical care, it was
‘game over’. Unsubstantiated clinical
guidelines and protocols in the use of the
technology were rolled out as part of drug
and device industry sponsored
‘educational’ strategies.
The failure to control the osteoporosis
disease management model was

facilitated by providing it a fee code within
the provincial health insurance payment
plan, albeit an old code not using the x-ray
technique. Furthermore, with a fee code in
place, individual hospitals exercised no
control over utilisation. For example, when
BMD was considered by the Greater
Victoria Hospital Society, Technology
Assessment Committee, they did not
consider the medical necessity of new
technology.
BMD remains as a dark moment in the
history of the Greater Victoria Hospital
Society TAC. It is a clear example of the
inducement mentioned earlier, the
opportunity to bill for hospital services
provided to ‘out-patients’ outside the
global budget. The committee could not
bring itself to adequately evaluate BMD
because it was such an important source
of sorely-needed funds.
6. Genetic Testing and Treatment
Decoding the human genome and
understanding the role of genes in health
and disease holds great promise and
challenge for the future. Genetic research
promises to provide greater understanding
of the origin and mechanism of disease,
possibly treatment and, at times, cure.
Genetic research also promises very
significant financial reward for a rapidly
growing, national and international, biotechnology industry. The challenges faced
by society include maintaining privacy,
ensuring access of individuals to health
insurance, and countering discrimination
based on disability and eugenics.
Public purchase of genetic tests and
treatments and the ethical review of
genetic research provide important
opportunities to weigh costs and social
consequences against potential health
benefits. My recommendation is that
decision making regarding public purchase
and ethical review should include very
clear and unbiased assessments of the
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scientific validity of effectiveness and
safety claims. With unbiased
assessments, science remains a very
powerful social tool. With biased
assessments, science risks further
absorption into the commercial enterprise.
Summary
I have described what provincial
opportunities exist to provide social
direction to the federal, pro-industry CBS
policy, at the points of purchasing and
research review. Few objective observers
will doubt the need for strategies of this

kind to combat the re-modelling of healthcare into a commercial market place.
With the advent of genetics-based
medicine, these strategies may serve to
help individuals and committees at the
provincial level who are soon to face the
incoming tide of genetic testing and
treatment options.
Social interests could also be greatly
furthered by co-ordinating ethical and
research review committees with one
another, and with provincial purchasers
and regulators.

References
Bassett KL. 1999. Using diagnostic tests to sell drugs: the case of bone mineral density
testing in BC. Centre for Health Services and Policy Research, Annual Health Policy
Conference, University of BC, Vancouver November 26.
Bassett KL, Morris V, Chambers K, Fry P, Foerster VA, Fatin N. 1998. Endovascular
graft treatment of infrarenal aortic aneurysms. Joint Health Technology Assessment
Series, BCOHTA 98:5J.
Bassett KL, Kazanjian A. 1996. Incorporating clinical effectiveness debates into hospital
technology assessment: the case of laser treatment of benign prostatic hyperplasia.
BCOHTA 96:1D.
Green CJ, Bassett KL, Foerster V, Kazanjian A. 1997. Bone Mineral Density Testing:
Does the Evidence Support its Selective Use in Well Women? BCOHTA 97:2T.
Green CJ, Hadorn D, Bassett KL, Kazanjian A. 1993. Prostate specific antigen in the
early detection of prostate cancer. BCOHTA 93:6D.
Kawachi I and Conrad P.1996. Medicalization and the Pharmacological Treatment of
Blood Pressure. In Peter Davis, editor, Contested Ground. New York: Oxford University
Press. 26-41.
Kazanjian, A., Green, C.J., Bassett, K., Brunger, F. 1999. "Bone Mineral Density Testing
in Social Context." International Journal of Technology Assessment in Health Care.
15(4):679-685.
Management of Type 2 Diabetes. 1998. Therapeutics Letter 23, Jan/Feb/Mar. Full text
available through www.ti.ubc.ca
NHS Centre for Reviews and Dissemination and Nuffield Institute for Health. 1996.
Preventing falls and subsequent injury in older people. Effective Health Care. 2(4):1-16.

168

Savoie I, Kazanjian A, Bassett KL. 2000. Cholesterol Testing Clinical Practice Guidelines
and the Clinical Expert Paradox. Journal of Health Services Research and Policy.
5(2):76-82.

169

Science Education for a Science Dependent Culture
Ellen Larsen

About the Author
Ellen Larsen is a Professor in the Department of Zoology at the University of Toronto.
Her interest in science education has led her to develop courses aimed at understanding
"science as a way of knowing". She has served on the Council of the Royal Canadian
Institute, an organisation devoted to making science accessible to the general public,
and has also served on a Science for Peace committee which examined Canada's
compliance with its international treaty obligations with respect to chemical and
biological warfare.
About the Article
Ellen Larsen addresses a fundamental question about the democratization of
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students trained in the liberal arts conceive of science. She recommends a shift in the
cultural understanding of science, from its characterization as an elite-based tool for the
few professionals who use it daily, to a common cultural artifact – a tool of the masses
as we interpret and explore our world.
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As an academic geneticist interested in
the arcane mechanisms of development, I
spend my days trying to understand how a
fruit fly's genes determine whether it will
have a leg or an antenna growing from its
head. The vocabulary and techniques I
use daily are often poorly understood by
colleagues in other biological disciplines,
let alone most lay people. Nevertheless,
the motivation for doing this research, and
my particular approach, should be
accessible to anyone. Unfortunately, the
lack of comprehension of science goes far
beyond problems of communicating the
essence of one's research to a broader
community.
My concerns in the area of women/ health/
genetics stem from the conviction that for
citizens to be empowered to make
decisions with respect to their health, and
that of their families, they should
understand the issues involved. As an
instructor in 1st year seminar courses
serving as the only science course that
many Arts students will encounter, I have
been startled by the inability of these
students to read newspaper and magazine
articles on genetics with comprehension.
This inability extends to recreational media
like the movies Jurassic Park and
GATTACA. Part of the problem is that the
vocabulary, and some of the concepts, are
not part of their knowledge base.
Another part of the problem is an antipathy
to "science as a way of knowing". When
asked what kinds of information they
would like to have before they decided to
use a new type of medical treatment, it
was astonishing to hear that if a relative
recommended it, that would be good
enough. These are bright, articulate
students for whom risk-benefit analyses

hold no charm and double-blind
experiments no hope. It would not be
surprising, therefore, that a few years
later, if issues of new reproductive
technologies or genetically modified foods
became important to them, they would be
incapable of doing more than putting their
trust in someone else’s analysis.
I do not understand the cultural dynamics
responsible for the disaffection with
science among many of our educated
citizens. It occurs to me, however, that
scientists may be looked upon as
belonging to a priesthood which has
access to information stored in Temples
(libraries) which is incomprehensible to the
lay public. This is not true for many
aspects of the science-based issues in the
health/ genetics areas, since a 1st year
university student with a grade 10 science
education can search out articles on
specific, technical subjects and
understand their key points. Web based
tools have the power to remove barriers to
such technical information because the
cyber library is open to the increasing
number of people with Internet access.
Yet the Web represents a double-edged
sword since one has to be able to evaluate
the information one is getting. The
challenge for the educational system at
both the high school and university level is
to integrate science into curricula as part
of our culture much as music, drama,
dance and the graphic arts. This will only
happen if the demand for such integration
exists in the community so that science as
a way of exploring our world and
understanding technology replaces the
notion of science as the province of the
relatively few who will use it professionally.
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About the Article
Patricia Lee approaches biotechnology from a particular vantage point: the development,
use and storage of DNA forensic information. By posing the question, what specific
effects will these seemingly generic technologies have on women? Lee unpacks a
wealth of crucial insights. DNA forensic technologies, her analysis reveals, are inserted
into existing social systems, with all the problems and inequities that exist therein.
Recounting the discouraging statistics on the percentage of sexually assaulted women
willing and able to gain legal redress, Lee asks “Will DNA collection and storage become
a further reason for victims to remain silent about their assaults?” In addition, she points
to the place of DNA evidence in an expansive network of state surveillance, with
especially harsh consequences for members of marginalised communities. A
considerable amount of further research, Lee argues, is warranted.

172

Introduction
As Canada enters the 21st century, many
DNA1-based biotechnologies are
developing rapidly. Among these are the
collection, analysis, storage and use of
DNA for the purposes of forensic evidence
in the legal system. Indeed there is almost
daily media coverage about the
significance of forensic DNA.2 Yet there
has been little analysis of the potential
negative consequences and effects of
collected forensic evidence on Canadian
society. Also missing is a thorough gender
critique.3
Forensic evidence is commonly derived
from the DNA in human fluids and tissues
– blood, semen, saliva, skin cells, hair, nail
clippings, finger prints, deposits found in
bodily orifices. This evidence is generally
substantiated with photographic or
diagrammatic and textual descriptions of
attack sites, bodily wounds and the
instruments of assault. Such evidence is
generally found in and on the bodies of
women.
It is becoming commonplace for police
investigators to obtain as much
information as possible from a crime
1

DNA is the acronym for deoxyribonucleic
acid, the genetic composition of all higher
living organisms.
2
The terms “DNA evidence”, “forensic DNA”,
“forensic evidence” all apply to the physical
collection of bodily, usually human, tissues and
substances, the analysis of the DNA contained
therein, and the subsequent storage of the
physical record and/or the reports based on
that evidence, and the use by the police and
courts of that information. The human
materials are called forensic because they are
specifically collected for legal purposes in the
pursuit of social justice. Otherwise they are
medical evidence collected expressly for
diagnostic and treatment purposes.
3
In the mid-1990s two strongly feminist
commentaries were published on this topic by
Kubanek 1997 and Miller 1996.

scene in order to reconstruct the crime
and to identify a known assailant, or
archive information that could lead to
identification of the unknown attacker at a
future time. Forensic DNA analysis,
sometimes referred to as “fingerprinting”
technology, is commonly performed in
cases of violent physical assault, including
sexual assault, homicides, and hit-and-run
accidents. By checking the suspect’s DNA
against DNA samples found at a crime
site, usually in the form of semen, saliva,
skin cells or hair follicles, charges can be
laid, court proceeding initiated and
convictions made.
While these potential case-solving aspects
of DNA forensics have been widely
publicized, the ways in which the evidence
is used once it is available have received
virtually no public attention. I argue that,
before we allow wholesale use of this
expensive and time-consuming DNA
biotechnology we ensure that women’s
rights4 to privacy, security and
confidentiality, and their proprietary
interests in their bodily parts, are
protected. Furthermore, women victims of
violent crime must have their right to
consent to their DNA being stored
enshrined, and enforced with medical,
ethical and legal standards of disclosure. If
this is not ensured, tracing the genetic
material once alienated from the body may
be impossible. Some would argue that this
happens all the time when one gives a
blood or tissue sample, and hospitals do
retain the samples for later reference.5
However, the concern with alienated DNA
resides in its potential use for surveillance
4

I would include under this umbrella the rights
of children and other vulnerable minorities.
This discussion paper focuses specifically on
women’s interests.
5
Recall the case of Moore v. Regents of the
University of California, where a man (John
Moore) being treated for cancer had his cell
line used for commercial purposes without his
knowledge.
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– purposes other than medical diagnosis
and treatment.
DNA Forensics in Canada
In 1995 DNA warrant legislation made it
possible for Canadian police to seize DNA
samples for a wide range of offences
included under thirty sections of the
Criminal Code. The expectation at the
Department of Justice was that this
legislation would diminish violent assaults
through deterrence and enhance
convictions (Canada, Solicitor General
1996). Consequently, it has become
routine for a finger prick blood sample to
be taken from a crime suspect, whose
DNA is typed in at least nine identifiable
ways, then checked against DNA found at
the crime site6, or filed for future reference.
As this practice has increased, a central
place to store DNA has become vital.
In 1996 a bill was introduced by the
Federal Government to establish a
National DNA Databank. Presently, under
federal government legislation a bank is
being set up in Ottawa housed on RCMP
premises. DNA samples along with crime
scene data will be stored for future
reference. Over time it is expected that
large numbers of Canadians will have their
DNA profile and a biological sample on file
in this costly bank.
The RCMP in 1996 projected that the cost
for DNA studies would be $6 million per
annum, plus $5.8 million to build the new
facility (Miller 1996:2). These estimates
pale in contrast to those of similar banks
already in existence in Britain, Australia
and the U.S. In Britain, the reported cost of
6

Site may include not only a place, but also a
human body, usually female, living or dead.
The Vancouver Police Department is
accelerating now their systematic search for
possibly in excess of 30 women missing
without trace from the Downtown Eastside.
Mitochondrial DNA evidence is beginning to be
used in the case of human remains found in
remote parts of the Province.
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their data bank in the first five years of
operation for the storage portion alone
was $300 million Canadian. The British
government introduced databanking as
part of a move to increase police and state
power, particularly in response to curtailing
terrorism from the IRA (Kubanek 1997:3).
Its motive was less about the issue of
public safety.
The perceived focus of DNA collection and
storage for the Canadian public has been
the identification of criminals,
predominantly male perpetrators, who are
responsible for the greatest proportion of
crimes (common assault, sexual assault
and hit and run road accidents). However,
there has been little discussion of the
repercussions of DNA evidence collection,
storage and analysis on Canadian
women’s experiences, or for marginalized/
minority populations in Canada. There is
minimal awareness of how pervasive and
extensive is the state’s surveillance
capacity in the analysis of individual and
collective DNA once it is collected and
stored.
DNA Surveillance: Implications for
Immigrants and First Nations
There has been some preliminary
research on the use of genetic information
in the immigration and refugee context in
Canada. Critics argue that the use of
genetic tests to establish or confirm
familial ties is premised on the assumption
that consanguineous links, as opposed to
culturally determined social relations, are
paramount in determining which significant
“family” members may be sponsored for
immigrant status. Therefore using genetic
testing as the standard tool to determine
legal residency in Canada compromises
the rights of applicants whose families are
based on non-genetic kinship models.
Moreover, the storage and use of the DNA
information from applicants, either within
Canada or in countries of origin, could

have serious consequences. Employing
genetics as a gatekeeper strategy to enter
Canada has sinister reminiscences of
socio-biological techniques to preclude
entry into Canada and the United States in
the early part of the twentieth century. At
that time new immigrant hopefuls were
subjected to physical and psychological
examination in order to assess their
worthiness for residency. Determinants
such as low IQ, small head size, diseases
such as tuberculosis, or being a member
of certain minorities (gypsies, Jews)
resulted in many travellers arriving
exhausted and sick from long journeys on
the immigrant ships from Europe only to
be sent back to their homelands.
Currently, DNA technology is being used
in the international context to analyze,
store and make available the genetic
blueprints of specified ethnic groups. This
data will be available in perpetuity, should
certain peoples become extinct. The
Human Genome Diversity Project (HGDP)
originally aimed to bank the DNA of 722
indigenous peoples globally. Despite the
fact that the Indigenous Women’s Caucus
at the UN Fourth World Conference on
Women unanimously declared the project
unacceptable, the project’s sponsors have
continued their efforts with the approval of
the international scientific community
(Kubanek 1997:4). The HGDP proper has
never actually started, largely because of
these protests. Yet bio-prospecting
continues. Canada has not been immune
to this investigation, as isolated
communities in the Canadian north,
composed of First Nations and Inuit
people have been the objects of
commercial and intellectual property
interests. Recently, the Icelandic
government agreed to collect and submit
the profiles of all their nationals to HGDP.
There is a clear need for more research in
this area.

DNA Surveillance: Implications for
Women Survivors of Sexual Assault
The remainder of this discussion focuses
on a narrower spectrum of DNA use in
Canada. It addresses some of the ways in
which the growth of medico-legal
examinations resulting in the collection
DNA evidence may affect women
adversely in their dealings with law
enforcement agencies and the courts. It
challenges the prevailing assumption that
identifying an assailant based on DNA will
help protect women in general against
assault, and ensure that the courts rightly
identify and convict known offenders. I
question whether DNA databanking is any
more than a new genetically based form of
state surveillance, where ethnicity,
disability and deviance are labelled and
manipulated by state practices which
evoke memories of past eugenic policies.
New areas of research are suggested
which can begin to address some of these
issues.
From the hospital setting, through to the
courts and extending into the realm of
federal policy, women’s health, safety and
well-being may be affected in unforeseen
ways by the perceived need to collect and
store evidentiary materials and release
pertinent information in sexual assault
trials. While I do not dispute that in certain
instances forensic evidence has great
value for bringing assailants to trial,
convicting them of heinous crimes and
compensating to some degree the
innocent victim, the discussion that follows
takes a cautionary approach. It questions
the degree to which the exponential
growth and concomitant validation of DNA
evidence serves the best interests of
specifically identified women, and by
extension, all women.
The first point I address concerns privacy,
confidentiality and the ethics surrounding
informed choice in the collection of
forensic evidence. At issue is whether
women realize that when they submit to a
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forensic examination following a sexual
assault that their own DNA will also be
identified and documented, and potentially
may end up in the National DNA
Databank. The second point involves
inappropriate stereotyping. Although
sexual assault (not to be confused with
domestic violence) is indiscriminate
throughout society, there is a misplaced
assumption that certain types of women
are the targets of sexual assault and thus
they deserve what they get. The third
point, which follows on from the second, is
that there is very little research as yet
about the relationship between
admissibility of forensic evidence in the
courts and women’s experience in court.
Privacy, confidentiality and the ethics
of informed consent in the collection of
forensic evidence
Patient autonomy (or self-direction or selfdetermination) is a central value in all
approaches to health care ethics as Sue
Sherwin has pointed out. Yet her concept
of relational autonomy also calls attention
to the context within which decisions are
made, the situational ethics. Protection of
autonomy is particularly difficult in health
care settings because sick patients are
dependent on the care and goodwill of
their caregivers. The tendency towards
paternalism in medical care “reduces
patients’ power to exercise autonomy and
it also makes them vulnerable to
manipulation, and even to outright
coercion, by those who provide them with
needed health services” (Sherwin
1998:20).
In the situation where medical/forensic
evidence is collected, it is particularly
important that patient autonomy is
respected and that the patient/victim’s
care is in the context of experienced,
sensitive assistance from trained sexual
assault examiners, counsellors and victims
service workers. BC Women’s Sexual
Assault Service (SAS), for example,
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actively promotes a woman-centred
approach, which ensures that a
patient/victim will be given all the time and
information necessary to understand
precisely what she is consenting to. SAS
has a clear mandate that the physical,
psychological, emotional and security
needs of the woman following a sexual
assault are primary. The forensic
examination, while available on consent,
takes second place to health services and
then only following stringent rules and
safeguards at every stage of consent.
Allied with the issue of consent is the
obligation for patient confidentiality and
privacy. Lack of consent to engage in
sexual activity, as occurs in sexual
assault, and limited understanding of the
consequences of the invasive medical
procedures which occur in a forensic
examination both relate to extreme abuse
of power. They are associated with the
violation of bodily integrity and acts of disempowerment which undermine the
dignity and control that women need for
self-determination, agency and autonomy.
A patient/victim’s right to confidentiality,
like consent, is a cornerstone of medical
ethics. Unfortunately if women fear that
evidence taken from their bodies may be
misappropriated by the law enforcement
and court systems, then their confidence is
shaken with respect to frontline health
care. Consequently, some women, who
are often the most vulnerable, are unlikely
to seek the medical and psychological
help they require for the effects of sexual
assault.
Although legal reform and other social
changes have brought about greater
efforts to eradicate biases that confront
those who press complaints of sexual
assault (Johnson 1996:36), it is well
documented that most women who are
sexually assaulted never involve the police
or seek medical care. It is estimated that
about 70% of women utilizing sexual
assault services do not report to the
police. In fact, only 1 in 10 women who are

sexually assaulted report the incident to
the police, and in the case of date rape,
the number rises to 1 in 100. According to
the Statistics Canada victimization survey
(1993) more than one in three adult
women have been sexually assaulted
since the age of sixteen, and 94% of these
cases never come before the criminal
justice system. Moreover, when SAS
tracked service records they found that
only 10 out of 100 cases where evidence
had been collected for the police had led
subsequently to a trial with a conviction
(personal communication).
Many women have valid concerns about
disclosure of an assault for fear of
repercussions from an abuser if they
report. Other women, as documented by
victim services workers, have legitimate
concerns about how they will be treated in
court. This rightful wariness of the medical,
law enforcement and judicial systems
raises the question: Will DNA collection
and storage become a further reason for
victims to remain silent about their
assaults? Therefore at the outset
assurances of confidentiality and nondisclosure are critical for victims who do
seek victims services or medical supports.

Recommendations for research
While issues of consent, confidentiality
and disclosure of personal records in
sexual assault cases7 are beginning to be
recognized and addressed in the health
care context unexamined to date are
proprietary rights to DNA in the broader
context. Should women be concerning
themselves with what happens to their
own DNA profile that is collected as part of
the forensic evidence following a sexual
assault? One way to investigate this would
be to evaluate studies conducted at DNA
databanks that have been operational for
7

See papers by Addison, Busby, Robinson
and Sampson in Metrac publication 1998. Also
unpublished confidential paper by Lee 1999.

a number of years. What kinds of
analyses, if any, have been conducted on
those records? What is the demographic
profile of those who have their DNA stored
in these banks? Furthermore, what kinds
of safeguards are in place to protect the
privacy and proprietary interests of any
given individual? In the short term it is
important to track the development of the
DNA databank as it is implemented in
Canada and the legislation surrounding
both its own internal operations and its
linkages with DNA forensic laboratories
under various police jurisdictions across
Canada, including the practices of private
laboratories.
Inappropriate stereotyping of sexual
assault victims.
DNA banking has the potential to feed into
the hierarchies and inequities already in
existence in the prosecution process.
There is an unfounded assumption that
certain men’s and women’s accounts have
more credence than others. Recall how
white, well-groomed, educated rapist and
murderer Paul Bernardo evaded
prosecution for sometime, and did not
have his DNA collected, while other men,
such as those who are poor, Native and/or
substance abusers are more likely to be
targetted immediately.
This section will discuss how certain types
of women are stereotyped as more likely
to be sexually assaulted, for example poor
women, sex trade workers, substance
abusers and certain ethnic groups e.g.
First Nations women. In Vancouver, this
assumption is based partly on the
backgrounds of women living in the
Downtown Eastside who tend to fall into
these categories and are identified as
being subject to frequent abuse. Women
who agree to evidence collection after a
sexual assault could unwittingly be
providing evidence that may be used
against them in an unrelated criminal
investigation.
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The Downtown Eastside scenario exists in
other inner cities in Canada, where the
destitute congregate and crime is rampant.
There is national evidence that native
men, men of colour and poor men are
jailed in Canada at a rate disproportionate
to the Canadian demographic profile.
Therefore the DNA of marginalized groups
is more likely to be retained in the National
Databank. The logical consequence is that
the DNA of sexually assaulted women,
who become labelled as “bad girls”, will fall
into the same categories as their male
counterparts and thus are more likely to
show up in this bank. We now know that
there is greater discrimination and a higher
incidence of physical and sexual abuse
among women “whose lives are
compounded by oppression, including
aboriginal women, women of colour,
lesbians, and disabled women. Race,
ability, age, class and their intersections
are known to impact on the quality of
health care service [and legal services] a
woman received” (Rodgers 1995:164).
There is much to be learned from the
critical insights of women of colour about
the perpetuation of hierarchies of power
within the medical institution, and the
forms of resistance that are transforming
medical ethics and health care systems
(Roberts 1996:117). These socioeconomic lessons also apply to law
enforcement and legal institutions.
In the near future, readily accessible
genetic data such as that retained by the
DNA Databank may well become a rich
resource for studies which seek to identify
certain genetic traits e.g. the propensity for
substance abuse, or violence, the inability
to become and remain employed,
homosexuality etc. There are alarming
privacy issues wrapped up in this type of
surveillance through the one-way mirror of
scientific observation. The institutionalized
deviant is seen in passive isolation,
leaving no recourse for the latter to act in
her/his own interests.
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Legislation must ensure that a person
retains rights over future research and
statistical use of her/his banked DNA. It is
unlikely that women, traumatized or not,
would be aware of the long term
consequences of the medical/forensic
examination. The immediate and
subsequent trauma for women who have
been sexually assaulted (including date
rape) makes them particularly vulnerable
to often well meaning health care workers
and police investigators, who encourage
them to submit to evidentiary examination
in order to aid the justice system or legal
proceedings.
Recommendations for research
It is important to assess and develop
strategies that provide all women with
adequate information about a range of
aspects relating to sexual assault. This is
particularly critical for victims faced with
the collection of forensic evidence.
Additionally, research needs to be done to
educate police officers and the courts
concerning the misplaced myths about
who gets sexually assaulted, and about
how women fare in the justice system.
Woman-centred approaches, particularly
feminist oriented work (where possible
conducted in conjunction with police
departments and various offices of the
Attorney General) is vital to ensure that
there are safeguards written into police
protocols and public policies such that
victims’ DNA will never become available
for subsequent analysis without their
informed consent.

The imperative to collect DNA samples
and its arbitrary use in sexual assault
trials
Paradoxically, despite increased pressure
on Sexual Assault Services and medical
examiners to collect forensic evidence for
the police, there is relatively little use of
that evidence in the courts. Examination of
court practices reveals that defense

lawyers often focus on negative
stereotyping of victims, on the meaning of
consent and the significance of the
complainant’s past sexual history, rather
than the difficult to dispute facts of the
forensic evidence.8 The assailant is
constructed as the maligned victim, while
the victim is re-victimized by being
characterized as unstable, unreliable and
a seductress of innocent men.
Research in British Columbia on court
proceedings demonstrate both the limited
number of sexual assault cases that
actually gain a court hearing, and the
limited percentage of these for which DNA
evidence was available, or useful, in
obtaining convictions.9 Kee’s (1996) report
for the B.C. Ministry of the Attorney
General verifies the minimal use of
collected evidentiary data in court, while
Herbert and Wiebe’s (1989) earlier study
for the BC Women’s Sexual Assault
Service found that more than half the
cases for which DNA evidence was
available did not proceed to trial. Recently,
McGregor et al (1999) conclude that “It is
important to have good evidence that the
time spent on the forensic part of the
examination does indeed influence the
legal outcome of the case” (1568-9). In
other words good documentation of
8

Contamination of forensic evidence samples
is now being given as a reason for its
inadmissibility in the courts. Since 1985
survival of DNA in evidence samples in
sufficient quantity and quality has made it
possible for genetic analysis directly at the
gene level. In relation to sexual assault,
specimens in the vagina may last up to seven
days, in the mouth for several hours and in the
anal canal for twenty four hours (Sensabaugh
and Blake 1994:417). In August 1999 for the
first time in a Canadian criminal trial,
mitochondrial DNA evidence, which makes
identification of older remains possible, was
used to implicate Shannon Murrin in the Mindy
Tran murder trial.
9
See research by Herbert and Wiebe 1989,
Kee 1996, McGregor et al 1999; also a recent
Ontario publication by DuMont and Parniss
1999.

moderate and severe physical injuries
which can be made available at the time of
charge laying may outweigh relying on the
often delayed laboratory report of DNA
typing to identify an assailant. The
McGregor report also identified the need
for more research into other variables that
predict laying of charges and even more
importantly the securing of convictions.
These variables included socio-economic
factors, and the possible bias of the justice
system towards certain characteristics of
victims, who are poor, sex trade workers,
substance abusers and uncooperative with
the police.
In spite of more cases of sexual assault
coming before the courts since the reform
legislation of 1983, when Parliament
reviewed the Criminal Code revision
related to assault, and R. v Chase (1987)
provided guidelines as to what constituted
sexual assault, the courts remain hostile
places for women pressing sexual assault
charges. Throughout the 1980s and
1990s, the courts have been a minefield
for female sexual assault victims. Some
judges continue to enforce old patriarchal
practices, legislation enforces production
of a complainant’s prior sexual history
records,10 while defense counsellors
strategize to discredit complainants by
producing discriminatory stereotypes of
women as fabricating allegations of rape
and as sufferers from “false memory
syndrome”.
Efforts by feminists to create a more
hospitable climate through legislation11
protecting women from in-trial exposure of
past sexual histories has been only
sporadically successful. So the scales of
justice continue to teeter, a balancing act
which leaves women unsure about their
10

See decisions in Seaboyer (1991), O’Connor
(1996) and the ongoing challenges to the
constitutionality of Bill C-46 in two Alberta
cases, Mills and Ewanchuk.
11
For example, Bill C-49 (1992), the rape
shield legislation.
179

survival in the courts. This distrust is well
voiced by victims’ service workers who
frequently attend court with victims.
Recommendations for research
Further research to follow up on the few
feminist studies which have started to
track some aspects of the collection,
admissibility and lack of use of DNA
evidence in the courts would be valuable.
If it is found that forensic evidence is not
consistently considered beneficial
information in sexual assault trials, then
the time of sexual assault examiners
would be better spent on medical and
psychological services to victims rather
than on legally based medical services.
Studies focussing on the various ways in
which women resist collection of forensic
evidence, and their experiences with
police investigators and defense counsels
in sexual assault trials would also serve to
illuminate women’s responses to a
biotechnology which seems to have
questionable value for women’s health and
security.
Summary
The above discussion encompasses the
ethical, social and cultural context within
which certain categories of women are
often served poorly by the very institutions
which purport to assist them. In both the
health care context and the courtroom, as

well as on the streets, women continue to
be vulnerable to oppression and control by
dominant hierarchies. This critique also
moves into the speculative realm of
whether women can trust what happens to
their genetic material if it is captured
through DNA banking. Here other forms of
surveillance and analysis may construct
and re-construct stereotypes of the types
of women who are sexually assaulted. As
Canadian society advances into a new
deterministic genetic age in which the
genetic blueprint of each person may be
investigated, it is important to examine the
new loci of power and control that are
emerging currently, which are sanctioned
by federal policies and regulations. At the
very heart of the matter is the need for
voiceless, violated women who are the
targets of sexual assault to be protected
from further violations by institutions that
do not always and fully respect
fundamental rights to confidentiality,
privacy and proprietary ownership of
personal bodily tissues and substances.
These rights underpin basic ethical
standards of health care, and in the case
of collection of forensic evidence, what
happens to the data after it has been
acquired. Within the Canadian
Biotechnology Strategy, there is urgent
need to ensure that those ethical, social
and cultural values principally affecting
women be given priority over the
predominant concern with commercial
issues.
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About the Article
Priscilla Settee outlines the work of Aboriginal peoples around the world to mobilise
against biopiracy – the appropriation of Indigenous knowledge, and Indigenous bodies.
The focus of much of this mobilising has been the Human Genome Diversity Project – a
DNA sequencing project proposed as a complement to the international Human Genome
Project. The HGDP is distinct in being intended as a way to gather the DNA of ‘diverse’
or ‘endangered’ peoples and thereby to ‘map the migration history of humankind.’ While
the official HGDP has been derailed by the protests of its many critics, biopiracy is alive
and well and commercially lucrative. As Settee here explains, Indigenous peoples have
organised around the HGDP to articulate their own priorities, and to formulate agendas
for tackling the large and growing problem of biopiracy.
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The Human DNA of identified Indigenous
groups is the focus of curiosity and activity
among an international consortium of
scientists, universities, governments, and
other interests in North America and
Europe.1
Over 700 Indigenous groups world-wide
have been identified to have samples
collected from them. Indigenous
communities targeted for DNA collection
include Africa (165), Asia (212), South
America (114), Oceania (101) North
America (107 tribes) and Europe (23).
Established in 1992, the Human Genome
Diversity Project (HGDP) will take blood,
tissue samples (cheek scrapings or
saliva), and hair roots from hundreds of
Indigenous communities throughout the
world. Through the Human Genome
Organization (HUGO) the project is
mandated to map the entire genetic
structure of the human race
HUGO seeks to sequence the DNA
information in all 100,000 genes in the
human body and is expected to cost 3
billion dollars over the span of the fifteen
year project; HUGO is now nearing
completion significantly ahead of
schedule; a ‘rough draft’ has already been
completed. While HUGO intends to
uncover the norm of the human genome
as a composite model, the Human
Genome Diversity Project seeks to map
and sequence genetic diversity. The
project is specifically mandated to take
blood, tissue, and hair samples from
1

This article draws on the following source
material: Indigenous Women Address the
World. Indigenous Woman Magazine. Special
Beijing Edition, Rapid City, South Dakota,
U.S.A. 1996; Indigenous Woman Magazine,
Rapid City, South Dakota, U.S.A., Vol, 2, No.
3, 1996; Dukepoo, F., & Harry, D. Indigenous
Peoples Coalition on Biopiracy, 1998; “Voice of
Native Grassroots for Environmental Justice.”
Indigenous Environmental Network News.
Vol.3 No. 2, 1997; Western Shoshone Defense
Project Newsletter, 1997.
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"endangered" indigenous communities
around the world.
The HGD project was formally adopted in
1994 by the Human Genome
Organization. It has sought massive
funding. This multi-billion dollar initiative by
scientists has plans to sequence the DNA
in the entire human genetic structure. The
HGDP seeks to map the genetic difference
of groups from the monotype genome that
will be identified by the HUGO effort.
Scientists believe that many of the world's
Indigenous people are in danger of
becoming extinct and refer to them as
‘isolates of historic interest’. Scientists
hope to gather DNA samples from the
living before they disappear forever, and
so avoid the irreversible loss of precious
genetic information. Indigenous peoples
find it reprehensible that scientists' interest
is purely to document scientific genetic
information rather than to preserve tribal
groups. In effect, the scientists are asking
endangered tribal groups to submit
personal samples before their group
disappears. The scientists' actions revive
out-dated and oppressive attitudes, and
their actions instil self-fulfilling pessimism.
Such actions are simply unethical.
Blood samples taken from Indigenous
peoples will become immortalized for
future study. A technique called "cell
conservation" will keep certain cells of an
organism alive and capable of multiplying.
Unlimited amounts of the organism's DNA
will be stored at various gene banks,
mostly in the United States.
Indigenous peoples have many concerns
with the HGDP. One is the issue of
informed consent. Although the HDGP
claims that it will seek the consent of the
individuals and populations concerned,
many people doubt whether this will, in
fact, happen. Some questions that remain
unanswered are:

• Can tribal leaders give consent for the
whole tribe?
• Can one person give consent while
others don't?
• How can some of these concepts be
explained in ways and languages for
people who have no concept or words
for these confusing terms?
• What are the benefits for the local
communities?
• Will decisions to refuse consent be
fully respected?

The HGDP North American Committee
secured a grant to develop a model
protocol or rules for the collection of
samples from Indigenous groups. It is felt
by Indigenous people that this protocol will
primarily be used to seek project cooperation.
The HGDP states that the research will
help reconstruct the history of the world's
populations, address questions about the
history of human evolution and migration
patterns, and identify the origins of existing
populations. While the HGDP is looking for
answers about human evolution,
Indigenous peoples already possess
strong beliefs and knowledge regarding
their creation and histories.
Danny Billie, traditional spokesman for the
Independent Seminole Nation of Florida,
stated in 1997
“The white people are trying to play
God. If they continue to do what they
are doing the impact to the human
species, insects, plant and animal life is
going to be devastating. They think that
they can get away with it, but they'll
also suffer the consequences.”

In response to the HGDP research
Indigenous peoples from various parts of
the world have mobilized against the
project. Documents such as the Ukupseni
Declaration from Panama and the National
Congress of American Indians Resolution
No. 93-118 have been signed. These
documents represent hundreds of
communities who declare their opposition
to the HGDP.
Karioca Declaration. In the early 1980's,
the Karioca Declaration was signed by a
group of Indigenous people who were
opposed to the HGDP and who met prior
to the 1993 United Nations Conference at
the Earth Summit in Rio de Janeiro.
Mataatua Declaration. The Karioca
Declaration was followed ten years later
by the Mataatua Declaration and signed
by over 150 participants from 14 United
Nations countries. The Declaration calls
for an immediate halt to the ongoing
HGDP until all aspects of it could be
understood by Indigenous peoples.
Article 29. In 1994 The United Nations'
working group on Indigenous populations,
along with the Sub-Commission on the
Prevention of Discrimination and
Protection of Minorities approved Article
29 of the Declaration of the Rights of
Indigenous Peoples which stated:
“Indigenous Peoples are entitled to the
recognition of the full ownership, control
and protection of their cultural and
intellectual property. They have the
rights to special measures to control,
develop and protect their sciences,
technologies and cultural
manifestations including human and
other genetic resources, seeds,
medicines, knowledge of the properties
of fauna and flora, oral traditions,
literatures, designs, and visual and
performing arts.”
New Zealand. In 1993 an assembly of
representatives of the tribes from the
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North and South Islands of Aotearoa (New
Zealand) passed resolutions condemning
the HGDP and the patenting of life-forms.

some of their people. Through effective
campaigning they were able to have the
patent claim abandoned.

National Congress of American Indians. In
that same year the National Congress of
American Indians (the oldest and largest
national organization, comprised of
representatives from 67l American Indian
tribal governments in the United States)
passed a resolution condemning the
HGDP and called upon all related activities
to cease immediately.

Workshop on “Intellectual Property
Rights”. In August 1994, the International
Academy of the Environment, along with
the World Wildlife Federation and the
United Nations Centre for Human Rights,
organized an information workshop on
"Intellectual Property Rights and
Indigenous Peoples" stating:

Central Australian Aboriginal Congress.
Coined as the "Vampire Project" by the
World Congress of Indigenous Peoples,
the Central Australian Aboriginal Congress
Position Paper stated in 1993:
“The Vampire Project is legalized
theft. The Vampire scientists are
planning to take and to own what
belongs to Indigenous People. We
must make sure that our people are
not exploited once more by
corporations, governments, and their
scientists.”
Maori Congress. In 1994 at the Maori
Congress Indigenous Peoples
Roundtable, Indigenous participants from
the World Council of Indigenous Peoples,
Greenland Home Rule Government,
COICA (Peru), Treaty Six Chiefs of
Alberta, and governmental representatives
from Vanuatu, Papua New Guinea, and
Fiji declared that:
“The collection of genetic samples from
Indigenous peoples such as the Human
Genome Diversity Project, is unethical
and immoral and must be brought to an
immediate halt.”
Patents on Indigenous Peoples. Also in
1994 in Panama, the Guaymi Indians,
along with citizens of Papua New Guinea
and the Solomon Islands, discovered that
the United States government had taken
patent claims out on the cell lines from
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“The issue of HUGO, and others
related to human genes, is a serious
violation of our peoples' rights. Without
consultation with the indigenous
communities, several projects are now
taking blood, hair, tissue and other
samples for purposes that are not clear.
This practice of collecting samples
without our approval is very dangerous
because in this way our genetic
material can be patented or used for
other purposes. Such practices not only
violate ethics and human rights, but
also violate nature, our spirituality, and
our knowledge of creation that
connects us with all forms of life.”
Latin and South American Consultation. In
Bolivia in September 1994, the Latin and
South American Consultation on
Indigenous Peoples Knowledge rejected
the HGDP and human genetic research.
Asian Consultation. Similarly in Malaysia
in 1995, the Asian consultation on the
Protection and Conservation of Indigenous
Peoples Knowledge rejected the HGDP.
Declaration of Indigenous Organizations.
In Arizona, at the same time, Indigenous
leaders from US, Canada, Panama,
Ecuador, Peru, Bolivia, and Argentina,
formulated a Declaration of Indigenous
Organizations of the Western Hemisphere.
It considered the responsibility to future
generations:

“We have a responsibility to speak for
all life forms and to defend the integrity
of the natural order. We particularly
oppose the HGDP which intends to
collect, and make available our genetic
materials which may be used for
commercial, scientific and military
purposes. We oppose the patenting of
all natural genetic materials. We hold
that life cannot be bought, owned, sold,
discovered or patented, even in its
smallest forms.”
PAHO. In April 1995 the Pan-American
Health organization passed a resolution
opposing the HGDP, and stated:
“This type of research will have a
negative impact on future health
programmes and projects in indigenous
communities, by undermining
indigenous peoples' trust in the medical
and health professions.”
The Pacific Consultation. The Pacific
Consultation on the Protection and
Conservation of Indigenous Peoples
Knowledge developed a Treaty declaring a
Life-Forms Patent Free Pacific, with
specific objections directed to the HGDP.
North American Indigenous Peoples’
Summit. In August of 1997, several
hundred Indigenous peoples representing
many tribes and over 60 organizations met
to discuss the impact of the new
biotechnology on their homelands and
their people. This meeting was called "the
North American Indigenous Peoples’
Summit on Biological Diversity and
Biological Ethics" It established the “Heart
of the People Declaration”. The preamble
"expresses our profound concern for the
well being of our Mother Earth and the
Indigenous circle of Life known as
'biological diversity'." The Declaration
further states:
“We wish to add our voices to ongoing
global discussions regarding the
protection of biological diversity, the

safeguarding of traditional knowledge
and sustainable development practices,
and the ethical use and treatment of all
forms of life in harmony, respect and
the spiritual interconnectedness of the
natural world.”
Ukupseni Declaration. In November of
1997, Indigenous people representing 25
organizations from 15 countries met in
Panama to discuss the HGDP and the
issue of human genetic piracy. This
meeting was one the first opportunities for
Indigenous people from Latin America to
meet with North American Indigenous
people who were working on the HGDP
issue. The Ukupseni Declaration on the
Human Genome Diversity Project was
established as a result of the two-day
meeting. The Declaration condemns the
HGDP:
“It calls for a moratorium on the
collection of genetic samples from
indigenous peoples, and demands the
repatriation of genetic samples and
data already obtained by unethical
measures. It opposes the application of
intellectual property law, and patents, to
human genes. It calls upon scientists to
denounce any research conducted in a
manner that violates the protocols that
protect the human rights of human
subjects. Finally it calls upon allies to
work with Indigenous Peoples to
demand protection for the human and
collective rights of Indigenous Peoples.”
The Indigenous Peoples Coalition on
Biopiracy. The Indigenous Peoples
Coalition on Biopiracy was established in
1998 to address the theft of Indigenous
blood, hair, and skin sampling, and as a
concerted response to the HGDP.
Coalition participants worked on strategies
to protect their communities from
exploitation. Members disseminated
information to the local grass-roots levels.
They built alliances for sharing current
information as well as for implementing
collaborative action and support among
187

the participating organizations and
individuals. An extensive list of key points
has been developed by this coalition, the
direct quotation from the document is as
follows:
“After careful review of HGDP and
other independent investigations on the
genome of indigenous peoples:
a. We declare absolute opposition to
the Human Genome Diversity Project,
and demand the immediate suspension
of any activities to collect genetic
samples, cell lines, or genetic data from
indigenous peoples, including our
deceased ancestors.
b. We demand the fullest cooperation
of any government agency or
independent research institute in the
return of all genetic materials, cell lines,
and data they may have in their
possession to the appropriate
governing authorities of the tribal group.
c. We oppose any attempt to
monopolize or commercialize the
genetic samples, cell lines, or data
derived from the cell lines of Indigenous
peoples through the application of
intellectual property law and patent
systems.
d. We oppose the genetic engineering
of Indigenous peoples’ genes and
cloning. This includes cloning
Indigenous peoples’ genes or gene
fragments into bacterial, viral,
mammalian cell lines, or other vectors.
We demand the immediate suspension
of activities that are currently using any
Indigenous peoples' DNA, genes or
fragments in any cloning
experimentation.
e. We demand the international
scientific community condemn any
research that has been carried out
contrary to recognized human values
and moral principles, and that violates
the international codes of ethics
described in the Nuremberg code and
the World Medical Association
Declaration of Helsinki.
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f. We reaffirm the governing entities of
Indigenous tribal peoples/nations have
the primary authority to deny access to,
refuse to participate in, or to authorize
any removal of genetic materials from
our peoples or territories. The ethical
principle of "individual informed
consent" is also applicable, and is
secondary to tribal governmental
consent.
g. We demand that scientific endeavors
and resources be prioritized to support
and improve social, economic and
environmental conditions of Indigenous
peoples in their environments, thereby
directly improving health conditions and
raising the overall quality of life.
h. We demand an immediate
moratorium on collections and/or
patenting of genetic materials from
Indigenous persons and communities
by any scientific project, health
organization, governments,
independent agencies, or individual
researchers.
i. We demand that the US government
and any governing agencies, to not
participate, fund or provide any
assistance to the HGDP, or any related
research projects which seek to
research the genome of indigenous
peoples.
j. We denounce the integrity of the
report by the Committee on Human
Genome Diversity of the National
Research council which gives unethical
endorsement to the Human Genome
Diversity Project while acknowledging
the "lack of a sharply defined proposal
that it could evaluate".”

As Indigenous peoples we have many
unanswered questions regarding the new
biotechnology industry, many of them
centre around the issue of respect and
some refer to the expropriation of the
circle of life or biodiversity. In many of our
communities these activities have been
referred to as the final act of colonialism
against Indigenous peoples. I have

reported the concerns that Indigenous
Peoples have not only about the HGDP
but about the potential threat to
sovereignty and well being that theft of
biodiversity has on Indigenous
communities in North America and
globally.
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About the Article
Catherine Frazee provides both a critique of how the CBS conceptualizes health,
disease and disability, and a commentary on the set of papers in this collection which
take biotechnology and community as their theme. In the face of the determined
obscurity of the CBS web site, Frazee unpacks the meaning of “health” by interrogating
the Strategy’s statements of principle. How, Frazee asks, will biotechnology actually
contribute to quality of life? And what does “quality of life” really mean? Throughout the
CBS, Frazee finds “majoritarian thinking [which] uncritically situates disability
disadvantage as intrinsic to individual impairment or nonconformance to physiological
and intellectual norms.” It is this thinking which masquerades behind the seemingly
benign phrase “Canadian values.” The papers which Frazee reviews have in common a
profound discomfort with these values. All share a concern with the prioritization of
biotechnology policy over other social policies, and all identify ways in which specific
biotechnologies can be problematic. Ultimately, Frazee suggests, what unites the critics
of the CBS’s goals and assumptions are a “set of ideas about what constitutes
personhood.” Frazee challenges us to consider carefully our beliefs about disability, and
to imagine a rather different “Ideal citizen.”
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Introduction
The Internet site to which our attention is
directed for information about the
Canadian Biotechnology Strategy
welcomes me with the Canadian flag, the
Industry Canada banner and the greeting,
"The Information Site That Means
Business!". I am seized by a familiar panic,
flashing back to border crossing
interrogations of my wayward youth, job
interviews from hell, close encounters with
hostile canines. I feel the disapproving
gaze of my cyberhost. This is not a site for
casual browsers. If idle curiosity is my
currency, I had best hasten my mouse
BACK toward the more homely terrain of
Yahoo.com. There is nothing for me here.
I take a deep breath and press past the
menacing greeting. I do have business
here. I am a stakeholder. And I have come
seeking purchase.

Purchase:

•Acquisition through the payment of
money or its equivalent.
•A grip applied to move something or
prevent it from slipping.
•A position affording mechanical
advantage or the means to move or
secure a weight.
•A means of increasing power or
influence; an advantage used in
exerting one's power (American
Heritage Dictionary, 1992).
I am a disabled woman. I feel something
slipping away, something integral. I sense
the dark approach of an icy glacial drift, its
advance propelled by the weight of layer
upon layer of values and ideology subtly
hostile to my own. I doubt my capacity to
influence the inexorable progress of
biotechnology's powerful agenda. I need
purchase.

I have been invited to bring "a disability
rights perspective" to a workshop for the
Working Group on Women and the New
Genetics. But I cannot come to the table to
discuss the CBS strategy with only my
gnawing, visceral, unease. I scour the site
– the press releases, fact sheets,
background papers, consultation
documents and committee reports. My
browser's find command storms through
each document in pursuit of a single
fugitive word. But "disability" appears
nowhere in the documents that highlight
the strategy's features, benefits, guiding
principles, goals, development and
progress. It is alluded to, in phrases like
"recognizable problems attributed to
chromosomal, monogenic or multifactorial
mutations" or "genetic deficiency" (CBS
1998a). It is implied, surely, in the promise
that "Genetic testing will provide a number
of diagnostic benefits such as the potential
for ... helping potential parents make
informed decisions..." (CBS 1998a). But
the shadowy foe never quite declares
itself.
I find myself remembering Kenzaburo Oe's
reference to medieval Zen poetry and its
concern with the "linguistic impossibility of
telling the truth" (Oe 1995:112). He spoke
of words "confined within closed shells",
baffling any attempt at full understanding.
Perhaps we must plumb for meaning
within the closed shell of the strategy's
promise "to enhance the quality of life of
Canadians in terms of health, safety, the
environment, and social and economic
development".
A delicate excavation. My quest for
meaning will cluster around four
phrasings. Each is extracted from CBS
documents and appears fundamental to
the strategy's health thread. Each states a
noble purpose, yet there is an equivocal
quality to each when viewed through a
disability lens.
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Biotechnology as a Key Contributor to
Quality of Life (CBS 1998b)
How does biotechnology contribute to
quality of life?
It would appear that this is intended in part
through the prevention of genetic disease
or defect. This presumes first, an
identifiable genetic "norm", and second,
some social consensus that the "norm" is
inherently more desirable than the
"deviant" form. It is the latter presumption
that is problematic from a disability
perspective. Those of us with genetically
non-typical characteristics are invariably
excluded from any alleged "consensus"
about what constitutes desired or
acceptable life states.
Implicit in the identification of "genetic
disease" (e.g., as applied to conditions
such as Down syndrome, Spina Bifida and
Muscular Dystrophy) is the assertion that
disability is a negative characteristic – "a
priori an undesirable trait" (Rioux 1996). I
would be the first to concur that disability –
like gender and race – correlates strongly
with disadvantage. But while it is widely
recognized that the disadvantage
experienced by women and racial
minorities is directly attributable to the
social and systemic evils of sexism and
racism, the non-disabled majority seems
to stumble again and again in applying a
similar analysis to the human rights claims
of persons with disabilities. Instead,
majoritarian thinking uncritically situates
disability disadvantage as intrinsic to
individual impairment or nonconformance
to physiological and intellectual norms.
Disability activists and theorists have
emphatically asserted that disability is a
social phenomenon, rather than a
biological one. Biotechnology’s vigorous
focus upon disability prevention by genetic
methods ignores the deeply embedded
and pervasive social, economic and
political determinants of disability
disadvantage. Disability is located in social
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and economic structures, more than it is in
genetic ones. How can we "popularize"
this inherently unpopular notion?
Of course I cannot deny that living with a
non-typical body can and often does add
to life a significant dimension of pain, loss
and restriction. But as I have argued at
length in other fora, the same can surely
be said of other states generally accepted
as socially desirable – for example,
growing up, entry into intimate relationship
and parenting. The point is, as Adrienne
Asch noted in her recent debate with Peter
Singer, that “disability is only one
characteristic of any person's life.... Along
with disability – whatever that disability
happens to be – come a whole range of
other characteristics... and redeeming
benefits... both intrinsic and extrinsic.”
(Singer and Asch 1999).
Disability per se cannot be presumed to
diminish quality of life. Unless, of course,
we are talking about the quality of life
(read privilege) enjoyed by non-disabled
Canadian citizens. Perhaps encoded in
the phrase "quality of life" are forecasts
about our national standard of living, and
embedded in these, concern for allocation
issues arising from escalating costs in
health care and health support. This may
well be so, but if it is, it must be made
explicit. How else can those of us with
genetically non-typical bodies find solid
footing from which to enter into allocation
negotiations?
Helping Potential Parents Make
Informed Decisions (CBS 1998a)
For persons with nontypical genetic
characteristics deemed undesirable by a
non-disabled majority, the very possibility
of entry into the human family becomes
contingent upon a prospective parent's
capacity to resist institutional pressure,
reject social stereotypes and withstand the
inevitable censure of peers and relations.

Most women over 35 elect to have
prenatal diagnosis, and if they are told that
their infant will have a "major defect" most
of them decide to abort. As Princeton
ethicist Peter Singer explains tersely, "If,
before life has begun, the prospects are
clouded, better to consider starting again"
(Singer and Asch 1999). His utilitarian
logic, it seems, is irresistible to many.
But what criteria or standards define an
"informed decision"?
For those of us with "undesirable" genetic
characteristics that could have been
detected before birth, the implications of
such informed decision-making are
genocidal. Had our parents or their
physician-advisers been "better informed",
how many more of us would have been
denied the possibility to experience life,
think our own thoughts or form our own
opinions and value systems?
The genetic structure of the fetus is such a
small piece of the story of who we are and
who we will become. Perhaps it is all that
is knowable. The gifts and contributions of
personhood will forever elude the
predictive capacity of biotechnology. It is
Singer's argument that some information is
better than no information when decisions
must be made in conditions of uncertainty.
But surely a shred of information – nothing
more than a dim flicker, enough only to
render the purity of darkness into a
labyrinth of shadowy distortions – surely
this does not transform a leap of faith into
an informed decision. After all, we withhold
otherwise relevant evidence from juries
when its prejudicial effect outweighs its
probative, "informative" value.
Each new reproductive technology
challenges us "to think better and harder
than we're used to about two mighty piers
of life's foundation: power and love."
(Angier 1999) How much power can we
have over the outcomes of reproduction?
As Angier asks, "Does that power give us
greater freedom, or does it deprive us of

one of life's most unsung freedoms: the
freedom to have things happen on their
own?"
R. Alta Charo, professor of law and
medical ethics at the University of
Wisconsin in Madison says, "Reproductive
technologies cumulatively reduce the
range of events that happen by serendipity
and increase the range of events that
happen by active planning. This changes
the texture of life. One of the rights we
have is the right to not have to make
choices." (Angier 1999)
At the dawn of the Age of Reason, Blaise
Pascal observed: "There are two equally
dangerous extremes: to shut reason out,
and to let nothing else in." (cited in Kumar
2000) We cannot turn back the clock, we
cannot suspend the knowledge that
biotechnology offers. How then can we
ensure that its juggernaut fury is
contained? How can we secure a
respected place for women's faith and
dreams within a discourse so dominated
by reason?
Reflecting Canadian Values (CBS
1998b)
What is our recourse when "Canadian
values" are at odds with the values of
social justice and feminism?
In the era of globalization, what are
Canadian values? To what extent will they
be shaped by those that dominate
contemporary American culture? (Money.
Knowledge. Social rank. Sex.
Individualism.) Are the courts, the
universities or the media our arbiters of
cornerstone values? In any case, is the
result not likely to have its roots in ideals
of wealth, aesthetics, autonomy and
power?
"[As we develop] increasingly
sophisticated means to detect – and
potentially to prevent – difference in
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genetic structure, [we find ourselves living
in] a time when our public policies reflect
an increasingly inhospitable climate for
difference. More and more, the Ideal
Citizen is seen as the individual who
demonstrates self-reliance, efficiency and
competitiveness." (Ticoll 1996)
The values and aesthetic preferences that
prevail in our society will determine
biotechnology's agenda, priorities and
presumptions. They will influence not only
how questions are answered. More than
this, they are the breath with which every
question does or does not find utterance.
The questions that we fail to ask of
biotechnology will be of most profound
consequence.
History teaches us that determinations of
human worth are always consistent with
the qualities that decision-makers have
presumed themselves to possess – “the
sort that facilitated passage through
schools, universities and professional
training." (Kevles, cited in Gray 1999) Put
in other words, as Eva Feder Kittay has
asserted, "The 'relevant' attributes for
personhood are invariably abstracted from
the lives of the people doing the
abstraction." (Montgomery, personal
communication)
Feminist economist Marilyn Waring
proposes that time, rather than money, is
the one commodity of intrinsic value in
human society. She argues convincingly
that radical transformations in economic
policy would flow from the recognition of
time and the natural environment in our
measurement and distribution of wealth. In
the same way, can we reinvent the Ideal
Citizen as one with the capacity to form
deep relationship, to give or experience
joy, to create, to open new pathways for
expression of personhood?

Biotechnology for Public Health
Advantage (CBS 1998b)
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How can those of us with genetically nontypical bodies reconcile CBS notions of
health promotion with our own identity and
experience as healthy disabled women?
Contrary to the expectations and
preconceptions of non-disabled
Canadians, many people with genetically
non-typical bodies – once they escape
detection and survive gestation and birth –
develop well-honed skills in the avoidance
of medical "attention," enjoying the quiet
and priceless joy of medically uneventful
living. By no means the exclusive privilege
of the genetically typical, wellness and
well-being correlate most strongly with
unencumbered access to the major health
determinants of adequate money, a clean
and safe environment, supportive personal
relationships, control over living
conditions, etc. Yet people with disabilities
are presumed to be unhealthy and
overlooked in the establishment of public
health standards and programming,
having to fight for information, access and
services at every turn.
How can we unmask the aesthetic
preferences embedded in definitions of
health?
School-aged children who are shown
pictures of a wide range of "potential
friends" and asked to pick the ones with
whom they would be most likely to
become friends choose children who look
like themselves and reject children who
look different. Obese children, children
with disabilities, children of different racial
groups are eliminated quickly, for reasons
the children making the selection find
difficult to articulate. Regrettably, adult
architects and engineers of public policy
commonly demonstrate the same
inclinations, similarly unconscious and
unspoken. The tyranny of designer culture
accounts for much of my unease with the
CBS and its squeamish reluctance to taint
the pretty vistas of our genetically rich
future with the nasty business of disability.

*****
How has this group interpreted those
pretty vistas? What is our collective
assessment of the "public health
advantage" of the Canadian Biotechnology
Strategy?
A review of the papers presented in this
series suggests that contributors share a
deep concern that enormous human and
economic resources are being directed
away from social, economic, cultural and
environmental health determinants and
used instead to fuel the development of
biotechnology and genetic interventions.
This point was made explicitly by Madeline
Boscoe, Sari Tudiver and Priscilla Settee,
it provided a starting point for Ken Bassett,
and formed an implicit underpinning for
most if not all of the arguments and
critiques recorded.
There is also apparent consensus that
biotechnology and genetic engineering are
fundamentally problematic. The papers
collected in the "community" series locate
the problem differently – quite naturally,
given the impressively diverse range of
activist perspectives from which they
originate. Fern Brunger and Sue Cox
alerted us to ethical issues that may arise
for collectives or larger groups when
individual members consent to participate
in research. Priscilla Settee provided a
specific example, identifying the violation
of cultural and intellectual property as a
colonialist assault upon the identity and
spiritual knowing of aboriginal peoples.
Patricia Lee warned of possible misuse of
DNA biotechnology in forensic contexts,
exposing women to state-sanctioned
violations of their propriety, privacy,
security and confidentiality.
Popular opinion polls – and indeed the
official documents of the Canadian
Biotechnology Strategy – would suggest
that the consensus that we appeared to
share is absolutely atypical, perhaps even
squarely in opposition to views espoused

by the majority of our friends, neighbours,
colleagues and fellow travellers.
This, of course, did not surprise us. But an
examination of the thread that linked our
various perspectives proved instructive
vis-à-vis our efforts to understand and
formulate strategies in response to
prevailing support for an aggressive
investment in biotechnology.
Surely what informs our shared opposition
to the Canadian Biotechnology Strategy is
a set of common values. I would suggest
that these go beyond values about the
meaning of health, extending to a shared
understanding of justice, and even more
profoundly, a set of ideas about what
constitutes personhood.
In the paper submitted by Fern Brunger/
Sue Cox, these values are explicitly linked
to a feminist understanding of power. They
are articulated in the recognition that
"genetic testing must be placed firmly in
the context of culture in its relation to
power. Bioethics, like genetics, is itself
culturally (and historically/ politically/
economically) shaped." Similarly, Patricia
Lee concludes her paper with reference to
"the new loci of power and control" in DNA
databanks. Priscilla Settee presents a
vivid description of a final act of
colonialism against Indigenous peoples.
Even Ellen Larsen, whose focus is quite
different, introduces the idea of scientists
"looked upon as belonging to a priesthood
which has access to information stored in
Temples". For each of us, the issue at the
starting point is one of power in its cultural
context.
Concrete suggestions as to where to go
from here display a range as broad as the
platforms from which the papers were
launched. Ellen Larsen proposes a
democratization of science – a more
fulsome integration of scientific ways of
thinking within scholastic contexts and the
community at large, rendering science less
mysterious, more comprehensible and
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accessible to non-scientists, enabling a
more informed critique of science as a way
of exploring our world and understanding
technology.
Ken Bassett proposes the assertion of
alternative values in provincial and
community settings charged with
purchasing social and health services and
technology. He suggests that another
possible site of similar action is on
university and hospital ethical review
committees charged with determinations
of research validity and conformance with
standards of public good.
Fern Brunger and Sue Cox propose that
we find the commitment and the resources
to engage in genuine community-based
research, examining the everyday
experiences that shape and are shaped by
genetic testing, negotiating standards of
collective acceptability and grasping

collective and perhaps foreign value
systems.
Finally, I extend a challenge to re-examine
even our own attitudes, recognizing that
we are a very long way, still, from a
collective recognition of disability as an
acceptable form of human variation. We
are still mostly complicit with the
medicalization of disabled women's bodies
and the construction of disability as an
individual defect or a personal or social
tragedy. I urge each of us to attend
carefully to the narratives of disabled
women who affirm themselves instead as
whole and endowed with great strength
and beauty. Then perhaps we can arm
ourselves for the struggles ahead with a
set of values that – to borrow from Nandita
Sharma's reference – are radical enough
to be worth the fight.
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Communities Constituted through the New Genetics:
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About the Article
Margaret Lock interrogates received wisdom about technologies in general, and
biotechnologies in particular. She provides a critique of the relations between
communities and the biotechnology promised by the CBS, and comments on several
papers in the collection which take biotechnology and community as their theme.
Technologies are neither autonomous nor value neutral, Lock argues. Rather, their
constitution and use reflects relations of power, and the complex ways in which they
construct the persons and things upon which they act. Genetic biotechnologies, in
addition, render the traditional rights of access and informed consent insufficient as
arbiters of use, since communities, and not just individuals, are implicated. Finally, Lock
notes that, when we talk about ‘communities,’ “we are dealing with a slippery concept.” If
individual access and informed consent are insufficient resources for engaging
biotechnologies, Lock suggests, adding ‘communities’ to such processes will not be a
panacea, but will necessarily involve debates about which ‘communities’ are implicated
and what ‘community’ means.
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The history of technology, including that of
medical technology, is usually told as a
narrative of progress, a means to enable
us to overcome the limitations that nature
places upon us. Dominant arguments,
following Heilbroner (1967) and others, are
that technology is, in effect, autonomous;
that technology itself is value neutral and
should be understood as empowering
through the production of more freedom
and flexibility in the world in which we live.
Emphasis on the rationality of technology
and the liberation it brings with it masks at
least four things: first that inevitably
relations of power are involved in the
production and application of all
technologies; notably the interests of
powerful elites ensure that debate about
new technologies does not, without great
public outcry, take place in the public
sphere; our institutions are designed to be
opaque, and protective of those holding
the reins. More troubling, is that in
contemporary society such elites are
located increasingly in the private sector or
function in partnerships created between
the private sector and universities.
Government and universities have less
and less say as to what should be
invested in and developed and who should
have access to the end product once it is
placed on the market. An economic
imperative has taken hold.
Second, and related to the previous point,
while some technologies, in Canada at
least, are available to us all, others,
notably the new reproductive technologies,
and genetic testing and screening do not
fall into this category, thus introducing
inequities into the system – something
which troubled the Royal Commission on
New Reproductive Technologies (1993)
but about which, as we all know too well,
nothing has as yet been done. It is not
only the inequities as such that are
troubling. Such a system fosters insidious
divisions among women to the detriment
of everyone except those who are clearly

wealthy. So, questions of access and
availability mask more fundamental issues
deserving of close attention.
Third, new technologies by their very
nature create new entities and populations
to be worked upon. As Foucault pointed
out, technologies and their associated
discourse create the objects on which they
operate and are in turn constituted by
these same objects. Until BRCA 1 and 2
were isolated, for example, there was no
sub-group of women who could be singled
out through testing as having the “gene or
genes for breast cancer” and who today
must face a slew of decisions to which
there is no satisfactory resolution, whether
the test results are positive or negative.
With the availability of genetic testing
many people now think of their genes as
quasi pathogens and worse yet, as
pathogens for which they can be held
responsible if passed on to the next
generation. Some individuals live their
lives as the “pre-symptomatic ill” – having
been labeled “at risk” for late onset chronic
diseases with a genetic component. In this
climate of impending danger, when great
value is also placed on control and on
creating “normal” populations, pressure
mounts daily for people to undergo genetic
testing, even when no therapies are
available. There is a will to know who we
are, genetically speaking. Meanwhile the
social and environmental determinants of
disease are relegated to the background
once again, as they have been in the past
decades.
Fourth, half a century ago, in response to
medical experimentation and concerns
about human rights, the idea of informed
consent was adopted and institutionalized
over the years, ensuring to a considerable
extent the protection of individuals in the
face of new biomedical technologies. But
protection, and the rights of families and of
segments of society in connection with
these same technologies, has not thus far
been considered necessary, and in any
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case individual rights continue to take
priority.
The emergence of the powerful
combination of population genetics with
molecular genetics has upped the ante
about the powers of technology and how it
can enable us as individuals and as a
society. The hype associated with the
human genome project and its associated
technologies is utopian. We all now have
the right, Daniel Koshland (1989) informs
us, to a full complement of healthy genes,
but it is clear that neither individual
informed consent, nor individual desire, or
the desire of couples, are adequate to deal
with what we are now facing. Each of the
papers under discussion makes it clear
why.
First, as Ken Bassett points out, we are
now clearly in an era of deregulation and
less stringent legislation, in large part
because funding for these activities has
been cut back. Technologies are in effect
assumed to cause no harm unless proved
otherwise – witness the introduction of GM
foods. It takes repeated tragedy before
moratoria are instated for interim periods.
No standing committees exist that
consider the social consequences of what
we are doing, suggesting that even today
biomedical technologies are thought of as
autonomous agents of progress that bring
us good. Bassett argues that university
and hospital ethical review committees
might take on the task of social evaluation.
Such committees could indeed spot
conflicts of interest, and even encourage
communal advocacy, if they could first
decide what constitutes a relevant
community and who should represent it.
But how can the participants in such
committees be expected to foresee the
larger social consequences, many of
which will have effects beyond
communities when, for example,
genetically engineered foods, patents,
xenotransplants, germ-line engineering,
and related technologies are involved?
Surely we need, in addition to ethical
200

review committees, national and
international bodies with legal clout who
can instigate policies that are rigorously
enforced? Something like the international
court at the Hague perhaps?
Brunger and Cox set out by making the
impact of the new genetics on collectivities
their prime focus of interest. They are
concerned about the non-clinical impact of
genetic testing on everyday life and
knowledge, something about which we
have very little information. They argue,
like Bassett, for the inclusion of community
representatives in research, and show
how the outcomes of research and testing
affect not only involved individuals, but
families and communities. A heterogeneity
of values must be acknowledged, leading
to the idea of “negotiating collective
acceptability” so that evaluation of the socalled risks and benefits of testing are
made communal. This is a forward looking
approach, vastly superior to outmoded
ideas of informed consent, but in reality
large portions of what will be negotiated
are things about which no one can predict
outcomes, and that in any case, we can do
nothing about. One can see how collective
acceptability may assist with testing
families for Huntingdon’s disease, in that
this knowledge can be used to make
marriage and reproductive choices,
although many people would still not want
to know this kind of information. When it
comes to late onset diseases with complex
and unreliable probability predictions, or
worse still, if and when it comes to making
decisions about genes erroneously
believed to determine behavior, should
families and communities be involved?
Should we be doing such tests at all? Who
should decide what may not go to the
table for negotiation at all?
Ellen Larsen is concerned about a dearth
of education in connection with genetics
because she has been startled by the
inability of students to comprehend articles
in the media on this subject matter. I am
startled about yet other things where the

media is concerned: the relationship of the
research community to the media, and the
common inability of the media to report
with accuracy findings about genetics or
predictions of risk. How many times have
we heard that 1 in 9 of all women are at
risk for getting breast cancer in the next
ten years? One of the recommendations
made by the committee for Medical,
Ethical, Legal, and Social Issues (MELSI),
that was part of the now defunct Canadian
Genome Analysis and Technology (CGAT)
program, was that money be put into the
training of science reporters who would
then build up close links with research
communities. This recommendation
should be taken seriously.
The two papers by Patricia Lee and
Priscilla Settee take a somewhat different
approach to problems raised by the new
genetics, namely the collection, storage,
and uses to which DNA materials are put.
Controls over data banks are almost nonexistent in Canada, and this needs to be
addressed urgently, but Lee points to a
more insidious problem to do with the way
in which bodies are “constructed” in
connection with DNA analyses. As Ian
Hacking (1998) puts it, we are dealing with
the problem of how people are “made up”
and to what collectivities they are assigned
by scientists, lawyers, and government, in
this particular case, the way in which
victims of violence are re-victimized by
characterization in the courts as unstable,
bad women. The question of whether the
forensic evidence supplied to the court is
properly protected is also crucial. If, as
Lee suggests, forensic evidence is not in
the end used much in trials, then we have
to ask two fundamental but related
questions: is the very availability of the
technology driving what is happening, and
should more control be exerted at this
point to prohibit its use? Or is there
something darker at work: the creation of
DNA data banks of marginalized peoples
for the testing of hypotheses about
stigmatized collectivities? Certainly, as
Lee shows so well, the biotechnology has

little value for the health and security of
the women in question.
The Human Genome Diversity Project
(HGDP) foundered right from its inception,
and Priscilla Settee sets out many of its
misguided principles in her paper.
Responses to the HGDP by indigenous
peoples have been mostly of
condemnation and with good reason. The
project is both unsound scientifically and
unethical. Among other things the
organizers argue that the project will
permit a better understanding of disease in
targeted populations. This is not possible
because DNA samples are collected in
isolation, along with no other data,
essential if links are to be made between
genotypes, phenotypes, and the
expression of disease.
Interest in genetic diversity is hot stuff
today, and by raising the issue of who
might have rights in, or even make claims
to own genetic material, the question is
brought to the fore of what exactly is a
“community.” While the papers have been
grouped together under the heading of
“community,” the authors either do not use
this concept explicitly or else apply it
rather loosely in a variety of ways,
suggesting that we are dealing with a
slippery concept. The papers group
individuals together as collectivities by
gender, ethnicity, as First nations, interest
groups, risk groups and so on, but we do
not know if these units should indeed be
conceptualized as communities; nor what
being located in a community might mean
for involved individuals. Apart from
anything else, individual interests usually
cut across several “communities.” It is
clear that authors are concerned that the
particular interests and needs of named
collectivities are not being attended to with
respect to the several technologies under
discussion, most of them related to genetic
modifications of one kind and another. It is
argued, and I agree, that collectivities
should be brought systematically into
future discussions and constituted as
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actors in decision making, and several of
the papers outline ways in which this might
be brought about. Parenthetically, several
papers argue that limiting attention to
individual rights and autonomy is no longer
sufficient when it comes to the new
genetics. Discourse about genes inevitably
presents a paradox: it reinforces
associations among people as families
and as genealogies having a shared
biological heritage, but it also divides
people, for individual genomes are unique.
Even so, the effects of genes on health
and knowledge about genes cannot be
thought of as a private matter.
Can body parts be owned? Whether it be
by individuals, families, communities,
nations, or humankind as a whole? Is it
appropriate for individuals or organizations
to make such claims? Do we need to find
some language other than property law in
order to deal with these new dilemmas? In
theory, with the abolition of the slave trade
we abolished the right to “own” persons,
perhaps now is the time to make a move
so that parts of the body are made
inalienable. At the very least such a move
must be debated. At present we live with
inconsistencies. It appears that massive
public opposition exists to the sale of
organs for transplants, on the other hand
eggs, sperm, and blood – repositories of
genetic material for future generations –
are sold daily with few controls in place. In
effect we are prepared to make
commodities of the stuff that produces
children, but not of kidneys that, if
procured in humane and sterile
surroundings, have the potential to prolong
the lives of recipients, sometimes for many
years, as productive members of society.
In sum, systematization of the
management and monitoring of the
collection and commodification of human
cells, tissues and organs is extremely
urgent and surely is something that cannot
be worked out other than by internationally
recognized legally binding agreements.
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In connection with the new genetics one of
the biggest issues to be confronted is that
of “individual interest” or what is perceived
to be in the interest of individuals, because
knowledge about the genes of individuals
and their manipulation can place these
individuals in potential conflict with the
interests of the larger groupings of people
of which they are a part – families,
communities, societies. If genetic material
is understood as belonging entirely to
individuals, and if so-called genetic
diseases are located entirely in the bodies
of individuals, then the social and cultural
issues associated with these entities will
inevitably be ignored or at the very least
set to one side. Depoliticization is the
result.
Disputes about disease causation being
the result of proximate or final causes –
due to external causes or confined to
causes internal to the body – are hundreds
of years old, and such disputes form the
basis for current arguments between
health prevention models and those of
clinical medicine and the associated basic
sciences. Even though we talk today about
multifactorial diseases little middle ground
has been created between the
reductionistic arguments of so many
molecular geneticists and those
researchers who use the tools of
epidemiology and make predictions about
human populations. A great deal of talking
at cross-purposes persists, permitting
obfuscations about the goals and
applications of the new genetics to go
unexamined.
What is particularly dangerous this time
round is that some proponents of the new
genetics are trying not simply to
institutionalize gene therapy but are
moving towards enhancement of the
human genome. This will affect not only
individuals, but communities everywhere
and future generations, and can only be
described as neoeugenics – a blatantly
political endeavor disguised as scientific
benevolence. Efforts at normalization of

the health and well being of individuals
through techniques such as
preimplantation genetic diagnosis followed
by selective disposal of unwanted fetuses
are already being put into practice, and will
affect the composition and condition of
future populations. Rather than limiting our
responses as feminists to issues of
informed consent and equal access to new
genetic technologies, we must at the same

time, I think, vigorously persist in
arguments about the social determinants
of ill health, including diseases where
genetic factors are implicated. At the same
time discussion of the social
consequences of allowing individual desire
and informed consent to shape policy
making in connection with the new
genetics is urgently called for.
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